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Cancer chemotherapy can reduce immunity.  The lowered immune response increases the risk 
of infection that can develop into a life threatening secondary complication called neutropenic 
sepsis.  The neutropenic sepsis causes a significant number of hospital admissions and an 
estimated 700 deaths within the United Kingdom (UK) each year.  Delays in patients reporting 
symptoms of neutropenic sepsis may exacerbate the problem, causing longer and more costly 
hospital stays and a greater risk of death.  Furthermore, chemotherapy treatment may also be 
delayed, which may affect prognosis. 
 
This study took an ethnographic and constructivist grounded theory approach to develop a 
theory to explain why patients delay presenting to hospital with neutropenic sepsis.  A 
longitudinal element of the study involved non-participant observation of women with breast 
cancer being provided with information about neutropenic sepsis by oncology doctors and 
chemotherapy nurses.  Interviews were carried out, with observed patients following the 
observation and at the end of treatment.  A retrospective element involved interviews with 
women with breast cancer who had developed neutropenic sepsis, their carers and doctors 
and nurses who worked within oncology and Accident and Emergency (A&E) departments.  
Analyses commenced with the earliest data gathered and a rich theoretical picture was built 
through comparing perspectives, pursuing areas of inquiry and recruiting particular 
participants who became of interest to the developing theory. 
  
A grounded theory evolved, which suggests patients may delay presenting to hospital with 
neutropenic sepsis because the seriousness of it is underplayed by clinicians, patients and their 
carers.  Findings of this study have immediate implications for clinical practice to ensure 
patients and their carers are adequately supported by clinicians to understand the seriousness 
and be equipped to identify and report neutropenic sepsis.  Furthermore, study findings 
should inform the design of future research to develop interventions, to promote earlier 
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Glossary of terms 
Carers 
Carers who participated in the study, were identified by participating patients, as the relative 
or friend who provided them with most support during chemotherapy treatment. 
 
Chemotherapy 
For this study, chemotherapy drugs are defined as cytotoxics, that destroy rapidly dividing 
cancer cells and that also cause damage to rapidly dividing normal cells that usually recover. 
 
Clinicians 
Clinicians who took part in the study were doctors and specialist nurses, who worked with 
patients in relation to chemotherapy consent, information and support.  Participating clinicians 
worked within oncology and accident and emergency departments.   
 
Neutropenic Sepsis  
Definition of neutropenia and fever 
Diagnose neutropenic sepsis in patients having anticancer treatment whose neutrophil count 
is 0.5 x 109 per litre or lower and who have either: 
– a temperature higher than 38oC or 
– other signs or symptoms consistent with clinically significant sepsis 
        (National Institute of Clinical Excellence (NICE), 2012, p.vi) 
 
Patients 
Patients who participated in this study were women aged over 18 years, with a diagnosis of 
breast cancer and prescribed chemotherapy with a risk of causing neutropenic sepsis.  They 
spoke English and were considered by clinicians as physically and emotionally able to 
participate.   
 
Patient-Centred Communication in Cancer Model 
A framework developed by the National Cancer Institute in America.  This is based upon 
mediating and moderating influences of communication between clinicians, patients and 




Absolute Neutrophil Count (ANC) 
Accident and Emergency (A&E) 
American Society of Clinical Oncology (ASCO) 
Critical Appraisal Skills Programme (CASP) 
The Common Terminology Criteria for Adverse Events (CTCAE) 
European Organisation for Research and Treatment of Cancer (EORTC) 
General Practitioner (GP) 
Growth Colony Stimulating Factor (G-CSF) 
Medical Subject Headings (MeSH) 
National Cancer Institute (NCI) 
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National Comprehensive Cancer Network (NCCN) 
National Confidential Enquiry into Patient Outcomes and Death (NCEPOD) 
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National Institute for Health Research (NIHR) 
Multinational Association of Supportive Care in Cancer (MASCC) 
Patient Care Monitor Neutropenia Index (PCM-N) 
Patient-Centred Communication in Cancer Model (PCC) 
Research and Development (R&D) 
Research Ethics Committee (REC) 
Systemic Anti-Cancer Treatment (SACT) 
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Over 331,000 people are diagnosed with cancer each year within the United Kingdom (UK) 
(Cancer Research UK. Cancer incidence statistics. [ONLINE] Available at: 
http://www.cancerresearchuk.org/cancer-info/cancerstats/incidence/. [Accessed 28 January 
14] an increasing number of whom are treated with chemotherapy.  Between 2002/03 and 
2006/07, it is estimated that programmes of chemotherapy prescribed in the UK rose from 
40,000 to 65,000 per annum (National Chemotherapy Advisory Group (NCAG), 2009).   
 
Chemotherapy involves the administration of drugs to destroy rapidly dividing cancer cells.  
Intended benefits of chemotherapy are: 
 Curative treatment. 
 Palliation, to control or reduce the size of the cancer.  To improve quality of life and 
survival. 
 Adjuvant treatment, following surgery to reduce the risk of recurrence. 
 Neo-adjuvant treatment, to reduce the size of the cancer before surgery. 
 
The most common routes for chemotherapy drug administration are intravenous and oral.  
Drug delivery typically occurs in three to four weekly cycles over many months to make up a 
treatment programme.  Within the UK the majority of chemotherapy is delivered within the 
outpatient setting.  Patients undergoing chemotherapy treatment typically receive intravenous 
drugs in the hospital.  Where oral chemotherapy is prescribed this is self-administered at 
home. 
 
Chemotherapy drugs unfortunately cause side effects, mainly because they destroy healthy as 
well as rapidly dividing cancer cells.  The challenge for prescribers of chemotherapy is to 
balance the delivery of drugs at the optimal dose, to improve outcome, whilst minimising 
toxicity.  The type and severity of chemotherapy side effects depend on the chemotherapy 
drug or combination of drugs administered and the variation in patients’ responses to 
medication.   
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Common complications of chemotherapy such as nausea and vomiting, mucositis, alopecia, 
diarrhoea, fatigue, weakness, hair loss, peripheral neuropathy, muscle and joint pain, are 
usually well managed.  However, patients can still become extremely debilitated by 
chemotherapy side effects and are at risk of developing bone marrow suppression.  Of concern 
is the ability of some chemotherapy drugs to cause a reduction in neutrophils, which are a type 
of white blood cell formed and inactive within the bone marrow and required by the body for 
first line immune defence.  Neutrophils take about six days to enter the blood stream (Dancey 
et al., 1976), where they circulate for between eight hours and five days (Pillay et al., 2010).  
Neutrophils respond to early signals from the body that infection or injury are present and 
migrate to kill cells, such as bacteria that might cause infection.  This is achieved, either 
through direct attack or by triggering other immune responses such as T cell activation 
(Nathan, 2006).  A low neutrophil count means the body’s ability to fight infections is 
compromised.  There is then an associated risk of infections quickly developing to septicaemia, 
which may progress to organ failure and death (Kurtz et al., 2006).  Septicaemia, under these 
circumstances, is often referred to as neutropenic sepsis.   
 
The National Institute of Clinical Excellence (NICE) have produced clinical guidance on the 
prevention and management of neutropenic sepsis in cancer patients.  NICE estimate around 
two patients die from neutropenic sepsis every day in the UK, which may be a conservative 
estimate (NICE, 2012).  Neutropenic sepsis can be effectively treated with intravenous 
antibiotics.  The earlier patients present to hospital with it, the better the outcomes in terms of 
survival and reduced debilitation from sepsis.   
 
A concern within my clinical practice related to a common behaviour, where patients delayed 
reporting symptoms of neutropenic sepsis that they developed following chemotherapy 
treatments.  This behaviour occurred, despite my clinical colleagues and I, believing we clearly 
informed patients and their carers about neutropenic sepsis, and of the symptoms they should 
monitor, and report, to dedicated 24-hour helplines.  Despite serious concerns about late 
patient presentation to hospital with neutropenic sepsis, there is a lack of research to explore 
why this occurs.  The purpose of this study therefore is to better understand this phenomenon.   
 
This study was conducted between November 2011 and February 2013 within a London 
Cancer Centre.  The research design consisted of an ethnographic approach for data collection.  
15 
Constructivist grounded theory was applied to direct data collection and the analysis.  A 
grounded theory research design was chosen, to enable development of a theory, to explain 
the likely complexities underpinning delayed patient presentation to hospital with neutropenic 
sepsis that could emerge from and be grounded in the data.  This evidence is required to 
reduce avoidable delays in presentation through changes in clinical practice and introduction 
























































2.1 Introduction  
An initial search of the literature did not identify any studies that specifically explored 
communication of risks of neutropenic sepsis to patients undergoing chemotherapy for cancer, 
or reasons they may delay presenting to hospital when this occurs.  This initial review did 
identify a large body of literature focused on neutropenic sepsis more generally.  Given the 
breadth of the literature and lack of suitability of this for a systematic review, a scoping review 
(Arksey and O'Malley, 2005, Gough et al., 2012, Norman and Griffiths, 2014) was carried out, 
to identify and describe evidence relevant to the research questions addressed by this thesis.  
The methods for this scoping review followed five stages, as outlined by (Arksey and O'Malley, 
(2005): 
 
Stage one: Identifying the review question 
Stage two: Identifying potentially relevant papers 
Stage three: Selecting papers for inclusion 
Stage four: Charting the data 
Stage five: Collating, summarising and reporting the results 
 
2.1.1 Stage one: Identifying the review question  
The intention of the scoping review was to set the context for the study reported within this 
thesis.  The review question was:  
 
What is known within existing literature about neutropenic sepsis, the risks of this to patients, 
the reasons for delayed presentation and good practice in relation to communicating risks? 
 
2.1.2 Stage two: Identifying potentially relevant papers 
The initial search indicated that very little evidence existed about why patients delay reporting 
neutropenic sepsis. Consequently, a search strategy was designed based up on a combination 
of searching electronic databases and augmenting.  The later stage (augmenting) included: 
citation searching; hand searching of relevant journals and expert knowledge of existing data 
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sources, including papers, guidelines, reports and websites.  Stage one of the search strategy 
involved a search of relevant bibliographic databases to capture published evidence.  Searched 
databases included: British Nursing Index, CINHAL, the Cochrane Database of Systematic 
Reviews, Embase, MEDLINE and PsycInfo.  Four key concepts emerged from the review 
research question: cancer, chemotherapy, neutropenic sepsis and patient education.  Mesh 
headings and keywords associated with each of the four concepts were identified and adapted 
according to various database conceptual frameworks, as demonstrated within table 2.1.  
These were then combined within concepts and between concepts using Boolean indicators 
(AND, OR, NOT) to focus the searches. 
 
 
Table 2.1.Search terms applied to Ovid MEDLINE 
 Cancer   AND /OR  Chemotherapy      AND      Neutropenic Sepsis    
MeSH 
Heading 
Neoplasm Antineoplastic agents Chemotherapy induced                                                                                                                                                              
neutropenia  





         Chemotherapy  
 AND  Patient Education  
MeSH 
Heading 
Patient Education  
 
 
Many papers that reported neutropenic sepsis data did not immediately appear relevant to 
the scoping review question.  However, reading of this more general literature identified data 
that were pertinent.   
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Stage two of the search strategy (augmenting) included citation searching,  hand searching, 
and expert knowledge of data sources including websites, papers, reports and guidelines.  
Citation searching included manual searches of reference lists in identified articles to reveal 
further relevant papers.  Citation searching also included a review of papers that cited the 
original article of interest.  Pertinent cancer journals, that were hand searched for appropriate 
articles, included: Oncology Nursing Forum; Supportive Cancer Care; Cancer Nursing; the 
British Journal of Cancer and the European Journal of Cancer Care.  Websites reviewed, 
included those which had produced guidelines important to the management of neutropenic 
sepsis: NICE, the Department of Health, the American Society of Clinical Oncology (ASCO), the 
European Organisation for Research and Treatment of Cancer (EORTC) and The UK Sepsis 
Campaign.  Further websites searched included The Oncology Nursing Society and the 
Multinational Association of Supportive Cancer Care (MASCC), both of which have online 
neutropenic sepsis forums for clinicians, and Macmillan Cancer Support, which produces 
information about chemotherapy for patients and others affected by cancer.   
 
2.1.3 Stage three: Selecting papers for inclusion  
Papers that included a focus on chemotherapy induced neutropenia in adult cancer patients 
were included.  Articles reporting neutropenia in non-cancer and paediatric populations and 
those not available in English language were excluded from the review.  The selection process 
(figure 2.1) was adapted from PRISMA guidance (Moher et al., 2009) developed to conduct 
systematic reviews.  An initial 37 papers were identified through database searching.  A further 
11 were identified through other sources.  All identified papers were read and 19 were 
rejected, due to these not answering the review question.  Of those rejected, fourteen related 
to medical management of neutropenic sepsis; three focused on the effects of treatment of 
neutropenic sepsis on patients and carers; one mentions  neutropenia to have a moderating 
impact on a cognitive behavioural intervention, designed to reduce chemotherapy symptoms.  
This did not provide data about patient identification and reporting of neutropenic sepsis.  One 
paper referred to chemotherapy symptom clustering, but did not relate this to symptoms of 
neutropenic sepsis.  Twenty nine papers were included in the literature analysis.  The papers 
were produced from a range of countries: USA, (12); UK (10); Europe (3); Multinational (2); 
Australia (1); and Pakistan (1). The reasons for inclusion are summarised in figure 2.1. 
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Figure 2.1. Process of information gathering.   
Adapted from PRISMA (Moher et al., 2009); p334 
For permission see appendix 2 
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37 papers identified through 
database searching 
 
11 additional papers identified 
through other sources  
Guidelines                    (9)  
Research articles         (2)  
 
48 papers screened 
19 papers excluded: 
Medical management of 
neutropenic sepsis    (14)  
Impact of treatment for 
neutropenic sepsis    (3) 
Effects of neutropenia  
on cognitive behavioral  
Intervention      (1)  
Symptom clustering           (1)   
29 papers included in the scoping review:  
 
Neutropenic sepsis clinical guidelines                   (7) 
 
Cancer guidelines                  (5)  
 
Effects of neutropenia on symptoms and functioning  
(quantitative (7)  qualitative (1) mixed method (1) 
 
Mortality and morbidity          (quantitative (5)  
 





2.1.4 Stage four: Charting the data 
Core information from each paper included in the scoping review was charted. This included 
the country of origin, study population, aims of the study, methodology, outcome measures 
and findings.  All included papers were read and the focus of each paper was examined to 
identify the aspects of the overall review question addressed by each paper. This resulted in 
the identification of four main themes covered by the papers (each paper may cover one or 
more themes):  
 
1. Defining neutropenic sepsis and the risks of this to patients undergoing  
chemotherapy for cancer. 
2. Symptoms of neutropenic sepsis that patients should report to clinicians. 
3. Knowledge about delayed patient presentation to hospital with 
neutropenic sepsis. 
4. Education of patients about neutropenic sepsis. 
 
Findings from each paper were then mapped to each of these themes.  Mapped data were 
compared, contrasted and drawn upon, to describe evidence in relation to each the four 
themes.  It was envisaged that the first three themes would provide information useful for 
educating patients and carers about recognising neutropenic sepsis symptoms.  Theme four 
would describe optimal strategies for clinicians to educate patients about neutropenic sepsis 
and associated risks.  Superscript numbers that relate to the themes (1-4) are applied to the 
scoping review question to demonstrate the applicability of the mapped data:  
 
What is known within existing literature about neutropenic sepsis, the risks of this to patients 
(themes 1, 2) the reasons for delayed presentation (theme 3) and good practice in relation to 
communicating risks (theme 4) 
 
Papers that are included in the scoping review are summarised within table 2.2.  Detail is 
provided about the: types of papers / methods employed; findings that are related to the 
scoping review question (the four themes) and the quality of the evidence described.  The 
quality rating approach will be described within the next stage (stage five: collating, 
summarising and reporting the results).  A more in-depth summary of these papers may be 
found at appendix 1. 
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Table 2.2  Scoping review: Characteristics of included papers  
 
Reference  Type of 
paper / 
method  
Important findings (Superscript 
numbers refer to foot note, 






Neutropenic sepsis clinical guidelines 
US Department of 




Suspect sepsis if temperature 38.30C, or 380C 
for more than one hour. (1) 
High  




Intravenous broad spectrum antimicrobials 
should be administered within one hour of 







Suspect NS if temperature >38oC, or clinical 
signs of sepsis (1) (low quality evidence). 
Intravenous antibiotics within one hour (1) 
(high quality evidence). Poor prognosis with: 
mucositis, temperature >39oC, clinical signs of 
infection, chills, confusion (1) (low quality 
evidence). Early symptoms of NS (2) and  










Symptoms of severe sepsis (1) (see table 2.8). 
Intravenous antibiotics and fluids within one 
hour. (1)  
High  
 





High risk indices for NS: chemotherapy 
regimens with > 20% risk of causing 
neutropenia, age >65 years, advanced 
disease, no antibiotic prophylaxis. (1) 
High  
 
Klastersky et al.,  
(2000) (MASCC) 
Quantitative High risk of complications from NS: age >60 
years, haematological malignancy and co-
morbidities. (1) 
High  




High risk indices for NS: chemotherapy 
regimens with high (>20%) risk of causing 
neutropenia, age>65years, advanced disease, 
co-morbidities. (1) 
High  
Scoping review themes: (1) Defining neutropenic sepsis and the risks of this to patients undergoing 
chemotherapy for cancer. (2) Symptoms of neutropenic sepsis that patients should report to clinicians. (3) 
Knowledge about delayed patient presentation to hospital with neutropenic sepsis. (4) Education of patients 
about neutropenic sepsis. Abbreviations: ASCO (American Society of Clinical Oncology); CTCAE (Common 
Terminology Criteria for Adverse Events); EORTC (European Organisation for Research and Treatment of 
Cancer); GRADE (Grading of Recommendations, Assessment Development and Evaluation); MASCC 
(Multinational Association for Supportive Care in Cancer); NICE (National Institute of Clinical Excellence); NS 




Table 2.2 continued: 
 
Reference  Type of 
paper / 
method  
Important findings (Superscript numbers refer to foot 






NCEPOD, (2008) Mixed 
method 
Poor clinical practice in relation to neutropenia.(1) Patients delayed 
presentation with NS symptoms by > 24-hours, (may increase 
mortality risk). (1)  
Medium 
NCAG, (2009) Expert 
opinion 
Patient education should be improved. (4) 24-hour on-call services 
should be provided for patients during chemotherapy. (4) 
Low  
 





Over half of admissions associated with feeling unwell or fever.(1) 





Peer Review, (2011) 
Expert 
opinion 
Expect 24-hour on-call services to be in place for cancer patients 
during chemotherapy. (4) 
Low  
National Cancer 
Peer Review, (2013) 
Expert 
opinion 
Require emergency cancer services to be in place. (4) Low  
Primary Research:   Effects of neutropenia on symptoms and functioning 
Fortner et al., 
(2005a) 
Quantitative.  Reduced physical and social functioning in grade 4 compared to 
grades 0-3. (2) 
Low  
Fortner et al., (2006) Quantitative  
  
Reduced physical and social functioning in grades 3 - 4 compared with 
grades 0 – 2. (2) 
Low 
Fortner et al., 
(2005b) 
Qualitative  Reduced physical and social functioning with grade 4 neutropenia. (2) Low 




Reduced physical and social functioning in grades 3 - 4 compared with 
grades 0 – 2. (2) 
Low 





Mucositis present in 37% of cases. (2) 
Mean delay in presenting 21 hours (range 1-72). (3) Co-morbidities and 
advanced cancer associated with later presentation. (3) 
Low 
Wagner et al., 
(2008) 
Quantitative FACT-N demonstrated reduced physical and social functioning. (2) Low 
Olsen et al., (2011) Quantitative PCM-N distinguished between grades 3-4 and 0-2. (2) Medium   
McKenzie et al 
(2011) 
Quantitative Some patients delayed presenting by 2-7 days. (3) Low 
Higgins and Hill 
(2012) 
Audit Presenting symptoms: Fever range: < 36o C - 400C. (2)  34% patients 
delayed presenting > 24 hours. (3) 
Low 
Scoping review themes: (1) Defining neutropenic sepsis and the risks of this to patients undergoing chemotherapy for cancer. (2) 
Symptoms of neutropenic sepsis that patients should report to clinicians. (3) Knowledge about delayed patient presentation to 
hospital with neutropenic sepsis. (4) Education of patients about neutropenic sepsis. Abbreviations:  FACT-N (The Functional 
Assessment of Cancer Therapy-Neutropenia Instrument); NS (Neutropenic Sepsis); NCAG (National Chemotherapy Advisory 
Group ); NCEPOD (National Confidential Enquiry into Patient Outcomes and Death); PCM-N (Patient Care Monitor Index 1.0 
Revised Neutropenia Index). 
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Table 2.2 continued: 
 
Reference  Type of 
paper / 
method 
Important Findings (Superscript numbers refer to foot 





Primary Research:   Morbidity and mortality associated with neutropenic sepsis 
Okera et al., (2011) Audit Risk indices for NS: advanced disease; age>65years; previous 
neutropenia; no G-CSF or antibiotic; chemotherapy > 20% risk. (1) 
Mortality 3 (4.2%) (1) Infection symptoms: Respiratory, GI, mucositis. (2) 
Low  
 
Kuderer et al., 
(2006) 
Audit Mortality rate 9.5% (range 0-50%). (1) 
Risk indices for mortality: Co-morbidities. (1) 
Cost estimate $1.06 billion. (1) 
Low  
Chirvella et al., 
(2009) 
Quantitative Disease free survival is positively affected by reduced chemotherapy 
treatment delays and maintaining dose intensity. (1).  
High   
 
Vincent et al., 
(2006)  
Quantitative  Prognostic variables:  Older age and co-morbidities. (1)   High   
Malik et al., (2001).  Quantitative  
 
Most patients in shock presented to A&E, were older and had 
advanced disease. (1)  Symptoms of septic shock: diarrhoea; altered 
mental state; bleeding and dyspnoea. (1)  
Patients delayed presenting. (3)  
Low  
Information and support 







Inconsistent guidelines, including symptoms of NS (2). Poor evidence 
to guide NS education for patients. (4)  
Low  





Nurse Knowledge and confidence in managing NS increase with 
greater experience and education. (1)  
Over half of nurses were unaware that NS is most likely after the first 
chemotherapy. (4)   




Survey Most patients had a chemotherapy alert card and kept it with them. 
Patients felt reassured there was a 24-hour on-call service. (4)  
Low 
Scoping review themes: (1) Defining neutropenic sepsis and the risks of this to patients undergoing chemotherapy for cancer. (2) 
Symptoms of neutropenic sepsis that patients should report to clinicians. (3) Knowledge about delayed patient presentation to 




2.1.5 Stage five: Collating, summarising and reporting the results 
Scoping reviews do not aim to formally judge the quality of the literature through systematic 
processes (Arksey and O'Malley, 2005).  Design and sampling characteristics of studies cited 
within this chapter, were reviewed in order to inform judgements about the strength of the 
evidence and consequent ability to draw conclusions from it (Griffiths et al., 2009).  
Specifically, the Critical Appraisal Skills Programme (CASP. 2014. [ONLINE] Available at: 
http://www.caspinternational.org. [Accessed 02 February 2014] tool for reviewing qualitative 
research (table 2.3) was applied to each identified qualitative study.  The Critical Review Form; 
Quantitative Studies (Law et al., 1998) (table 2.4) was completed for each quantitative 
research paper due to the range of reviewed study designs and the need for a generic 
quantitative tool. These tools were used to identify key strengths and limitations of papers. 
Papers were categorised into high, medium or low quality based upon an overall subjective 
judgement of the trustworthiness of the findings.  Jones et al., (2014) have used this 
methodology to synthesis finding across multiple design types / source and to take account of 
quality. Nine studies were considered to be of high quality, three were deemed to be of 
medium quality and seventeen were considered as low quality (table 2.2). 
 
 
Table 2.3. CASP qualitative research checklist (2014)  
For permission see appendix 2 
 
Q1    Was there a clear statement of the aims of the research? 
Q2    Was a qualitative methodology appropriate? 
Q3    Was the research design appropriate to address the aims of the research? 
Q4    Was the recruitment strategy appropriate to the aims of the research? 
Q5    Was the data collected in a way that addressed the research issue? 
Q6  Has the relationship between researcher and participants been adequately                                                                                                                                                      
qw   considered? 
Q7    Have ethical issues been taken into consideration? 
Q8    Was the data analysis sufficiently rigorous? 
Q9    Is there a clear statement of the findings? 







Table 2.4. Critical review form quantitative studies (Law et al., 1998)  
For permission see appendix 2 
 
STUDY PURPOSE: Was the purpose stated clearly?  (Outline the purpose of the 
study.  How does this study apply to research areas and/or your research 
question?). 
LITERATURE:  Was relevant background literature reviewed? YES NO 
(Describe the justification of the need for the study). 
DESIGN:  Describe the study design.  Was the design appropriate for the study 
question?  Specify any bias that may have been operating and the direction of 
their influence on the results.   
SAMPLE:  Was the sample described in detail (who; characteristics; how many, 
how was sampling done?).  If more than one group, was there similarity between 
the groups?  Was the sample size justified?  Describe ethics procedures.  Was 
informed consent obtained? 
OUTCOMES:  Specify the frequency of outcome measurement, outcome areas 
and measures used.  Were the outcome measures reliable?  Were the outcome 
measures valid? 
INTERVENTION:  Provide short description of the intervention.  Is the 
intervention described in detail?  Was contamination avoided?  Was co-
intervention avoided?  
RESULTS:  Were results reported in terms of statistical significance (what were 
the results? Were they statistically significant (i.e.  p<0.05)? If not statistically 
significant, was the study big enough to show an important difference if it should 
occur? If there were multiple outcomes, was that taken into account for the 
statistical analysis?  Were the analysis method(s) appropriate). Was clinical 
importance reported (What was the clinical importance of the results? Were 
differences between groups clinically meaningful (if applicable)?  Were drop outs 
reported (Did any participants drop out from the study? Why? Were reasons 
given and were drop outs handled appropriately?). 
CONCLUSIONS AND CLINICAL IMPLICATIONS: 
Were conclusions appropriate given study methods and results? (What did the 
study conclude? What are the implications of these results for practice? What 




Charting the data, required breaking down the review question into its’ component parts.  
Findings from each study that were relevant to the scoping review question were identified 
and aligned under four overarching themes for reporting the findings.  Finally findings from all 
the included papers were appraised and described, within each of the four themes.  This 
formed a summative understanding of the latest research evidence, pertinent to understand 
why patients’ may delay presenting to hospital with neutropenic sepsis. 
 
 
2.2 Findings from the scoping review 
Analysis and synthesis of the findings and consideration of the strength of these informed the 
state of the knowledge within each of the four themes. 
 
2.2.1 Theme one: Defining neutropenic sepsis and the risks of this to patients undergoing 
chemotherapy for cancer. 
2.2.1.1  Defining neutropenic sepsis   
Neutropenic sepsis arises from the administration of cancer chemotherapy treatments.  
Chemotherapy can cause bone marrow suppression, leading to anaemia through lowered 
haemoglobin production, thrombocytopenia due to reduced platelet production and 
neutropenia which is a low absolute neutrophil count (ANC).  Depending on the chemotherapy 
drugs and timing of treatment cycles, patients tend to develop neutropenia around 10 to 14 
days after chemotherapy has been administered.  NICE (2012), within neutropenic sepsis 
guidance, describes an associated increase in illness and mortality, with declining 
immunosuppression following chemotherapy, as defined by the absolute neutrophil count.   
 
The stages of neutropenia and neutropenic sepsis are represented within table 2.5 (US 
Department of Health and Human Sciences, 2009, NICE, 2012, The UK Sepsis Trust, 2013, 
Dellinger et al., 2013).  This supports a distinction required by NICE (2012), between 
neutropenia (low neutrophil count), uncomplicated neutropenic fever (low neutrophil count 
with a fever) and severe sepsis and shock (low neutrophil count, life threatening sepsis, with or 
without a fever).  Neutropenic fever can quickly progress to sepsis and shock.  It is these stages 
that represent a medical emergency that requires immediate treatment with intravenous 
broad spectrum antibiotics (acting before an identified pathogen or full blood count result are 
known) (NICE, 2012, The UK Sepsis Trust, 2013, Dellinger et al., 2013).  This is because septic 
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shock, can cause extensive infiltration of fluid into the tissues and a reduced blood supply to 
major organs, including the kidneys, liver, lungs and brain and consequently can cause death 
(The UK Sepsis Trust, 2013, Dellinger et al., 2013).   
 
Importantly, NICE (2012) point to confusion regarding definitions of febrile neutropenia and 
neutropenic sepsis, resulting in such terms being used interchangeably by clinicians in practice.  
This is also the case with the literature cited and discussed within this chapter.  Consequently, 
as adopted by NICE (2012), the term neutropenic sepsis is applied within this thesis to cover 
the range of illness from febrile neutropenia, to neutropenic sepsis that is also referred to as 
severe sepsis or septic shock.   
 
Neutropenic sepsis is most likely to occur during initial chemotherapy treatments (e.g. cycle 
one or two) (Aapro et al., 2011).  It is defined by the absolute neutrophil count and body 
temperature, although there is lack of consensus regarding the parameters for these indicators 
and they are based on low level evidence.  NICE (2012) state that neutropenic sepsis should be 
diagnosed and treated in patients undergoing chemotherapy who have a neutrophil count of 
0.5x109 per litre or lower alongside either a temperature higher than 380C or clinical symptoms 
of sepsis, which may not include a fever.  The Common Terminology Criteria for Adverse 
Events (CTCAE) (US Department of Health and Human Sciences, 2009) is also commonly used 
in clinical practice.  Absolute neutrophil count and temperature parameters are not defined for 
grade one (mild) and grade two (moderate) neutropenia, which would not require medical 
treatment.  Grade three and grade four neutropenia do fit with the NICE (2012) definition of 
neutropenic sepsis, although parameters of temperature and absolute neutrophil count differ.  
Grade 3 (severe) febrile neutropenia includes an ANC <1.0x109/L with a single temperature 
reading of >38.30C or a sustained temperature of >38oC for more than one hour.  The CTCAE 
suggests grade three neutropenia can rapidly progress to grade four (life threatening) 












Table 2.5. Stages of neutropenia (Based on: US Department of Health and Human 
Sciences, 2009, NICE, 2012, UK Sepsis Trust, 2013, Dellinger et al., 2013) 
 
Normal Neutropenia Neutropenic Sepsis 
Febrile neutropenia Life threatening Severe 













Often occurs between 













C (NICE 2012) 
Neutropenic with or 
without a fever and 
symptoms of sepsis 
e.g.  low blood 
pressure, confusion 
(CTCAE Grade four 









C for more than 
one hour (CTCAE Grade 
three neutropenia) 




2.2.1.2. Neutropenic sepsis related incidence, mortality, morbidity and cost to the health 
service 
The incidence of neutropenic sepsis within the UK is unknown due to differing definitions and 
the inability of healthcare clinical coding systems to adequately capture this (NICE, 2012).  Data 
is available that suggests an increasing number of patients die from neutropenic sepsis each 
year within the UK (NICE, 2012) and studies have identified the incidence of death once this 
develops (Okera et al., 2011).  In addition, evidence demonstrates sepsis is debilitating and 
expensive for the health service to treat (Kuderer et al., 2006; Vincent et al., 2006). 
 
Data presented by NICE (2012) suggests deaths from neutropenic sepsis doubled within the UK 
between 2001 and 2010 to over 700 per year, which equates to around two per day.  This 
increase reflects a rise in cancer incidence and associated chemotherapy usage within the UK, 
but is also likely to be an underestimate due to previously mentioned issues with clinical 
coding systems.  Cancer has evolved into a chronic illness often controlled by multiple lines of 
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treatment, including newer cancer drugs such as Taxanes and targeted therapies that have 
high risk indices for neutropenia.  Another reason for the increase is the change to treatment 
approaches, informed by research showing a survival benefit with dose intensity in some 
chemotherapy regimens.  Consequently, chemotherapy treatments are often not delayed to 
allow the absolute neutrophil count to recover which places patients at increased risk of 
developing neutropenic sepsis during subsequent treatments (Aapro et al., 2011). 
 
Research suggests that mortality rates from neutropenic sepsis range from 2-21% of patients 
affected (Kuderer et al., 2006, Okera et al., 2011).  A large American retrospective study of 
over 40,000 hospital admissions across 115 health centres, identified the overall hospital 
mortality rate from febrile neutropenia was 9.5% (range 0%-50%).  Furthermore, mortality for 
patients with leukaemia (18%) was double that for patients treated for solid tumours (9%) 
(Kuderer et al., 2006).  A more recent UK prospective study  which included 61 patients over 71 
hospital admissions for febrile neutropenia reported a mortality rate of 4.2% (Okera et al., 
2011).  Findings from these studies should though, be viewed with some caution.  The UK 
study (Okera et al., 2011) may not be generalisable to the wider population, due to the small 
sample size and location within one cancer network within the UK.  Furthermore, the mortality 
rate in the American study (Kuderer et al., 2006) may be an underestimate.  The researchers 
relied on hospital coding to identify incidents of neutropenic sepsis, which they acknowledged 
may not have accurately captured all episodes.  Okera et al (2011) overcame this problem by 
identifying cases of neutropenic sepsis through haematology laboratories and cross 
referencing these with patient hospital admission details. 
 
Neutropenic sepsis is not only associated with mortality but has further harmful 
consequences.  Morbidity or debilitation from sepsis often results in subsequent 
chemotherapy treatment delays and dose reductions, both of which have been shown to 
adversely affect prognosis, including in breast cancer (Chirivella et al., 2009).   
 
Neutropenic sepsis also impacts on healthcare resources.  Emergency assessment and 
treatment is required for all cases of neutropenic sepsis.  Admission to hospital is required for 
some and intensive care management is needed for the most unwell patients (NICE, 2012). 
Limited data are available on healthcare financial burden associated with neutropenic sepsis.  
This does not include a breakdown of costs.  A European Study published in 2006 suggests the 
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cost of treating a patient who develops severe sepsis, including organ failure, is approximately 
£20,500 for intensive care treatment (Vincent et al., 2006).  Furthermore, in the United States, 
the previously mentioned study of 41,779 patients admitted to hospital with neutropenic 
sepsis (Kuderer et al., 2006), identified the total cost of hospital admissions to exceed $1.06 
billion, which equates to an average cost of £24,000 per episode.   
 
2.2.1.3  What predisposes patients to neutropenic sepsis and associated complications?  
Evidence based guidelines produced by the EORTC (Aapro et al., 2006, Aapro et al., 2011) and 
ASCO (Smith et al., 2006) inform clinicians about chemotherapy drugs and patient risk factors, 
associated with a higher incidence of neutropenic sepsis.  Guidelines produced by MASCC 
(Klastersky et al., 2000) suggest risk factors, that render patients at less risk of complications 
once this has developed.  There is strong evidence, that chemotherapy drugs with a >20% risk 
of causing neutropenia and the presence of advanced cancer, put patients at greater risk of 
developing neutropenic sepsis (Aapro et al., 2006, Aapro et al., 2011).  Furthermore, high level 
evidence suggests, age >65years as a risk factor for developing neutropenic sepsis (Smith et al., 
2006, Aapro et al., 2006, Aapro et al., 2011) and complications from it (Klastersky et al., 2000).  
In addition, high level evidence suggests an increase in morbidity and mortality, in patients 
with co-morbidities, who develop, neutropenic sepsis following chemotherapy (Kuderer et al., 
2006) and sepsis within the general population (Vincent et al., 2006).   
 
ASCO (Smith et al., 2006) and the EORTC (Aapro et al., 2011, Aapro et al., 2006) have 
synthesised  evidence to identify the risk factors that predispose patients to neutropenic 
sepsis.  This process was carried out to inform guidelines for prescribing of prophylactic growth 
colony stimulating factors (G-CSF).  This may be administered subcutaneously, as part of 
chemotherapy treatment to stimulate neutrophil production, thereby reducing the risk of 
developing neutropenic sepsis.  High level evidence identified within these reviews, 
particularly in relation to chemotherapy drugs, age and advanced disease may also be used to 
inform clinicians and patients who might be at risk of developing neutropenic sepsis. 
 
It is not clear if systematic processes were followed to retrieve and review the evidence that 
informed the ASCO guidelines, which may affect reliability and validity.  The EORTC graded the 
evidence from level one to level five.  Level one evidence related to meta-analysis of multiple 
well designed studies or high powered randomised controlled trials.  Grade five evidence 
related to case reports and expert opinion.  This assessment of quality of evidence was applied 
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Step 2
Assess factors that increase the frequency/risk of FN
Increased risk Advanced disease
(level I and II History of prior FN
evidence) No antibiotic prophylaxis, no G-CSF
High risk Age >65 years 
Other factors: Poor performance and/or nutritional 
(level III and IV status
evidence) Female gender
Haemoglobin <12g/dl
Liver, renal or cardiovascular disease
Prophylactic G-CSF recommended
FN risk 10-20%FN risk >20% FN risk <10%
Step 3
Define the patients overall FN risk for planned chemotherapy regimen
Step 1
Assess frequency of FN associated with the planned chemotherapy regimen
Overall FN>20% Overall FN risk <20%
G-CSF prophylaxis not indicated
by the EORTC, to develop an algorithm to help clinicians to assess the risk of febrile 
neutropenia, for individual patients based on percentage risk of chemotherapy drugs 
administered and individual risk factors (Figure2.2).  The majority of evidence for patient 
related risk factors was poor (level three-four).  Level one evidence was identified for the 
following risk indices, which were included within the algorithm: being aged >65 years, having 
advanced disease and receiving no antibiotic prophylaxis.  These risk factors were also 
identified, as important within the ASCO guidelines.  Common chemotherapy regimens, 
considered by the EORTC to have a high (>20%), or intermediate (>10-20%) risk, of causing 
febrile neutropenia, were also identified and included within the algorithm.  EORTC guidelines 
(figure 2.2) include patient risk factors for febrile neutropenia, that are supported by less 
robust evidence including: a previous neutropenic episode (EORTC grade two) and poor 
performance or nutritional status (EORTC grade three).  Interestingly, receiving no G-CSF 
prophylaxis (EORTC grade two) is included as a risk factor for febrile neutropenia, alongside 
receiving no antibiotic prophylaxis (EORTC grade one), which may indicate a bias towards G-
CSF.  The rationale for including G-CSF prophylaxis is explained, through a concern not to cause 
antibiotic resistance (Aapro et al., 2011). 
 
Figure 2.2. EORTC patient assessment algorithm (Aapro et al., 2011)  
For permission see appendix 2 
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Not all patients who develop febrile neutropenia (CTCAE grade three) go on to develop 
neutropenic sepsis (CTCAE grade four).  One study identifies predisposing factors for 
developing neutropenic sepsis that may also increase the risk of morbidity and mortality once 
this occurs.  The MASCC risk index was developed through a multinational prospective study of 
756 cancer patients with febrile neutropenia (Klastersky et al., 2000).  The MASCC tool 
identifies patients at low risk of developing serious medical complications, once febrile 
neutropenia has developed.  These patients may be managed more conservatively than 
patients with higher risk indices (Klastersky et al., 2000).  Participants included adults >16 
years, diagnosed with cancer, treated with chemotherapy and who subsequently developed 
neutropenia as defined by CTCAE (2009) criteria (ANC, <0.5x109/L and fever, >38OC).  The 
median age of participants was 52 years.  Three hundred and thirty one (44%) patients had a 
haematological malignancy, which reflects the population at risk of neutropenic sepsis.  The 
researchers identified patient indicators in the presence of fever, which predicted a low risk of 
complications from neutropenia.  Identified indicators were assigned integer weights, in order 
to calculate an overall risk index score which was subsequently validated.  Indicators included, 
being aged < 60 years (OR 2.45; 95% CI 1.51-4.10) and having a solid tumour (OR 5.07 95% CI 
1.97-12.95) as shown in figure 2.3.  Validation demonstrated, that a  score of >21 correctly 
identified patients at low risk of developing complications of neutropenic sepsis, with a 
positive predictive value of 91%, specificity of 68% (false positive) and sensitivity of 71% (true 
positive). 
 
Although the MASCC tool is not used to predict patients at high risk of developing neutropenic 
sepsis, the risk indicators do identify factors that may make certain patients a riskier group 
once they have it, such as being aged >60 years, having chronic obstructive airways disease, 
having a haematology malignancy, or having a previous fungal infection within the duration of 
chemotherapy.  Unsurprisingly, this suggests patients, who are less physically fit prior to 
developing neutropenic sepsis, are more likely to develop complications from it.  This finding is 
reflected in a later American retrospective study of over 40,000 hospital admissions across 115 
health centres, (Kuderer et al., 2006).  This study identified that overall hospital mortality rates 
from febrile neutropenia was 9.5% and that high mortality risk was related to having major 
patient co-morbidities, such as heart disease, cerebrovascular disease, lung disease, diabetes 
mellitus, peripheral vascular disease and liver disease.  Having no co-morbidities was 
associated with a 2.6% risk of mortality and one co-morbidity with a 10.3% risk.  Patients who 
had more than one major co-morbidity had a 21.4% risk of dying from neutropenic sepsis. 
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Figure 2.3. MASCC Risk index to identify low risk febrile neutropenia  
  (Klastersky et al., 2000).  For permission see appendix 2. 
 







Burden of illness 
    No or mild symptoms 












No hypotension Hypotension 5 7.62 2.91-19.89 






4 5.35 1.86-15.46 
Solid 
tumour/lymphoma or 






4 5.07 1.97-12.95 
No dehydration Hydrated 3 3.81 1.89-7.73 
Outpatients status at 
onset of fever 
Inpatient 
status 
3 3.51 2.02-6.04 
Age <60 years Age >60 years 2 2.45 1.51-4.01 
MASCC ( Multinational Association for Supportive Cancer Care) 
 
 
Taken together, the EORTC, ASCO and MASCC guidelines (table 2.6) may provide useful 
information showing which patients are at higher risk of developing neutropenic sepsis or are 
more at risk of complications once this develops.  High level evidence suggests, important risk 
indices for neutropenic sepsis include, chemotherapy drugs that have a >20% risk of causing 
neutropenia and advanced cancer (Aapro et al., 2011, Aapro et al., 2006).  In addition, high 
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level evidence suggests, patients who are aged >65years are at greatest risk of developing 
neutropenic sepsis (Smith et al., 2006, Aapro et al., 2006, Aapro et al., 2011).  Patients aged > 
60 years or who have co-morbidities, are further more likely to develop complications from 
neutropenic sepsis (Klastersky et al., 2000).  Such information should influence communication 
with patients about the risks of neutropenic sepsis.  Targeted information and monitoring 
towards those at greatest risk will be observed for within the current study. 
 
 
Table 2.6.   High level evidence for neutropenic sepsis risk factors  
 Risk factor for developing 
neutropenic sepsis 
Increased risk of morbidity 
and mortality  
Chemotherapy regimen 
with 20% risk of 
neutropenia 
EORTC (level one evidence) 
ASCO (high level evidence 




Age >65 years   
EORTC (level one evidence).  
ASCO (high level evidence)  




 MASCC (OR 5.07) 
Advanced disease EORTC (level one evidence) 
ASCO (high level evidence) 
from clinical trials) 
 
Co-morbidities  MASCC COPD (OR 5.35)  
Kuderer et al (2007) 
(% Mortality + 95% CI) 
0   2.6.   + 0.2 
1   10.3 + 0.5 
2   21.4 + 1.1 
3  38.6  + 2.3 
4  50.6  + 5.3 
No antibiotic 
prophylaxis  
EORTC (level one evidence)  
References: MASCC  (Klastersky et al., 2000); EORTC (Aapro et al., 2006; 2011); ASCO 
(Smith et al., 2006). 
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2.2.2 Theme two: Symptoms of neutropenic sepsis that patients should report to clinicians 
Clinicians want patients to identify changes in symptoms and functioning that possibly indicate 
neutropenic sepsis, and report these changes promptly in order to reduce morbidity and 
mortality.  Seven low quality studies, that used convenience sampling, unsurprisingly suggest 
worsening neutropenia is associated with worsening physical and social functioning and 
symptom severity.  Researchers have also developed scales suggesting symptom and function 
changes that indicate neutropenic sepsis.  Importantly, these scales are designed to assist 
clinicians to identify neutropenic sepsis, rather than patients.  Furthermore, there is a lack of 
evidence required to give definitive guidance regarding the degree of fever, or the associated 
symptoms indicating risk of neutropenic sepsis.  Sources of infection are often not isolated and 
suggested symptoms of neutropenic sepsis are varied, and many - including diarrhoea and 
mucositis - are expected side effects of chemotherapy.  These can occur in the absence of 
neutropenia.  Evidence does exist for later signs and symptoms of septic shock, which include 
hypotension, high or low temperature, reduced urine output, confusion, unconsciousness and 
oedema.  These symptoms are associated with delayed presentation and poor outcomes 
(Malik et al., 2001).  There is consequently, a lack of evidence to support communication with 
patients and carers about early symptoms of neutropenic sepsis to report before these 
become more serious.  Furthermore, patients may become confused by warnings of differing 
and multiple symptoms to look out for, which may or may not be important in determining the 
presence of neutropenic sepsis (NICE, 2012). 
 
2.2.2.1 Effects of neutropenic sepsis on symptoms and functioning 
Researchers from Memphis University attempted to understand the effects of different grades 
of chemotherapy-induced neutropenia (CTCAE, 2009) on symptoms and functioning.  Two 
questionnaire based studies (Fortner et al., 2005a, Fortner et al., 2006) and a third qualitative 
interview study (Fortner et al., 2005b) attempted to understand the effects of worsening 
neutropenia.  Findings across these studies suggest that reduced physical and social 
functioning is associated with worsening neutropenia. However, the studies are limited 
methodologically (e.g. use convenience samples, small sample sizes and exclude those 
prescribed G-CSF and chemotherapy regimens, with low risk indices for neutropenia).  These 
limitations, and thereby the poor internal and external validity, reduce confidence in the 
findings.  Consequently, changes in symptom and function identified within these studies 
cannot be confidently attributed solely to worsening neutropenia, or generalised to other 
patients who are at risk of developing neutropenic sepsis during cancer chemotherapy.   
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These longitudinal studies (Fortner et al., 2005a, Fortner et al., 2005b, Fortner et al., 2006) 
employed similar methodologies, including convenience sampling of patients with varied 
cancer diagnoses, undergoing a range of chemotherapy treatments likely to cause 
neutropenia.  Grades of neutropenia were identified through blood tests, temperature 
readings and clinical assessments carried out at key points during the first 21 days of 
chemotherapy treatment.  Grades were defined, according to the previously mentioned 
Common Terminology Criteria for Adverse Events (CTCAE) (US Department of Health and 
Human Sciences, 2009).  Grade one (mild) and grade two (moderate) neutropenia, do not 
require medical treatment.  Grade three (severe) febrile neutropenia and grade four (life 
threatening) neutropenia or neutropenic sepsis and septic shock (CTCAE 2009) require urgent 
treatment with intravenous antibiotics.    
 
The initial longitudinal questionnaire single site study (Fortner et al., 2005a), found that 
patients (n=71) with grade four neutropenia were more likely to report increased bodily pain, 
less improvement in anxiety and reduced interest and participation in social activities, than 
those with grades 0-3 neutropenia.  The second multicentre study (n=84) (Fortner et al., 2006), 
reported significantly worse scores for patients with grade 3-4 neutropenia, than those with 
grades 0-2 neutropenia, for physical symptom distress, overall valuation on life, depression 
and isolation.  Results from both studies, should be viewed with caution, though as sampling 
strategies, including power calculations and response rates are not clearly described.  
Participant numbers are small, which means the studies are likely to be underpowered.  This 
may be further compounded within the second multicentre study (Fortner et al., 2006), as the 
clustering design (shared characteristics of patients and clinical practice, within each of the 
nine included healthcare settings) would have required an increased sample size, to be 
adequately powered.  The precision of effect sizes (size of the difference in symptom severity 
between grades of neutropenia) is difficult to interpret, due to the authors omitting 
confidence intervals.  Type two errors are likely, which mean non-significant findings may 
actually be significant.  Regardless, the effect sizes were small for most statistically significant 
findings across both studies e.g. bodily pain (0.37) (Fortner et al., 2005a), so may not be 
clinically meaningful.  A potentially important (though unsurprising) finding was the large 
effect sizes identified within the second study (Fortner et al., 2006) for reduced physical and 
social functioning. Patients who developed grades 3-4, compared to those with grades 0-2 
neutropenia had significantly worse physical and social functioning scores (Physical functioning 
grade 0-2 adjusted mean 1.59 (standard error 6.91) grade 3-4 adjusted mean -8.70 (7.42); 
Social functioning grade 0-2 adjusted mean 10.80(8.20) grade 3-4 adjusted mean -1.12(8.64). 
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The third study (Fortner et al., 2005b) was a qualitative study comprising 100 interviews with 
34 patients, who developed grade four neutropenia during their first cycle of chemotherapy.  
Interviews were provisionally scheduled for days 7, 10, 14 and 21 following chemotherapy but 
were commenced at the point patients developed grade four neutropenia.  Consequently, only 
data collected from patients who developed grade four neutropenia were included in the final 
analysis.  Fatigue was identified as the most frequent and overwhelming symptom of 
chemotherapy (n=31, 91%).  Over half the patients interviewed (n=19, 56%) noted their normal 
daily routine was interrupted as a result of chemotherapy treatment.  They reported a loss of 
usual roles, as they were unable to take part in normal physical and social activities that made 
life pleasurable.  Over a quarter of patients told interviewers they dreaded starting the next 
chemotherapy treatment and felt low as a consequence of chemotherapy side effects.  This 
study also identified physical symptoms in patients with grade four neutropenia including: 
muscle aches, feeling achy or swollen joints (n=13, 38%) pain (n=10, 29%) and cough, sore 
throat, mucous in throat or difficulty swallowing (n=8, 24%).  This study may be criticised 
because interviews only took 20 minutes, which is unlikely to have been long enough to 
capture an in-depth picture of significant issues for patients.  Furthermore, it is not clear from 
the report, what training was provided for the psychology students who conducted the 
interviews, the questions asked, whether these were open or closed for example or how 
consistency between interviews was ensured.  The researchers also did not include interview 
data from patients with different grades of neutropenia, so it is not possible to attribute 
identified changes in symptoms and functioning solely to grade four neutropenia. 
 
Although the University of Memphis series of studies suggest an unsurprising association, 
between worsening symptoms and functioning and worsening neutropenia, they do not 
provide evidence of specific symptoms associated with grades three and four neutropenia that 
patients need to recognise and report urgently to clinicians.  In addition to limitations posed by 
convenience sampling, most participants were white, highly educated women, usually with a 
diagnosis of lung or breast cancer.  Patients admitted to hospital with neutropenia, who would 
be the most unwell, were further under represented.  The authors did not explore symptom 
clustering in relation to neutropenia.  They failed to discuss possible reasons for psychological 
symptoms associated with declining ANC, which may in part relate to neutropenic imposed 
isolation and treatment delays, rather than an intrinsic aspect of neutropenia.   
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2.2.2.2 Can knowledge about presenting symptoms of neutropenic sepsis assist in early 
identification?  
Researchers have identified symptoms in patients who present to hospital with neutropenic 
sepsis.  They have also developed scales based upon symptom clusters that aim to assist 
clinicians to diagnose neutropenic sepsis.  This evidence is unlikely to assist patients to identify 
early symptoms of neutropenic sepsis.  This is because studies lack internal and external 
validity.  Neutropenic symptom scales have been developed for clinician, rather than patient 
use and interpretation, through the use of technical terms, definitions and measures.  
Furthermore, there is lack of consensus regarding the body temperature that indicates a risk of 
neutropenic sepsis.  Other proposed associated symptoms cannot be distinguished from the 
expected side effects of chemotherapy for everyone.  High quality evidence does identify later 
and more serious symptoms of septic shock. 
 
Only one small UK study (Higgins and Hill, 2012) presents body temperature in patients 
diagnosed with neutropenic sepsis.  This study reports on an audit of a neutropenic sepsis 
clinical pathway across a cancer network, using a review of 88 patient admissions to hospitals 
over a period of six months.  Presenting temperatures were found to range from below 36oC to 
40oC, with the majority of patients having a temperature between 37.5oC and 40oC.  This 
suggests the focus of a temperature of around 38oC, as cited within definitions of neutropenic 
sepsis (US Department of Health and Human Sciences, 2009, NICE, 2012), as an indicator to 
patients of neutropenic sepsis may not be reliable. 
 
Two further studies report the symptoms of neutropenic sepsis that patients present to 
hospital with (Nirenberg et al., 2004, Okera et al., 2011).  Researchers within the UK, studied 
71 patient admissions to hospitals with neutropenic sepsis, involving 64 patients (Okera et al., 
2011).  The researchers found that patients presented with the following key infection related 
symptoms: respiratory (49%); gastrointestinal (46%); and mucositis (18%).  More female (59%) 
than male (41%) patients with a range of cancer diagnosis were reviewed.  The median age 
was 60 years (20-78 years).  Four deaths occurred, three of which were related to neutropenic 
sepsis.  Demographics, such as ethnicity and socioeconomic status are not stated within the 
paper, so results may not be generalisable to different socio-cultural communities.   
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A second prospective descriptive study of a small number of patients (n=19), who presented to 
American emergency departments with febrile neutropenia following chemotherapy, 
identified seven (37%) who experienced mucositis, and 11 (58%) who had a central venous 
access device (CVAD) in situ, which may have represented a source of infection.  Participants 
included equal numbers of male and female and Caucasian and non Caucasian patients 
(Nirenberg et al., 2004).   
 
Difficulties with capturing the data for all episodes of neutropenic sepsis, including 
inconsistencies in definitions, are likely to have affected internal and external validity of 
findings, across these studies.  Okera et al., (2011) were unable to identify patients admitted 
with neutropenic sepsis to hospitals, outside the cancer network.  Nirenberg et al., (2004) 
could not capture episodes, where patients presented directly to doctors, who took their own 
night calls.  Higgins and Hill, (2012) acknowledge problems with data collection.  Further, it was 
unclear how patients were identified for inclusion in their study.    
 
Suggested symptoms of neutropenic sepsis are further detailed within the Patient Care 
Monitor Neutropenia Index (PCM-N) (table 2.7).  This was developed by the Memphis 
University researchers, on the basis of previously mentioned studies, in an attempt to measure 
differences between grades of neutropenia.  The PCM-N quality of life tool was designed to 
measure 13 symptom and function changes associated with neutropenia.  The PCM-N was 
developed from items within a database of symptoms present in patients, who developed 
neutropenia (approximately 10,000 observations), a literature review and expert opinion.  
Thirteen items for the PCM-N scale were generated and patients scored items on a tablet 
computer, out of 10, with a score of 0 meaning no problem and a score of 10 being the worst 
case scenario.  Scores range from 0-130, with higher scores being correlated with increased 
symptom and functioning burden associated with neutropenic sepsis (Fortner and Houts, 
2006, Olsen et al., 2011).   
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Table 2.7. Items on the Patient Cancer Monitor 1.0 Revised Neutropenia 








Fatigue, tiredness, or weakness 0.61 0.81 0.663 
Trouble with bowel movements (e.g. 
diarrhoea, constipation) 
0.49 0.83 0.503 
Sore throat or trouble swallowing 0.53 0.82 0.645 
Reduced sexual enjoyment, interest or 
performance 
0.38 0.84 0.424 
Trouble sleeping 0.53 0.82 0.576 
Nausea or vomiting 0.54 0.82 0.621 
Numbness or tingling 0.47 0.83 0.479 
Dry mouth 0.61 0.82 0.695 
Loss of interest in people he or she used 
to want to be around 
0.47 0.83 0.482 
Fever or chills 0.54 0.82 0.653 
Swollen glands 0.4 0.83 0.493 
Headache 0.46 0.83 0.705 
Mouth sores 0.39 0.83 0.529 
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2.2.2.3 Validation of the PCM-N 
 
Two studies report use of the PCM-N.  In the first study, Fortner and Houts (2006) extrapolated 
patient (n=51) self-report symptom data from the PCM-N index.  This was correlated with 
absolute neutrophil counts (ANC data).  Key results indicated that PCM-N identified symptom 
burden scores, were higher in patients with grade 3-4 neutropenia (n=24), than those with 
grades 0-2 neutropenia (n=27).  Results should be viewed with caution because these are 
based on a small sample.  Only 51 out of 741 (7%) consented eligible patients could be 
included in the study, due to incomplete data in the remaining cases.  This low response rate is 
not explained by the authors, but may indicate lack of acceptability of the scale to patients, 
and/or difficulty in capturing data at pre-determined time frames.  The small sample size 
means, that the study may have been underpowered, to detect other significant findings.  
Furthermore, details were not provided about who collated the data.  The quality control may 
have been compromised, if multiple coders were involved.  The tool does not include ‘anchors’ 
or descriptions of scores for each level, on the scale to help ensure reliability between 
different raters. 
 
Within a second study, Olsen et al., (2011) gathered data from four samples, one of which was 
the sample from the study described above (thereby the same methodological limitations 
were applied).  The researchers pooled the samples (n=424) to test the psychometric 
properties of the PCM-N.  As with previous Memphis studies, this demonstrated an association 
between worsening neutropenia and worsening symptoms.  The PCM-N demonstrated 
discriminant validity in terms of being able to distinguish between patients with grades 3-4 
neutropenia and those with grades 0-2 neutropenia (p<0.05).  The researchers also tested the 
internal consistency of the scale in each of the four samples.  They found strong internal 
consistency (0.81-0.91).  This suggests it is an internally valid model. 
 
One way ANOVA was applied to sample four (n=90), to compare PCM-N scores for three 
differently graded neutropenia status groups (febrile neutropenia, non febrile neutropenia and 
no neutropenia).  The result showed, that there were differences between the groups (F [2, 87] 
=44.67, P<0.001).  Tukey post hoc comparisons (conducted to identify where the differences 
lay) demonstrated poorer scores in both neutropenia groups than the non neutropenic group.  
Patients with febrile neutropenia had poorer scores than non febrile neutropenic patients.  In 
order to determine the accuracy of the PCM-N, the authors also conducted a Receiver 
Operator Characteristic (ROC) analysis, in combination with Youden’s index scores with sample 
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four, to determine the most psychometrically robust threshold score.  Results suggest that a 
score of 20 (out of 130) or higher is sensitive to 81% of patients with neutropenia (febrile 
neutropenia or non febrile neutropenia) and 78% of patients who did not have neutropenia 
(sensitivity, true positives 81% and specificity, false positives 22%).  Because the study was 
designed to test the PCM-N psychometrics, no details of frequency of symptoms experienced 
or clusters of symptoms, at different grades are reported.   
 
In summary study findings indicate that the PCM-N tool could have good sensitivity/specificity 
for identifying patients requiring treatment for neutropenic sepsis.  In addition, the research 
that informs the PCM-N suggests neutropenic sepsis presents, as a complex profile of 
symptoms that all contribute to one overriding factor (neutropenic sepsis).  It may be the 
severity of symptom clusters that are important indicators of it, rather than individual 
symptoms.   
 
The FACT-N (Wagner et al., 2008) is another patient self-report tool,  designed to  measure 
patient symptoms related to neutropenia.  The 19 items for the FACT-N were generated 
through patient and clinician interviews and subsequent identification of items perceived to be 
important from an existing bank of cancer symptoms.  Although a study (Wagner et al., 2008) 
suggested the FACT-N may be sensitive to the presence of neutropenia, the researchers were 
unable to demonstrate the ability of it to distinguish between grades of neutropenia.  This is 
likely to be important to patient symptom reporting because patients need to understand, 
which symptoms indicate neutropenic sepsis.  The PCM-N appears to be a more clinically 
applicable and robust tool than the FACT-N because this is able to distinguish between grades 
of neutropenia.  The PCM-N is though, only able to identify general changes associated with 
grade three and four neutropenia, rather than specific symptoms.  It does not help identify 
early symptoms which should be highlighted to patients.  Furthermore, it was designed for 
clinicians to interpret, so the acceptability of it as a tool to assist patients in recognising, when 
they need to contact clinicians remains unknown. 
 
2.2.2.4 Signs and symptoms of life threatening neutropenic sepsis / septic shock  
Neutropenic sepsis is life threatening once this progresses to CTCAE grade four neutropenia, 
also defined as severe sepsis and septic shock (US Department of Health and Human Sciences, 
2009; NICE, 2012; Dellinger et al., 2012, UK Sepsis Trust, 2013).  In terms of worsening 
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prognosis NICE (2012) found low level evidence of symptoms related to patients with fever 
and neutropenia that predict poor outcomes, including death, need for critical care, having 
unresolved fever and bacteraemia.  Specific symptoms identified with poorer prognosis 
included: mucositis, feeling generally unwell (which fits MASCC’s identification of symptom 
burden as a prognostic factor for complications), temperature over 39oC, clinical signs of 
infection, chills and confusion.  NICE (2012) found no evidence for flu-like symptoms (e.g. 
aching and feeling hot and cold), rigor, diarrhoea, vomiting or carer worry, as predicting poorer 
outcomes from neutropenic sepsis.  A further prospective study conducted over five years in 
Pakistan (Malik et al., 2001), identified symptoms associated with neutropenia induced septic 
shock.  The researchers reviewed 576 episodes, where adult patients over 16 years presented 
to hospital with neutropenic sepsis.  The researchers identified 22 (3.8%) of the 576 patient 
episodes related to septic shock.  They compared outcomes for this group with the remaining 
patients with neutropenic fever, who did not develop septic shock.  Significant symptoms of 
septic shock were reported as diarrhoea, altered mental state, bleeding, and dyspnoea.  The 
effect sizes and their precision (confidence intervals) are not presented in the paper (only the P 
value is provided).  The comparison of 22 (3.8%) with 544 (96.2%) neutropenic sepsis 
admissions is likely to be underpowered to detect differences, so other clinically meaningful 
symptoms between the two groups may not have been statistically significant. 
 
2.2.2.5 Relevance of sepsis within the general population 
There appears to be a disconnect in the literature between studies that explore symptoms of 
neutropenic sepsis and studies that explore general clinical knowledge about the condition of 
sepsis, which can arise in cancer and non cancer populations.  Patient information about 
symptoms associated with worsening sepsis, has been developed by the UK Sepsis Trust (2012) 
(table 2.8).  Many of these symptoms have been reported within studies examining the 
presenting symptoms of neutropenic sepsis, reported in this chapter.  High quality quantitative 
and qualitative studies are required, to accurately and simply describe typical symptoms of 
neutropenic sepsis to help patients identify and promptly report it to clinicians.  It may, for 
example be important to identify if mucositis or difficulty eating, are early indicators of 
neutropenic sepsis because these may be obvious early symptoms for patients to report.  It 







Table 2.8.   Symptoms of sepsis (The UK Sepsis Trust, 2012) 
 
Early symptoms  
 
As worsens  As progresses 
 Cold and shivery 
 Hot and flushed 
 High temperature  
 Aching muscles 
 Tired 
 Nausea  and vomiting  
 Not feeling like eating 
 Confusion / slurred speech  
 
 Low blood pressure 
 Fast pulse rate 
 Shortness of breath  
 Skin; cold, pale, 
mottled, hot or flushed  
 Lower blood pressure  
 Reduced urine output 
 Worsening shortness of breath 
 Darkening and blistering skin 




2.2.3 Theme three: Knowledge about delayed patient presentation to hospital with 
neutropenic sepsis. 
Neutropenic sepsis is a dangerous side effect of chemotherapy.  CTCAE grade four  
neutropenic sepsis (severe sepsis or septic shock), which manifests through organ failure and 
tissue hypoperfusion (Dellinger et al., 2013) is associated with late identification and treatment 
of neutropenic sepsis and increased risk of death (National Confidential Enquiry into Patient 
Outcome and Death, 2008).  A study carried out in Pakistan (Malik et al., 2001) reported that 
82% of patients who developed septic shock from neutropenic sepsis died, mostly within 72 
hours of hospital admission.  Within the UK, the mortality rate for those developing sepsis 
within the general population is 30%.  For septic shock this rises to 50% (Bernard et al., 2001).  
Furthermore, each hour of delayed treatment with intravenous antibiotics for septic shock is 
associated with an 8% increase in mortality (Kumar et al., 2006).  The literature regarding safe 
management of neutropenic sepsis is focused on early intervention with intravenous 
antibiotics, to be given within one hour of patients presenting to hospital, if neutropenic sepsis 
is suspected.  Indications for administration of intravenous antibiotics before the neutrophil 
count is known include recent treatment with chemotherapy, a temperature over 38oC and 
other clinical symptoms of sepsis (NICE, 2012).   
 
There is also an under researched clinical concern that late reporting of neutropenic sepsis 
arises, despite clinicians thinking they convey risks of this, and actions to take if symptoms of it 
develop (including providing patients with 24-hour on-call telephone numbers) (Nirenberg et 
al., 2004).  At the outset of this study no research could be identified that specifically explored 
why patients delay presenting to hospital when they develop neutropenic sepsis.  Some 
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studies provide data that suggest such delays may range between 24-hours and seven days 
(Malik et al., 2001, Nirenberg et al., 2004, National Confidential Enquiry into Patient Outcome 
and Death, 2008, McKenzie et al., 2011, Royal College of Physicians, 2012, Higgins and Hill, 
2012).  A retrospective UK study published by the National Confidential Enquiry into Patient 
Outcomes and Death (NCEPOD 2008) investigated deaths following chemotherapy 
administration and identified areas of poor practice in relation to neutropenic sepsis.  Data 
collected within this study included an organisational questionnaire, which was completed by 
each hospital, who declared themselves as systemic anti-cancer treatment (SACT) providers.  
This identified staffing numbers, facilities and local protocols relating to neutropenic sepsis.  
Data were also collected on patients who were treated with SACT over a two month period 
and who had died within 30 days of treatment.  Patient case notes were reviewed and two 
questionnaires were completed for each identified patient.  The first questionnaire related to 
the treatment plan and chemotherapy administration and was completed by the treating 
consultant.  The second questionnaire related to follow up, toxicity and death.  It was 
completed by the consultant responsible for the care of patients who died as inpatients or by 
the treating consultant where patients died in the community.    
 
Evidence was reviewed by a multidisciplinary expert advisory group which included haemato-
oncologists, medical and clinical oncologists, a palliative care doctor, pharmacists and 
chemotherapy nurses.  Quantitative data were analysed descriptively, using Microsoft Access 
and Excel.  Qualitative data, from questionnaires were coded and reviewed by NCEPOD staff to 
identify recurring themes.  Of 546 cases reviewed during the NCEPOD enquiry, 83 patients 
developed neutropenic sepsis and all were admitted to hospital.  The report identified that 
some patients delayed presentation to emergency departments with severe, classified as 
CTCAE grade three or four, symptoms of neutropenic sepsis by at least 24-hours.  Although 
data on the number of patients who delayed is not presented, this is a valuable report which 
provides the first indication in the UK that some patients delay presenting to hospital with 
neutropenic sepsis.   
 
Further studies also provide data, which demonstrates that some patients present late to 
hospital with signs and symptoms of neutropenic sepsis.  A prospective descriptive American 
study (Nirenberg et al., 2004) found that 23 patients admitted to the emergency department 
and diagnosed with neutropenic sepsis had been aware of a fever for a mean of 21-hours 
(range 1-72) before seeking help from clinicians.  Delayed patient presentation with signs and 
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symptoms of neutropenic sepsis, were also noted by Higgins and Hill (2012) during the 
previously mentioned retrospective audit of a UK cancer network neutropenic sepsis clinical 
pathway.  A case note review (n=88) revealed 30% of patients admitted to hospital with 
neutropenic sepsis, waited for over 24-hours before presenting to hospital.  A subsequent 
patient survey was sent, although this did not ask about delayed presentation/reporting of 
symptoms.   
 
A further patient survey (n=262) about acute oncology care (Royal College of Physicians, 2012), 
identified patients who delayed presenting to hospital with a range of conditions for two days 
or more.  This included patients who were subsequently diagnosed with neutropenic sepsis, 
although the number of patients this related to is not provided within the report. Interestingly, 
patient delays for a variety of cancer related conditions occurred despite 90% of respondents 
indicating they had been informed about chemotherapy symptoms to report (although their 
knowledge was not tested), and were provided with helpline numbers.  A final Australian 
retrospective study (McKenzie et al., 2011) explored the nature and occurrence of unplanned 
admissions to hospital over one year amongst patients treated with chemotherapy for a solid 
tumour within the previous six months.  Results suggested that 316 patients made 469 
unplanned visits to the cancer centre or emergency department.  Of these 233 patients 
(73.7%) accounted for 363 admissions to hospital.  23.4% of admissions were related to fever 
or febrile neutropenia.  Of all patients presenting to hospital, the mean age was 58.9 years, 
with equal numbers of male and female participants presenting.  The most common 
malignancies were breast, lung and colorectal.  The authors found that patients with a range of 
symptoms, frequently delayed presenting between two and seven days but as with the 
previous study, the finding was not specific to neutropenic sepsis.   
 
In terms of riskier groups, patients with co-morbidities or advanced cancer were suggested in 
one study to wait longer than other patients to present to hospital with neutropenic sepsis 
(Nirenberg et al., 2004).  A further study (Malik et al., 2001) identified cancer patients who 
presented to hospital with septic shock (CTCAE grade four neutropenia) as having advanced 
disease and being significantly older than patients with febrile neutropenia (CTCAE grade three 
neutropenia).  Together this research (Malik et al., 2001, Nirenberg et al., 2004) suggests that 
being older and having reduced functionality may be risk factors for patients delaying 
presenting to hospital with neutropenic sepsis. 
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The research carried out in Pakistan (Malik et al., 2001) also identified that patients in septic 
shock tended to present to an emergency department (Malik et al., 2001).  This appears similar 
in the UK.  The NCEPOD (2008) study that reviewed the care of patients who died within 30 
days of chemotherapy (including deaths from neutropenic sepsis) found the majority of 
patients admitted to hospital initially presented to A&E departments.  Within the study 
conducted by Malik et al, (2001) the mean duration of fever before admission (standard 
deviation in brackets) was reported to be 9.2(17.6) for the septic shock and 3.1(5.2) for the 
non septic shock group (Malik et al., 2001).  This suggests there may be an association 
between delayed presentation to hospital and septic shock.  It is not clear from the research 
paper, however, if this data refers to hours or days and attempts to clarify this with the 
researchers have not been successful.  As previously mentioned, this study was likely to be 
underpowered to detect smaller effect sizes that may also be clinically meaningful.   
 
These findings concur with level one evidence cited earlier within this chapter that patients 
who are older, or have advanced disease are at higher risk of developing neutropenic sepsis 
(Smith et al., 2006, Aapro et al., 2011).  Furthermore, increased morbidity and mortality in 
patients who develop neutropenic sepsis following chemotherapy is related to age > 60 years 
(Klastersky et al., 2000) and the presence of co-morbidities (Klastersky et al., 2000, Kuderer et 
al., 2006).  Within the general population, patients aged > 65 years also experience worse 
outcomes from sepsis, than younger patients (The UK Sepsis Trust, 2013). 
 
Across these studies, most patients presented with neutropenic sepsis within 10-14 days of 
chemotherapy either direct to oncology, haematology or emergency departments.  Prior to 
conducting the study presented in this thesis, reasons for delays had not been systematically 
studied.  Assumptions within studies include information about neutropenic sepsis solely being 
provided to patients at the start of chemotherapy (NCEPOD, 2008), patients not understanding 
the urgency for reporting neutropenic sepsis symptoms, and/or poor explanations of 
neutropenic sepsis by clinicians (NCEPOD, 2008, Higgins and Hill, 2012).  Further assumptions 
for patient delays, include: (1)  that they were too unwell to go to hospital (Malik et al., 2001, 
Royal College of Physicians, 2012); and (2) not wanting to bother clinicians or to go to hospital 
when they developed neutropenic sepsis (Nirenberg et al., 2004, McKenzie et al., 2011).  
Provider delay, was also identified as an issue by The Royal College of Physicians (2012) who 
found patients sometimes made contact with clinicians, who themselves failed to recognise 
the importance of symptoms of neutropenic sepsis at an early stage. 
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2.2.4 Theme four: Education of patients about neutropenic sepsis. 
This chapter has identified that some patients may be at greater risk of developing 
neutropenic sepsis depending on treatment and patient factors.  Particular symptom and 
functional changes may or may not indicate the presence of neutropenic sepsis.  Patients can 
present late with such symptoms, which increases the risk of septic shock and death.  The 
reasons for patient delays remain unknown.  Neutropenic sepsis further typically occurs when 
patients are at home.  Consequently, patients and their carers are responsible for recognising 
symptoms of this in order to promptly report these to the hospital.  The National 
Chemotherapy Advisory Group (NCAG, 2009) responded to concerns highlighted within the 
NCEPOD (2008) report, that greater attention should be paid to education, to prepare patients 
to recognise and report symptoms of neutropenic sepsis by advising: 
 
All patients should be given both verbal and written information about their 
treatment, likely side effects and whom they should contact if problems arise 
(either within or outside normal working hours).  All patients should have access to 
24-hour telephone advice with active management of access to appropriate 
emergency care.                             (NCAG, 2009; p6) 
 
Consequently, patients in the UK are required to have access to 24-hour on-call services, if 
they are at risk of developing neutropenic sepsis as a result of oncology treatment, according 
to standards set out through a peer review process (NICE, 2012, National Cancer Peer Review - 
National Cancer Action Team (NCAT), 2011). Further, newer acute oncology standards requires 
emergency cancer services to be provided for patients, who become unwell due to cancer or 
cancer treatments, including those who develop neutropenic sepsis (National Cancer Peer 
Review - National Cancer Action Team (NCAT), 2013).  Patients are typically given information 
about how to recognise and report symptoms of neutropenic sepsis when a doctor takes 
written consent for chemotherapy and during a chemotherapy nurse led pre-treatment 
consultation.  Importantly, the rationale for timing of information delivery about neutropenic 
sepsis is not evidence based.  Twenty-four hour on-call telephone numbers are provided for 
patients, further information about neutropenic sepsis may be given at subsequent visits and 
obtained by patients and carers via other sources, such as the internet (Higgins, 2008, NCAG, 
2009).  Patients who develop symptoms of neutropenic sepsis, may subsequently present to 
A&E departments or direct to acute oncology services.   
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Clinicians consider supporting patients, to recognise and report neutropenic sepsis to be an 
important part of their role (Nirenberg et al., 2006b, Nirenberg et al., 2010).  The American 
Oncology Nursing Society explored nursing knowledge and practice in relation to the 
management of patients with neutropenic sepsis within two studies (Nirenberg et al., 2006b, 
Nirenberg et al., 2010).  The first study  (Nirenberg et al., 2006b) was based on a review of 
available literature and neutropenic sepsis management guidelines from hospitals across 
America, which were discussed at an oncology nursing symposium.  Within the subsequent 
study, Nirenberg et al., (2010) aimed to describe oncology nurses use of National 
Comprehensive Cancer Network (NCCN) clinical practice guidelines for chemotherapy induced 
neutropenia, and to test their knowledge of evidence based standards.  A cross sectional, 
purposive sample (n=309) of members of the oncology nursing society (N=3,834), completed a 
web based questionnaire.  Both studies indicate that oncology nurses viewed themselves as 
playing a role in educating patients about neutropenic sepsis and Nirenberg et al., (2010) 
found 84% of surveyed oncology nurses believed they had a professional obligation to 
undertake risk assessments and to deliver patient education to help patients identify and 
report symptoms of neutropenic sepsis. 
 
In terms of perceived nursing confidence and competence most respondents within the 
second study (Nirenberg et al., 2010) indicated they felt able to identify patients at risk of 
developing neutropenic sepsis (97%) and that they provided instructions for patients about 
post chemotherapy home care (98%).  Knowledge scores were generally high.  Experienced 
nurses with advanced qualifications had significantly higher perceived confidence and 
competence scores (certification, None 13.5 SD 2.1; General 14.9 SD 1.5; Advanced 15.7. SD 
0.8) and were more likely to answer questions correctly.  Sampling bias is though, evident, 
which means the population is under represented: only 8% of the population sample 
responded, who were more highly educated and experienced than average oncology nursing 
society members.   
 
Importantly, although nurses may feel confident in preparing patients for the possibility of 
neutropenic sepsis, NICE - within evidence based guidance (NICE 2012) - point to a lack of 
evidence for interventions to assist patients with this process.  This includes, as identified 
earlier in this chapter, poor evidence for symptoms of neutropenic sepsis.  Consequently, it is 
unsurprising that Nirenberg et al (2006b) found a lack of nursing knowledge to guide the 
education of patients about neutropenic sepsis.  Nirenberg (2006b) identified vast 
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inconsistencies across neutropenic sepsis patient management guidelines, including in relation 
to the symptoms of neutropenic sepsis and the severity of these that patients should seek 
support for.  A key and important inconsistency, concerns the level of fever that patients 
should report, which reflects a lack of scientific knowledge regarding body temperature 
indicative of neutropenic sepsis (Nirenberg et al., 2006b, NICE, 2012).  Poor knowledge to 
identify symptoms of neutropenic sepsis is also evident within chemotherapy patient 
education literature.  An example is information provided for patients and carers on the UK’s 
Macmillan Cancer Support website at www.macmillan.org.uk (Macmillan Cancer Support), 
who advise patients to contact a clinician simply if they develop a temperature above 38oC or if 
they suddenly feel unwell, even with a normal temperature.  Importantly, Nirenberg et al 
(2006b) also identified that only 39% of nurse respondents indicated they knew that the risks 
of patients developing neutropenic sepsis are higher during the first chemotherapy cycle; 
which the authors state is knowledge that may be of use when educating patients and families 
at the start of treatment. 
 
In addition to poor evidence on which to base neutropenic sepsis symptom advice, 
interventions commonly used to support patients undergoing chemotherapy (such as patient 
information, DVDs and newer telephone based chemotherapy symptom logging systems) have 
not been evaluated in relation to promoting early patient presentation with symptoms of 
neutropenic sepsis.  Suggested verbal or written approaches to assist patients to present early 
with symptoms of neutropenic sepsis are also not research based.  These include explaining 
the risks and consequences of neutropenic sepsis, the reason for early treatment with 
antibiotics and who to call if symptoms of neutropenic sepsis occur (Nirenberg et al., 2004, 
Nirenberg et al., 2006a, NCAG, 2009).  Some authors argue that proactive monitoring and 
support should be provided for patients at home, in order to help them manage symptoms of 
chemotherapy, (Nirenberg et al., 2010, NCAG, 2009).  As with other interventions the impact 
of this on the reporting of neutropenic sepsis remains unknown. 
 
It can be inferred from NCAG guidance (2009), that provision of 24-hour on-call services for 
patients undergoing chemotherapy will promote early patient presentation and treatment for 
neutropenic sepsis.  Only one small UK questionnaire study (Higgins, 2008) evaluated an 
intervention based upon this type of service.  This study explored patient experience with a 
chemotherapy alert card, linked to a specialist 24-hour on call service.  One side of the alert 
card provided details of symptoms for patients to report urgently and the other side of the 
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card provided clinical management advice for clinicians.  The questionnaire contained nine 
multiple choice questions and three open questions.  This focused on what patients found 
most helpful and unhelpful about the alert card, with space for other comments.  Fifty seven 
patients returned the questionnaires from three hospitals within one cancer network.  Most 
respondents (89%) said they had been provided with the alert card and 82% said they carried it 
with them at all times.  Patients found it reassuring to have the card, which made them feel 
safe.  The study sampling frame is not described and therefore the response rate is unclear.  
Further, the focus is on acceptability of the alert card to patients and not on their use of it.  
Consequently, the impact of the alert card and availability of 24-hour helplines on promoting 
early presentation with neutropenic sepsis remains unknown.   
 
2.3 Chapter conclusion 
In conclusion, limited evidence suggests patients sometimes delay contacting clinicians, when 
they develop neutropenic sepsis and the extent and reasons for this behaviour are unknown.  
Clinicians are likely to struggle to communicate clearly with patients about the symptoms of 
neutropenic sepsis, because there is no consensus on the early indicators of it.  Consequently 
and importantly, patients are likely to be confused about which symptoms they should expect 
following chemotherapy and those that may indicate neutropenic sepsis and should be 
reported to clinicians urgently.  The lack of evidence to help clinicians convey to patients, how 
they are likely to feel during a neutropenic sepsis episode, led NICE (2012) to recommend a 
prospective study is carried out, to identify symptoms that predict neutropenic sepsis in 
patients in the community.  NICE (2012) further recommend that qualitative studies are 
conducted, to explore how effective information exchange between patients and clinicians 
about neutropenic sepsis may be achieved.  The study outlined within this thesis aims to go 
beyond NICE guidance to understand why patients delay reporting symptoms of neutropenic 
sepsis to clinicians and to identify potential factors that may encourage earlier presentation.  
These may then be explored through future intervention studies.  Within this study, close 
attention will be paid to how clinicians, patients and carers communicate about neutropenic 
sepsis and how clinicians draw upon available - albeit weak - knowledge about neutropenic 
sepsis symptoms, and on stronger evidence regarding risk factors to educate and support 
patients.   
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Chapter summary:   
Previous research has not studied how risks of neutropenic sepsis are communicated or why 
patients delay presenting to hospital when this occurs.  A scoping review of the literature 
synthesised knowledge about neutropenic sepsis, the risks of this to patients, reasons for 
delayed presentation and good practice in communicating risk.  The evidence was mapped 
within four themes, thought to be important to the research outlined within this thesis.  
Judgments about the strength of the evidence were made through application of the Critical 
Appraisal Skills Program (CASP) tool for reviewing qualitative research and the Quantitative 
Critical Review Form. 
 
Theme one identified neutropenic sepsis as a life threatening immunosuppressive 
complication of chemotherapy, which accounts for a significant number of high cost hospital 
admissions and at least two deaths each day within the UK (NICE, 2012).  Definitions of 
neutropenic sepsis differ, although distinctions are always made between early febrile 
neutropenia and later sepsis.  High level evidence suggests risk factors for developing 
neutropenic sepsis.  These include regimens with >20% risk of causing neutropenia, age > 65 
years and advanced disease (Smith et al., 2006, Aapro et al., 2011).  Furthermore age > 60 
years or the presence of co-morbidities is associated with an increased risk of complications 
once neutropenic sepsis develops (Klastersky et al., 2000).   
 
Studies reviewed within theme two do not identify symptoms of neutropenic sepsis that 
patients should look out for.  Evidence unsurprisingly, suggests declining physical and social 
functioning are associated with worsening neutropenia (Fortner et al., 2006).  More specific 
symptoms, that patients should recognise and report to clinicians, cannot be defined or 
distinguished from expected chemotherapy side effects (Olsen et al., 2011, Okera et al., 
2011).  These require further exploration through large high quality prospective cohort 
studies.  Stronger evidence exists regarding later symptoms of CTCAE grade four 
neutropenic sepsis (severe sepsis / septic shock), that include shortness of breath, oedema 
and confusion, but these are also associated with poorer clinical outcomes (Malik et al., 
2001, The UK Sepsis Trust, 2012, Dellinger et al., 2013). 
 
Theme three identified studies that suggest patients may delay presenting to hospital with 
symptoms of neutropenic sepsis by two days or more (NCEPOD, 2008; NCAG, 2009; 
Nirenberg et al., 2004; McKenzie et al., 2011; Royal College of Physicians, 2012).  The 
reasons for such delays remain unknown.  Weak evidence suggests, patients with advanced 
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disease (Nirenberg et al., 2004, Malik et al., 2011), or with co-morbidities (Nirenberg et al., 
2004) and those aged > 65 years (Malik et al., 2001), may delay reporting symptoms of 
neutropenic sepsis for longer and thus become more unwell than fitter or younger patients.  
This is a concern, as those who are most unwell or aged >65 years are at greatest risk of 
developing complications from neutropenic sepsis (Klastersky et al., 2000, Kuderer et al., 
2007).  Furthermore, worse symptoms on presentation represent a higher risk (Klastersky et 
al., 2000).  The patients who delay may be more likely to develop septic shock and die (Malik 
et al., 2001). 
 
There is concern within the literature that patients should be educated to report symptoms 
of neutropenic sepsis promptly and suggestions are made for improving patient education.  
The literature described within theme four, does not explore how clinicians communicate 
with patients about neutropenic sepsis, how they draw on available knowledge to support 
such consultations, or how successful different approaches to patient communication are, in 
terms of assisting patients to present early with signs and symptoms of neutropenic sepsis.  
Furthermore, there is a lack of evidence to underpin patient information about the 









































An aim of this study was to generate a deep understanding of communication events as 
shaped by patients, carers and clinicians to explore how such events related to patients 
reporting of neutropenic sepsis symptoms.  Communication within cancer settings should help 
patients to: deal with bad news and the emotional consequences of a cancer diagnosis, 
process complicated information, communicate and build trusting relationships with many 
clinicians, manage uncertainty whilst retaining hope, make treatment decisions and adopt self-
management behaviours (Epstein and Street, 2007, Venetis et al., 2009).  Despite a large body 
of research into cancer communication between patients and clinicians, it is suggested this 
remains the most poorly rated aspect of the doctor patient relationship (Epstein and Street, 
2007).  In addition, the focus of previous research is on communication between doctors and 
patients and neglects the impact of other members of the multidisciplinary team, including 
nurses (Arora, 2003, Marks and Evans, 2005).   
 
Outcome studies tend to focus on patient satisfaction with doctor’s communication behaviour, 
their understanding of information provided, perceived participation during consultations and 
adjustment to a cancer diagnosis (Epstein and Street, 2007).  There is limited evidence to 
understand the contribution of communication between patients and clinicians to longer term 
health outcomes such as adherence with treatment and alignment of clinician and patient 
communication goals such as both parties striving for an outcome of early reporting of 
neutropenic sepsis symptoms.  Theories and models of communication may be usefully 
applied to the study outlined within this thesis, to assist in understanding why patients may 
delay presenting to hospital with neutropenic sepsis. 
 
3.2 A framework for patient-centred communication in cancer care 
A key issue for communication research, is a paucity of theoretically based frameworks to 
underpin research methodologies (Arora, 2003, Epstein and Street, 2007).  This has resulted in 
researchers tending to, either develop tools for measuring patient perceptions of physician 
behaviour, without priori conceptual frameworks or beginning with predefined categories and 
labelling findings purely on empirically driven factor analysis (Arora, 2003).  A model of 
patient-centred communication in cancer care (PCC) produced by Epstein and Street (2007) on 
behalf of the National Cancer Institute (NCI) in America, was developed in an attempt to 
address such issues.  This framework includes mediating and moderating factors for patient-
centred communication and was developed through a systematic literature review, small 
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qualitative studies and extensive consultations with experts.  The PCC framework does not 
solely focus on outcomes in relation to clinician communication behaviours.  Rather the 
framework encompasses: 
 
...the patient, family communication as well as the clinicians and the qualities of 
the interaction itself that are jointly created by all parties...   
                  (McCormack et al., 2011, p. 1086) 
 
Crucially, this enables a distinction between assessments of communication encounters from 
evaluation of these.  This is important because what is viewed as a good communication 
encounter, for example through patient and clinician reports, may not be effective, in terms of 
health outcomes such as early reporting of neutropenic sepsis.  This phenomenon was seen in 
the field of diabetes, where one study demonstrated that patients who were more satisfied 
with their care had worse weight control (Kinmonth et al., 1998).  Patient-centred 
communication is described as the facilitator for the delivery of patient-centred care 
(Figure3.1), which is based on healthcare systems that value and account for individual patient 
requirements, views and experiences; enabling self-care where desired and optimising 
relationships between physicians and patients (Epstein and Street, 2007).  Patient-centred 
communication is said to be optimised, where communication occurs through relationships 
symbolised by reciprocal trust, respect, and commitment rather than through merely 
imparting information (Epstein and Street, 2007).  Examples of patient-centred clinician 














Figure 3.1. Patient-centred care (Epstein and Street 2007, p2) 























Table 3.1. Examples of positive clinician and patient communication  
behaviours (Epstein and Street 2007 p4 and p23).  For permission see 
appendix 2 
 
Patient-centred clinician  Active patient  
Nonverbal behaviours 
 Maintaining eye contact 
 Forward lean to indicate attentiveness 
 Nodding to indicate understanding 
 Absence of distracting movements (e.g. 
fidgeting) 
Verbal behaviours 
 Avoiding interruptions 
 Establishing purpose of visit 
 Encouraging patient participation  
 Soliciting the patients beliefs, values and 
preferences 
 Eliciting and validating emotions 
 Asking about patient and social context  
 Being honest 
 Providing sufficient information  
 Providing clear, jargon-free explanations 
 Encourage patients to ask questions 
 Repeat and summarise 
 Check for patient understanding 




 Offering opinions 
 Stating preferences 
 Interrupting if necessary 
 Sharing beliefs about health 
 Introducing topics for discussion 
Expressing concerns and feelings 
 Expressing emotions 
 Disclosing fears and worries 
 Noting frustration 
 
(Telling one’s health “story “ in the context 
of everyday life) 
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3.3 Application of the PCC framework 
 
The PCC model is organised around six domains that represent core mediating functions of 
patient-clinician communication (figure 3.2) and additional moderating factors between 
patient-centred communication and health outcomes.  If applied to prevention of delayed 
presentation with neutropenic sepsis, the communication model (figure 3.2) would start with a 
patient’s need to present early with symptoms of neutropenic sepsis.  This would lead through 
mediating pathway A to the six core domains of patient-centred communication between 
clinicians, patients and carers which include: Fostering healing relationships; Exchanging 
information; Responding to emotions; Managing uncertainty; Making decisions and Enabling 
patient self-management.  Pathway B suggests the six PCC domains can lead to proximal 
outcomes such as trusting relationships between patients, carers and clinicians and effective 
information exchange.  This may in turn lead through pathway C to intermediate outcomes, 
such as ability and motivation to recognise and report early symptoms of neutropenic sepsis, 
resulting in the completion of treatment at full dose with minimal delays, following a 
neutropenic episode.  Finally, through pathway D overall health outcomes, may include cancer 
remission and reduced chemotherapy side effect burden.  Although these mediating pathways 
are based on the literature and appear to offer a reasonable explanation for patient delayed 
presentation with neutropenic sepsis, this is not a certainty because the PCC framework is a 
hypothetical model, which does not appear to have been tested in clinical practice. 
 
3.3.1 Mediating domains  
3.3.1.1  Domain one: Fostering healing relationships 
Evidence suggests, that effective healing or therapeutic relationships between patients and 
clinicians can improve medicine adherence (Pringle et al., 2011).  Feeling connected to 
clinicians who care and understand patients concerns, preferences, beliefs and values is an 
important aspect of healing relationships (Bakker et al., 2001, Wright et al., 2004, Salander and 
Henriksson, 2005) and trust, which is an intermediate communication outcome, may be 
particularly pertinent to non adherence (McCormack et al., 2011).  Chronic disease studies 
have shown that where patients have been educated to participate more actively in 
consultations with clinicians, they engage more effectively in self-care activities such as blood 






Figure 3.2. Patient-centred communication conceptual model 
(Epstein and Street 2007, p43) For permission see appendix 2 
 
Survival, health-related quality of life
Mediators of the relationships between communication outcomes and health outcomes
Mediators of the relationships between communication processes and intermediate health outcomes
DOMAINS: Fostering healing relationships, exchanging information, responding to emotions, 
managing uncertainty, making decisions, enabling patient self-management 
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In addition, when patients and doctors share preferences for control in the relationship, for 
example where both parties wish the doctor to be more directive, patients can appear more 
satisfied and report increased doctor endorsement and intention to adhere to treatment 
requirements (Epstein and Street, 2007).   
 
There is some evidence that patient clinician communication can be affected by race, sex, age 
and education status (Epstein and Street, 2007).  For example, female physicians are said to be 
more patient-centred in their communication styles, which is associated with greater patient 
adherence, whereas male physicians are said to often be more directional and authoritarian in 
consultations with patients (Marks and Evans, 2005).  Further, research suggests that some 
doctors provide patients who are more highly educated with more information (Street, 1991, 
Waitzkin, 1985) and may provide simpler information to older patients (Roter et al., 1988).   
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It may be important for patients and clinicians to have shared understanding of each other’s 
roles and responsibilities and discuss and negotiate shared goals (McCormack et al., 2011).  
Positive communication involves trust, honesty, openness and disclosure from both patients 
and clinicians.  This suggests clinicians should not provide information to patients that is 
incomplete or misleading (McCormack et al., 2011) about side effects of treatment, such as 
neutropenic sepsis.  For patients this includes their sharing information about health and 
health behaviours (McCormack et al., 2011). 
 
3.3.1.2 Domain two: Exchanging information  
This domain relates to addressing patients’ information needs, preferences and knowledge.  
Sharing information is described by Epstein and Street (2007) as a reciprocal concept where 
patients share their experiences and understanding of cancer and where clinicians provide 
information in line with patient preferences.  Communication techniques should help patients 
to understand information provided and to apply it to their own situation (Arora, 2003, Epstein 
and Street, 2007).  Clinicians may not always help patients to achieve this and can under or 
over estimate patients understanding (Arora, 2003, McCormack et al., 2011).  It is suggested 
patients should not be overwhelmed with information, rather the most relevant facts should 
be provided following an assessment of understanding and information need (Epstein and 
Street, 2007, Fallowfield et al., 2006).  Importantly, information should be provided slowly, 
whilst avoiding technical jargon (Arora, 2003, Fallowfield et al., 2006).  Facilitating assimilation 
and recall of information incorporates, assisting patients to understand and retain key 
information, through repetition of salient points, use of plain English and supportive 
information resources and through encouraging patients to make notes during consultations 
(McCormack et al., 2011).  Further, it is suggested patients should be assisted if required, to 
source information from reputable agencies (McCormack et al., 2011). 
 
A number of studies indicate that people with cancer do not always adhere with cancer drug 
management requirements (Tsang et al., 2006, Partridge et al., 2010, Weingart et al., 2011), 
suggesting that techniques which can facilitate information assimilation, either may not be 
effective or are not being applied.  Furthermore, the literature relating to neutropenic sepsis 
described within the literature review chapter (chapter two) of this thesis, suggests patients do 
not always adhere with advice to present to hospital when they develop symptoms of it 
(National Confidential Enquiry into Patient Outcome and Death, 2008, Malik et al., 2001, 
Nirenberg et al., 2004, McKenzie et al., 2011).    
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Other researchers have also described how some people prefer to know and others prefer to 
avoid frightening information about cancer.  Such differences in peoples’ information seeking 
behaviour are not referred to within the PCC model but may be important to understanding 
why patients may delay reporting symptoms of neutropenic sepsis to clinicians.  Miller’s theory 
(Miller, 1995) of coping strategies employed by patients facing threatening situations, broadly 
characterises people as monitors, who seek out information and blunters who avoid the same 
information (Miller and Mangan, 1983, Miller, 1995, Miller, 1998, Ong et al., 1998, Nordin et 
al., 2002).  Miller states the threat and associated anxiety for monitors may be lowered by 
providing detailed information and emphasising the value of early detection and management.  
It is further suggested that the attention of blunters should be drawn to risks in a succinct, non 
threatening way alongside a suggested course of action (Miller, 1995).  Other researchers 
suggest differences in information seeking or avoidance behaviours may depend on 
circumstance, rather than individual monitoring and blunting traits.  Lazarus theory of stress 
(Lazarus, 1966, Cohen and Lazarus, 1973) suggests that people seek out information, when 
they feel threatened in order to alleviate fears and increase coping, whilst other researchers 
suggest patients with cancer can block or filter out information that appears distressing or 
confusing (McCaughan and McKenna, 2007).   
 
Clinicians are described as often misjudging patients’ health beliefs, information needs, 
feelings and concerns, as well as their likelihood to follow treatment plans (Epstein and Street, 
2007).  The PCC model suggests that patients and clinicians may have different illness 
representations of neutropenic sepsis.  Illness representations are used to understand and 
make sense of the cancer experience and are informed by prior experiences, beliefs, others 
experience, knowledge, psychological status and goals (Epstein and Street, 2007, McCormack 
et al., 2011).  The PCC model supports exploration of patients’ illness representations and 
concerns, through encouragement of verbal expression of such feelings, through employment 
of patient-centred communication skills detailed in table 3.1 (page 59).  These include open 
ended questions that address psychological aspects of communication; empathy and active 
listening (Epstein and Street, 2007, Arora, 2003).   
 
3.3.1.3 Domain three: Responding to emotions  
According to the PCC model fostering healing, co-operative relationships when providing 
information to patients, should assist them to make informed decisions to present early with 
symptoms of neutropenic sepsis (Donovan and Blake, 1992, Arora, 2003, Epstein and Street, 
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2007).  The PCC model also suggests emotions may negatively impact on successful 
information delivery.  According to research 23-40% of cancer patients experience 
psychological distress, which is a barrier to effective communication (Fallowfield et al., 2006) 
and can lead to poor adherence (McCormack et al., 2011).  Emotions may be expressed by 
patients and carers in various ways during consultations with clinicians, through for example 
fear, humour, nervousness, anxiety, sadness or fatalistic views (Epstein and Street, 2007).  
Patients are likely to have heightened emotions, when information about neutropenic sepsis 
risks is conveyed to them, as this usually coincides with attempts to make sense of a new 
cancer diagnosis and the need for chemotherapy treatment and a perceived potentially life 
threatening situation.  Emotions may consequently, impact on patients ability to process 
information about neutropenic sepsis (Treacy and Mayer, 2000).  Unfortunately though, 
clinicians may miss emotional cues and focus more on physical aspects of health (Epstein and 
Street, 2007) rather than eliciting psychological issues, through sensitive questioning and 
responding with constructive help and empathy (Epstein and Street, 2007).   
 
3.3.1.4 Domain four: Managing uncertainty   
Little research exists on managing uncertainty in cancer care and the PCC model focus is on 
prognosis, rather than presentation with chemotherapy side effects.  Never the less Mishel’s 
uncertainty and illness theory (Mishel and Braden, 1988, Mishel, 1990) which informs the PCC 
model provides a useful framework to explore uncertainty experienced by patient participants 
going through chemotherapy.  Mishel and Braden, (1988) defines uncertainty during illness as:  
 
…the inability to determine the meaning of illness related events.  It is the 
cognitive state created when the person cannot adequately structure or categorise 
an event because of the lack of sufficient cues.  Uncertainty occurs in a situation in 
which the decision maker is unable to assign definite value to objects or events 
and / or is unable to predict outcomes accurately  
                                                                                                                       (Mishel, 1988, p. 225) 
 
Mishel’s theory (Mishel and Braden, 1988, Mishel, 1990) positions uncertainty as affected by 
the stimuli frame, cognitive capacity and structure.  The stimuli frame relates to patients’ 
ability to produce a mental schema of events (Mishel and Braden, 1988) which if unclear 
increases uncertainty.  Symptom profile; event familiarity and event congruence are 
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incorporated within the stimuli frame.  The symptom profile, in relation to this study would 
refer to the extent patient participants are helped to predict normal chemotherapy symptom 
patterns.  Event familiarity would refer to the extent health events, important to neutropenic 
sepsis are recognised by patients as familiar.  Event unfamiliarity during complex cancer events  
can be significantly related to uncertainty (p<0.05) (Mishel and Braden, 1988) which may be 
important to delayed reporting of neutropenic sepsis.  Event congruence might refer to 
consistency between actual events and expected scenarios (Mishel and Braden, 1988) during 
chemotherapy and episodes of neutropenic sepsis.   
 
Cognitive capacity, the second influence to affect uncertainty, relates to the ability to process 
information about neutropenic sepsis.  The third influence, structure providers, is the 
resources that assist patients to determine symptom patterns, event familiarity and increase 
event congruence and thus reduce uncertainty.  Structure provider elements include credible 
authority, education and social support.  Credible authority incorporates patient-centred 
communication behaviours, which Epstein and Street (2007) indicate should reduce and help 
patients to manage uncertainty.  Important relationship elements known to reduce 
uncertainty include trust and confidence in clinicians.  Educational structure relates to 
providing information to reduce patient uncertainty, at the required educational level, so 
accounts for those with lower cognitive ability taking longer to process and construct 
meanings (Mishel and Braden, 1988).  The third structure provider identified by Mishel and 
Braden (1988) to reduce uncertainty is social support provided by other patients and carers. 
 
Research carried out in primary care, suggests that patient confidence can reduce where 
clinicians express clinical uncertainty (Epstein and Street, 2007) and uncertainty in cancer 
patients has been shown to lead to emotional distress and a sense of poor control over health 
and quality of life (Dunn et al., 1993, Andreassen et al., 2005).  Epstein and Street (2007) 
suggest that uncertainty can be exacerbated through information overload and that patient-
centred communication should moderate uncertainty and importantly assist patients to 
manage it.  There is some evidence that cognitive behavioural techniques can help patients 
monitor for cancer symptoms (Epstein and Street, 2007).  The PCC model suggests that 
provision of context in terms of the likely impact of neutropenic sepsis for individual patients 
and an agreed plan for dealing with uncertainty may be helpful (McCormack et al., 2011).   
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3.3.1.5 Domain five: Making decisions  
This domain refers to patients making decisions in relation to treatment options.  This suggests 
most patients prefer making these decisions in partnership with clinicians.  As with the 
managing uncertainty domain, the principles appear pertinent to patients who are required to 
make decisions about presenting to hospital with symptoms of neutropenic sepsis.  Application 
of the PCC model suggests patients who develop symptoms of neutropenic sepsis may 
assimilate information obtained from various sources and weigh up the pros and cons of taking 
particular courses of action, before making a final decision.  This domain suggests decision 
making by patients, who have symptoms of neutropenic sepsis may be optimised by effective 
information exchange and their beliefs and understanding of the information provided, 
including the rationale for presenting early.  Furthermore, additional literature, not included in 
the PCC model also suggests that emotions (Fallowfield et al., 2006) and cognitive impairment, 
cited in the literature as “chemo brain” referring to memory loss and poor concentration 
(Mitchell and Turton, 2011) may impact on decision making.   
 
3.3.1.6 Domain six: Enabling self-management  
The enabling self-management domain draws from the primary care chronic disease 
management model and is a relatively new area for cancer care  (Epstein and Street, 2007, 
McCormack et al., 2011).  This domain focuses on enablement through collaboration between 
patients and clinicians, to identify and solve problems, take action and set goals in relation to 
health.  This requires a shift in focus from treating patients as passive recipients of information 
to active participants in their care.  More specifically, the PCC framework suggests that 
enablement of early reporting of symptoms of neutropenic sepsis, may require adoption of 
patient-centred communication skills by clinicians to identify and remove obstacles to self-
management and to increase patient autonomy and the ability to self-care, whilst making 
informed choices (Epstein and Street, 2007).  This domain draws on three theories including: 
self-efficacy theory (Bandura, 1977); self-determination theory (Ryan and Deci, 2000) and the 
5 A’s for patient-centred counselling (Glasgow et al., 2003). 
 
Self-efficacy theory (Bandura, 1977) is the most commonly cited theory to understand self-
management.  This describes personal motivation to change behaviour, driven by a belief in 
ability to achieve the change.  Bandura (Bandura, 1977, Bandura, 1994) states people will 
undertake required action, if they believe themselves competent and self-efficacy is associated 
with persistence to succeed.  Importantly, Bandura says people, who believe they are 
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incapable of achievement may view required behaviours as a threat and avoid performing 
these.  Self-efficacy is determined by cognition of four information sources or influences 
(Bandura, 1994).  Enactive attainments, the most influential information source suggests 
achievement or mastery of a new behaviour; vicarious experiences or modelling relates to 
learning from others’ experiences and verbal persuasion facilitates belief in capability to carry 
out a required action.  Physiological or somatic and emotional state relates to an association 
between visceral arousal of negative stress reactions and reduced self-efficacy and ability to 
perform.   
 
Self-determination theory, like self-efficacy theory relates to motivating patients to draw upon 
inner resources to act in healthy ways.  A core difference is a perception by Bandura of 
perceived confidence as a mediating role to achievement.  Self-determination theory is more 
concerned with a natural inclination towards intrinsically motivated behaviours which interest 
and satisfy, as opposed to attempts by others to extrinsically motivate behaviours through 
external goals that may not be of interest.  Deci and Ryan (Deci and Ryan, 2000, Ryan and Deci, 
2000) identify three basic innate psychological needs of competence, autonomy and 
relatedness that should be fulfilled in order to be self-determined.  Competence refers to a 
need to experience mastery; relatedness to a need to feel connected to others and experience 
reciprocal caring relationships and autonomy, to feeling in control and responsible for one’s 
life.  It is suggested all three needs should be met to be self-determined although; some 
become more important at different times and depending on circumstances and culture.  If 
these three needs are supported, positive outcomes are said to include encouragement of 
intrinsically motivated behaviour and integration of extrinsic motivation.  If needs of 
competence, relatedness and autonomy are not met, negative outcomes are said to include 
declining motivation, performance and health (Deci and Ryan, 2000, Ryan and Deci, 2000). 
 
Cognitive evaluation theory informs self-determination theory and suggests intrinsic 
motivation may be enhanced by enabling competence and autonomy through positive 
feedback and rewards whereas negative feedback is said to reduce intrinsic motivation (Deci, 
1975, Deci and Ryan, 1985).  Organismic integration theory also informs self-determination 
theory, and suggests a continuum along which extrinsically motivated behaviours may become 
autonomised.  Externally regulated behaviour is proposed as associated with least autonomy 
because this is driven by rewards or outside stipulations.  The most autonomous extrinsically 
motivated behaviours are said to be achieved through integrated regulation by fully 
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internalising externally motivated behaviours as core to personal beliefs and needs (Deci and 
Ryan, 2000).  Importantly, organismic integration theory indicates internalisation of externally 
motivated behaviours is more likely when the need for relatedness is met (Deci and Ryan, 
1985).    
 
In relation to the PCC self-management domain Epstein and Street (2007) say that competence 
may be instilled through provision of clear guidance, access to resources and development of 
appropriate skills.  Further, promotion of  autonomy may instil competence, which may reduce 
where clinicians are more instructive (Ryan and Deci, 2000, Epstein and Street, 2007).  
Importantly autonomy does not mean being independent from others (Deci and Ryan, 2000).  
PCC behaviours which may promote this include providing simply put and jargon free advice 
and adoption of recall prompting techniques like repeating and summarising key points and 
asking patients to articulate their understanding of advice provided (Epstein and Street, 2007).  
Autonomy may further be promoted through exploring patients’ uncertainty about taking 
health promoting action and providing different options to achieve the same outcomes by, for 
example, assisting patients to understand when they should call chemotherapy helplines, or to 
think about different options for getting to hospital, should this be required.  Training patients 
to have useful discussions with clinicians, based on the patient’s agenda may also promote 
autonomy (Epstein and Street, 2007).  Relatedness incorporates clinicians and patients 
developing connected, trusting relationships which should encompass advocacy, through 
clinicians being available when needed to help patients navigate the healthcare system.  In the 
case of neutropenic sepsis, this would mean equipping patients to access high quality 
information and 24-hour acute oncology services, designed to facilitate fast identification and 
treatment of neutropenic sepsis.    
 
 
The third theory is the “5A’s” (Assess, Advise, Agree, Assist, Arrange) model of behaviour 
change which aims to help patients develop personal action plans (Glasgow et al., 2006).  For 
enabling symptom reporting in relation to neutropenic sepsis, the “5A’s” model would suggest, 
clinicians should assess patients beliefs and knowledge about this; advise on the risks of 
delayed presentation and the benefits of early presentation; agree on goals for early 
presentation; assist in identification of potential barriers to early reporting, develop strategies 





Mediating aspects of patient-centred communication incorporated within the PCC model that 
may impact on patients’ adherence with reporting symptoms of neutropenic sepsis, have been 
described.  In addition, factors identified by the PCC framework, may moderate relationships 
between communication and timely reporting of neutropenic sepsis (figure 3.3).  This two 
dimensional model presents moderators along the vertical axis, that range from being intrinsic 
(native) or extrinsic (external) to patient, family and clinician relationships.  The horizontal axis 
relates to the extent to which a moderator is stable (difficult or impossible to change) or 
mutable (modifiable).  It is important to recognise, the moderators on the left hand side of the 
grid may be less open to change and could represent barriers to adherence.  Moderators on 
the right hand side of the grid may be more malleable to change and responsive to patient-
centred communication, that may result in patients experiencing increased agency and self-
efficacy.  Epstein and Street (2007) describe complexities associated with extrinsic moderators 
and the multiple layers within, which health communication occurs and which lead to different 
outcomes dependent on the situational context.  Illness related factors, social situations, 









Figure 3.3. Intrinsic and extrinsic moderating factors for PCC and health outcomes 
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3.4. Chapter conclusion 
The research outlined within this thesis seeks to understand why patients delay presenting to 
hospital when they develop neutropenic sepsis.  The PCC model was identified rather than 
only self-efficacy theory as the most suitable framework to apply to this study.  Firstly, the 
enabling self- management domain incorporates self-efficacy theory; and each of the following 
principles identified by NICE (2007), as relevant for promoting behaviour change and which 
may be important to self-management of neutropenic sepsis symptoms: 
 
 Understanding of benefits and consequences of actions 
 Personal relevance of a required behaviour 
 Positivity about behaviour  
 Self-efficacy  
 Descriptive norms or copying positive behaviours from others in a similar position  
71 
 Promoting personal and moral commitment 
 Goal setting 
 Identifying potential barriers and ways to deal with these  
                                (NICE, 2007, p. 10) 
 
Secondly, the PCC framework allows for the complexities of communicating with patients who 
have cancer.  Finally, this incorporates a possible mediating effect of relatedness achieved by 
clinicians, who connect with patients emotional responses to cancer and cancer treatments 
and who engage with their social networks in relation to health outcomes.  Consequently, the 
PCC model will be drawn upon within this thesis, to inform initial areas of research inquiry and 
to compare and contrast findings.  It is anticipated this will assist in the identification of 
reasons for patients presenting late to hospital, when they develop neutropenic sepsis.  
Furthermore, this study may generate knowledge regarding clinical applicability of the 
research based, hypothetical PCC model and identify particular mediating and moderating 





Chapter summary:  
Associations between clinician and patient communication behaviours and health outcomes 
are poorly studied.  Most research focuses on the impact of communication on a limited 
range of intermediate health outcomes, such as patient satisfaction with their interactions 
with clinicians, which may not equate to behaviour change or actions by patients.  Epstein and 
Street (2007) sought to overcome such problems through the development of the PCC 
framework.  They applied available evidence to develop six patient-centred communication 
domains they believe mediate health outcomes through complex pathways.  Suggested 
proximal outcomes include trust and effective information exchange.  This in turn may lead to 
intermediate health outcomes such as improved advocacy and quality of medical decisions; 
patient knowledge; emotional self-management; therapeutic alliances; family and social 
support; ability to self-care; access to care and improved patient agency through self-efficacy, 
empowerment and enablement.   
 
The PCC model appears most suitable to apply to this study because it is cancer focused.  It 
also incorporates an association between patients’ knowledge, beliefs, behaviour and the 
principles for behaviour change.  This was identified as important within a NICE evidence 
review (NICE, 2007).  Furthermore, the PCC model includes a suggested association between 
the clinician and patient relationship and adherence that may be important to the reporting 
of neutropenic sepsis.  This model as described by Epstein and Street (2007) will consequently 
inform early data generation in the current study and explore possible mediators and 
moderators of patient-centred communication.  This model will be applied to compare and 
contrast study findings and to identify any important factors relating to patients delaying their 
presentation to hospital with neutropenic sepsis.  It is suggested that the application of the 
PCC framework to the findings from this study, may improve understanding of any benefits or 









Chapter Four: Research 
methodology   
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4.1 Research questions 
The grounded theory research approach required initially starting with a broad area of inquiry 
related to patients with neutropenic sepsis delaying reporting to hospital.  Other areas of 
inquiry emerged as important as data analysis progressed.  The research question was: 
 
Why do some patients delay reporting to hospital with signs and symptoms of neutropenic 
sepsis, and what assists patients to present earlier to reduce the effects of neutropenic 
sepsis? 
 
During initial data collection the following areas of inquiry were explored through observations 
and interviews:  
1. How patients, carers and clinicians communicate about risks of neutropenic sepsis. 
2. How clinicians prepare patients and carers to manage risks of neutropenic sepsis. 
3. What affects intentional and non-intentional patient non-adherence to reporting signs and 
symptoms of neutropenic sepsis. 
 
 
4.2 Study design 
A qualitative research design was employed for this study in order to explore new areas of 
inquiry, allow complex social phenomena to be understood and rich insightful data to be 
collected (Green and Thorogood, 2004).  Ethnography was the methodological approach for 
data collection and grounded theory was applied to direct data collection and analysis, in order 
to develop a theory that arose from the data.  Data were gathered through non-participant 
observation and in-depth interviews which included longitudinal and retrospective elements.  
Data were analysed using the constructivist grounded theory approach described by Charmaz 
(Charmaz, 2006) which focuses on social processes, interaction and meaning.    
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The research design allowed, from the earliest point of data collection, an ability to gradually 
refine and focus the enquiry and emerging analytical ideas.  This was through comparison, 
immersion in the data and alternating between this and the research field.  This process was 
assisted by a flexible approach of a co-ordinated but not sequential research process.  This 
included theoretical sampling, where the emerging data analysis was used to drive the 
identification of areas of inquiry and the participants to be included within the next stages in 
the research process.  The grounded theory approach enabled development of conceptual 
categories, which were reconstructed to develop a theory grounded in the data. This would 
provide insight into how patients developed an understanding of risks of chemotherapy 
induced neutropenic sepsis and the complexities related to associated patient self-
management.   
 
The research was undertaken in a large London Cancer Centre and involved patients with a 
diagnosis of breast cancer who were at particular risk of developing neutropenic sepsis during 
chemotherapy according to available guidelines.  This included the study of those receiving 
chemotherapy regimens with >20% risk; age >65 years or with metastatic disease.  Participants 
included patients admitted to hospital with neutropenic sepsis, their carers (identified by 
participating patients as the relative or friend who provided them with most support during 
chemotherapy) and the clinicians (medical and nursing staff) who interacted with them about 
this treatment side effect.  Observational and interview data were collected and analysed until 
data saturation was reached; i.e. when nothing new came out of the data and categories 
appeared fully developed with regards to properties and dimensions. 
 
4.2.1 Steering group and user involvement  
The impetus for this research evolved from patient and clinician feedback based on personal 
experiences.  Clinicians who provided chemotherapy services were concerned that patients 
often delayed presenting to hospital with neutropenic sepsis.  Additionally, local patient 
surveys and focus groups identified a need to improve information and support for those 
undergoing chemotherapy.  A chemotherapy patient working group, who had previously been 
involved in chemotherapy service development work, endorsed the importance of research to 
establish why patients delay contacting the hospital when they develop neutropenic sepsis.  
Carers were further engaged in this study through a carers’ reference group, previously 
established within King’s College London.  Academic colleagues and clinicians involved in 
chemotherapy service delivery were also invited to join the steering group set up for the 
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research presented here.  The final steering group consisted of patients and carers with 
experience of neutropenic sepsis, an oncologist, specialist chemotherapy and acute oncology 
cancer nurses and a patient education expert.  The group met on two occasions and terms of 
reference and minutes of these meetings are enclosed in appendix 3.  The steering group 
meetings focused on assisting in refining the research question and discussing the 
intermediate findings.  Further meetings to present the final study findings and to explore the 
design of an intervention study will be held following submission of this thesis. 
 
 
4.3 Ethnography  
Ethnography stems from anthropology which researches culturally rooted beliefs and customs 
within small communities (Savage, 2000).  Utilisation of ethnographic methods allowed sharing 
in the patient experience and an understanding of the complexities related to patient self-
management of neutropenic sepsis.  Insight was gained into how patients developed an 
understanding of the risks of chemotherapy induced neutropenic sepsis and how such 
perceptions impacted on their behaviour and actions.  Brewer (Brewer, 2000) offers the 
following definition of ethnography: 
 
Ethnography is the study of people in naturally occurring settings or ‘fields’ by 
means of methods which capture their social meanings and ordinary activities, 
involving the researcher participating directly in the setting, if not also the 
activities, in order to collect data in a systematic manner but without meaning 
being imposed on them externally                                                            
                                                      (Brewer, 2000, p. 10) 
 
Although not participating directly in the research field ethnographic methods, which included 
non-participant observation and in-depth interviews, enabled familiarity with activities 
associated with communication and action in relation to neutropenic sepsis.  The ethnographic 
approach also enabled an understanding of patients’, carers’ and clinicians’ behaviours, beliefs 
and meanings in relation to it.  Employment of ethnographic methods enabled the generation 
of rich, reflexive data to demonstrate the cultural context of experiences and actions related to 
patients delayed presentation to hospital with neutropenic sepsis and how this was 
constructed between researcher and participants. 
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4.4 Grounded theory 
Ethnographic research can generate large amounts of data which can be difficult to manage 
and make sense of.  Grounded theory developed from ethnography can specifically enhance 
ethnographic data analysis through structuring ongoing focused data collection and analysis.  
This is achieved through promoting closeness to the data, making connections between events 
and through the study of basic social processes (Glaser and Strauss, 1967, Charmaz and 
Mitchell, 2001, Charmaz, 2006, Timmermans and Tavory, 2010).  Grounded theory includes the 
following non-linear processes described by Charmaz and Mitchell (2001) as common to all 
forms of grounded theory: 
 
1. Simultaneous data collection and analysis. 
2. Pursuit of emergent themes through early data analysis. 
3. Discovery of basic social processes within the data. 
4. Inductive construction of abstract categories that explain and synthesise these processes. 
5. Integration of categories into a theoretical or conceptual framework that specifies causes 
conditions and consequences of the process (es). 
                                (Charmaz and Mitchell, 2001, p. 160) 
 
The grounded theory approach to data analysis has been successfully applied to recent other 
ethnographic research in cancer care.  These include an ethnographic study (Tuffrey-Wijne et 
al., 2009) which explored experiences of people with learning disabilities who had cancer and 
informative PhD research (Eliasson et al., 2011) which explored cancer patients intentional and 
non intentional adherence with taking oral chemotherapy drugs.  An overview of grounded 
theory from its roots in positivism and a justification for applying the constructivist approach, 
developed by Cathy Charmaz, to this study (which explored why patients delayed presenting to 
hospital with neutropenic sepsis) will be provided.  This next section is in part informed by 
attendance at an interactive four day grounded theory summer school in Italy during 2012.  
This course was run by world leaders in grounded theory, including Professor Massimiliano 
Tarozzi; Professor Janice Morse, Professor Maria Mayan and Juliet Corbin.  Juliet Corbin has 




4.4.1 Objectivist grounded theory 
Qualitative methods have been heavily criticised by positivists who cite lack of scientific 
controls, unsystematic, overly subjective methods and findings that cannot be generalised as 
key problems.  In response to this, some qualitative researchers adopted a positivist approach 
to their research by attempting to remove researcher effect from data collection and quoting 
rich text as standalone interpretations of data (Hammersley and Atkinson, 2007).  Humanistic 
(naturalism) ethnography and original grounded theory, developed by sociologists Glaser and 
Strauss (Glaser and Strauss, 1967) supposes that text may be interpreted by the researcher 
without recourse to their own influence on data generation and analysis.    
 
Grounded theory epistemology was developed at a significant time in social science research, 
within the University of California Nursing School by Glaser and Strauss in the 1960’s.  Barney 
Glaser had undergone quantitative training and original grounded theory was based on 
positivism which represented the inductive discovery of truth and the neutral researcher.  The 
Discovery of Grounded Theory (Glaser and Strauss, 1967) aimed to legitimise and raise 
qualitative research to be on a par with the quantitative paradigm, through the addition of 
rigour and systematic processes.  The Glaser and Strauss (1967) approach aimed to discover 
theory which emerges from and is grounded in qualitative data rather than forcing findings 
into existing theory (Glaser and Strauss, 1967).  An understanding of meanings of experiences 
is gained through breaking up the data and reconstructing these.  Data analysis involves 
staying close to the data to develop concepts rather than description.  Concepts provide a 
language for talking about the emerging data and are described by Corbin and Strauss as:   
 
Words that stand for ideas contained in data.  Concepts are interpretations, the 
products of analysis  
                         (Corbin and Strauss, 2008, P. 159) 
 
The grounded theory approach enables exploration of processes and actions and categories 
through which these are organised.  Charmaz (2006) describes processes as:   
 
..unfolding temporal sequences that may have identifiable markers with clear 
beginnings and endings and benchmarks in between.  The temporal sequences are 
linked in a process and lead to change                   (Charmaz, 2006, p. 10)  
79 
Corbin and Strauss (Corbin and Strauss, 2008) describe processes as a complex continuing 
interplay of multiple actions, interactions and emotional reactions that often occur in response 
to a problem and usually in an attempt to overcome it.  Research participants may not be 
directly aware of these responses and they may also not be immediately obvious to 
researchers (Corbin and Strauss, 2008).  Corbin and Strauss also point out that actions, 
interactions and emotional responses will vary greatly depending on contextual factors and 
the way a problem is perceived by the individual.    
 
Glaser and Strauss (1967) state that theory emerges initially out of conceptual categories and 
their conceptual properties grounded in the data, which then become increasingly refined 
throughout the research process.  Glaser and Strauss state:  
 
 A category stands by itself as a conceptual element of the theory.  A property, in 
turn, is a conceptual aspect or element of a category 
             (Glaser and Strauss, 1967, p. 36) 
 
Properties are components that characterise and define concepts and are further developed in 
terms of dimensions which delineate variance within a property.  The second element of 
theory are hypotheses or generalised relations among categories and their properties (Glaser 
and Strauss, 1967).  Together these elements provide an overarching theoretical picture that 
represents each case included within a study.    
 
The purist grounded theory approach is inductive, in that researchers do not seek to test 
preconceived ideas or a prior hypothesis.  Rather, Glaser and Strauss (1967) state that through 
a systematic approach, the neutral researcher discovers and constructs a supposedly unbiased 
theoretical representation of the truth.  Constant comparison is core to this process and 
requires the researcher to continuously move back and forward between the data and 
analytical thoughts to combine data collection, coding and analysis.  Ideas are generated about 
the data and the data is employed to change and develop ideas.  This is achieved through 
focused inquiry and theoretical sampling, to identify participants most likely to assist with 
exploration of emerging ideas from the data.   
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Glaser and Strauss’s grounded theory, along with post-modern ethnography, were heavily 
influenced by Chicago symbolic interactionism (Blumer, 1969) and the philosophy of 
pragmatism (Mead, 1956).  Both of these consider that knowledge develops from action and 
interaction and focuses on emerging concepts from the data (Corbin and Strauss, 2008).  This 
would suggest an interpretive approach, although original grounded theory (Glaser and 
Strauss, 1967) was criticised, as was the humanistic ethnographic approach, for its alignment 
with the positivist paradigm and a realist ontology considered to relate to a naive realism.  This 
was because it assumes that objective realities can emerge from qualitative research that are 
not influenced or constructed by researchers or respondents (Denzin and Lincoln, 2005).  A risk 
is the positivist approach may not represent subjective influences of participants’ knowledge, 
experience and meaning or the social world they inhabit.  It may further give too much weight 
to researcher interpretation and authority.  This may create inaccurate data representation 
that does not account for the extent a researcher can be neutral and purely inductive.    
 
During the 1960s the positivist paradigm was in stark contrast to the modernist movement, 
which was aligned with interpretive qualitative research approaches (Denzin and Lincoln, 
2005).  In the 1980s Glaser and Strauss parted company and carried out separate research 
activities.  Glaser stayed true to the original positivist principles of his grounded theory 
approach and Strauss joined forces with Corbin.  Together, Strauss and Corbin produced 
Grounded Theory in Practice (Strauss and Corbin, 1997), which was interestingly although 
objectivist, more aligned to a relativist ontology than the Glaser and Strauss’ method.  Strauss 
and Corbin (1997) attempted to provide greater structure and guidance for researchers 
wishing to use the approach, and focused more on new procedures for data analysis rather 
than emphasising the comparative method (Charmaz, 2006).  Strauss and Corbin’s work was 
criticised by Glaser (1992) as being overly prescriptive and analytical, forcing data into 
preconceived categories.  Glaser stated this was not grounded theory; rather a new 
methodology had been developed by Strauss and Corbin (Glaser, 1992).  Corbin, following the 
death of Strauss, has continued to develop grounded theory but is now less prescriptive than 
in early versions of the method. 
 
Key concerns about objectivist grounded theory that remain today, include a view that data is 
broken up and treated as cold and separate from researcher influence and participants lived 
experiences; thus preventing insight into their worlds and meanings.  Researchers choose how 
to tell the story, how to represent the data, what to leave in and leave out.  Their own values 
81 
and experiences are also likely to influence analysis (Charmaz, 2006).  Charmaz states that 
objectivist grounded theory separates: 
 
...the experience from the experiencing subject, the meaning from the story and 
the viewer from the viewed     
                                                                                             (Charmaz and Mitchell, 2000, p. 521) 
 
4.4.2 Constructivist grounded theory 
A key development in the evolution of qualitative research methods from a positivist to an 
interpretive paradigm was the introduction of a constructivist approach which has been 
applied to this study.  This evolved through postmodern, reflexive ethnography and within 
grounded theory, work carried out by Kathy Charmaz, a student of Glaser and Strauss.  
Charmaz’s work challenges the assumptions of objectivity within the positivist paradigm and 
returns to the original grounded theory of examining processes.  Charmaz’s constructivist 
approach moves grounded theory further towards a relativist ontology.  That assumes 
existence of multiple perspectives on reality and a subjectivist epistemology that views 
knowledge as co-created by researchers and participants.  Charmaz and Mitchell, (2000) state:  
 
“…people create and maintain meaningful worlds through dialectical processes of 
conferring meaning on their realities and acting within them”  
                                                                                      (Charmaz and Mitchell, 2000, p. 521) 
 
Glaser and Strauss (1967) consider they discover theory which emerges from the data whereas 
the constructivist stance takes a more interpretive approach to grounded theory, aligning this 
with its original influence of symbolic interactionism which accentuates meaning but is open to 
the existence of multiple realities.  Charmaz (2000) points out that data and analysis are a 
construction of reality; they form an interpretation of this rather than the absolute truth or an 
exact picture and one greatly influenced by socio-political influences.  Importantly, 
constructivist grounded theory answers critics by being clear about the place of the researcher 
within the research as a reflexive co-constructer of knowledge who puts participants’ stories at 
the heart of the final theoretical interpretation (Charmaz 2006).  The ethnographic approach 
and the grounded theory method followed within this study (that seeks to understand why 
patients do not report symptoms of neutropenic sepsis) allowed for a reflexive constructionist 
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approach.  Corbin, within the core grounded theory text, (Corbin and Strauss, 2008) specifically 
aligns their approach with constructivism and stresses; she understands there are multiple 
realties waiting to be discovered:   
 
I agree with the constructionist viewpoint that concepts and theories are 
constructed by researchers out of stories that are constructed by research 
participants who are trying to explain and make sense out of their experiences 
and/or lives, both to the researcher and themselves              
                 (Corbin and Strauss, 2008, p. 10)  
 
Rather than providing a set of research directives for undertaking grounded theory, Corbin and 
Strauss (2008) suggest these are applied as a set of qualitative procedures and analytical tools 
to aid analysis and stimulate thinking.  Charmaz (2000) too considers grounded theorists are 
able to use analytical tools flexibly to explore subjective experiences without the constraints of 
the positivist approach.  This is the position taken within this study which seeks to understand 
why patients delay reporting symptoms when they develop neutropenic sepsis.   
 
 
4.5 Research process 
4.5.1 Recruitment 
4.5.1.1 Ethical permission 
Ethical approval was obtained from the NRES Committee, London (REC reference 11/LO/0488) 
and local research and development (R&D) permission to carry out the study was also secured 
(appendix 4).  The main ethical considerations for this study related to potential risks 
concerning participant coercion, distress and anonymity or researcher identification of a 
concerning clinical issue.  Experience of working in cancer care and the training and support 
available through the associated National Institute of Healthcare Research (NIHR) Training 
Fellowship enabled the appropriate management of ethical issues raised during the research 
process.  The Head of Nursing for Cancer at the research site agreed to act as a contact person 
for anyone who may have concerns regarding the study and in case of any clinical concern 
identified during the research.  There was a risk that clinicians would feel coerced to 
participate in this study, particularly as senior members of staff or potential gate keepers 
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approved the research.  Clinicians may, furthermore, have altered their behaviour in response 
to being observed during the study and may have felt under inspection, judged or 
disempowered.  Prior research experience ensured that permission was sensitively secured for 
undertaking non-participant observations.  Further, undertaking research outside of the usual 
researcher work place was expected to reduce the pressure to participate in the study.   
 
It was carefully explained to participating clinicians that the purpose of the research was not to 
judge and that data collected would remain anonymous.  Participants were informed that data 
would be held in a secure data base and that anonymised quotes and pseudonyms would be 
used in the final report.  Names or other identifiers would not appear within records used to 
document observations, interviews or papers reporting the project.  Details of the participating 
hospital have been removed from ethical documentation detailed within the appendices of 
this thesis and this information will not be included in other papers or reports.  In addition, no 
individuals will be recognisable from the data that are presented in either this thesis or 
subsequent publications.  It was confirmed that all participating clinicians understood they 
were under no obligation to participate in the study, that no-one in their organisation would 
know if they did or did not take part in the study, and that their participation or non-
participation would not affect their employment.  Once recruited, consent was reconfirmed 
with clinicians at each stage of the research process. 
 
Patient and carer participants may also have felt under pressure to participate in the study or 
to consider their privacy was compromised.  Furthermore, patients may have felt too unwell to 
participate in the research, particularly around the time of an inpatient admission for 
neutropenic sepsis.  Consequently, it was agreed that the clinical team would advise whether a 
patient was sufficiently well to be approached to participate.  Potential participants suitable 
for inclusion were offered flexible times for the interviews.  Patient and carer consent was 
reconfirmed throughout the data collection process; and they were informed their care would 
not be compromised should they decide not to participate in the study or to withdraw from it 
at any point.  There was also a risk that sensitive issues about the disease or treatment may be 
raised during the research process and that clinical issues may be identified.  The agreement 
was that in such cases patients would be referred to the appropriate clinical teams who were 
in a position to arrange additional support.   
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4.5.2 Sampling strategy  
The grounded theory approach required data to be collected in a flexible, co-ordinated but not 
sequential fashion.  The research process was inductive.  The PCC model was used to inform 
early stages of data collection rather than to identify hypotheses.  Knowledge generated from 
emerging data and questions arising from developing categories focused the direction and 
order of ongoing data collection.   
 
The research site was a breast cancer unit within a London Cancer Centre.  The data collection 
methods involved four participant samples, and longitudinal and retrospective elements.  The 
longitudinal sample was required to capture data related to information exchange about 
neutropenic sepsis and the impact of this on symptom reporting.  The longitudinal element 
was informed by data collected from a pilot patient (which will be elaborated within chapter 
five) and included recruiting women who had breast cancer prior to them starting 
chemotherapy and following them through treatment.  They were initially observed – through 
non-participant observation – when they were provided with information about neutropenic 
sepsis during outpatient chemotherapy consent appointments with doctors and separate 
chemotherapy nurse consultations.  Short informal interviews were conducted immediately 
following observed appointments with participating clinicians, patients and carers.  This was to 
explore feelings and views in relation to neutropenic sepsis and the consultation.  In addition 
and as part of the retrospective element, separate in-depth interviews with patient 
participants who took part in non-participant observation were carried out following 
completion of chemotherapy.   
 
The retrospective sample was required both to explore carer and clinician’ experience of 
neutropenic sepsis and also that of patients.  This was because it could not be predicted if 
those who participated in the longitudinal element would experience symptoms of 
neutropenic sepsis.  Planned in-depth interviews were conducted with the remaining three 
participant samples: (1) patients admitted to hospital with neutropenic sepsis; (2) carers of 
patients who developed symptoms of neutropenic sepsis; and (3) clinicians who interacted 
with patients in relation to neutropenic sepsis.  The aim was to gather rich data, to illuminate 
emotions and behaviours within the context of the lived experience of communication about 
neutropenic sepsis and patient delays (Charmaz, 2006).  The purpose of attaining data from 
different participants (including patients, carers and clinicians) from different data sources 
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such as interviews and observation, and at different times was to gain a comprehensive 
understanding of patients’ and carers’ preparation for managing episodes of neutropenic 
sepsis.  Perceptions of risks or perceived confidence and willingness in managing these 
episodes and actions taken when neutropenic sepsis occurred were also explored.   
 
Data attained in this way were to provide different perspectives of the same phenomena, 
which is understanding and beliefs about neutropenic sepsis and its attendant risks, so these 
could be compared.  This would be enhanced further, as data were gathered from participants 
with shared experiences in relation to neutropenic sepsis, in order for different perspectives 
on a story to be gathered.  Confidence in findings may be improved where parallel conclusions 
(developed through challenging with disconfirming cases) are drawn from these different data 
sources.  This also poses different threats to validity, so together may lead to improved validity 
of the study (Charmaz, 2006).  Different data sources helped to build a meaningful picture; as 
Glaser and Strauss state:  
 
Different kinds of data give the analyst different views or vantage points from 
which to understand a category and to develop its properties; these different 
views we have called slices of data.      
                                                                        (Glaser and Strauss, 1967, p. 65) 
 
The purpose was to develop theory not to prove population representativeness through 
gathering  high volumes of data (Glaser and Strauss, 1967, Charmaz, 2006).  Patients and 
clinicians considered of most interest to the study were to be initially, recruited and 
theoretical sampling, through constant comparison, would evolve using emerging findings to 
direct the next steps of data collection.  Ideas and hunches or hypotheses were followed up 
through focused inquiry and sampling participants with characteristics most likely to assist in 
exploring and elaborating identified concepts further.  Focused inquiry fits with the funnel 
approach of ethnography to gradually build and develop a focused picture of patient 
understanding and reporting of neutropenic sepsis as proposed by Hammersley and Atkinson 
(2007).   
 
Clinicians, including oncologists and cancer nurses attended study briefing sessions and written 
consent was obtained from all participants prior to observations and interviews.  Outpatient 
clinics and inpatient wards were attended and e-mail contact kept with clinicians to identify 
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potentially suitable patients for inclusion in the study.  Patients were selected purposively 
through asking the clinical team to identify those with required characteristics.  The clinical 
team approached and explained the study to suitable patients and asked for permission to 
introduce them to the researcher.  The researcher next provided these patients with more 
detailed information and encouraged them to ask questions, before obtaining informed 
consent.  Carers were recruited via patients enrolled in the study.  When clinicians who 
worked outside of the oncology team became of interest, the area clinical leads were initially 
approached to gain approval and an introduction to suitable candidates.  Six information 
sheets were produced for the different groups of participants involved and an example is 
presented in appendix 5. 
 
4.5.3 Participants 
4.5.3.1 Patients  
It was initially intended to recruit patients to this study with a variety of cancer diagnoses to 
explore their understanding and experiences of neutropenic sepsis.  There is though a lack of 
empirical evidence related to why patients do not present to hospital with neutropenic sepsis.  
Consequently, it was decided to concentrate on one patient group comprising different socio-
psychological backgrounds and the clinicians, who interact with them in relation to 
neutropenic sepsis, rather than to dilute or complicate study findings by including a range of 
cancer types.  Breast cancer patients were identified in ASCO (Smith et al., 2006), EORTC 
(Aapro et al., 2006, Aapro et al., 2011) and MASCC (Klastersky et al., 2000) guidelines as a 
particular group at risk of developing neutropenic sepsis during chemotherapy.  This is mainly 
due to the chemotherapy drugs prescribed which pose a >20% risk for neutropenic sepsis 
(Smith et al., 2006, Aapro et al., 2006, Aapro et al., 2011).  It was also established that 
clinicians provided information about recognising and acting upon neutropenic sepsis to this 
group of patients.  Furthermore an adequate sample of patients at risk of developing this could 
be recruited.  Women with a diagnosis of breast cancer and receiving chemotherapy were 
therefore recruited to the study.  The aim was to explore issues related to initial 
communication about neutropenic sepsis and any subsequent decision to present to hospital 
for treatment.   
 
As previously mentioned, the longitudinal element included patients who allowed 
observations of clinical encounters where chemotherapy was first explained to them, and who 
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further participated in informal interviews immediately afterwards to discuss the witnessed 
events.  The purpose was to explore how information about neutropenic sepsis was provided 
and the patient’s immediate thoughts, feelings and understanding about this.  Follow up in-
depth interviews after the final chemotherapy treatment, enabled exploration of issues 
identified during observations and analysis and to identify and discuss any symptoms of 
neutropenic sepsis that developed during treatment, and patient response to these.   
 
In order to ensure knowledge was gained from those who had experience of neutropenic 
sepsis, audio recorded interviews (offered face to face at home/hospital or by telephone) were 
also carried out with a retrospective patient sample, who had been admitted to hospital with 
neutropenic sepsis.  These interviews enabled an exploration of the patient’s perception of 
information given about neutropenic sepsis, their beliefs about this condition, any admission 
to hospital and delays in the identification and treatment of neutropenic sepsis.   
 
4.5.3.2 Clinicians  
Clinicians were observed providing information to patients and carers about neutropenic 
sepsis during the longitudinal study element.  Clinicians also took part in audio recorded in-
depth interviews (face to face hospital interview or by telephone).  Initially interviews were 
carried out with clinicians who provided information about neutropenic sepsis to patients.  
These were confined to immediate members of the breast cancer team including 
chemotherapy nurses, breast care nurses and doctors.  In line with the grounded theory 
approach other clinicians were recruited as they became of interest.  The purpose of 
interviews was to explore clinicians’ experience and perceptions of patient safety management 
in relation to neutropenic sepsis.  Initially, the inquiry focused on clinicians’ views about how 
risks of neutropenic sepsis should be explained to patients and carers, their experiences and 
perceptions of the process of risk communication and their understanding and feelings about 
patient interpretation and actions in relation to risk and safety.  As the research progressed 
other issues became of interest and data gathered through observation and informal 





4.5.3.3 Carers  
For the purpose of this research, carers were defined by patients as the person who provided 
them with the most practical and emotional support during their chemotherapy treatment.  
This was either a relative or a friend.  Carers participated in the longitudinal element 
(observation and informal interviews).  One audio recorded in-depth interview (offered face to 
face at home/hospital or by telephone) was also carried out with carers to explore their 
understanding of the risks of neutropenic sepsis and their role and experience in identifying 
and reporting symptoms of the condition to hospital staff.  As data collection progressed, it 
became obvious that carers of patients who had developed symptoms of neutropenic sepsis 
would be of most relevance to the study as they could talk about experience of identifying and 
reporting these to clinicians.   
 
 
4.6 Data collection methods 
4.6.1 The longitudinal element: Non-participant observation and Informal Interviews  
Charmaz (2006) recommends following patients over time as perceptions may change.  This 
allows for follow up of previously identified issues, making connections between witnessed 
consultations and later interviews and developing relationships with participants which can 
lead to improved disclosure (Charmaz, 2006).  A longitudinal, prospective element was 
therefore included within this study, involving non-participant observation of initial 
chemotherapy information sessions and in depth interviews at the end of treatment (offered 
face to face at home / hospital or by telephone).  The design of the longitudinal element was 
informed through recruitment of a pilot patient which will be described in more detail within 
the following chapter.  For the remaining patients who took part in the non-participant 
observation element, this involved them being accompanied to two key consultations before 
chemotherapy treatment started and where neutropenic sepsis was discussed.  The first 
observed consultation was between doctors, patients and carers, where written patient’ 
consent for chemotherapy treatment was obtained.  The second observed consultation was 
the pre-treatment information session with a chemotherapy nurse that was dedicated to 
informing patients about the imminent treatment and potential side effects of chemotherapy, 
including neutropenic sepsis. 
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Non-participant observation aims to generate data through watching and listening to what 
people naturally do and say (Hammersley and Atkinson, 2007).  The aim was to identify a 
picture of how patients were informed about neutropenic sepsis in terms of what was 
happening, who was involved, where it happened and how.  The focus was on discovering 
behaviours, roles and thinking within the context of micro-influences related to participants 
and witnessed situations and the macro cultural and institutional conditions from which these 
arise.  Observation promoted closeness to the data of naturally occurring conversations 
related to neutropenic sepsis that occurred within the natural environment of the outpatient 
clinics and the chemotherapy day unit.  The focus was on the social construction of 
neutropenic sepsis, the purpose being to share in the experience of consultation interactions 
and to talk to participants about how they interpreted these witnessed events and the social 
meanings behind these.   
 
Conversations between clinicians, patients and their carers who accompanied them during 
these appointments were observed and digitally audio-recorded.  Hand written field notes 
were kept which contained details of where and when consultations took place, who were 
involved or present as well as impressions of the consultation (including general atmosphere 
and mood, physical positioning of participants, striking actions or behaviours, non-verbal 
behaviours and interruptions).  An observation grid was developed and used, which related to 
the six patient-centred cancer communication model domains identified within chapter three: 
Fostering healing relationships; Exchanging information; Responding to emotions; Managing 
uncertainty; Making decisions and Enabling self-management.  As part of observation work, 
patients and carers (where present) were engaged in joint informal interviews immediately 
following the observed planned consultations.  Participating clinicians were also interviewed 
informally on the same day as observed consultations.   
 
Informal discussions initially guided by the PCC domains, observation notes and recall of 
witnessed behaviours, explored participants’ perspectives.  This was to gain a deeper 
understanding of witnessed behaviours and how understanding of neutropenic sepsis was co-
constructed.  Discussions were held with patients about their experience of witnessed 
interactions, their perceptions of chemotherapy symptoms and their feelings about pending 
chemotherapy treatments.  Clinicians were asked how they thought patients received 
information about neutropenic sepsis and might cope with reporting chemotherapy 
symptoms.  Patients were encouraged to speak about any prior communications related to 
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reporting of neutropenic sepsis, which may illuminate observations further.  At the end of the 
observation period, similarities and differences between observations and notes of what to 
look out for or explore in more detail at the next observation were documented within 
observational field notes. 
 
4.6.2 The retrospective element: In-depth Interviews  
In-depth interviewing in grounded theory is distinguished by continual reflection and 
increasingly focused inquiry as research progresses.  Reduced topic areas were covered as 
irrelevant categories were cast aside or important categories were fully developed in terms of 
properties and dimensions (Charmaz, 2006).  This approach assisted with overcoming a 
common mistake made within grounded theory when researchers do not develop an in depth 
picture of the social processes studied.  This was important for this research as it was likely 
participants, including the clinicians, would not be consciously aware of deep rooted emotional 
or psychological reasons why patients do not present to hospital with neutropenic sepsis.  At 
the International Grounded Theory Summer School attended by the researcher, Janice Morse 
(an international expert in grounded theory) spoke about good grounded theory exploring 
below the surface whilst remaining in touch with the surface, so that these kinds of deep 
rooted thoughts can be related by researchers to actions.  Juliette Corbin also pointed out 
that: 
 
....analysis requires getting into the heads of participants, taking the role of the 
other and trying to identify what it is that they are telling us or doing through their 
actions and interaction  
              (Corbin, 2012, Grounded Theory Summer School) 
 
An aim consequently, was to “get inside the heads of participants” to elicit responses that 
represented, as far as possible, their experiences, meanings, views and beliefs.  Interviews 
were digitally audio-recorded and semi-structured to allow participants to speak about issues 
that were important to them and to tell their own story about chemotherapy and neutropenic 
sepsis.  Interview guides or discussion topics initially informed by the PCC model were referred 
to during interviews to ensure all topics were considered and these became increasingly 
focused as the research process progressed (appendix 6).  The same questions were asked in 
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different ways to address possible differing participant interpretation.  Participants were 
offered the choice of a telephone or face to face interview for their convenience and it was 
anticipated some might feel able to speak more openly over the telephone (Novick, 2008).  
Multiple interactions with observed patients resulted in closer relationships and deeper 
exploration of their feelings and experiences during interviews (Charmaz and Mitchell, 2000).  
This was also the case for observed clinicians where observation and informal interviews 
generated insights which were explored further with them during in-depth interviews. 
 
Observation, informal discussions and in-depth interviews enabled an insider perspective of 
the context and culture within which clinicians talked about the risks of neutropenic sepsis 
with patients and carers and allowed exploration of participants’ thoughts, feelings, beliefs and 
understandings about neutropenic sepsis.   
 
 
4.7 Analysis  
4.7.1 Analytical tools 
4.7.1.1 Constant comparison 
Constant comparison is core to grounded theory and there are no apparent differences 
between objectivist and constructivist approaches.  Key authors in the field advocate 
comparing “everything everywhere” including:  
 
 Comparison of emerging data with data collected from the outset not after data collection 
is completed. 
 Participant perceptions, stories, actions and experiences. 
 Participant responses at differing times. 
 Events with events. 
 Identification of relationships between concepts and categories.   
                                 (Charmaz, 2000, p. 515, Charmaz, 2006, p.23) 
 
Constant comparative analysis was central to the coding process within this study which 
explored why patients delayed reporting to hospital with neutropenic sepsis.  This involved 
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constant movement between the data and developing concepts to compare those coded in 
the same way in order to develop and refine these to core categories which related to areas of 
interest and concern for participants.  Comparative analysis assisted in becoming theoretically 
sensitive to the data through working closely with it and asking probing or sensitising 
questions.  This was to explore further what was happening, what was seen as important by 
participants and to stimulate further related areas of inquiry.  Barney Glaser (Glaser, 1978) 
states the researcher should focus from the start on identifying the basic social and 
psychological processes.  The data was subsequently interrogated to establish how processes 
were constructed through action, how they manifested, which ones were important and to 
whom, who controlled them and how, how they were spoken about, how perceptions and 
actions changed and who viewed processes as fundamental or marginal (Charmaz, 2006).   
 
Further analytical techniques used included examining the data closely and picking out words 
that seemed significant, writing down different meanings and checking or validating these with 
the text.  Techniques like the “flip flop technique” (Corbin and Strauss, 2008) were used to 
stimulate analytical thinking by comparing and contrasting extremes of dimensions.  This 
technique involved thinking about a concept and what the opposite perspective might be, in 
order to generate new questions to ask of the data.  Systematic comparison was employed to 
explore how dimensions within categories differed.  Language expressed, emotions, 
metaphors and similes and disconfirming cases were examined and particular attention paid to 
anything puzzling and for red flags which indicated areas for further inquiry.  Phrases like “that 
never happens”, “that could not happen”, “it’s always been like”, may indicate participants’ 
biases, assumptions or beliefs and these were identified as areas for further exploration 
(Corbin and Strauss, 2008).   
 
4.7.1.2 Theoretical sampling 
Areas of inquiry, initially informed by the PCC domains and participants thought to be of early 
interest who might explain why patients delay presenting to hospital with neutropenic sepsis 
were initially included.  This became increasingly focused through theoretical sampling 
employed to follow up on ideas and hunches.  Glaser and Strauss (1967) describe theoretical 
sampling as:  
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The process of data collection for generating theory whereby the analyst jointly 
collects codes and analyses his data and decides what data to collect next and 
where to find them, in order to develop his theory...        
                (Glaser and Strauss, 1967, p. 45)  
 
Emerging findings were used to direct next steps in data collection through observation or 
interviews with participants considered most likely to assist in exploring identified concepts 
further.  Theoretical sampling often involves many data collection sources and documentation 
also became important.  Charmaz (2000) points out that theoretical sampling assists the 
researcher to:  
 
– define properties of categories 
– identify the contexts in which they are relevant 
– specify the condition under which they arise, are maintained and vary  
– discover their consequences 
                         (Charmaz, 2000, p. 519)  
 
This process encourages questioning about what is known and the certainty of this and what 
inquiry routes to pursue.  Throughout the research process hypotheses were developed in 
relation to patients delaying going to hospital when they developed neutropenic sepsis.  Ideas 
about what was happening in the research field and possible meanings were explored through 
constant comparison of data from new participants and by returning to previous data sources.  
As the inquiry became increasingly focused, all witnessed events did not require 
documentation and interviews deepened and narrowed to focus on information required to 
develop categories.  Some categories emerged as more important and required further 
exploration and development than others and some not relevant to the study were discarded 
(Glaser and Strauss, 1967). 
 
4.7.1.3 Analytical memos and diagrams  
Analytical memos and diagrams were used throughout the research process to assist with the 
constant comparison process.  These facilitated and documented progressive analytical ideas 
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and thoughts which informed further areas of inquiry.  Memos and diagrams encouraged 
immersion in the data from the outset.  This assisted in becoming theoretically sensitive to the 
data through gaining an early understanding of possible meanings behind witnessed actions.  
Memos and diagrams assisted in conceptual thinking, acted as an audit trail of analytical 
thoughts and ensured that ideas were not lost as data collection and analysis progressed 
towards theory development.  Diagrams encouraged taking a step back to think logically about 
the content and direction of analysis, as well as potential relationships between the data.  
Memos were written about each interview and observation and described early ideas and 
categories.  Charmaz (2006) advocates not fussing with early memo writing, rather letting 
thoughts flow onto paper without attention to grammar or spelling.  This produced early 
simple and awkward memos and diagrams but ones which captured spontaneous and often 
insightful thoughts and sensitising concepts or questions for further inquiry.  Sensitising 
concepts describes a way of thinking deeply about the data and asking questions of it to 
explore what lays beneath the text to develop a representative, meaningful reconstruction 
(Glaser and Strauss, 1967, Blumer, 1969).  As Corbin suggested at the Summer School, 
attention was paid to what was really happening around patients not reporting neutropenic 
sepsis and the significance of that.   
 
Memos and diagrams were reviewed and developed as the research progressed and became 
increasingly sophisticated and conceptual as analysis moved towards theory development.  A 
list of sensitising questions and analytical ideas were informed by memos, immediate post 
interview analytical thoughts, and annotations generated during the coding process.  Memos 
were compared with each other, which often raised further questions and stimulated 
generation of another memo (Corbin and Strauss, 2008).  Memos and diagrams were discussed 
with Juliette Corbin, during Skype calls and memos were sorted as described by Charmaz 
(2006) to assist in developing theoretical connections: 
 
 Sort memos by the title of each category 
 Compare categories 
 Use your categories carefully 
 Consider how their order fits the logic of the categories 
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 Create the best possible balance between the studied experience, your categories and 
your theoretical statements about them  
                 (Charmaz, 2006, p. 117) 
 
4.7.2 Application of the literature and the patient-centred cancer communication model 
Theoretical sampling encourages the researcher to reflect on biases and predetermined ideas.  
Opinions differ amongst grounded theorists on exploration of the literature before or during 
the data collection and analysis period.  Glaser and Strauss (1967) caution against referring to 
the literature until the analytical categories have emerged:  
 
An effective strategy is, at first, literally to ignore the literature of theory and in 
fact on the area under study, in order to assure that the emergence of categories 
will not be contaminated by concepts more suited to different areas.  Similarities 
and convergences with the literature can be established after the analytic core of 
categories has emerged  
                       (Glaser and Strauss, 1967, p. 37) 
 
Other grounded theorists including, Corbin and Strauss (2008) and Charmaz (2006) consider 
the grounded theory process is open to simultaneous literature review and that it is impossible 
to bracket prior knowledge and views.  Rather, the constructivist approach encourages 
reflexive thinking about how the literature impacts on research.  For this study a scoping 
review of the literature (chapter two) was carried out that demonstrated that some patients 
present late to hospital with symptoms of neutropenic sepsis.  This was associated with poor 
clinical outcomes and increased cost to the health service.  What is not clear from this review 
is how patients and carers are educated and equipped to recognise and report symptoms of 
neutropenic sepsis, or why some patients who develop it, present late.  Following a review of 
the PCC model, described within chapter three it was anticipated this would assist with the 
inquiry process to better understand this phenomena.  In alignment with recommendations by 
Corbin and Strauss (Corbin and Strauss, 2008) the PCC framework was applied to inform 
questions for initial in depth interviews and observations and during analysis to compare and 
contrast with emerging findings, whilst taking account of different culture and work practices 
within America where the PCC framework was developed. 
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Grounded theory requires researchers to have as few preconceived ideas as possible in order 
to be open and sensitive to the data.  Consequently, it was application and reflection on prior 
knowledge to inform and enhance data generation and analysis, rather than to drive the 
analysis, that was important.  Prior knowledge included the PCC framework, other literature 
which emerged as important as analysis progressed and reflection on experiences of working 
within chemotherapy services.  The PCC domains were applied to the grounded theory process 
as follows: 
 
4.7.2.1 Domain one: Fostering healing relationships 
This domain informed exploration of roles and relationships formed between patients and 
clinicians.  It included both parties’ perceptions of these, their nature and potential impact on 
adherence with early reporting of symptoms of neutropenic sepsis.  Specifically, during in 
depth interviews and observations attention was paid to the kinds of relationships 
demonstrated between patients, carers and clinicians.  Exploration focused on how patients 
and clinicians behaved during witnessed interactions.  It also included how goals related to 
early reporting of neutropenic sepsis were negotiated and agreed and to what extent patients’ 
concerns and beliefs about reporting of neutropenic sepsis were identified, explored and 
addressed.  Interest was taken regarding any differences in healing relationships between 
different types of patients and clinicians to focus ongoing enquiry.   
 
4.7.2.2 Domain two: Exchanging information  
This domain was applied to explore how information was provided to patients and their carers 
about chemotherapy and the effects of this on reporting symptoms of neutropenic sepsis.  
Attention was paid to how involved patients and carers were in discussions about neutropenic 
sepsis, in terms of being given the opportunity or encouraged to ask questions and to seek 
clarification.  Consideration was paid to the pace and amount of information delivered, the 
words used to describe neutropenic sepsis, any tips or advice provided to assist with early 
presentation, the degree to which information was personalised and how clinicians checked 
patients’ understanding of this chemotherapy complication.  Interest was taken in regard to 
patients’ and carers’ understandings and beliefs and perspectives of neutropenic sepsis 
including the risk of this happening to them, how equipped they felt to deal with it and their 
awareness of the risks involved should neutropenic sepsis occur.  Further, exploration focused 
on any tensions in risk management for patients who developed symptoms of neutropenic 
sepsis, to gain an understanding about how they made sense and prioritised these.    
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4.7.2.3 Domain three: Responding to emotions  
In relation to the responding to emotions domain, attention was paid to emotions experienced 
by patients and their carers related to chemotherapy side effects and in particular neutropenic 
sepsis, how these were responded to by clinicians, patients and carers and how they affected 
reporting of neutropenic sepsis. 
 
4.7.2.4 Domain four: Managing uncertainty   
The communication literature suggests it may be advisable for clinicians to manage patient 
uncertainty about when to call chemotherapy helplines through explaining typical scenarios in 
terms of recognising, reporting, diagnosing and treating neutropenic sepsis.  This domain 
informed exploration of the concept of uncertainty, the extent of this, as well as any attempts 
to manage it through communication enquiry, provision of scenarios and illustration of actions 
to take should symptoms of neutropenic sepsis arise. 
 
4.7.2.5 Domain five: Making decisions 
The making decisions domain directed attention to understand how clinicians equipped 
patients to make decisions about reporting symptoms of neutropenic sepsis and the thought 
processes employed by patients to make such decisions.  Attention was paid to how 
information was framed in terms of clarity around severity of symptoms to report, any 
scenarios provided and checking of understanding.  Interest was taken in any phenomena that 
may have affected decision making to make contact with the hospital in the event of 
neutropenic sepsis symptoms developing, such as impaired cognition, emotional influences 
and home commitments.   
 
4.7.2.6 Domain six: Enabling self-management 
Attention was paid to how clinicians worked with patients and carers to develop self-
management strategies to identify and report neutropenic sepsis and the ability, confidence 
and commitment of patients to seek appropriate care when required.  Observation included 
the content of information provided, the extent to which communication styles were 
facilitative or instructive, when information was provided and any support provided between 
chemotherapy treatments.  Techniques employed by clinicians were observed for, that may 
assist patients to develop self-management strategies, such as agreeing goals for early 
presentation with symptoms of neutropenic sepsis, identification of potential barriers and the 
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development of strategies to overcome these.  Attention was paid to the extent clinicians 
checked patients’ understanding, clarified misconceptions and rehearsed action to take should 
symptoms of neutropenic sepsis occur.  In addition, moderators, which may impact on patient’ 
engagement with self-management to report neutropenic sepsis were identified through 
constant comparison and theoretical sampling.    
 
4.7.3 Preparing data for analysis 
Data for analysis consisted of observation notes, a reflective diary and interview transcripts.  
Organisation of data was an important precursor to data analysis.  Paper work was ordered 
chronologically and NVIVO software (version 9) was used to store, manage, index and organise 
the data electronically.  Interviews and observational notes were transcribed as soon after the 
events as possible and included details of dates, times, places and people involved in 
observations and interviews.  Early interviews and observations were transcribed to assist with 
familiarity of the data and for later transcripts this was carried out by a paid transcriber.  All 
data recordings were listened to and for initial observations and interviews this was at least 
twice.  This facilitated checking all data transcribed to ensure accuracy, continued closeness to 
the data and accurate coding.  Prior to carrying out follow up observation or interviews, 
previous analytical notes and recordings were revisited.  This refreshed the memory and 
allowed deeper exploration of topics discussed in earlier interactions.   
 
4.7.4 Coding 
Coding within grounded theory should retain the integrity of participant accounts and facilitate 
reflection (Charmaz, 2006).  The coding process described by Charmaz (2006) and core to 
constructivist grounded theory was applied and is illustrated within figure 4.1 (Tarozzi, 2012).  
Three types of coding were applied to the data.  Initial coding was descriptive and grounded in 
the data.  This was followed by focused and theoretical coding carried out at a conceptual 
level.  This process was assisted by pilot work, reflections from the field and discussions with 







Figure 4.1. Constructivist grounded theory coding process.  Presented at Grounded 
Theory Summer School (Tarozzi, M., 2012)  
For permission see appendix 2  
 
Coding: the ensemble of 




4.7.4.1 Initial open coding 
Analysis started with open coding which required immersion in the data and retaining an open 
mind.  Each line of interview and observation text was carefully examined and any interesting 
emerging actions or events labelled.  The principles of open coding were followed for the first 
10 data sets as described by Charmaz (2006): 
 Remain open 
 Stay close to the data 
 Keep your codes simple and precise 
 Construct short codes 
 Preserve actions (ing) 
 Compare data with data 
 Move quickly through the data  
 
                             (Charmaz, 2006, p. 49) 
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This generated an initial 80 codes which were grounded in or close to the data and reflected 
and described actions.  This prevents researchers making conceptual inferences too early in 
data collection and analysis (Charmaz, 2006).  Moving quickly through the data can spark 
analytical thinking so documented reflexive thoughts included why particular codes were 
identified, how personal biases and experience influenced interpretation of data and why 
particular sensitising questions were identified (Charmaz, 2006).  Initial codes were labelled 
with analytical descriptions, where possible using in-vivo codes which represented participant’ 
views and often included direct participant quotations.  NVIVO was used to allocate text to 
identified codes and the annotation function used to document analytical notes and sensitising 
questions. These contributed to analytical thinking and memo building.  The first ten coded 
data sets were ordered under the six PCC domains which assisted with early analytical 
thinking.  This represented a combination of emergent and a-priori approaches, as in keeping 
with the grounded theory method the intention was not to fit findings to the analysis.  
Constant comparison was used to review data sources to ensure that all data was coded in the 
same way and nothing had been missed.  If, for example, a new issue was discovered at the 
sixth data source, previous data sources were checked for the same phenomena. 
 
4.7.4.2 Focused coding  
Once the initial ten data sources had been coded using open coding, focused coding was 
carried out which involved a paper based system.  Initial codes were printed onto paper and 
cut into individual strips to create a coding map.  Paper strips were arranged on a table and 
codes that seemed to relate to each other were clustered together to represent early 
categories (figures 4.2 and 4.3).  This assisted analytical thinking about what categories were 
about and to label these conceptually.  Initial codes, which essentially described the same 
process, were joined together or collapsed.  This resulted in the development of early 
conceptual categories and properties of these.  This represented a move away from the 
patient-centred communication model which had assisted with earlier analytical thinking.  Six 
categories were identified as more conceptual and reflective of the emerging data.  Theoretical 
sampling and constant comparison were employed to develop early categories further.  In 
order to reflect and develop the theory regular breaks were taken from data collection to 
become immersed in the data and to ensure the same information was not merely collected 
from subsequent participants.  Rather, breaks in data collection enabled time to write memos, 
draw diagrams and develop categories and their properties and dimensions.  This enabled 
identification of the categories which could either be developed further or discarded.  There 
was time to carefully develop theoretical sampling strategies and sensitising questions to 
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probe deeper into emerging important issues related to patients delaying reporting to hospital 
with neutropenic sepsis.  Suggested hypotheses were quickly developed to be tested against 
prior and emerging data.  As the analysis progressed relationships could be tested between 
emerging categories and properties (Glaser and Strauss, 1967).  As the research moved further 
towards theory development and there was enough data to understand categories and 
properties, the category dimensions were developed as suggested during the summer school 
by Professor Janice Morse, “through thinking about these people act like this and these people 
act like that.” Essentially, this enabled identification of participant’ characteristics or 
moderators that appeared more associated with delayed reporting of neutropenic sepsis.    
 
 













4.7.4.3 Theoretical coding 
As the analysis progressed, a theoretical model was generated through establishing 
explanatory connections related to processes, between categories developed through focused 
coding, through representative text.  The sophisticated process of theoretical coding was 
assisted by a succession of analytical diagrams developed to think about and illustrate possible 
relationships between categories.  Corbin and Strauss (2008) suggest axial coding is applied to 
make these connections and bring fractured data back together through asking on a 
conceptual level, when, where, why, who, how and with what consequences.  Axial coding is 
seen as too prescriptive by Glaser and constructivists who consider it may force artificial 
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connections between categories (Charmaz, 2006).  Rather, constructivist grounded theorists 
view coding as being more flexible and creative.  As previously mentioned, analytical tools 
should earn their way into the theory building process to fit rather than force a relationship 
(Charmaz and Mitchell, 2000). 
 
Glaser developed 18 theoretical coding families (Glaser, 1978) to assist in weaving the 
deconstructed or fractured story back together rather than forcing and complicating it.  
Theoretical codes can sharpen the theoretical analytical edge and can assist with identifying 
and understanding temporal and structural ordering and thus processes (Glaser and Strauss, 
1967).The grounded theory to explain why patients delay reporting neutropenic sepsis was 
developed through application of a theoretical coding model developed by Morrow and Smith 
(1995) to developing categories (figure 4.4).  This facilitated questioning processes in the data 
in terms of: 
 
(a)  The causal conditions that trigger participants’ responses to the threat of neutropenic 
sepsis.  
(b)  The central phenomena or core explanatory category, which provides a conceptual 
explanation for why patients and carers adopt particular coping strategies. 
(c)  The contextual conditions that show how systems and processes might influence how 
patients respond. Contextual conditions are identified by asking where, when and 
how the central phenomena /core explanatory category happens and with whom. 
(d)  The intervening conditions or factors that might influence different participant 
responses.  (Intervening conditions are termed moderators within the patient-centred 
communication model).  
(e)  The strategies or reactions and behaviours patients adopt to deal with the central 
phenomena / core category.   
(f)  The consequences of strategies employed by patients to cope with the threat of 






Figure 4.4. Model framework (Morrow and Smith 1995; p305) 
For permission see appendix 2  
 
      Context 
 
Causal conditions          Central Phenomena            Strategies               Consequences 
                                            (Core category)        
        Intervening Conditions  
              (Moderators) 
 
 
As categories developed, theoretical coding also involved validating proposed connections 
through searching data for confirmatory and contradictory accounts and by adding to 
categories that needed further filling out in terms of dimensions or properties.  Disconfirming 
accounts amended and extended the data.  The coding process continued until categories 
were filled out in terms of properties and dimensions.  This is termed data saturation which for 
grounded theory signals that new data will not add to the development of identified categories 
or identification of new ones.  This does not mean stopping data collection when the 
researcher is hearing the same stories, rather:  
 
Categories are ‘saturated’ when gathering fresh data no longer sparks new 
theoretical insights, nor reveals new properties of your theoretical categories…..it 
is not the same as witnessing repetition of the same events or stories…  
                (Charmaz, 2006, p. 113) 
 
Analytical tools including, constant comparison, the flip flop technique and memos and 
diagrams continued to be employed to integrate and delimit the theory around an identified 
core explanatory category to which the other categories were related.  The core category 
meets the criteria set out by Juliette Corbin at the Summer School as an abstract concept that 
represents the complete picture as a process (e.g. Playing down the seriousness) or a 
phenomenon (e.g. fear).  Although abstract it should remain grounded in the data (Glaser and 
Strauss 1967).  Corbin and Strauss (2008) states the core category should be applicable and 
identified in each case studied and that other categories should interact with it without forcing 
the relationship.  Finally, the theoretical framework should be applicable to study other 
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situations to generate the theory further.  The completed model represented a theoretical 
representation of the research findings.   
 
The linear but non sequential process employed to develop  the grounded theory is illustrated 
within  figure 4.5 which was presented by (Tarozzi, 2012) at the Grounded Theory Summer 
School in Italy.  This demonstrates the inductive nature of grounded theory with continuous 
movement between data collection and analysis, whilst applying analytical tools to gradually 
develop the emerging theory. 
 
 
Figure 4.5. Che cos¹è la grounded theory.Roma:Carocci (Tarozzi, 2008). 




4.8 Research rigour 
Published grounded theory studies are sometimes criticised for paying lip service to using the 
approach, rather than using this accurately.  This is because some researchers apply grounded 
theory techniques to analysis, rather than embedding the research process throughout the 
whole study (Tarozzi, 2012).  Research rigour was in part achieved through acquiring the 
necessary knowledge and skills to become an ethnographer and grounded theorist.  Training 
commenced prior to undertaking this research and new skills and knowledge were robustly 
applied to this study.  This was achieved through wide reading of relevant literature, 
attendance at the Grounded Theory Summer School in Italy in 2012 and follow-on support 
throughout the thesis from Juliet Corbin.    
 
Positivist researchers have criticised qualitative approaches for lacking methodological 
controls core to scientific research.  Postmodern qualitative researchers counter these 
criticisms by arguing that qualitative research gets nearer to reality than the quantitative 
approach.  Qualitative research can lead to a more accurate representation of social worlds 
which are changing entities that are created, recreated and perceived by people within them.  
Qualitative researchers do not take data as factual and separate from the people it relates to.  
Rather, they generate knowledge of social worlds through voices of participants within them 
who are best understood in their own familiar environments.  Data, including interviews and 
observation notes reflected experiences of delayed attendance to hospital with neutropenic 
sepsis.  This is because they were gathered and analysed within systematic, rigorous, 
transparent and trustworthy research processes which are inbuilt to post modern 
constructivist research.   
 
Reflexivity is presented as the key solution to what is termed the crisis of representation of 
qualitative researchers, who align themselves with the positivist paradigm (Hammersley and 
Atkinson, 2007).  Qualitative researchers are part of the social world under study and work in 
close proximity to the research field.  Consequently, data and analysis were in part informed 
by clinical experience, identity, background, cultural beliefs, views and the authority and 
relationships built with participants.  The aim of reflexivity was to ensure transparency about 
role and effect on data generation and analysis.  Diaries written whilst undertaking the data 
collection, and memos about data interpretation were used to explore how prior held 
thoughts, views, clinical experiences, beliefs and authority might impact upon the data 
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collection and analysis.  Critical reflection particularly focused on presence in the research field 
and perspectives on the data collected and how these related to a position as an experienced 
chemotherapy nurse.  Importantly, a key role of academic supervision during the development 
of this thesis was to support reflexivity. 
 
Research rigour is also made visible within this thesis through demonstration of researcher 
integrity.  This is achieved through showing how field relationships were forged and how data 
saturation was achieved, by making clear problems encountered through the research process 
and including, within research reports, the process for data categorisation and interpretation.  
This was further achieved through considering alternative explanations for data organisation 
and providing numerous rich and contradicting participant quotations to allow the reader to 
make their own interpretations.  This demonstrated data complexity through not positioning 
this as a neat representation of the social world under study and looking for and discussing 
















Chapter summary:  
Data were collected from participants including women who were prescribed chemotherapy 
for breast cancer, their carers and clinicians.  They participated in non-participant 
observations of chemotherapy information sessions and in-depth interviews.  Ethnography 
was employed for data collection.  Constructivist grounded theory (Charmaz, 2006) was 
applied to direct data collection and analysis and to develop a theory that was grounded in 
the data.  The ethnographic approach facilitated understanding of the culture within which 
neutropenic sepsis was managed through observation and participants telling their stories in 
their own words.  This was assisted by the iterative process of grounded theory which 
encouraged deep exploration of emotions, beliefs and perceptions.  This generated data 
which when reconstructed illuminated experiences and taken for granted constructs that 
informed behaviours related to reporting of neutropenic sepsis.    
 
Grounded theory enhanced ethnography because the focus was on understanding social 
processes, interaction and meaning, at a conceptual level rather than through description, 
whilst making clear the position of the researcher in constructing knowledge (Charmaz, 
2006).  Grounded theory ethnography led to focused and reduced data collection because 
data analysis began at the start of the research process and drove data collection.  Similar 
data were not collected and analysed at the end of the research as with other qualitative 
methods.  Rather, data were gathered to develop categories and data that would not add to 
emerging or completed categories ceased to be pursued (Charmaz and Mitchell, 2001, 
Charmaz, 2006, Timmermans and Tavory, 2010).  Ongoing analysis and data collection 
lessened the chance of missing something important and enabled development of a more 
complete rich description, likely to be aligned with respondents’ experiences.  Grounded 
theory also made sense of ethnographic data that can feel unconnected.  It enhanced 
researcher sensitivity to the emerging theoretical concepts and progressed ethnography 
towards theory development (Charmaz and Mitchell, 2001, Charmaz, 2006).  Grounded 
theory and ethnographic methods were appropriate as reasons that patients delayed 
presenting to hospital with neutropenic sepsis were unknown.  It was envisaged that 














Chapter Five: Characteristics of 
participants and application of 
analytical techniques to generate 




5.1 Introduction  
Data were collected over a 15 month period between 25.11.11 and 13.2.13 from 35 
participants, including women with breast cancer (n=13), their carers (n=9) and clinicians 
(n=13).  The longitudinal element of the study included observation of interactions where 
clinicians explained neutropenic sepsis to patients and carers, informal interviews immediately 
after witnessed interactions and one in-depth interview with observed patients following their 
final chemotherapy treatment.  A pilot patient participated in two additional interviews during 
the course of her chemotherapy to inform the study design.  The retrospective study element 
consisted of in-depth interviews with patients following an admission to hospital for treatment 
of neutropenic sepsis, clinicians who engaged with patients about neutropenic sepsis and 
carers of patients who developed symptoms of this.  Detail regarding participants who were 
recruited solely to the longitudinal or retrospective elements or both of these is provided 
within table 5.1.  Participants were offered the conduct of in-depth interviews either face to 
face at home/ hospital or by telephone.  In the event, the majority of interviews took place 
within the hospital or over the telephone for participant convenience (table 5.2). 
 









Patients  5  8  - 13 
Carers 3 6 - 9 
Doctors   3 2 5 
Nurses 5 1 2 8 




Table 5.2. Location of in-depth interviews 
 Home Hospital  Telephone Total 
interviews 
Patients 1 (3 interviews) 
Pilot patient. 
4 (4 interviews) 8 (9 interviews) 16 
 Carers   6 (6 interviews) 6 
Clinicians  9 (9 interviews)  9 
Total 3 13 15 31 
 
 
5.1.1 Reasons provided for declining to participate in the study   
Two patients declined to participate in the longitudinal study element; one because she did 
not think she would gain anything from the interactions and the second because she did not 
want to stay for informal interviews following chemotherapy appointments.  A further patient 
was willing to participate in the longitudinal element but was introduced to the researcher on 
the day of her chemotherapy consent appointment, so informed consent could not be 
obtained in advance.  One patient and two carers did not provide reasons for declining to 
participate in an in-depth interview and a further two carers did not respond to the invitation 
passed onto them by patients.  No clinicians declined to participate. 
 
5.1.2 Sampling strategy  
Four conceptual categories to explain the theory about why patients delay presenting to 
hospital with symptoms of neutropenic sepsis were developed through constant comparison 
and theoretical sampling which are core to grounded theory.  Hypotheses about emerging 
findings were developed through constant comparison which involved comparing everything 
everywhere including participants’ accounts, stories, actions and responses (Charmaz and 
Mitchell, 2000).  Theoretical sampling is evident within table 5.3 which details a flexible, co-
ordinated but not sequential process to recruit participants over a period of 15 months.   
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Sophia Ox2 I I     I                     
Sophia's Husband       I                         
Doctor 1 (ONC) O             I                 
CNS 1     (BCN) O     I                         
CNS 2     (CTN) O           I                   
Adanna               O               I 
Adanna's Friend               O                 
Doctor 2 (ONC)               O                 
CNS 4     (BCN)               O                 
Melanie               O O       I       
Melanie's Friend                 O               
Doctor 1 (ONC)               O                 
CNS 5     (BCN)               O                 
CNS 6     (CTN)                 O               
Melanie's 
husband 
                          I     
Jackie                 Ox2       I       
Jackie's Friend                 Ox2               
Doctor 1 (ONC)                 O               
CNS 5     (BCN)                 O               
CNS7      (CTN)                 O               
Hannah                   O I       I   
Doctor 2 (ONC)                   O       I     
Lynda     I                           
Lynda's Mother       I                         
Paula       I                         
Sam       I                         
Helen         I                       
Zeena         I                       
Zeena's Niece               I                 
Wendy               I                 
Fayola                   I             
Fayola's Husband                     I           
Alice                         I       
Alice's Friend                         I       
Doctor 3 (on call)                   I             
Doctor 4 (on call)                       I         
Doctor 5 (A&E)                         I       
CNS 3 (CTN)               I                 
CNS 8 (A&E)                         I       
                 
  Patient participant ONC (Oncologist)     
  Clinician participant BCN (Breast Care Nurse)   
  Carer participant CTN (Chemotherapy Nurse)   
O Observation         
I Interview         
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Data were collected only from participants and at times when they were of interest to the 
developing theoretical categories.  Furthermore, gaps in data collection illustrate breaks taken 
to reflect on the emerging theory and new areas of inquiry to pursue in order to develop this 
further.  Theoretical sampling represents a different approach to other qualitative methods 
where data is collected prior to analysis.  Application of theoretical sampling to this study 
ensured data collection ceased when new information did not add to the theory, rather than 
burdening participants through unnecessary data collection.   
 
5.2 Patient and carer summary 
A contextual summary for each patient and carer is provided in table 5.4.  The aim is to 
illuminate demographics and characteristics of each participant and a synopsis of stories 
related to delayed presentation to hospital with neutropenic sepsis.  Pseudonyms are used 
throughout.   
 
5.2.1 Patient participants (Including the pilot patient) 
Pilot data gathered from Sophia informed the design of the longitudinal element.  Sophia was 
observed being provided with information about neutropenic sepsis by a doctor during a 
chemotherapy consent appointment and during a separate information session with a 
chemotherapy nurse.  She also participated in three in-depth interviews over a five month 
period: on day seven of her first chemotherapy treatment, at the midpoint of chemotherapy 
and following completion of this.  Pilot work demonstrated the benefits of non-participant 
observation.  A close relationship that developed with Sophia over a five month period 
enabled in depth exploration of her thoughts and feelings related to her preparation to 
recognise and report signs and symptoms of neutropenic sepsis.  This was later explored in 
relation to her accounts of willingness or ability to do so.  Importantly, there were also 
opportunities to reflect and follow up on topics of interest identified during observations 






Table 5.4. Contextual summary of patient and carer participants  
Patient Contextual summary 
PILOT PATIENT 
Pt 1.  Sophia  




Sophia was 64 years old and lived with her husband.  They both 
worked within healthcare, were highly educated, analytical and self 
reflective and had two adult children who lived away from home.  
Sophia was recruited as a pilot patient and her husband was also 
interviewed.  Sophia was followed most closely and unlike other 
patient participants knew the study focus was neutropenic sepsis.  
Sophia was independent and devastated when instructed by a breast 
nurse to stop working during chemotherapy.  She attended 
chemotherapy consultations alone and lived under the shadow of 
possible metastatic disease from the start of chemotherapy.  Bone 
secondaries and thus a likely reduced life expectancy were confirmed 
midway through treatment.  Sophia knew what neutropenic sepsis was 
before starting chemotherapy, but she delayed presenting to hospital 
with infections on two occasions.  On the first occasion she waited to 
attend a routine clinic appointment.  On the second occasion Sophia 
was abroad with her husband who purchased antibiotics from a 
chemist.  They delayed calling and ignored advice from the helpline to 
attend a local hospital and instead caught a plane home. 
Pt 2.  Lynda  







Lynda was a 44 year old independent professional who received 
adjuvant chemotherapy and attended chemotherapy information 
sessions alone.  She took responsibility for and held the knowledge 
about her treatment.  Lynda did not want to be seen as a sick person 
and lived with her male partner who was not involved with her 
treatment.  Lynda’s mother was interviewed and travelled a long 
distance from her home to provide practical help after each of Lynda’s 
chemotherapy treatments.  Lynda was protective of her mother who 
was distressed by her daughter’s diagnosis.  Lynda developed 
neutropenic sepsis and delayed presenting to hospital for several 
hours, claiming not to initially recognise her symptoms as important.  
Lynda considered hospital care during her admission with neutropenic 
sepsis was poor because she believed the clinicians concerned lacked 
the necessary expertise.    






Paula was a 52 year old hospital clerical worker.  She had an active 
social life and lived between her home and her partner’s home.  Paula 
had metastatic breast cancer and did not perceive she had a good 
relationship with the oncology team.  Paula was given bad news about 
her diagnosis and was provided with information about neutropenic 
sepsis at the same appointment. She delayed presenting to hospital 
with severe mucositis and developed neutropenic sepsis the day 
following her admission to hospital.  On another occasion she delayed 
presenting with diarrhoea.  On both occasions Paula initially attended 
her General Practitioner (GP). 
115 
(Table 5.4. continued) 
Patient Contextual summary 






Sam was a 45 year old woman who received adjuvant chemotherapy 
for breast cancer.  She lived with her husband and children aged 3, 8 
and 11 years.  Sam, like Lynda took responsibility for and held the 
knowledge about her treatment and her husband was not involved in 
her chemotherapy treatment.  Sam called the helpline when she 
developed generalised pain due to Docetaxel chemotherapy and felt 
she was made to feel a “bother”.  Sam subsequently did not call when 
she developed a sore throat and felt significantly unwell.  A doctor at 
the next hospital visit made Sam feel she could call the hotline.  She 
consequently called when she developed neutropenic sepsis following 
her second Docetaxel treatment.  Sam delayed attending the hospital 
because she waited for her husband to get home from work to look 
after the children. 







Helen was a 62 year old retired woman who received chemotherapy 
for metastatic breast cancer.  Helen lived with her husband and her 
daughter lived nearby.  Helen developed early chemotherapy side 
effects, called the helpline and was advised to go to her local hospital.  
Helen felt a nuisance for bothering A&E staff (about non-serious 
chemotherapy side effects) and was sent home.  As Helen became 
more unwell due to neutropenic sepsis she did not call the hotline, 
rather her daughter called Helen’s GP when Helen became seriously ill.  
Helen’s experience of her treatment for chemotherapy side effects 
caused her to lose confidence in the clinical team, so she decided to 
stop chemotherapy. 
Pt 6.  Zeena  





Zeena was a 61 year old widow from Somalia who was undergoing 
adjuvant chemotherapy.  She lived with her two adult sons whom she 
appeared to exclude from her treatment.  Zeena’s niece was also 
interviewed, who was single and lived near to Zeena with her one year 
old child.  Zeena’s niece was the key person to support her during 
chemotherapy and they held the knowledge about chemotherapy 
rather than Zeena’s sons.  Zeena felt unwell for several days before 
being persuaded by her niece rather than her sons to call the helpline.  
Zeena and her niece spoke positively about their experience of calling 







(Table 5.4. continued) 
Patient Contextual summary 






Wendy was 61 years old, lived alone and did not work.  She was 
undergoing adjuvant chemotherapy for breast cancer and her key 
source of support was her sister, who travelled a long distance from 
her home in Scotland to provide practical help following each 
chemotherapy treatment.  Wendy had another sister who was dying 
from breast cancer.  Wendy did not present to hospital when she 
became unwell with symptoms of neutropenic sepsis following 
chemotherapy.  On a subsequent occasion when Wendy developed 
neutropenic sepsis she was persuaded to contact the hospital by her 
sister. Wendy waited to call a breast nurse whom she knew rather 
than calling the hotline number.   





Adanna was 56 years old, married and attended chemotherapy 
information sessions with her friend.  She had a strong religious faith 
and did not believe she would develop an infection.  She regularly 
travelled between the UK and Africa and was reluctant to stop doing 
this during chemotherapy.  Adanna was not someone who sought out 
information about chemotherapy and preferred such information to 
be provided in a straightforward fashion.  It apparently, did not upset 
her when the doctor told her that infections can be fatal and she may 
not get the right care if she developed an infection in Africa.  She took 
the doctor’s advice seriously and did not travel.  Adanna did not 
develop an infection during chemotherapy.  When she developed 
other chemotherapy side effects she called her breast care nurse, 
rather than the helpline. 
P9.  Melanie 
C9a Friend 





Melanie was a 56 year old confident company director, for whom 
working during chemotherapy was important for a sense of normality.  
Melanie attended the chemotherapy consent appointment alone and 
was accompanied by her friend for moral support for the first nurse-
led chemotherapy treatment and information session with a nurse.  
Melanie described herself as a detailed person who sought and 
checked out information until she believed she had all she needed.  
Melanie said she followed instructions, but explained she delayed 
presenting to hospital with two infections because she did not 
recognise her symptoms as important and did not believe clinicians 
could help her.  Melanie’s husband was also interviewed and she 
described him as the diametric opposite to her.  He said he did not do 
his own research, relied on Melanie to give him important information 
and was unable to persuade her to contact the hospital when she 
became unwell with symptoms that may have indicated neutropenic 
sepsis.    
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(Table 5.4. continued) 
Patient Contextual summary 
P10.  Jackie  




Jackie was a 53 year old divorced personal assistant who lived alone 
but near to her sister.  Jackie and her sister had recently suffered a 
bereavement and were both devastated by her cancer diagnosis.  
Jackie had a wide circle of friends who accompanied her to 
chemotherapy information sessions for moral support.  Jackie’s sister 
did not attend and was unable to persuade Jackie to call the helpline 
when she developed debilitating diarrhoea.  Jackie was reluctant to 
keep calling the helpline because she felt she was becoming a bother. 
P11.  Fayola  






Fayola was a 31 year old care home assistant who lived with her 
husband and two year old child.  Fayola was in control of her 
chemotherapy treatment and made final decisions regarding this.  She 
underwent adjuvant chemotherapy and delayed presenting for several 
days when she developed neutropenic sepsis because she and her 
husband did not perceive her symptoms to be important.  An 
indication that Fayola did not take neutropenic sepsis seriously was 
further evident when she eventually called the helpline from work. She 
was advised to go to hospital, but finished her shift in a nursing home 
first. 





Hannah was a 74 year old retired nurse.  She had experience of friends 
who benefited from chemotherapy but a friend and a brother had also 
died from cancer.  She had a wide circle of friends but lived alone and 
appeared isolated.  She had suffered with depression for many years 
and appeared low during interviews.  Hannah said her friends worried 
she would not report chemotherapy symptoms because her inclination 
was to ignore serious symptoms, as she had done when she previously 
had a transient ischemic attack and when she found a breast lump, 
which she strongly suspected was cancer and turned out to be so.  
Hannah did not think she would be ill during chemotherapy and 
aligned herself with apparently well patients undergoing 
chemotherapy.  She did not call when she developed a fever and 
diarrhoea following her first chemotherapy treatment. She did present 
without delay on a second occasion because a doctor she had a good 






(Table 5.4. continued) 
Patient Contextual summary 










Alice was a 61 year old therapist who lived alone.  During an 
appointment with a doctor Alice was told she had metastatic breast 
cancer, provided with information about chemotherapy side effects and 
signed the chemotherapy consent form.  Alice was an intelligent, 
independent woman who appeared anxious and talked a lot.  She was 
devastated by her diagnosis, wanted all the information and took 
friends to chemotherapy information sessions to note this down as well 
as for moral support.  Alice’s friend lived a long distance away and came 
to her chemotherapy information sessions.  Alice followed instructions 
implicitly but delayed reporting symptoms of neutropenic sepsis, 
explaining she did not recognise these as significant.  Her friend who 
had accompanied Alice to chemotherapy information appointments was 
able to persuade her to call the helpline.  Alice was advised to go to A&E 
but was sent home despite having a low white count.  Alice was 
subsequently asked to return to hospital by an oncology doctor, but 
refused stating this was because they had a poor relationship and she 
wanted to enjoy a planned day out.   
 
 
Pilot work informed revisions of the research protocol which was taken back to the ethics 
committee as a minor amendment (appendix 2).  Revisions included addition of digital audio-
recording of observed chemotherapy consultations between clinicians and patients, to 
improve recall and concentration on witnessed interactions.  Sophia was aware at the outset 
the research focus was on neutropenic sepsis, which in retrospect might have altered her 
perception and behaviour.  Subsequent patients were consequently informed the study intent 
was to explore their experience of chemotherapy side effects.  They were informed only at the 
end of treatment interview that the study focus was on neutropenic sepsis.  The pilot further 
identified one interview at the end rather than three throughout treatment would reduce 
patient burden.  The first interview, carried out at day seven of chemotherapy, was removed 
from the protocol.  This was because captured data about the pilot patient’s experiences and 
views of information and support provided about neutropenic sepsis could have been 
gathered within the observation period.   
 
The second interview scheduled for mid treatment was also removed from the study protocol 
because Sophia’s experience of two infections she developed during chemotherapy could have 
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been captured within her final interview.  Consequently, four subsequent patients who were 
recruited to the longitudinal element were not interviewed on day seven or at the mid 
treatment point.  Rather, they were recruited to participate in non-participant observation of 
chemotherapy information appointments conducted separately with a doctor and a 
chemotherapy nurse and one end of treatment in-depth interview.  Scheduling conflicts due to 
the researcher being on annual leave resulted in missed opportunities to observe Adanna and 
Hannah’s information sessions with a chemotherapy nurse.  An additional interview was 
carried out with Hannah shortly after the unobserved appointment which captured her 
experience of initial information and support provided by chemotherapy nurses.  This was not 
possible for Adanna who did not respond to attempts to contact her by telephone. 
 
During the third month of pilot data collection following non-participant observation and 
interviews with Sophia, her husband and the clinicians providing her care, initial concepts 
began to emerge to pursue with other participants.  Audio recorded retrospective in-depth 
interviews (offered face to face at home / hospital or telephone) were then commenced with 
participants identified through theoretical sampling and constant comparison as important to 
the developing theory.  In depth interviews carried out with patients (n=8) following an 
admission to hospital with neutropenic sepsis enabled explorations of their perceptions of 
information and communication about neutropenic sepsis, beliefs about this condition, 
admission to hospital and any delays in identification and treatment of it.  Constant 
comparison raised hypotheses about patient characteristics that may have influenced delayed 
presentation.  Consequently, a range of patients were recruited (table 5.5) to the longitudinal 
(n=4) and retrospective (n=8) elements through theoretical sampling.  Patients’ ages ranged 
from 31 to 74 years and ethnicity was mixed; for five patients English was not their first 
language.  Five out of thirteen patients lived alone and one did not have an identified carer. 
There was an imbalance in educational status as nine patients held degree level qualifications 
or above.  Disease status became of interest during the research.  However, clinicians 
appeared to find it more difficult to identify patients for the study who had metastatic or 






Table 5.5. Patient demographics (n=13) 







Regimen   
FEC (5-Fluorouracil, Epirubicin, 
Cyclophosphamide)  and a Taxane           
4 
FEC (5-Fluorouracil, Epirubicin, 
Cyclophosphamide)  OR EC  
Epirubicin, Cyclophosphamide)               
5 
Docetaxel   3 
Docetaxel & Cyclophosphamide    1 
Treatment Intention  
Palliative                    4 
 Adjuvant                    9 
Living Arrangements   
Alone 5 
Husband/partner 7 
Identified carer 10 
Adult children 1 
Ethnic Group  
White 8 
Black British 1 
Black African 2 






(Table 5.5. continued) 
 Number of patients 
Education   
Secondary School 4 
College degree 1 
University degree 5 
Post graduate degree 3 
Occupational group   




Employment status  
Never worked 2 
Not working due to ill health 5 
Retired 2 
Working part time 1 
Working full time 3 
Dependents  
Child under 18 2 
Elderly or sick relative 0 
 
 
5.2.2 Carer participants  
Carers (n=9) were recruited through patients.  Three carers participated in the observation 
element and six each took part in an audio recorded in-depth interview.  Accounts of carers of 
patients who had been admitted to hospital with neutropenic sepsis or who had developed 
infections were pursued as these appeared most significant to the developing theory.  
Theoretical sampling resulted in a range of carer characteristics (table 5.6).  A range of 
relationships were also represented and 50% of carers lived with patients.  Some carers were 
recruited because patients identified them during interviews as assisting in the identification 
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and reporting of neutropenic sepsis symptoms and others because they did not appear as 
involved.  Carers were highly educated and all held qualifications of degree level or above. 
 
 
Table 5.6. Carers demographics interviews (n=6) 
 Number of carers 





Living with patient  
Yes             3 
No 3 
Ethnic group  
White 2 
European 1 
Black African 1 
African Asian 1 
Italian 1 
Education   
Secondary School 0 
College degree 0 
University degree 3 
Post graduate degree 3 
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(Table 5.6.  continued) 
 Number of Carers 
Occupational group   




Employment status  
Never worked 0 
Not working due to ill health 0 
Retired 1 
Working Part time 1 
Working Full time 3 
Student 1 
Dependents  
Child under 18 3 
Elderly or sick relative  0 
 
 
5.2.3 Clinician participants  
Thirteen clinicians were recruited, four of whom took part in observation and in-depth 
interviews, a further four took part in the observation element only and five participated in an 
in-depth interview only.  Demographical details provided in table 5.7 demonstrate that the 
majority of doctors were male and the majority of nurses were female.   
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Table 5.7. Clinician demographics (n=13) 
 








Doctor 1  F Consultant Medical 
Oncologist  
√  √ 
Doctor 2  M Consultant Medical 
Oncologist  
√  √ 
Doctor 3  M Clinical Fellow in Medical 
Oncology 
  √ 
Doctor 4  M SPR    √ 
Doctor 5  M A&E Consultant     √ 
CNS1 F Breast Care Nurse  √  √ 
CNS2  M Chemotherapy Nurse   √ √ 
CNS3 F Chemotherapy Nurse    √ 
CNS4 F Breast Care Nurse  √   
CNS5 F Breast Care Nurse  √   
CNS6 F Chemotherapy Nurse   √  
CNS7 F Chemotherapy Nurse   √  
CNS8 F A&E Nurse    √ 
Total    5 3 9 
 
 
Initially, the recruitment of clinicians were confined to members of the breast cancer team 
including chemotherapy nurses, breast care nurses and oncology doctors who provided 
information about neutropenic sepsis to patients.  Theoretical sampling next led to the 
recruitment of clinicians who managed the on call service or who worked within the A&E 
department.   
 
Two doctors who manned the chemotherapy helpline were recruited because early analysis 
suggested patients did not want to use the service.  Furthermore, observed doctors (unlike 
chemotherapy nurses) were not directly involved in providing this service.  Analytical 
questioning developed through memo writing directed exploration of perspectives of these 
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doctors about dealing with patient calls.  These included types of conversations held with 
patients about neutropenic sepsis and any competing pressures or frustrations.  A nurse and a 
doctor who worked within the A&E department were also recruited.  This was because 
patients, carers and oncology clinicians indicated patient’ experiences of being treated for 
chemotherapy side effects within A&E departments impacted on their willingness to attend 
again.  Areas of enquiry that emerged as important during analysis that were explored with the 
two recruited A&E clinicians included experiences of: communicating with the oncology team; 
patients’ awareness of neutropenic sepsis and any thoughts about why they might delay. 
 
 
5.3 Application of analytical techniques  
5.3.1 A worked example 
The grounded theory approach enabled development of four conceptual categories made up 
of 11 properties.  These evolved and were reconstructed to develop a theory grounded in the 
data.  This describes why patients delay presenting to hospital with symptoms of neutropenic 
sepsis.  Categories include: “Playing down the seriousness and piling on the fear” (Core 
category); “Getting away with It”; “Making the connection” and “Relationships core to 
accessing help”.   
 
Categories were developed and collapsed to represent the emerging theory.  For example the 
categories “Relationships facilitate adherence” and “Accessing help” were combined to the 
more conceptual category “Relationships core to accessing help.” Properties that conceptually 
described the same phenomena were also collapsed and the most pertinent title chosen.  
Categories and properties that became irrelevant to the theory including “chemotherapy 
brain” were discarded.  A summary of coding phases is presented in table 5.8 and examples of 







Table 5.8. Coding phases: summary 
Coding phases Dates Data sources  Codes Categories  




First 10 80  (allocated to 
PCC domains) 
- 




First 22 156 (allocated to 
PCC domains) 
- 





First 22 41 6 early 
categories 
















5.3.2 Developing the core category 
A worked example focuses on the development of the core category (Playing down the 
seriousness and piling on the fear). Coding phases (table 5.9) included initial coding. This 
involved staying close to the data to identify 32 descriptive codes that formed the early 
category.  Initial descriptive codes were transcribed onto strips of paper and those that 
appeared conceptually similar were clustered together (see figure 4.2., p101). This process 
resulted in the category provisionally being labelled “Conveying the seriousness”.  Properties 
were further refined by collapsing / joining together initial codes that essentially described the 
same process.  For example the following initial codes were grouped or collapsed under the 
more conceptual property, “Playing down the seriousness, skirting round the issue.”: 
 
“Playing down the seriousness, skirting round the issue;” “Saving face avoiding criticism;” 
“Seeking to reassure;” “Focusing on infections”; “Backed into a corner”, “Resenting 
chemotherapy”; “Giving the worst case scenario” and “Not engaging in conversations about 
serious side effects”. 
  
The early category was made up of six properties.  Further focused coding narrowed properties 
to four and developed the more abstract and conceptual category title, “Playing down the 
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seriousness piling on the fear.” Conceptual development of the category is further evident 
through collapsing the properties “Fearing dying” and “Requiring chemotherapy brings home 
the seriousness of my situation - being hit by the gravity” to develop a final property entitled 
“Reality hitting.”   
 
Focused coding was assisted by systematic comparison, memo writing and diagrams employed 
to build the category and to explore dimensions within this.  As data were collected the 
language used by participants, emotions expressed metaphors and similes and negative cases 
were explored and particular attention paid to anything puzzling and red flags which indicated 
areas for further enquiry.  Sensitising concepts were used to ask questions of the data, to look 
for what was behind the text, to move the theory along.  Reflective thought included asking 
what seemed to be going on, and what struck as significant about it.  This process is 
demonstrated through building up an interconnected picture of thoughts, beliefs, actions and 
consequences in relation to conveying the seriousness of neutropenic sepsis.   
 
Analytical thinking behind the development of the core explanatory category; “Playing down 
the seriousness and piling on the fear” and the four properties within it is next described.  




Table 5.9. Coding phases to develop the core category 
 
Phase two.  Initial coding 
(32) 
Phase three.  Focused 
coding (6).  Category: 
Conveying the 
seriousness 
Phases four and five 
Focused coding (4).  
Playing down the 
seriousness, piling on the 
fear 
Uncertain if patients will 
call 
Property one.  
Clinicians 
worrying/frustrated 
Property one.  
Holding in the frustration 
Frustrating for clinicians  
Worried clinicians 
Playing down the 
seriousness, skirting round 
the issue 
Property two. 
Playing down the 
seriousness, skirting 
round the issue 
Property two. 
Playing down the 
seriousness  
Backed into a corner 
resenting chemotherapy 
Seeking to reassure 
Providing prophylaxis 
Not engaging in 
conversations about 
serious side effects 
Giving the worst case 
scenario 
Saving Face avoiding 
criticism  
Focusing on infection 
Recognising and informing 
riskier patients 
Property three.  
Informing riskier patients  
Property three.  
Piling on the fear 




Drumming it into me, it’s 
their job  
Instructing and obeying the 
rules 
Making me accept the risk  
Drip feeding  timing of 
information 
Scary information 
No time to take it in 
Standard repertoire – going 
through the motions 
Property four. 
Standard repertoire.  






Having enough time for me 
Developing a rapport 
Explaining my personal risk 
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(Table 5.9.  continued) 
 
Phase two Initial coding 
(32) 
Phase three.  Focused 
coding (6).  Conveying 
the seriousness 
Phase four and five. 
Focused coding (3) 
Playing down the 
seriousness, piling on the 
fear 




brings home the 
seriousness of my 
situation: Being hit by the 
gravity  
Property four. 
Reality hitting  





Dealing with cancer 
uncertainty 
Property six.  
Fearing dying  
Dealing with other 
bereavements 
Fearing I might die 
 
 
5.3.2.1 Property one:  Holding in the frustration 
Initial enquiry with clinicians focused on their experiences of patients who delayed presenting 
to hospital with neutropenic sepsis and beliefs about why such delays occurred.  Clinicians 
expressed frustrations associated with this, and these appeared important so were explored 
further to identify why these happened and the impact of these on communication with 
patient and carers about neutropenic sepsis (See Property two: Playing down the seriousness 
and Property three: piling on the fear). 
 
5.3.2.2 Property two:  Playing down the seriousness 
Conflicting or negative accounts that appeared to challenge the emerging theory were 
compared.  For example, clinicians believed they explained the risks and symptoms of 
neutropenic sepsis to patients but some patients and carers denied knowledge of this.  
Constant comparison between clinicians’ accounts of their feelings and observation of their 
practice in relation to explaining neutropenic sepsis to patients underpinned the property, 
“Playing down the seriousness.” This was also informed by patient’ and carer’ accounts of their 
reactions to hearing about neutropenic sepsis and written explanations of it.  A discomfort was 
identified in that clinicians avoided fully explaining neutropenic sepsis to patients who often 
also did not want to hear about it.  
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The flip flop technique, described by Corbin and Strauss (2008) involved thinking about a 
concept and what the opposite perspective might be, in order to generate new questions to 
ask of the data.  Consequently, thought was given to what it might be like for patients and 
carers to be explicitly told about the risk of death from neutropenic sepsis.  Discussions with 
subsequent patients and carers explored their understanding of neutropenic sepsis and the 
risk of death. They were also asked how they would have felt about being given this 
information before starting chemotherapy.  Questioning of clinicians and the data further 
focused on gaining a greater understanding of clinicians’ feelings and attitudes about talking 
with patients about the risk of death from neutropenic sepsis and occasions where this was 
more or less explicitly explained and why.   
 
5.3.2.3 Property three:  Piling on the fear  
Observation of the tone and language used by clinicians to explain neutropenic sepsis to 
patients identified that this explanation did not appear personalised and lacked emotion. The 
need to attend hospital if unwell was also often repeatedly stressed.  Clinicians were asked 
about their relationships with patients and carers and how they coped with providing the same 
information about chemotherapy side effects to multiple patients.  This was to identify any 
connections between this and their frustrations (See Property one: Holding in the frustration) 
and apparent unwillingness to speak about neutropenic sepsis with patients (See Property 
two: Playing down the seriousness).   
 
Focused questioning with patients and carers explored perceptions about their relationships 
with clinicians, their experience of information provided about neutropenic sepsis and their 
reactions to it.  Most patients feared and did not want to hear about neutropenic sepsis. 
Properties in grounded theory are extended or developed through seeking out disconfirming 
cases. A conflicting account enabled greater understanding of fear that affected patients’ 
ability to hear about neutropenic sepsis. Melanie, unlike other patients, understood 
neutropenic sepsis and was not fearful of it. However, she appeared unable to hear about it 





5.3.2.4 Property four: Reality hitting 
During observed consultations with clinicians, patients appeared to become progressively 
anxious as chemotherapy side effects were explained.  In order to better understand this, 
patients and carers were asked about pre-existing emotions.  It emerged fears related to 
having a life-threatening illness and starting chemotherapy were important to engaging with 
information about neutropenic sepsis.  This led to close observation of the language used by 
clinicians (See Property three: Piling on the fear) and focused exploration with patients and 
carers about why this information made them feel anxious.  As this property developed, it 
became clear that information about neutropenic sepsis heightened fears and further 
attention was paid to how different patients and carers were affected by and reacted to this 
information. 
 
The four properties were brought together as different facets to develop the overall category 
of “Playing down the seriousness and piling on the fear.”  This conceptually defined a process 
where clinicians who were frustrated by patient delays in reporting neutropenic sepsis and 
uncomfortable about talking about the risk of death attempted to convey the risks of 
neutropenic sepsis by frightening patients but not explaining why this could be dangerous.   
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Chapter summary:   
Data were generated over a period of 15 months from 35 participants who included women 
with breast cancer undergoing chemotherapy (n=13), their carers (n=9) and clinicians, 
comprising of nurses (n=8) and doctors (n=5).  The longitudinal element was refined through 
recruitment of a pilot patient.  For subsequent patients this involved observations of two 
appointments where neutropenic sepsis was explained to patients and carers by clinicians 
and informal interviews about witnessed events.  One in-depth interview was further 
conducted with patients following their final chemotherapy treatment.  The retrospective 
element comprised of in-depth interviews with patients with experience of neutropenic 
sepsis, carers and clinicians.   
 
Four categories and 11 properties emerged from the data.  This was achieved through 
identification of initial descriptive codes which were developed through focused coding to a 
conceptual level.  This process was assisted by analytical techniques core to grounded 
theory, including constant comparison and theoretical sampling.  Constant comparison 
involved becoming immersed in the data and alternating between this and new participants 
to compare everything everywhere.  The process was aided by analytical memos and 
diagrams to generate hypotheses. These were developed or discounted through theoretical 
sampling of participants thought to be of interest to the emerging theory.  Participants who 
were recruited included patients commencing chemotherapy, those who had developed 
neutropenic sepsis and carers of patients who had developed symptoms of it.  Patients and 
carers held a range of characteristics and relationships.  They tended to be highly educated 
and it was difficult to recruit patients who had metastatic disease.  Clinicians who 
participated in the study included nurses and doctors who worked within oncology and A&E 
settings.  Importantly the co-ordinated but not sequential research process meant 
participants were not burdened with unnecessary data collection as this ceased as 

















Chapter Six: Findings 
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6.1 Findings  
 
Findings demonstrated that 12 of 13 patients, who participated in this study, delayed 
contacting clinicians when they developed symptoms suggestive of neutropenic sepsis (table 
6.1).  Seven patients delayed presenting with symptoms of infections (not confirmed as 
neutropenic sepsis) on eight occasions.  Two of these patients called the helpline, one waited 
for a routine appointment and two patients waited to contact their GP to report their 
symptoms.  Three patients did not contact a clinician about symptoms indicative of 
neutropenic sepsis.  All eight patients who were diagnosed with neutropenic sepsis also 
delayed presenting to hospital.  They included three of the previously mentioned patients, two 
of whom had not earlier contacted clinicians about their symptoms and one who had sought 
advice from her GP.  Of the eight patients who developed neutropenic sepsis, five presented 
through calling the helpline and one waited to contact the breast care team.  A further two 
patients reported their symptoms to GPs.  
 












Called the hotline Jackie, Sophia Sam, Fayola, Zeena, Alice, 
Linda 










contact the GP 
Melanie, Paula Paula, Helen  
Deaths  0 0 
Total Delays 8 (7 patients) 8 (8 patients) 
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Four categories made up of eleven properties (table 6.2) emerged to describe why patients 
may delay presenting to hospital when they develop neutropenic sepsis. 
 
 
Table 6.2. Categories and properties  
Core category:     Playing down the seriousness and piling on the fear 
Property one:  Holding in the frustration 
Property two:  Playing down the seriousness 
Property three:  Piling on the fear 
Property four:  Reality hitting 
Category two:    Getting away with it, wanting normality and control 
Property one:  Ignoring the risk 
Property two:  Feeling protected from infection 
Property three:  Getting away with it 
Category three:   Making the connection 
Property one:               Not hitting my radar  
Property two:               Getting a wakeup call 
Category four:   Relationships core to accessing help 
Property one:               Bothering the helpline   




6.1.1 Core category: Playing down the seriousness and piling on the fear  
Clinicians felt frustrated that patients delayed presenting to hospital with neutropenic sepsis 
because they knew this heightened the risk of serious illness or death.  They conveyed their 
frustration to patients by repeatedly stressing the need to call with a fever, whilst trying to 
save face and avoid criticism by minimising neutropenic sepsis to an infection in attempts to 
avoid instilling fear.  Clinicians only explained that infections during chemotherapy could kill as 
a ‘scare tactic’ to patients considered being at risk of not reporting neutropenic sepsis.  
Importantly, starting chemotherapy heightened patients’ fears of dying which were further 
exacerbated through clinicians piling on the fear about neutropenic sepsis.  In addition, 
patients who had recently experienced a close bereavement (death of a close friend or family 
member) or who had metastatic disease appeared most fearful of neutropenic sepsis.  This 
may have been due to pessimism about surviving cancer. 
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6.1.1.1 Property one: Holding in the frustration 
Clinicians had experience of patients who had quickly become seriously ill due to neutropenic 
sepsis. This was alarming, as described by doctor 3:  
 
“…there was one youngster…he had just finished his high dose chemo…we saw him on the 
ward round and he was sat up sweating, looked terrible, trying to force a smile because he 
wanted to go home and then we walked away and within about 15 minutes a crash call went 
out, his blood pressure had dropped, he was overtly septic”  
(Doctor 3) 
 
Consequently, neutropenic sepsis was a high profile condition amongst clinicians  and an 
educational priority for junior doctors as explained again by Doctor 3: “…we’re taught about 
manning the chemotherapy hotline we’re made aware that that’s one of the big things we 
have to look out for...we know that’s very dangerous…”  Clinicians also referred to patients 
delaying seeking medical help when they developed neutropenic sepsis. This was the case for 
all patients from this study who developed infections (n=12).  Delays were a source of 
frustration for clinicians, especially when patients came close to death or died.  Doctor 2 spoke 
about: 
 
“…a patient who became severely ill at home and went to bed for a couple of days before she 
got admitted through casualty straight to ITU and jolly nearly died… is only just up and about 
now over a year later and of course never got all her planned adjuvant treatment either 
chemotherapy or radiotherapy...  why did she stay at home for two days semi-conscious, her 
family calling into her but nobody actually contacting us, I don’t know...  it is devastating.  I’ve 
had one death…very knowledgeable patient but she sat at home presented too late and once 
you get established gram negative septicaemia as opposed to just the bacteremia then it is 
very hard to reverse the consequences”. 
(Doctor 2) 
Clinicians were eager to avoid this happening to other patients and as Doctor 2 pointed out 
wanted them to: “…know what to do to be safe.” Doctor 3 reiterated: “…from my own 
experience… how things can go so bad so quickly and that ultimately it’s better to prevent that 
from ever happening”.  Clinicians used words like “frustrating” “disappointing” “pissed off” 
“annoyed” and “cross” to describe their feelings about patient delays and blamed patients for 
not taking responsibility for this chemotherapy complication.  Doctor 2 said patients: “…have 
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got to be prepared to participate in their care” and Doctor 1 said: “…it’s sort of their 
foolishness… it can potentially be so dangerous …you’ve tried to give good advice that’s then 
just completely ignored…it’s quite frustrating…” Some clinicians reprimanded patients  when 
they did not adhere to instructions (See Property three: Piling on the fear), but others referred 
to holding in the frustration as described by Doctor 3: “…you can’t get angry…we’re like well 
done for checking again, can you get to [name of ward] right now, as soon as possible”. 
 
6.1.1.2 Property two: Playing down the seriousness  
Clinicians appeared to be frustrated by patients’ delayed presentation to hospital with 
neutropenic sepsis.  However, they also apparently minimised neutropenic sepsis to an 
infection and did not inform patients this could rapidly lead to secondary complications of 
sepsis, organ failure and death.  Words including neutropenic sepsis, septicaemia, blood 
poisoning or blood infection were never used by clinicians when informing patients about risks 
of infections and did not appear in written patient chemotherapy information.  The words 
“Neutropenic Sepsis” and “Emergency” were only included within written information provided 
to patients to show clinicians (e.g., GP’s or those working within A&E departments) should 
they become unwell during chemotherapy, including a chemotherapy alert card (figure 6.1).   
 





Observed clinicians generally used emotive words like “it’s serious” “we worry” “you need to 
call us quickly” when hinting at serious infections and the importance of reporting fevers (See 
Category three: Making the connection), rather than explaining the risk of death from sepsis.  
Lynda said:  “…[name of hospital] had done a very good job of drumming it into me that eh if I 
notice anything like a temperature then to call it straight away and don’t delay”.  Doctor 1 was 
observed advising Sophia “…don’t just think prrrr it’s a bit of a cold, I’ll be fine because 
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ordinarily of course you would be, but on chemotherapy you may not be, so if you get a 
temperature, you let us know”.  and CNS 6 told Melanie: “The most important thing out of all 
the side effects… is the temperature, because that’s the one big thing, infection is one big 
thing”.  Written chemotherapy information provided to patients also focused on infections and 
the importance of reporting a fever rather than sepsis as demonstrated within the following 
example:  
 
Risk of infection:  FEC can reduce the number of white cells in your blood, which 
help fight infection.  White blood cells are produced by the bone marrow.  If the 
number of your white cells is low you’ll be more prone to infections.  A low white 
cell count is called neutropenia… Contact your Doctor or the hospital straight 
away if:Your temperature goes above 38OC (100.4OF) You suddenly feel unwell 
even with a normal temperature   
(Reproduced from Macmillan Cancer Support FEC (5 fluorouracil, Epirubicin and 
Cyclophosphamide) information sheet (accessed 8/10/2012). 
 
Some clinicians indicated they believed this approach got the message across to patients that 
infections during chemotherapy could be serious.  CNS 8 said: “…I would never be honest and 
say look it can kill you but I would say it’s really severe this neutropenic”.  CNS 2 told patients: 
“…in a very subtle way that it is the number one cause of death among patients having 
chemotherapy” and CNS 3 thought: “…without even telling them that you are at risk of dying 
they already know.” Even when patients were informed they could die from neutropenic sepsis 
this remained minimised to an infection, was glossed over and not explained or discussed.  
Doctor 2 said: “Occasionally this [neutropenic sepsis] results in very severe illness or death, 
which is what I try and warn them about”.  This Doctor was observed to mention the risk of 
death to Adanna and Hannah but said he did not tell patients why: “…infections could be 
fatal”.  Similarly, CNS 1 was not observed to encourage discussion when she told Sophia:  
“…you don’t have the ability to fight infection.  It’s a life or death situation (speaking quickly).  
We are talking about a temperature of 38…” 
 
Some clinicians appeared concerned that conveying the risk of death from neutropenic sepsis 
may unleash emotions they would struggle to deal with in patients already anxious about 
starting chemotherapy.  Doctor 4 said: “I know that not everyone stresses the fact that it could 
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be fatal… and I didn’t when I first became a registrar and I think it’s quite a hard thing to say to 
people…” and Doctor 5 said: “…it’s a difficult conversation to have”.  CNS 8 said she: 
“…personally didn’t want to scare patients so tried to go down the nice nice route” and further 
explained: “…it’s quite a hard thing to go about saying”.  A discomfort and unfamiliarity about 
discussing the risk of death from neutropenic sepsis was evident within the accounts of 
Doctors 1, 2 and 4.  Doctor 2 said: “We don’t like hurting our patients; we don’t like killing them 
so we have difficulty admitting that this is the consequence of our action”.  Doctor 1 said a new 
chemotherapy consent form had: “…life threatening infection as a tick box…I guess we 
will…discuss it in those terms more...  life-threatening is still a bit more pleasant… than saying 
risk of death” and Doctor 4 also said: “…there is an area of possibly fatal side effects [within the 
chemotherapy consent form] I think it even says…neutropenic sepsis…”  
 
Some clinicians’ accounts further suggested an underlying concern that patients already 
reluctant to have chemotherapy may refuse this if they fully explained the risks including 
neutropenic sepsis.  Most patients feared chemotherapy but felt they had no choice but to go 
ahead with it.  Chemotherapy was described by Sophia, Jackie, Alice and Lynda’s mother as 
“poisonous” by Melanie as “toxic” and by Jackie as “alien”.  Sophia, during her first interview 
said:  “…we are still using mustard gas which was used to kill people in the war (both laugh)…” 
For some patients chemotherapy went against usual healthy principles.  CNS 2 said some 
patients: “… will tell you oh I don’t like to take a lot of medications…” Sophia said during her 
first interview: “…I’m not into pills too much… just the idea of pure” and Melanie: “…didn’t 
want it [chemotherapy]….As somebody who hates taking medication… whose generally very 
healthy…a toxic cocktail put into my veins was something that really I was not happy about…”.  
Other patients spoke more specifically about fears of possible organ damage.  Jackie said: “...  
will it affect my heart later on or my liver or my lungs...” and Fayola said: “… I’m young I still 
want to have a child …I was thinking I don’t need it [chemotherapy] and she also worried: “… 
chemotherapy can cause a second cancer…”  Some patients appeared less reluctant to have 
chemotherapy.  Zeena said: “ I’m not worried about so much about the chemo….I hope it [the 
cancer] goes away, it doesn’t come back” and Hannah had: “…total faith that once it was all 
over… the cancer would be gone” and she: “…didn’t feel scared of it [the chemotherapy]… I 
thought it’s something that I’ll get through and I felt that I would stand up to it pretty well [See 
category two: Getting away with it]”.  Patients who feared damage from chemotherapy felt 
backed into a corner.  Doctor 1 was observed advising Jackie and Melanie: “… you can change 
your mind anytime…” both of whom laughed quietly to themselves.  Melanie was then 
observed to inform Doctor 1: “I’m going to get this toxic cocktail, come what may” and Jackie 
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said:  “… I was in two minds whether to have it or not…if I don’t have it there’s a possibility it 
will come back… might be a bit more serious…I sort of decided to have it…endure the next five 
months of treatment… I felt I didn’t really have a choice…”. 
 
Clinicians were aware that many patients reluctantly agreed to have chemotherapy.  CNS 1 
believed:  “…patients think oh god as much as I don’t like being on chemo, I know I need to 
have it…”.  Some clinicians may have consequently avoided discussions with patients about 
possible benefits and disadvantages of chemotherapy through a concern not to encourage 
refusal.  Doctor 5 who worked in A&E and had oncology experience said: “…our gut instinct is 
that we should give them this treatment and we don’t want to tell people things that mean 
they are going to refuse….”.  This behaviour is also evident within the accounts of some 
oncology doctors.  Doctor 2 volunteered unprompted: “… I don’t particularly worry about 
telling them things that might stop them having the treatment but it’s just helping them 
manage the anxiety state that they’re already in...” Doctor 1 said: “…people are so worried you 
have to spend a lot of time reassuring them,  that in fact you’ll get them through the 
treatment.  It won’t be that awful”.  Doctor 1 also said: “…it’s the same as with cardiac damage 
from the anthracyclines and leukaemia, I don’t tend to talk about them because they are so 
rare.  I will if asked…it’s not something you want to be telling them about you want to highlight 
the seriousness of it but not kind of the risk of death because that is so rare…”. 
 
Doctors may have further particularly avoided discussions about prognosis and potential 
benefits and risks of chemotherapy including neutropenic sepsis with patients who had a 
worse prognosis.  Doctor 4 said: “There are some patients when you can see they are 
absolutely terrified by the whole prospect of chemotherapy and you know that chemotherapy is 
going to be very beneficial to them.  They’re the kind of patient I probably would say it’s 
important to call us rather than telling them that [the risk of death from neutropenic sepsis]”.  
For Melanie requiring chemotherapy meant her prognosis was worse than she initially 
thought.  Melanie was observed to ask about her prognosis during her chemotherapy consent 
appointment.  Despite this, her husband said after she finished chemotherapy 6 months later: 
“…nobody has said … people who get a secondary cancer in your condition after 5 years is X 
and after 10 years is Y.  That’s not been done and I know that she has kind of asked that once 
or twice....” Melanie’s husband also indicated the severity of chemotherapy side effects had 
been underplayed by clinicians who: “… don’t really want to give bad news.  ….nobody has said 
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to her look this is changing your life…you’re going to go through six months of hell…I think 
that’s about treating people as grown-ups”.    
 
A behaviour, where clinicians appeared to avoid discussing the benefits and risks of 
chemotherapy with patients is also evident within the accounts of Sophia, Alice, Paula and 
Helen who had metastatic disease.  Sophia was observed during her chemotherapy consent 
appointment to be most worried about the possibility of having bone secondaries.  During her 
first interview Sophia said: “…I just couldn’t imagine that anything could make me better and 
during her final interview when she knew she had metastatic disease said: “…its 
*chemotherapy+ such a sort of poisonous substance …I did worry…that the treatment might be 
worse … than having the cancer….”  Sophia also said clinicians caring for her did not like her 
describing chemotherapy as poison and told her: “… you’ve got to stop thinking in this way ...” 
and “Everyone said oh you’ve got to be really positive...  but I didn’t think you could be that 
positive…you can’t just say it’s going to be alright because it probably might not be…”.  Doctor 
1 was observed to advise patients receiving adjuvant chemotherapy they could choose not to 
have chemotherapy.  Doctor 1 did not offer Sophia the same choice and by her final interview 
Sophia said she: “… still don’t know what it really means [to have bone secondaries] except 
that it’s stopped for the moment”.   
 
Similarly, Paula said she started chemotherapy unaware of the risks involved: “…because the 
way they were speaking…it [chemotherapy] would not have such a greater impact…” and: 
“…the importance of it [infections] just was not emphasised”.  Alice had refused adjuvant 
chemotherapy six years previously because: “I saw myself doing chemo and I saw it like  a tree 
with all the leaves blown off, and not doing chemo and the tree with leaves still on but coming 
to the same point”.  Alice’s friend described an oncology Doctor instilling: “…a sense of hope, 
even though we are looking at palliative care… that this treatment would have some positive 
effects on her whole life” and Alice conceded: “…I’ve got to this time, I didn’t do it 
[chemotherapy] before….” When Alice developed neutropenic sepsis she inferred she had 
been misled because: “…they minimise the side effects so nobody was busy saying this is how 
it’s going to be” and: “…they don’t want people not to do chemo”.  Helen also alluded to 
feeling misled about chemotherapy side effects and decided not to continue with this 
following an episode of neutropenic sepsis.  Helen said: “I wasn’t told much about this illness 
[neutropenic sepsis] I didn’t even know what it was… I just thought well everyone gets handed 
one of these cards [chemotherapy alert card] to carry around with them… he [chemotherapy 
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nurse] says to me… you probably won’t need it…”  Helen also said: “…I had been assured before 
I got this chemotherapy… I was told well sickness isn’t one of the side effects of this.  My God, 
was I sick.  So I decided then you know they can’t cure me, and it’s spread to my lungs, I 
decided I wasn’t going to take the chance and be like that again”.   
 
6.1.1.3 Property three: Piling on the fear  
Clinicians did not want to tell patients about the risk of death from neutropenic sepsis.  Most 
patients also held pre-existing fears about chemotherapy.  Doctor 1 said patients had a: “… 
huge amount of pre-conceived baggage… of how awful it’s going to be...” Alice said: “…I was 
terrified of it…” and Melanie, during an observed consultation with Doctor 1 said she felt:  
“…routine panic and terror”.  When asked during an informal interview what she had meant, 
Melanie elaborated:  “…it has a dreadful reputation…so I was like…this is going to be 
horrendous”.  Alice’s friend said: “…there is so much fear around at that time…although it’s 
important to understand what the risks are so that you can really act on anything very quickly 
it’s also quite difficult to stop piling on more fear”.    
 
The way information about neutropenic sepsis was delivered appeared to heighten patients’ 
anxiety in part because clinicians’ frustrations emerged through repeatedly stressing the need 
to call urgently with a fever on up to three occasions as explained by Doctor 4:  
 
“..we see them twice when we are consenting them, we see them the very first time and I say it 
then and then you give them the information to read and then you see them back a week later 
and you say it to them again how important it is and then when they go for their first dose of 
chemotherapy they have a talk from one of the chemotherapy nurses upstairs and then they 
tell them about that as well.  So really just trying to stress that as many times as possible and in 
fact with all the side effects [fever] that is the one I say to the patients is the most important…” 
 
Clinicians delivered information about neutropenic sepsis to patients alongside complex 
information about a number of frightening sounding chemotherapy side-effects.  This emerged 
as a dispassionate standard repertoire with an apparent aim of transferring responsibility for 
chemotherapy side effect management to patients.  Doctor 4 referred to using: “…the same 
sort of stock phrases…” and CNS 3 said: “….you just get really tired of… it’s just automatic that 
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you say…the side effects…” Doctor 1 echoed this view:  “…it’s almost sort of comical … you just 
go into kind of automatic… it’s the most standard patter you have….” This was a tick box 
exercise and chemotherapy consent forms and checklists were used to ensure everything had 
been covered as described by CNS 3 who said: “…it’s already pre-printed all you need is to just 
tick what you’ve discussed with the patient…”.    
 
This approach to information delivery caused some patients to feel processed through a busy 
inflexible system which did not adjust to individual needs.  Sam said:  “It’s the doctors they just 
have to do their job…” and she described being told: “…Your hair will fall out in three weeks’ 
time (laughs)…You know it’s quite shocking…” and Sophia elaborated: “I realised it was a kind 
of, it wasn’t a spiel but I realised she has to do that…but in fact it’s all a bit stupefying the 
whole process.”  Sophia’s husband said: “They haven’t got time enough to adjust…to the 
individual…” and Paula said: “…you don’t have time to think and ask questions.  It’s like this is 
it, I’ve done my job now get out…” Jackie said: “I think the oncologists… see so many 
patients...they can’t give you each…special attention so sometimes you feel… you are on a 
conveyor belt”.  Jackie’s experience is highlighted within the following field note extract: 
 
Field note extract: Chemotherapy consent appointment between  
                                            Doctor 1 and Jackie 
 
…doctor filling out consent form *1 min 38 secs] atmosphere feels tense, 
mainly silent; just hear doctor breathing and the pen on paper.  Doctor starts 
to read through the consent form (almost singing) “What are we proposing? 
5FU, Epirubicin, Cyclophosphamide, Why? To prevent the cancer coming back.  
What are the side effects?” Doctor lists; sickness, mouth, bowels, taste, hair 
loss “…..this is me saying I confirm I’ve explained it all to you and this is you 
saying you agreed to what’s being proposed…..  So this is my one and that’s 
your one...Good so you’re all sorted”  
 
Clinicians tended to only inform patients chemotherapy infections could kill out of frustration 
and as a shock tactic, to instil fear and to reprimand.  Only CNS 1 spoke about routinely 
informing patients of the risk of death because: “…you have to scare them a bit, otherwise, it 
doesn’t hammer home”.  It appeared usual practice for  clinicians to stress the risk of death 
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from neutropenic sepsis only to patients whom they judged were not taking this seriously or 
during subsequent consultations with patients who had delayed presenting to hospital with it.  
Doctor 4 said he informed people he considered: “…very stoical and the kind of people who 
don’t want to make a fuss that an infection left untreated could kill you” and Doctor 1 said:  
“very rarely do I talk about death.  I can think of one woman.  She was a single … She had two 
kiddies, one was young and one was in her twenties and she [daughter in her twenties] said my 
mum won’t phone, because she won’t want to leave the child… I told her.  That’s why it’s so 
important to [call the helpline] because you can die …” The following field note extract 
demonstrates how Doctor 2 and CNS 4 stressed the risks of neutropenic sepsis to Adanna who 
persisted with a desire to go to a wedding in Africa: 
 
Field note extract: Chemotherapy consent appointment between  
Doctor 2, CNS 4 and Adanna 
 
… during the consultation CNS 4 and Doctor 2 both focused mainly on dangers of 
infections and associated risks of going to Africa.  Both said several times this was 
serious and life threatening.  Words used by Doctor 2 included: “urgent” “severe” 
“fatal”  “danger.” Words used by CNS 4 included: “anything can happen” “life-
threatening” “serious” “patients have got really ill and more difficult to manage.” 
Doctor 2 told Adanna she could get ill very quickly, would need urgent treatment 
and it wouldn’t be safe for her to travel.  Doctor 2 said during an informal interview, 
he stopped stressing the seriousness when he felt reassured Adanna had heard the 
message about risks of neutropenic sepsis and would not travel abroad during 
chemotherapy.   
 
Clinicians also referred to chastising patients and using stronger language about death, during 
consultations subsequent to starting chemotherapy. This was with those patients who had 
delayed or failed to present with symptoms of neutropenic sepsis (See Property one: Holding 
in the frustration).  This was evident within CNS 1’s response to Wendy calling her rather than 
the helpline when she developed a chest infection (See Category four: Relationships core to 
accessing help).  CNS 1 spoke about being: “… firm and assertive…I do use the words life 
threatening because otherwise they don’t take it as seriously…I felt I had to like say… you 
should have rung the hotline, this is nearly 24-hours… so she won’t be doing that again…” 
Doctor 1 also said: “…once they have kind of disobeyed…that’s when I tell them the seriousness 
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of it, you really drum it home that people can die…If they don’t erm contact us”.  Doctor 4 said:  
“you do feel like you want to shake them a little bit and I do… tell them off… tell them that if 
you have an infection once your immune system is down and it’s left untreated that it could kill 
you and I find that using the strength of “it could kill you” is quite a good way of getting people 
to take it seriously rather than just oh you might be a bit unwell”.    
 
6.1.1.4 Property four: Reality hitting 
Patients appeared to be hit by the reality of having a life threatening illness during 
chemotherapy information sessions. This made it difficult to engage with information about 
neutropenic sepsis which also sounded frightening.  This situation appeared further 
exacerbated for those possibly more pessimistic about dying due to a recent bereavement or 
having metastatic disease.   
 
Information about neutropenic sepsis was provided by doctors as part of the chemotherapy 
consent process, at which point having a life threatening illness appeared to become a reality 
for many patients.  Doctor 1 explained: “The whole enormity of them coming to see you and 
you telling them… they’ve got however many lymph nodes involved and they’re going to need 
chemotherapy and why they’re going to need it.  I think that’s the point at which they kind of 
grasp that…” and Jackie said following her chemotherapy consent appointment: “… it’s just all 
happened so fast…and in the space of two months…it’s just come to this…” The reality of 
having a life threatening illness also seemed to hit patients as chemotherapy nurses provided 
chemotherapy information within the busy day unit immediately prior to the first treatment.  
CNS 8 said information was provided on:  “… the first day of their chemo so it was all very 
daunting”.  Alice found her information session with a chemotherapy nurse: “…kind of scary… 
you are in a strange chair, there’s other people having different sorts of chemo, they seem to 
look at different stages of wellness or not”.  Following an information session with a 
chemotherapy nurse Melanie said: “It does feel a bit like oh god, right so this is it now…” 
 
It seemed patients who were going through a family bereavement or who were dealing with 
unexpected bad news about their prognosis were particularly disengaged from hearing 
information that heightened their fears of dying. This included information about neutropenic 
sepsis.  Wendy, Hannah and Jackie had experienced recent family bereavements.  Hannah 
became upset when she spoke about her brother who: “…died of lung cancer two years ago 
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and one of the things that really upset me was that he suffered so badly….” and she indicated 
she found news about heart problems discovered prior to chemotherapy difficult to cope with: 
“…I did feel depressed then because I thought well not only have I got the cancer but there’s all 
the other stuff comes up as well”.  Wendy’s sister died from breast cancer towards the end of 
Wendy’s chemotherapy treatment and Wendy indicated she did not like hearing about 
infections during chemotherapy information sessions:  “…because they said you’ve got to get 
in straight away or you could be dead the next day or something (laughs)”.  Jackie, whose 
mother had recently died, was observed to appear:  “…worried, subdued, tense, shocked, flat, 
rabbit in the headlights” during chemotherapy information sessions.  Jackie said: “…the fact 
that you have to ring somewhere just for that [infection]… I’d feel a bit awkward about it… it 
brings back home…You are being treated for something serious”.  Jackie also appeared highly 
anxious during a nurse led chemotherapy consultation as highlighted within the following 
observation extract:  
 
Field note extract:  Chemotherapy information session  
between Jackie and CNS 7  
 
I met Jackie and her friend in the corridor outside the waiting room, which was 
packed.  Her appointment was 2:30pm on a Friday.  Jackie said she felt really 
nervous about having the chemo...  The receptionist showed her into the 
department, was very kind and introduced her to the nurse.  The chemotherapy 
bay was busy (6 patients being treated) and was manned by CNS 7 with other 
nurses helping out.  The atmosphere was tense and noisy due to chemotherapy 
pumps alarming, scalp cooling machines and people talking.  CNS 7 told Jackie she 
was sorry, she had run out of chairs, so showed her to a bed.  She provided Jackie 
with lots of scary information about chemotherapy side effects… During the 
information session, the emergency alarm went off and the nurses all left the bay.  
Jackie’s friend told me a patient had reacted badly to chemotherapy… As Jackie’s 
treatment was about to start she looked extremely tense and asked her friend to 
pass her rosary which she played with during the chemotherapy treatment... 
 
 
Some patients also appeared unable to hear information about neutropenic sepsis because 
they were reeling from the shock of needing chemotherapy.  Doctor 4 said: “…it’s still a lot to 
take in especially if you are going there not knowing if you are going to need chemotherapy” 
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and Doctor 5 said when: “…you get told now you are going to start this.  I think it’s all a bit of a 
blur to them.” CNS 3 also said “…the shock…of being said that you’ve got cancer and explaining 
[the chemotherapy] so it’s not really absorbing in the first sitting”.  Melanie was a chief 
executive who sought out information.  Her husband said: “…we were both devastated…the 
news that we were given was actually this is an aggressive tumour and that it requires 
chemotherapy so we both knew that this was actually a very different ball game”.  Melanie 
could not remember information about neutropenic sepsis that was provided immediately 
following bad news about her prognosis.  A week later, Doctor 1 said during an informal 
interview: “…She’s [Melanie] coming back today with a lot more questions…The neutropenia 
question was as if it hadn’t been mentioned [the previous week]”.  Melanie also indicated 
during an informal interview that neutropenic sepsis had not previously registered with her as 
important.  Melanie said:  “I’m just astonished that of all the things I’ve prepared for…We just 
forgot about the thermometer.  It’s just bizarre…” Melanie required time to adjust to needing 
chemotherapy before dealing with information about neutropenic sepsis and explained: “…by 
the time I got here I had kind of got myself through that, again through research and talking to 
people and I’d kind of reconciled myself to it…”  
 
Bad news left Melanie unable to hear information about neutropenic sepsis.  Some patients 
were told they had metastatic disease and were provided with information about 
chemotherapy side effects during the same appointment.  For these patients information 
about neutropenic sepsis appeared to be further bad news they could not cope with.  Paula 
said she was: “…taken into a room by a nurse who’s dishing out all these leaflets and just 
telling you, well you’ve got to have this card and take your temperature…she might have 
mentioned something about white cells and infections but at that time no-one’s going to take 
in all that… information… it was very very rushed...  after someone’s been told that kind of 
news… eventually it’s going to kill me”.  Alice said: “…everyone was saying oh this is Alice’s big 
D day and we’ll find out [if the cancer has returned], so I was a bit sort of nervous about the 
Friday…she [the doctor] was like well it’s just definitely breast cancer…I was frightened but the 
diagnosis was a shock… I was in shock then, I mean real shock...” Alice said she: “… went 
through terror…”  Alice’s friend also said: “There is a lot to take in…she was very scared and it’s 
very difficult to hear things, so she knew the number was there but I don’t think she felt so easy 
about calling it as I thought I felt”. 
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For Sophia, fears of dying appeared particularly enhanced because in addition to having 
metastatic disease a relative was dying.  Sophia said the thought of having to call the helpline 
with symptoms of neutropenic sepsis was: “… quite terrifying…” and she: “… felt a bit 
frightened at all the information…that things were worse than I had thought, I thought oh my 
gosh here I am all this poisonous stuff coming… he [chemotherapy nurse] was very very very 
important about contacting the helpline, the hotline… and I think he said that more than 
once…” She elaborated: “I think realising that I am in a serious position and I did think ooh I 
wonder if I’m going to get through all this …it was all a bit doom and gloom…” Sophia, also 
indicated she could not hear information about neutropenic sepsis because: “…there is so 
much going on and you are slightly frightened and I think when you’re frightened your your 
mind does cloud over you don’t think so clearly”.   
 
6.1.2 Category two: Getting away with it, wanting normality and control  
Patient and carers dealt with fears of neutropenic sepsis by ignoring the risk, thinking it would 
not happen to them and by taking precautions against catching infections.  All patients who 
developed infections during chemotherapy initially ignored their symptoms and concentrated 
on normal life.  Some patients took increasing risks with infection exposure and reporting as 
they got away with not being seriously ill and this was particularly evident in those for whom 
the reality of death seemed more heightened.    
 
6.1.2.1 Property one: Ignoring the risk 
Patients and carers appeared to respond to fears of dying from infections by ignoring the risk 
and were observed to not ask questions about neutropenic sepsis during chemotherapy 
consultations.  Doctor 4 said: “… infection is usually quite low down on people’s list of things 
that they are worried about.” Alice’s friend said:  “…pile on more fear and people won’t hear it 
[information about neutropenic sepsis] they don’t want to know, they’ll just close down”  This 
appeared to be the reaction of many patients and carers.  Lynda said the:  “…thought of the 
low white blood count hadn’t erm really concerned me at all…even though I knew it could 
happen ” and Adanna said:  “…if you are infected you might die… if you …don’t report quickly to 
the hospital… I don’t even think about it…I know but it doesn’t come to my mind…”.  
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Patients who were going through a bereavement or who had metastatic disease, and some 
carers, appeared to particularly avoid knowing about the risk of death from neutropenic 
sepsis.  Wendy, Hannah and Jackie referred to recent family bereavements. Wendy appeared 
alarmed she: “…could be dead the next day…” from an infection and did not read 
chemotherapy literature because she did not: “…think I’m a good reader to digest things in the 
brain (laughs)”.  Instead Wendy:  “…didn’t think about it [infections] didn’t worry about it….If 
it’s going to be it’ll be…” Hannah said she: “…wasn’t frightened by that [infection] even though 
[name of doctor] told me you can die… if you do nothing about it” and was observed to move 
Doctor 2 on from talking about neutropenic sepsis as detailed in the following observation 
extract: 
 
Field note extract: Chemotherapy consent appointment between 
Doctor 2 and Hannah 
Doctor 2:   ...so if you’re not well you ring and you get ready to come into 
hospital straight away and have antibiotics.  Because if you do 
that you will be safe  
Hannah: right, yes 
Doctor 2: but if you don’t and stay at home and wait and see what I’m like 
tomorrow the infection could get very severe or even fatal.  So it’s 
important and although it’s a rare problem we want to get you 
through it safely.   
Hannah :  yes, the only side effect I’m worried about is permanent hearing 
loss 
 
Hannah also appeared to avoid written chemotherapy information she found frightening.  She 
said:  “…there is information in there [blue chemotherapy book] which I hadn’t looked at 
because I felt I couldn’t bear any more”.  Hannah also did not look at the chemotherapy alert 
card which mentions neutropenic sepsis.  She said: “…I didn’t read that [the alert card]...  I did 
think it was for a hospital and that if I was unconscious or something they hopefully would find 
it in my handbag”.  Hannah and Jackie also spoke about avoiding other cancer information 
which highlighted their fears of dying.  Hannah: “…didn’t read the information about the 
general anaesthetic [for breast cancer surgery] …I’m glad I didn’t read all that because I’d have 
worried…one of first side effects …it mentions is death”. Jackie said: “…what I found was quite 
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daunting was listening to other women’s cases and some of them were quite scary… I decided 
not to read too much of it because… it was frightening…”. 
 
Paula, Alice and Sophia who had metastatic disease also appeared unable to cope with 
knowing about neutropenic sepsis.  Paula indicated she did not read chemotherapy 
information because fears of dying took over.  Paula said: “…the leaflet, I’ve never looked at it 
again.  When I first sat there and tried to read it...but it just didn’t make sense because the 
chemo took over, the chemo, the chemo”.  Alice said: “I suppose I haven’t let myself think about 
that [infections]…” and Sophia who was also going through a bereavement was observed to 
avoid talking with Doctor 1 about emotive issues, in a similar way to Hannah as she attempted 
to lighten the mood: 
 
Field note extract: Chemotherapy consent appointment  
between Doctor 1 and Sophia 
 
Sophia appeared nervous going in to see the doctor.  The consultation started 
with a general conversation about how she was feeling.  The doctor was 
empathetic about Sophia appearing tired.  Sophia stopped this line of 
conversation by moving the conversation on.  Sophia said:  “…good ready to go” 
and she understood there would be three chemotherapy treatments, then 
reassess, then possibly more chemotherapy and radiotherapy.  Sophia tried to 
lighten the mood by saying “it will be fun”.  Lots of information was given by the 
doctor about chemotherapy side effects.  Sophia did not ask questions and 
jumped in saying:  “OK I don’t have any more questions” and: “ready to sign”.   
 
 
Sophia also avoided written information about neutropenic sepsis.  During her first interview 
she said: “I think I have been avoiding some of that information which is in the car...” At her 
final interview having developed two infections she said: “…I assume there must be statistics.  
I’ve never asked…” and: “I don’t even say the name properly…neutropenic sepsis…so there’s a 
part of me that doesn’t obviously want to know that much about it”.  Sophia indicated she 
avoided information about neutropenic sepsis because she could not face up to thinking she 
might die.  During her first interview she found it: “…hard to believe that in a matter of a day 
you could suddenly dip.  I don’t quite believe it but I have to believe it” and during her final 
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interview she said: “…I just knew it was important to act fast Yeah but you could get sick very 
quickly but I didn’t think very much beyond that except, Oh God, you know”. 
 
Of concern were Lynda’s mother and Zeena’s niece indicating their avoidance behaviours 
which could hinder their ability to help patients access help if they developed neutropenic 
sepsis (See Category four: Relationships core to accessing help).  When speaking about 
neutropenic sepsis Lynda’s mother said:  “I’m afraid sheer cowardliness has kept me away 
from… becoming more knowledgeable…think it’s due to the shock and the stress…I want to do 
everything to help but I’m terrified of what someone’s going to tell me”.  She also said: “...  as 
her mother… it’s like a death sentence.  Anything that makes that seem more certain… I am 
reluctant to… I do face up to it inside myself but I don’t want the confirmation…some things hit 
you quite hard.” Zeena’s niece who actively pursued information about chemotherapy side 
effects described a similar response: “I did know you could die from the chemo 
thing…Sometimes I do this thing in my head…you don’t want to accept it so you just put it in 
the back of your head or you choose what you want to hear”. 
 
6.1.2.2 Property two: Feeling protected from infections 
Patients also dealt with fears of infections by hoping or believing they would not develop these 
during chemotherapy.  Hannah coped with the risk by not associating herself with those who 
became unwell during chemotherapy.  During her first interview Hannah was:  “…shocked at 
the way… the other patients looked pretty ill and I almost felt like a fraud…” Hannah spoke 
later during her end of treatment interview about having: “… a gung-ho attitude…” to 
chemotherapy, which she: “…went into it thinking that I wasn’t going to suffer like anybody 
else.  I was terribly optimistic or cut off…I didn’t want to know that I was going to be ill”. 
 
Jackie, Helen, Zeena and Adanna, also appeared to deal with fears and lack of control over 
neutropenic sepsis through believing it would not happen.  Jackie hoped she would get away 
with it.  She worried: “…whether I will end up getting a temperature or not feeling too well on 
these drugs.  I’m, hoping it will go really fast … complete the treatment and then… be able to… 
breathe a sigh of relief”.  Jackie also indicated she thought the risk of infections was 
exaggerated: “…they do give you the worse sort of scenario… it might not happen…I might not 
react…to the drugs as badly as… they say (light laugh)”. Adanna also inferred exaggeration of 
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risk when asked if she thought infections would be a problem for her.  Adanna said: “…I don’t 
think so …I’m not the first person to take it and I’m not the last (laughs)”.  I saw some people 
having the chemotherapy…they were not laying on the chair…they walk by their legs, so it’s OK 
and I will be no different…”. 
 
Wendy, Jackie, Zeena and Adanna also coped with the threat of neutropenic sepsis through 
fatalism, which for those who were from ethnic minority groups included designating 
responsibility to God to protect them.  Adanna said: “God is there he will fight it for me 
(laughs) I know it will come out fine…”and “… you pray not to have an infection”  Zeena said: 
“…everything I leave in God’s hands…so I’ll survive” and Jackie believed: “…my faith…that’s 
gonna help me through it as well”. 
 
Understanding of reduced immunity during chemotherapy and fears of infections may have 
also encouraged beliefs that natural or boosted immunity could protect patients from 
infections (See Category three: Making the connection) and that infections could be avoided.  
Doctor 1 said patients often asked about: “…people who have colds and coughs, should they 
avoid going out…” and spoke about an: “…elderly lady who’d gone through chemotherapy 
absolutely fine and then she said can I go out now?’ and she’d stayed in the whole time”.  Most 
patients and carers spoke about taking precautions to avoid infections and this behaviour 
appeared exaggerated in patients dealing with bereavement or who had metastatic cancer and 
in carers who feared infections.  Jackie and Wendy had been through recent bereavements.  
Wendy said: “…I was keeping myself safe in the house.  I only went out a couple of times to do 
shopping…” and Jackie: “…wasn’t in places where there were lots of people and if any of my 
friends had a cold or they weren’t well then I would tell them not to come and visit me.  
Obviously washing my hands and just keeping clean really” and she said she stayed away from 
work during her second week following chemotherapy: “…because you are quite prone to 
catching infections”. 
 
Alice, Helen and Sophia who had metastatic cancer also appeared to take increased infection 
precautions.  Alice took her: “…temperature quite obsessively” and said: “…I suppose you get 
infection that’s terribly serious you can die but as I said I haven’t sort of even entertained the 
idea.  I was like I mustn’t get infection, I mustn’t get infection…” Helen said: “…there was 
chicken pox going round the school, so she [her daughter] stayed away and kept the boys away 
153 
from me and my son, when his daughter had a cold, he didn’t come to the house”.  Helen 
decided: “…if any of them had bugs or anything to stay away…your immune system is not 
working”.  Sophia initially said: “if you go on the bus during the day you’re not standing with 
lots of people on a tube train at peak time or anything… I’m washing my hands constantly 
cleaning my face… and so is my husband and my daughter…”  Carers who feared infections and 
did not want to think about associated risks were particularly protective.  Lynda said her 
mother: “...brought me a load of masks to wear…” and her mother said: “…any infections, any 
colds would not go near her and she changed: “…all the household cleaning materials and hand 
washing and body washes”.  Similarly, Zeena’s niece said: “…they were saying about anyone 
with a cold… can’t go near her because she risk infection” and: “I think everyone felt a bit 
stressed out with me… because I kept saying you can’t do this, you can’t do that and this has to 
be cleaned because she could catch an infection easily and we had the anti-bacterial hand 
wash”.  Sophia’s husband also said:  “… as soon as I get in the house first thing I wash my 
hands… I do not want to be the one…bringing in… the viruses”.   
 
6.1.2.3 Property three: Getting away with it 
Doctor 2 considered neutropenic sepsis was: “…one of these uncontrollable risks which we 
manage by ignoring…” and Doctor 5 said: “…if you don’t admit it it’s not happening”.  Some 
patients appeared to initially ignore symptoms of infections out of fear of what these may lead 
to.  When Hannah developed an infection she had: “…a dread of what it might be and you 
don’t want to face up to it” and although Adanna did not develop an infection during 
chemotherapy she said: “…when you see that you have fever and you know that this thing can 
kill you because without going quickly to them to check you and to give you the right necessary 
medicine one might die and nobody wants to die and you have if you like you didn’t go 
immediately maybe that’s who they are”.  Jackie said she found neutropenic sepsis 
information: “…worrying… if you’ve got a temperature or you’re not feeling well you have to 
contact them… day or night for them, TO GIVE, … you something for it and that’s quite 
frightening… it sounds serious…” When Jackie developed symptoms of neutropenic sepsis she 
said: “I did feel very ill, that Saturday I felt like death really...”  She did not call the hospital for 
two days because she hoped: “…maybe it’s like flu and it will get better…” Many patients tried 
to make symptoms of neutropenic sepsis go away.  They often repeatedly took their 
temperature in the hope this would go down, possibly because they knew this was a key 
symptom to report (Category three: Making the connection).  Some patients also tried to 
reduce their fever.  Doctor 3 spoke about an: “…ex-GP, he was rigoring… just took 2 
paracetamol didn’t take his temperature”.  Fayola and Zeena took paracetamol when they 
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developed neutropenic sepsis.  Zeena said: “You try co-codamol, you try this, still the thing is 
still there...” and Fayola said: “…I was like oh I’m fine, this Lemsip is working…” Lynda, Wendy 
and Hannah also tried to reduce their temperatures Lynda was: “…trying to cool down because 
I thought oh maybe it’s just lying under this blanket and I was just boiling up…” Wendy: “…ran 
a cold bath and my temperature went down…” and Hannah: “…didn’t ring… the 24-hour help 
centre because I thought perhaps if I drink some fluids my temperature will come down, which 
it did”.   
 
Some patients may also have ignored symptoms of neutropenic sepsis because they focused 
on their normal lives rather than thinking about cancer.  Some patients continued working for 
normality.  Jackie said: “…if I’m at home then it’s because I’m sick…so going back to work will 
just give me some sort of normality” and Melanie continued working during chemotherapy 
because she thought it: “… would help me to feel more normal through the treatment…”.  
Work commitments meant some patients could not afford to be ill when they developed 
infections or could ignore these.  Melanie said:  “… literally a 24-hour period I realised that I 
was developing a very red and inflamed breast…I was working and feeling fine… but I could see 
that this was an infection… I noticed it really getting inflamed about one and then I arranged to 
see the GP so I was with her at five…she made the connections to the unit…so I was here by 
seven pm”.  Similarly, Fayola continued working in a care home to: “…avoid spending: my days 
lying in bed and feeling sorry for myself, I have to get myself busy”.  Fayola called the helpline 
from work when she developed neutropenic sepsis and was asked to go to hospital: “…before 
five that’s when I rang but I haven’t finished my shift so I just had to wait until seven to finish…” 
possibly because: “…I’m an agency worker and so it’s like work I didn’t get paid”.  Sam 
appeared to not have time to be ill due to childcare commitments.  By the time she called the 
helpline when she developed neutropenic sepsis, she was: “… mentally not in a state to get 
myself out of bed and to…get clothes on because I had flu like symptoms… I was shaking.  I felt 
very unwell”.  Caring for her children also meant a delay in getting to hospital because Sam 
was:  “…in bed with my little one just waiting for my husband to come home…” (See Category 
four: Relationships core to accessing help). 
 
Delays related to wanting a normal life may have also extended to a desire to be seen as 
normal by others and to not create a fuss or burden carers with additional hospital visits.  
Zeena said her niece: “…always comes, she stays with me and she’s got a small baby” and 
Helen was reliant on her daughter to take her to hospital, because she was: “…told to make my 
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own way [to hospital]”.  Sophia gave: “the impression that I’m coping quite well.  So I’m always 
the first to say don’t worry you go, you know, have a normal day”.  Lynda’s mother said her 
daughter: “…didn’t want (name of husband) to see her as a sick person, that he found her 
attractive.” When Lynda developed neutropenic sepsis she said: “… I had friends staying…they 
all went to the pub… (laughs) and I stayed at home… so it was like look I’m fine…I‘m just a 
bit…run down at the end of the day...” When Lynda’s Mother spoke about this she thought 
there was a: “...desire in those circumstances not to cause a fuss”.   
 
Some patients also seemed to take increasing risks with infections, in favour of a normal life, as 
they got away with not becoming seriously ill.  Lynda: “…thought I was being careful…as far as 
you can be around people and I hadn’t kind of caught anything…I say that but…the whole 
Christmas period there was a whole week there of activity where I saw people….  I remember 
one at least very definitely having a cold or something...  and I’d eaten out quite a lot… but I 
was like ohh I’m fine you know, none of this seems to be affecting me (laughs)”.  Escalating risk 
taking seemed more apparent in patients who had metastatic disease or who were recently 
bereaved.  Wendy whose sister was dying of breast cancer, failed to present to hospital the 
first time she developed neutropenic sepsis symptoms and came to no harm so appeared 
reluctant to call the hotline during a subsequent episode because: “… the first time after I get 
this I was ill, really I was.  I was like frozen and shivering and I couldn’t get heat in my body.  If I 
felt maybe something like that I’d have felt Oh well I’d better go in…” Alice had metastatic 
disease and did not let neutropenic sepsis get in the way of her birthday plans.  She:  “…was on 
my way to have a facial…*name of doctor+ phoned me and said your blood count is incredibly 
low… you’ve got to come back today and I refused, I said it’s my birthday, I’ve got things 
planned I’m not coming to hospital“.  Alice went to hospital when it suited her and she 
appeared to hope she would not come to harm in the meantime by being: “gentle with myself, 
I took taxis and I was with a friend … and the next day…she [the doctor] rang me again and I 
said don’t worry I’m coming into *name of hospital+ now”. 
 
Sophia and Paula, who also had metastatic disease, stopped monitoring their temperatures 
following chemotherapy.  This appeared due to the fact they got away without developing 
neutropenic sepsis and because monitoring reminded them of their poor prognosis.  Paula 
said: “…after a couple of weeks you just get bored of doing it [taking her temperature] because 
nothing’s happening…so you just don’t do it anymore”.  Paula elaborated:  “Maybe it’s 
psychological.  Maybe it’s a reminder that there’s something wrong, or there could be”.  Sophia 
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like Paula said she was advised: “I must take my temperature everyday which I’m afraid I 
haven’t done”.  Sophia also said:  “The more I know about it [chemotherapy side effects].  The 
more I don’t look”.  Paula and Sophia also did not allow infections to get in the way of their 
normal lives and took increasing risks as they came to no harm.  Paula had been: “…acting a 
normal life…” and in terms of infection exposure said: “… I’ve had a drink and whatever and I 
don’t really look...”  At the start of chemotherapy, Sophia diligently tried to avoid infections.  
By the end of chemotherapy she said she could not: “…live in a bubble and I have sat in the 
theatre with quite God knows how many germs are running around the theatre…..I’m afraid 
the pleasure outweighs my assessment of risk”.  Paula and Sophia also appeared to persistently 
put up with symptoms of infections because they did not want to acknowledge they were ill.  
When Paula developed neutropenic sepsis she said: “I had the fever on the Monday and erm 
ended up in hospital on the Friday.” Paula also delayed presenting to hospital on a subsequent 
occasion when she developed diarrhoea.  Paula said she was: “…a stubborn one...(Laughs)… I 
had diarrhoea for…seven or eight days.  But then it really got chronic like.  It got to the stage 
where it was 22 times in a day … I thought no this is enough and that is when I rang the 
hospital and came in”.  Paula said she delayed seeking help because: “I just carry on like 
normal.  I have since… cause I find if you lie in bed and feel ill you’re gonna be ill”.    
 
When Sophia developed a breast infection she: “…thought well I’m going to the hospital 
tomorrow morning.  So, I didn’t go that night”.  Sophia got away with it because: “He [a doctor 
at the hospital] gave me a prescription for some antibiotics … He was playing safe…and within 
a very short time, I was fine”.  Sophia took greater risks when she visited a dying relation 
abroad following a subsequent chemotherapy treatment.  Sophia: “…defied the hospital 
slightly…” because: “…It was just one of those personal decisions...we would just go and say 
goodbye….” Sophia developed a chest infection during the visit and was advised to go to 
hospital by the helpline doctor.  Sophia chose to take a risk by taking oral antibiotics obtained 
from a chemist, possibly because this had worked with her first infection, and took a plane 
home.  Sophia knew she did not take the infection: “…fully seriously…just whack a few 
antibiotics down me...  and she realised: “…the necessity for really finding out, what was going 
on…” but she did not want to know because she felt: “it can’t happen to me on top of 




6.1.3 Category three: Making the connection  
Infections were not on patients’ and carers’ radar as likely or important potential side effects 
during chemotherapy information sessions (See Category one: Playing down the seriousness 
and piling on the fear) so they focused on more likely side effects commonly associated with 
chemotherapy such as nausea and vomiting.  Patients also apparently did not make or want to 
make the connection between their possible symptoms of sepsis and infections described to 
them by clinicians (See Category two: Getting away with it, wanting normality and control).  
Most patients and carers realised neutropenic sepsis was not a simple infection after patients 
had developed this and said that had they understood more about it they would have called 
the hotline sooner.  However, preferences differed regarding how explicitly this should be 
explained. 
 
6.1.3.1 Property one: Not hitting my radar  
Neutropenic sepsis did not hit most patients’ and carers’ radar because they thought of this as 
an infection they could be protected from, did not make the connection between their 
symptoms and infections described by clinicians (See Category one: Playing down the 
seriousness and piling on the fear) and because neutropenic sepsis did not happen 
immediately after chemotherapy (See Category two: Getting away with It, wanting normality 
and control).   
 
Neutropenic sepsis was not on many patients’ and carers’ radar because clinicians minimised 
this by describing it as an infection (See Category one: Playing down the seriousness and piling 
on the fear).  Clinicians, including Doctor 1 spoke about neutropenic sepsis being:  “…a difficult 
concept… to explain, to grapple with…it effects the white cells that are going to help you fight 
infection, they then don’t know how long that’s going to be for...” Similarly Doctor 2 said: “…it’s 
hard to summarise… I’ve been dealing with neutropenic sepsis for…years and they’ve never 
seen it before…” and CNS 1 said:  “… if you go round the houses about your white cell count … 
you’ve lost them ….”  Patients were observed to be informed by clinicians they were at risk of 
infections during chemotherapy because this affected immunity.  CNS 1 advised Sophia: 
“…when white cells fall you don’t have the ability to fight infection…” and Doctor 1 told Jackie:  
“…chemotherapy affects…the cells in the bone marrow that help you fight infection”.  Doctor 2 
advised Adanna: “…white cells which protect against infection are low…” and CNS 6 told 
Melanie: “…you’re more prone to infection, because the chemotherapy’s affecting …your 
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normal cells, so the likelihood of the immune system going down… is increased…” Most 
patients and carers heard this message.  Helen said: “…it’s common knowledge that the chemo 
batters your immune system” and Alice’s friend knew: “…your white blood cells are kind of 
blasted…so you don’t have any resistance to infection…”. 
 
Patients and carers did hear the words infection and reduced immunity so often focused great 
efforts on avoiding infections and believed their natural immunity could protect them and be 
enhanced (See Category two: Getting away with it, wanting normality and control).  However, 
most did not know what neutropenic sepsis was or how serious it could be.  Patients’ beliefs 
about their natural immunity may have been reinforced by clinicians in attempts to reassure 
(See Category one: Playing down the seriousness and piling on the fear).  Doctor 1 was 
observed to advise Jackie: “…from what I’ve seen of you, erm and your general health… and 
your age, I would think you’ll go through this pretty well ...  all you get [chemotherapy side 
effects] will be very manageable” and Jackie said she was:  “…fairly healthy, I’m not somebody 
who gets lots of colds and coughs … so I’m hoping my immune system is strong enough, to… 
cope with it”.  Doctor 1 also advised Melanie: “…it’s unlikely you will get them all 
[chemotherapy side effects] …I don’t think it will be as bad as you fear, it will be fine…” and 
Melanie felt neutropenic sepsis would be: “…very unlikely, I tend to be generally a fairly robust 
sort of physical person …” Sophia also found the possibility of becoming seriously ill with an 
infection: “…hard to believe because I’m feeling quite sturdy”.  Lynda: “…had a flu jab before 
doing chemo… I wasn’t really worried because I was in pretty good health” and Hannah said:  
“I’ve never had many infections in my life…”.  Some patients and carers also thought they could 
boost their immunity by eating a healthy diet.  Melanie’s husband said: “…she’s been taking 
juices every day… after she did that you could see that her neutrophils were much, much 
higher”.  Sophia, during her second interview said when her: “…whites looked a bit low …I’ve 
been really trying to eat proteins...” and Alice relied on her complementary therapist who gave 
her: “herbs for everything…she said we’ll help boost your immune system”.  Most patients were 
not told if chemotherapy eradicates white blood cells, neutropenic sepsis could not be avoided 
because as Doctor 4 pointed out during his interview: “…a lot of the time we never actually find 
the source of where someone’s infection is coming from…we’ve all got millions of bacteria in 
our gut so people actually catch the infections from themselves”.  Doctor 4 also said: “…people 
have sort of misconceptions…get very concerned about going on public transport when they’re 
on chemotherapy”.   
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Infections were also not on the radar as important when patients developed these because 
they apparently believed symptoms were only important if they felt unwell and had a fever 
(See Category two: Getting away with it, wanting normality and control).  Clinicians spoke 
about a fever being the most obvious indicator of neutropenic sepsis.  Doctor 3 said this was: 
“…a very good indicator…that’s the big one” and Doctor 4 said: “…the temperature is the main 
one…” Doctor 4 spoke about his colleagues going: “…on too much… about this magic 38 
degrees, only call us if your temperature is over 38 degrees whereas you could be home as sick 
as a dog with a temperature that’s normal”.  Doctor 4 also said: “… if you are really, really sick 
then you can be hypothermic…”  Other symptoms of neutropenic sepsis did not appear as well 
described.  Doctor 1 explained: “…it’s that more subtle feeling unwell without a fever that’s 
more difficult to understand” and Doctor 4 said:  “I always say if you just feel unwell you can 
give us a call, I guess that can be quite vague for some people because they’re expecting to feel 
unwell from the chemotherapy…” Some clinicians spoke of attempts to explain feeling unwell.  
Doctor 4 said: “I always say if you feel unwell… a cough…dysuria, anything that makes you 
worried then just give us a call even if your temperature is normal” and CNS 2 was observed to 
advise Sophia that symptoms might include: “…shivery (hunches shoulders), cold, any sign of 
infection or a sore throat, cough”.   
 
Advice about symptom reporting was confusing but key messages included a fever and feeling 
unwell.  Doctor 1 was observed to advise Sophia: “… if you feel unwell or get a temperature 
you must call any time of the day or night” Doctor 2 advised Adanna: “…infections don’t 
normally show up as anything you can see.  They just make you feel bad and you start to run a 
high temperature” and CNS 6 advised Adanna to: “…take your temperature straight away if 
you feel unwell…” Doctor 1 advised Jackie: “…if you get a temperature on chemotherapy…you 
let us know day or night…but if it’s above 38 or if you are feeling poorly even if it’s not above 
38… you let us know…” and CNS 3 advised: “…if they spike a temperature of 38 and above or if 
they notice that it’s creeping up that they need to ring us.  Also if they are unwell...”.  Because 
patients heard fever and feeling unwell, they delayed contacting the helpline until these 
occurred simultaneously (See Category two: Getting away with it, wanting normality and 
control and Category four: Bothering the helpline).  Doctor 1 said: “…they explain it away… it 
was just once…I felt fine or it never went up.  They’d be feeling unwell but then maybe their 
temperature isn’t quite 38… so I didn’t need to bother anyone”.  In terms of solely having a 
fever, CNS 1 said: “…they can forget that having a high temperature is something that is 
potentially life threatening” Doctor 1 said: “…they think it’s bit of a fever it’s nothing…” and 
Doctor 3 spoke about patients who called: “…they’ve had a fever, it’s been 38, it was 38 an 
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hour ago and they’ve checked it again and it’s gone up to 38.5, they don’t necessarily feel flu-
ish.” Wendy and Hannah who had suffered recent bereavements and feared infections could 
not or would not see the connection between a fever without other symptoms and serious 
infections and delayed calling.  Wendy: “…was just doing a routine check… I had a high 
temperature.  But I felt OK” and when Hannah got: “…a temperature at first I couldn’t believe it 
because I thought I’ve only got a cold and so I kept taking it…”. 
 
Most patients delayed contacting clinicians because they initially felt unwell without a fever.  
CNS 2 said: “…there are some patients who will wait for their temperature to go up to 38 or to 
39 or they feel really, really bad ….” Doctor 4 said some patients told him: “…they felt unwell 
but their temperature was normal and then they are phoning in maybe a few hours maybe 
even a day later saying oh my temperature is up now”.  Doctor 3 said: “… a lady rang me saying 
she was feeling very unwell…had a headache and she felt very warm” and CNS 3 said: “when 
they phone, oh I’m not feeling well, I’m feeling hot…” Patients waited for a fever because this 
enabled them to distinguish between expected chemotherapy side effects and infections 
which they could not ignore (See Category two: Getting away with it, wanting normality and 
control) or would not feel a nuisance calling about (See Category four: Relationships core to 
accessing help).  This was especially difficult following the first treatment.  Alice’s friend said:  
“…they were saying…people react differently…. it was not like she’d had chemotherapy before 
or she has any idea how she should be feeling”.  Lynda’s mother also said: “…this is just a whole 
new world...anything that happens you think oh it’s the chemotherapy”.  CNS 1 also spoke 
about patients thinking: “…this is just part and parcel of being on chemo” and CNS 3 said: 
“…they might be thinking oh this is normal”.    
 
Sophia, Hannah, Zeena and Jackie justified not calling the helpline because they did not have a 
fever of 380C.  Sophia said: “…it was definitely up…but it didn’t go up anymore…” and her 
husband added: “…it wasn’t 38, 37.5,  I said look it’s not, it is an alteration…”  Hannah said: 
“…my temperature went up as far as 37.8 and I didn’t ring them…”  Zeena who had taken 
paracetamol also would not call the hospital because: “…the temperature is not so high…” and 
although Jackie knew she: “…could have an infection without a temperature…in my mind I’m 
thinking well I’ve haven’t got a temperature so I probably don’t have an infection”.  Lynda 
delayed calling because she did not initially recognise she had a fever.  She described feeling: 
“…really cold I was shivering really crazy and I could only heat up with a bath…I had to sort of 
lie down and cover myself up you know a load of blankets…and then…I was actually getting 
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hotter and I took my temperature around that point and I think I was about 80, 38.4…” Lynda 
delayed taking her temperature because: “…I was so cold (laughs)…I knew it would probably be 
quite low…” Fayola, like Zeena took paracetamol and her husband said: “… OK you don’t have a 
fever…” and Fayola said: “I was like OK fine, there’s no temperature so it might be just a cold”.  
Melanie and Alice were looking out for infections by monitoring their temperatures and 
appeared to believe the absence of fever meant they did not have an infection, rather than 
using this as an excuse not to call.  Melanie: “…was taking my temperature every day, twice a 
day… it was always 36.3, 36.5.  Melanie said: “…with the chest infection… I was sick so I wasn’t 
really talking to people…the GP said it was viral … I just thought well there’s nothing I can do 
other than just get over it and I didn’t have a temperature so I didn’t have the trigger”.  Alice 
said she: “… felt dizzy on the Friday, Saturday and Sunday… She also took her: “…temperature 
quite obsessively and my temperature never really… went up to 37 even...” so Alice: “…thought 
oh well this is chemo, you know it’s just knocking me sideways”.  Melanie and Hannah had read 
the Macmillan BACUP chemotherapy information which advises calling the helpline if: “You 
suddenly feel unwell even with a normal temperature”.  Melanie said: “…if I’d have seen 
something that said if you are unwell for 3 or 4 days…even with no obvious temperature call us.  
I would have done that.  So just suddenly unwell, no it wasn’t sudden… I just had an infection”.  
Hannah also said: “…my temperature went up as far as 37.8 and I didn’t ring them...but it does 
say in the literature if that you suddenly feel unwell you should ring them…”.  
 
A further reason for neutropenic sepsis not being on patients’ and carers’ radar seemed 
related to timing of information provision and timing of neutropenic sepsis.  When information 
was provided about neutropenic sepsis, patients and carers were more worried about 
imminent side effects commonly associated with chemotherapy (See Category one: Playing 
down the seriousness and piling on the fear).  Doctor 1 said: “I think people know that they’ll 
lose their hair and they’ll feel sick…and it will be absolutely awful...” Fayola’s husband said: “…I 
was more worried about…sickness, the hair loss…that we kind of knew would happen but the 
infection was something that probably might not happen…” Melanie also appeared to think 
she was unlikely to develop an infection.  Melanie sought out information and worried she: 
“…would end up vomiting excessively”.  She did not enquire about neutropenic sepsis because:  
“…I wouldn’t ask a great deal…unless something really worried me”.  Some patients were also 
preoccupied with fears about chemotherapy administration.  Jackie asked a chemotherapy 
nurse: “…will I feel any effects when the chemo is going in?” and Melanie told Doctor 1: 
“…because I’m a coward and I don’t like pain”.   
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Infections also fell off patients’ and carers’ radar as important because these occurred around 
10 to 14 days after chemotherapy and were not generally spoken about beyond initial 
chemotherapy information sessions.  Paula and Alice who could not hear about neutropenic 
sepsis whilst reeling from the news they had metastatic disease indicated they would not be 
alert to infections during the second week of treatment because they did not know there was 
a risky time.  Paula: “…didn’t know about a white count, I wasn’t told about that…” Alice said: 
“…I was susceptible to infection was all I knew” and Alice’s friend said: “...the white blood cells 
being at their lowest right in the middle of the cycle…I may have had the information given to 
me but I certainly didn’t take that in….  I don’t know if Alice did either”.  Some patients further 
believed infections were unlikely to happen to them as they got away without developing 
these immediately following chemotherapy (See Category two: Getting away with it, wanting 
normality and control).  This view appeared partly fuelled by a lack of knowledge about timing 
of neutropenic sepsis.  Hannah: “…assumed it would have been about four or five days after 
the chemotherapy” and Lynda was: “…more worried about having that low count in the first 
few days after chemo”.   
 
Advice provided by clinicians about checking the temperature may have contributed to 
patients not being alert to infections during the risky time.  Doctors tended to advise patients 
to check their temperatures if they felt hot or unwell, whereas nurses told Wendy to: “…keep 
checking it, don’t forget to check your temperature…” and CNS 2 was observed to advise 
Sophia to: “…start from tomorrow and once a day and if you feel hot”.  Following her 
chemotherapy consent appointment with a doctor Melanie thought a fever was a: “…key 
indicator for the first 24 to 48 hours…” then CNS 6 advised her to: “…keep an eye on your 
temperature.  You don’t have to take it every day....” which left Melanie thinking: “…it’s 
something I need to be aware of right throughout the three week cycle”.  Some patients who 
knew the risky time still did not appear to make the connection between their symptoms and a 
need to report these (See Category two: Getting away with it, wanting normality and control).  
Sophia knew: “…the white blood corpuscle count will …at its worse…the mid period….” Jackie 
took the week off work after chemotherapy: “…because that’s the week they were telling me 
that you are quite prone to catching infections…” Fayola knew she was most at risk of 
infections: “…about 10 days… after your chemo” and Melanie knew by her final interview she 
was at most risk: “…from day 10 to, well it’s 14, 16…” 
 
163 
Because infections fell off patients’ radar it may have been helpful to revisit information about 
neutropenic sepsis.  Clinicians though, appeared to underplay the importance of neutropenic 
sepsis (See Category one: Playing down the seriousness and piling on the fear) by not generally 
discussing this with patients beyond the start of chemotherapy.  Sophia said: “…at the second 
and third chemo no-one mentioned this at all anymore”.  Patients spoke about being in the 
chemotherapy, which was a time when they had experienced the first chemotherapy 
treatment and were observed to visibly relax.  Melanie said after her first chemotherapy: “I 
feel I’m kind of I’m in it you know, I’ve had my first… I really thought it was going to be far more 
erm uncomfortable and difficult…” Sophia said this was a good time to take in information 
about neutropenic sepsis: “…maybe once treatment is underway…That’s a good moment then 
to give another really good pep talk, because also you relax a bit”.   
 
6.1.3.2 Property two: Getting a wakeup call  
Clinicians spoke about patients having to experience neutropenic sepsis to take this seriously.  
CNS 2 said: “…maybe they have to experience the impact first before they totally get 
compliant” and Doctor 3 said:  “… it feels like it takes one episode of a neutropenic sepsis 
before they truly, truly realise how important it is”.  Lynda also said: “…it doesn’t ram home to 
you until something actually happens”.  Most patients and carers understood the importance 
of neutropenic sepsis and the risks they had taken (See Category: two: Getting away with it, 
wanting normality and control) after patients became seriously ill with it.  Patients and carers 
then realised or acknowledged that neutropenic sepsis was not a normal infection that could 
be avoided or easily treated.   
 
Patients who waited for a fever of 380C to develop before reporting neutropenic sepsis 
symptoms described a rapid and frightening deterioration as they developed neutropenic 
sepsis which could not be ignored (See Category two: Getting away with it, wanting normality 
and control and category four; relationships core to accessing help).  Sam said: “I felt really 
good and then very quickly erm I felt unwell and I got a temperature and erm a chest 
infection… chest pain…I packed a bag knowing that I'd have to go into hospital…I had flu-like 
symptoms I was shaking...”  For Lynda and Fayola who had tried to make fevers go away, the 
deterioration happened in A&E.  Lynda said this was: “…scary…I feel like I’m just getting hotter 
and hotter and could have passed out… I don’t know what’s gonna happen.” Fayola said: “…by 
the time I finish work…and get to the A&E it was something else entirely...  I was really feeling 
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sick.” Her husband also:  “…could tell that she was really unwell… It was a bit scary at the 
time”.   
 
Alice had felt unwell for several days before she: “…got completely dizzy and collapsed on the 
doorstep …it stopped me in my tracks… if I hadn’t collapsed… I wouldn’t have rung them”.  
Alice did not appear confident to call the helpline unless she had a fever.  Alice’s friend said: 
“…she phoned me up in an absolute panic…because she couldn’t find her thermometer...”  
Zeena’s symptoms started with a sore throat.  Her niece said: “…she had a really bad 
headache… from the day before.” By the following afternoon Zeena: “…was feeling so bad… 
shaking… my legs were killing me…couldn’t eat…My head was, oh my god, as if somebody was 
knocking me… and the neck…Fever, when it was high I said yes I need to call….  this is 
different”.  When Sophia developed a chest infection all she: “…wanted to do was sit in an 
armchair with my head leaning forward…didn’t want to eat”.  She said:  “…my chest was 
hurting…I couldn’t breathe properly… I thought I had lung cancer… It was just so different to 
how I’d been feeling the day before.  It was a very quick downward slide…” She knew: 
“…distinctly, it wasn’t my chemo reaction… headache… feeling very very fluey…a high 
temperature.  So I don’t know how you would have ignored that…”.   
 
Although patients understood reduced immunity during chemotherapy increased the risk of 
infections, most had not understood the rationale for reporting infections was the risk of 
sepsis.  Doctor 3 said:  “…it doesn’t seem like they recognise it’s serious … they’ve been told to 
ring if they’ve had a temperature so I don’t know if it’s recognition or if it’s more… doing what 
they’re told”.  Similarly, Doctor 5 who worked in A&E said: “…I’m not sure they necessarily 
understand about neutropenia…but they know that having a temperature is a bad thing”.  
Clinicians were concerned that telling patients and carers about neutropenic sepsis might instil 
fear (See Category one: Playing down the seriousness and piling on the fear).  Many patients 
had assumed clinicians had referred to normal easily treatable infections during chemotherapy 
information sessions.  This included Paula who said: “…I didn’t know about a white count, I 
wasn’t told about that…It’s like they’re putting it as two separate things and it seems so minor 
the way they explain it…”  Paula felt she was: “…one of the lucky ones…Because I’ve come out 
of that hospital not knowing how dangerous…” Jackie said: “…infection could mean anything… 
because infections people can get… a dose of antibiotics and you are fine…” Helen: “….just 
thought I‘d get really sick and it could take longer to get rid of…” and Zeena’s niece thought: 
“…they’ll just give her medicine and then she’ll be OK…” Fayola also: “…thought they were 
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going to give me antibiotics to go and use at home and her husband assumed:  “…it will 
probably be a case of…giving her some antibiotics… I didn’t think it was going to be as serious 
as her having to stay in hospital”.    
 
Clinicians did not think patients would understand the term ‘neutropenic sepsis’.  CNS 1 said: “I 
don’t even say neutropenic because what does that mean to someone…” and Doctor 1 said: 
“…an overwhelming sepsis… I don’t know whether people necessarily know what that means”.  
Patients and carers indicated terms like blood infection, blood poisoning, sepsis or septicaemia 
created a better understanding of neutropenic sepsis than infection, although preferences for 
how explicitly this should be explained differed.  Patients who sought out information 
indicated a preference to be told explicitly and unemotionally what neutropenic sepsis was 
and the risk of death.  Melanie said: “…I go for absolutely detail, I need to know everything”.  
Before starting chemotherapy Melanie through her own research: “… found out...  my immune 
system was going to be particularly weak …if I did get an infection …my body wouldn’t be able 
to throw it off and if it didn’t get treated then I could actually end up with sepsis…it’s life 
threatening...” In terms of explaining the risk of death from neutropenic sepsis Melanie said:  
“I would go straight to it…” and when asked to compare Macmillan Cancer Support 
chemotherapy information with NHS Sepsis patient information Melanie said: “…neutropenia 
doesn’t mean anything to people…this [NHS Sepsis information] is really straight forward, 
septicaemia another name for blood poisoning refers to a bacterial infection of the blood…+ you 
would understand that, [and puts you at risk…+ because you don’t mention septicaemia on this 
one [Macmillan Cancer Support Information] or sepsis on the risk of infection, it’s all very not 
direct….I’d be inclined to say simple things like that.  This could be blood poisoning; the sooner 
you have treatment the better the result is so call us immediately”.    
 
Helen and Alice also sought out information, but had metastatic disease, so piling on the fear 
about neutropenic sepsis appeared to have resulted in their not hearing or wanting to know 
about this.  Alice referred to the chemotherapy alert card: “…I didn’t know what a neutropenic 
sepsis is, I said oh risk of that whatever that is” (See Category two: Getting away with it, 
wanting normality and control).  Alice and Helen also expressed concerns at the risks they had 
taken.  Alice realised during her interview: “…you get septicaemia which is kind of blood isn’t 
it?” and she had:  “…absolutely no white blood cells...I had no idea… if I hadn’t rung the chemo 
hotline...goodness knows what would have happened…when *name of doctor+ said…go and get 
some antibiotics, I said no, whereas if I had been maybe a bit more aware…” Helen and Alice 
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also expressed a preference to be explicitly told about neutropenic sepsis.  Helen said: 
“…nowhere in this paperwork [patient information] was this illness” and after developing 
neutropenic sepsis she: “...actually went on the computer and I read up on it myself...  I think… 
it should be explained to them what that illness is…they should be told how dangerous it could 
be…I would imagine you actually die with it…” Helen said: “…the infection could take over your 
whole body and affect your blood system…” and she thought the risk of death would: “…be 
quite easy to take in because…you would look for it and you would know the signs not just to 
ignore it and think… this will wear off in a couple of days.” Alice also said: “…You can’t just 
leave people to assume…” and:  “…I prefer to be told everything…I don’t mind anything spelt 
out, I’m not good at things kind of chucked at me, which I suppose is what happened”.    
 
Fayola and her husband also sought out information and wanted the hard facts about 
neutropenic sepsis.  Fayola’s husband said: “…the only time…I heard the phrase [neutropenic 
sepsis] was in hospital…” He asked a nurse: “…can you please explain to me what it is that she 
has that‘s made you wear these masks...explained… neutropenic sepsis… I didn’t really 
understand what they were talking about.  But, when they explained… because she can’t fight 
infections right now…that’s…when we really understood what's happening…” Fayola’s husband 
looked neutropenic sepsis up on the internet and realised: “…your white cells aren’t strong 
enough to fight off infection…I don’t know whether it was impressed upon us how serious it 
could be”.  He also said: “…if it’s stressed upon what could happen if you don’t call maybe that 
would make people call a bit sooner”.  For Fayola it was: “… a wake-up call.  When I got home I 
read up on it…because my white blood cell was 0.2 so it was that low.  Had it been I just took 
paracetamol and I didn’t go to the hospital… I could have killed myself…I can catch something 
and I could have died…” Fayola felt people starting chemotherapy should: “know what could 
happen when your white blood cell is low…” and said “They did make you understand that it is 
risky for your white blood cell to be low, you are prone to infection but the seriousness of it I 
think most people don’t know it…”  
 
It appeared Melanie, Helen, Alice, Fayola and her husband preferred clear factual descriptions 
of neutropenic sepsis and this also seemed to be the case for other male carers.  Sophia’s 
husband searched the internet and understood from the outset: “...the immune system 
becomes compromised because the bone marrow is affected, the bone marrow...produce the 
white cells…the lowering  of the cells…means the weaker immune system… internal infections 
means… your death…infection could mean septicaemia?”.  Melanie described her husband as: 
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“… the kind of person who says they can tell me what to do and I’ll just do it, I don’t need to 
know any more…” and he also indicated a straightforward message was better for him.  He 
said clinicians: “should be braver about it really.  Chemotherapy will reduce your blood cell 
count, if it goes too low and you get an infection, if you get septicemia that could kill you.  
That’s simple really…”. 
 
Some patients who feared and avoided knowing about neutropenic sepsis also indicated they 
should be told explicitly about this to prevent them ignoring the risk.  Hannah said: “...the 
trouble with saying things in softer ways is that you don’t really take on board the seriousness 
of it” and: “I think now I would call earlier… Because…talking to you about neutropenic sepsis… 
it does sound alarming…I think I would have taken it on board more seriously”.  Sophia also 
needed to: “…understand a bit better that people do die of neutropsepticimia…what it meant 
that day when I didn’t have my bloods done…” Sophia only appeared to take this more 
seriously when a Doctor in clinic: “… ticked me off in a sort of fairly nice manner.  YOU DIDN’T 
HAVE YOUR BLOODS DONE?  WHAT? ...she was giving me a message”.  Sophia also said: 
“…when I relate it to myself, I think oh I wonder if I really could have been that ill so quickly if 
I’d left it another day… I wonder if it’s being a bit exaggerated”.  Doctor 2 also appeared to 
correctly deliver a harsher message to Adanna about neutropenic sepsis.  He was observed 
informing Adanna infections during chemotherapy can be fatal to dissuade her from going to 
Africa during chemotherapy.  Following the consultation CNS 4 believed Adanna took the 
infection risk seriously because: “…She has listened…accepted our recommendations…knowing 
the patient ever since she got diagnosed…you establish that relationship...” It appeared this 
approach was successful.  Adanna said during her end of treatment interview: “…when I was 
about to take the chemo I asked the doctor if he can permiss me to go to [Africa] because they 
have already fixed the date…and the doctor said no… you can’t go …I said OK…I called my 
husband… and they shifted the date.” Adanna knew during her final interview: “…for the body 
to fight the infection would be tough and one might lose his own life”. 
 
CNS 3 thought telling patients about the risk of death from neutropenic sepsis may cause them 
to be: “…more scared of ringing” and some patients and carers who avoided information and 
feared infections indicated they would have preferred a softer message.  For Jackie using 
language that indicated sepsis was enough to get her to take it seriously as demonstrated 
within the following interview extract: 
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Researcher:  The problem that people can get is called neutropenic sepsis.  Have you heard 
of that? 
Jackie:    No… So what is that then? 
Researcher:    basically if you get an infection your body can’t fight it and you can get a 
secondary thing happening which is this neutropenic sepsis…it gets into your 
blood stream  
Jackie:  ahh 
Researcher: so it’s sort of blood poisoning. 
Jackie:    Septicaemia. 
 
Jackie knew what septicaemia was:  “…because my mum died from it.  I know how serious it is 
so…I wouldn’t have probably waited that long to do something about it”.    
 
Patients and carers who preferred a softer message indicated clear practical advice would 
assist in managing fears about neutropenic sepsis.  Lynda following her admission with 
neutropenic sepsis was: “…more aware of it… I appreciate I could catch anything going…you 
can’t fight it off… it’s extremely hard to treat and now I’m like oh my god… I suppose you could 
die from that rather than dying from your cancer”.  Lynda said:  “…if they’d said… you could die 
then that would have freaked me out… if they’d said look this could be a serious thing… you 
may not even realise you have this…until you actually catch something that floors you…so you 
have to be careful…I remember…being told…don’t worry too much, you know like don’t avoid 
everything…” Lynda’s mother also indicated: “I’m quite happy to hear what the side effects are 
if there is some purposeful activity I could engage in and help… tell me this is going to happen 
and you can do nothing, well that doesn’t help anyone really”.  Zeena’s niece did not know 
about neutropenic sepsis and when Zeena became ill they: “… kept going through the side 
effects and she [Zeena] got her booklets and then she said no it’s fine”.  Zeena’s niece: “… 
would have called them way earlier” had she known about neutropenic sepsis.  However, 
when asked if she should be told about the risk of death she said: “I don’t know, maybe….  I 
think if I did know of that I would have been so scared…” Zeena’s niece was advised: “… to call 
as soon as possible but they weren’t clearly asked to say that if you do get it earlier then it’s 
better because then she won’t be as ill as long…” When neutropenic sepsis was explained to 
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Alice’s friend she said: “Well I had no idea about it”.  She also felt practical advice, focused on 
the benefits of acting quickly, may counterbalance a harsher message about the risk of death 
as highlighted in the following interview extract: 
 
Researcher:  …the white cells…they go low midway between treatment cycles… you are 
more prone to infection… that can lead to this secondary thing which is this 
neutropenic sepsis which is a blood infection, so it’s septicaemia….basically, 
that’s why we say call us if you have a temperature or you are unwell because 
people can die from that quite quickly if they become septic....how do you think 
you and Alice might have felt… if it had been described like that? 
Alice’s friend:  I think she would have been in an even worse panic….  though she may have 
been more careful (laughs).  But when feeling a little ill she would have been, I 
don’t know I say in an even worse panic I mean she was really panicked, she 
thought she was going to die anyway… 
Researcher:   How about…if we…explained what it was and then we said well this can 
happen but actually…if you get to us we can get the antibiotics in you and deal 
with it quickly and the likelihood is it won’t lead to anything. 
Alice’s friend: That would be alright yes… that would be fine, that would be fine.   
 
6.1.4 Category four: Relationships core to accessing help  
Patients who initially ignored symptoms of neutropenic sepsis (See Category two: getting away 
with It, wanting normality and control and Category three: Making the connection) often felt 
extremely unwell by the time they called the helpline and were disinclined to go to hospital for 
something they believed was probably not serious (See Category one: Playing down the 
seriousness and piling on the fear).  Relationships with clinicians appeared important to 
accessing help for neutropenic sepsis.  These appeared especially important to patients who 
had metastatic disease or who were recently bereaved.  Delays in accessing the service were 
associated with patients feeling a bother for calling the helpline and especially busy 
chemotherapy nurses who did not seem to engage with them emotionally or with side effect 
management.  For the participants, delays were also associated with feeling abandoned by the 
oncology team when admitted to hospital with neutropenic sepsis.  Patients appeared more 
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inclined to call the helpline following good experiences of accessing help for chemotherapy 
side effects and their relationships with carers also appeared important to calling the helpline.   
 
6.1.4.1 Property one: Bothering the helpline  
 
Patients were often slow to access the helpline because they did not want to know about 
neutropenic sepsis (See Category two: Getting away with it, wanting normality and control) or 
did not realise the significance of their symptoms (See category three: Making the connection).  
Delays also appeared more likely if patients had previously felt a bother for calling the helpline 
or abandoned by the oncology team when they had presented to hospital with earlier 
chemotherapy side effects.  The helpline service was provided by chemotherapy nurses during 
the day and oncology doctors outside of normal working hours.  Some patients did not appear 
to view symptoms that indicated neutropenic sepsis as important enough to bother the 
helpline.  Patients told CNS 3: “…I don’t want to bother you” Doctor 1 spoke about patients 
who: “… didn’t want to bother anyone or didn’t think it was important so they don’t phone” 
and Doctor 4 said: “…some people will feel quite unwell and they just don’t like to bother 
people”.   
 
Relationships with clinicians appeared important to feeling a bother about accessing help for 
neutropenic sepsis.  Patients seemed disinclined to call chemotherapy nurses who seemed 
busy, technically focused and uninvolved in side effect management.  CNS 2 indicated she did 
not have time to provide side effect support.  She said: “…every time they come here they 
should be reminded clearly of monitoring their temperature or themselves for signs of 
neutropenic sepsis.  So if I only have enough time…” Melanie spoke about chemotherapy 
nurses who: “…seemed to be hugely rushed and quite technical…they feel like plumbers… 
attaching tubes to you…very little continuity between one [chemotherapy nurse] and the other 
and nobody saying well how’s it going, are you OK…” Melanie and Jackie spoke of snatched 
opportunities to speak to chemotherapy nurses.  Melanie said:  “…the only time there’s any 
conversation is when the nurse is having to give you the pink one...  And they actually have to 
sit and inject it… and that’s usually pretty banal.  So there’s no real space for relationship 
building …” and Jackie said: “…that’s the only time I had a chance to chat to them 
[chemotherapy nurses] because they have to sit with me for 15 minutes.” Paula said she did 
not have a nurse-led chemotherapy information session, rather: “…It was us asking questions” 
and Alice suggested this be incorporated into someone’s role who knew:  “…the possible 
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effects of chemo and they actually… come and talk to you while you are having it...even a 
volunteer”.   
 
Patients indicated they did not have relationships with chemotherapy nurses that encouraged 
checking out of chemotherapy symptoms.  Sam did not consider calling the chemotherapy 
nurses when she developed neutropenic sepsis.  Sam said: “…not really…I really rate them but 
they don’t…have that relationship with you…” and Sophia, during her first interview felt: 
“...inclined not to bother the poor nurse in the chemo unit cause, my god they’re busy people 
and they: “...don’t know what bits and bobs have gone wrong with me.” They just see…she’s 
been on time six sessions”.  Some patients spoke about doctors who knew them providing side 
effect support rather than chemotherapy nurses.  Melanie said: “…all that’s left with your 
monthly discussions with the medic…” and Hannah said the chemotherapy nurses: “...didn’t 
really ask me about side effects...  but … [name of Doctor 4] who I saw every 3 weeks I did talk 
to him about the side effects … although the clinic was obviously busy he used to give you the 
impression that he’d got all the time in the world”. 
 
Reluctance to call the helpline was also associated with previous experiences of feeling a 
bother for calling to check out chemotherapy side effects with clinicians who struggled to 
manage the service alongside other roles.  Doctor 2 said the chemotherapy nurses: “…don’t 
have somebody dedicated to answer the phone, they can’t talk to the patients, they are doing 
too many patients at once.  I think it’s very stressful for them….” Doctor 4 said: “…if it keeps on 
ringing that means you can’t get into the ward round…” and Doctor 3 said: “…it can be a bit of 
a burden…” Clinicians also referred to frustrations associated with calls they considered 
inappropriate.  CNS 3 said:  “…some of them [patient calls] are just plain nonsense” and Doctor 
1 said: “…its things that are perhaps trivial that don’t need to be called about in the middle of 
the night…” Doctor 3 spoke about: “…over cautious patients… you get calls about sometimes 
the silliest little things… you are busy clerking in patients, you have ward patients you are 
worried about… and then some calling the chemotherapy hotline for their appointment date”.  
Doctor 4 also said: “You get people phoning up at 3am… …saying oh could you just tell me 
when my appointment is? …people will phone up…11pm on Friday night saying oh I’ve been 
having this pain for the last week” . 
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Doctor 3 assumed: “…obvious complications would be spelt out to them [patients]… I’d like to 
think it’s not a case of, any problem ring that number”.  However, patients were not given 
guidance about calling the helpline (See Category three: Making the connection).  CNS 7 
advised Jackie: “…there is a hotline number there that you can call anytime if you’ve got any 
problems regarding your chemotherapy” CNS 6 advised Melanie: “…it’s ok to call you’re not 
bothering us” and Alice’s friend was also told: “…you can phone us any time, it didn’t have to 
be an absolute emergency”.  Sam illuminated a possible reason for calling the hotline about 
appointments because:  “…my chemo card that gives my appointment and it’s got the phone 
number of the chemo helpline on the back…  I would have been told earlier on that that was 
the number to call if there were any problems”.   
 
Doctor 4 said he would: “…rather be called over something that’s silly and not important than 
them stay at home with a real problem…” Doctor 2 also suggested clinician’s frustrations with 
the helpline resulted in: “…some people just don’t then respond appropriately”.  An apparent 
impact of feeling a bother for calling the helpline was reinforcement of some patients’ beliefs 
they should not call if symptoms did not include a fever (See Category three: Making the 
connection).  Jackie called the helpline when she developed diarrhoea and vomiting: “…on the 
Friday because it was still really bad and I wasn’t able to keep any food down… but they 
said…because it’s only five days after the chemo…it’s just a bit of a reaction… by Sunday I was 
really feeling ill.  On Monday morning I phoned…they just kept asking have you got a 
temperature, I said no I haven’t…” Sam: “…phoned up… to say I feel very unwell and they’d said 
well what do you mean, unwell.  If you’re worried go to A&E…” Sam: “…didn’t have the 
temperature… But you know I felt terribly terribly unwell...”  Chemotherapy nurses frustrations 
about being expected to care for patients who became unwell during chemotherapy appeared 
to also cause Alice and Melanie to feel a nuisance when they attended the chemotherapy day 
unit for review.  Alice said a chemotherapy nurse: “...screamed at *name of doctor+ for not 
telling them....  they were a bit grumpy about it” and Melanie said:  “…the nurse on duty…was 
a little bit dismissive, he didn’t quite know why are you here, your GP shouldn’t have sent you 
here, we are going to close down...”. 
 
In addition to feeling a bother, some patients who did not want to go to hospital and whose 
chemotherapy symptoms had previously turned out to be unimportant told themselves 
hospital visits for neutropenic sepsis symptoms were probably an unnecessary disruption (See 
Category one: Playing down the seriousness and piling on the fear) which may have 
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contributed to delays.  Doctor 1 said patients were: “… just trying to get through it all 
[chemotherapy] with as minimal sort of intervention as possible….they’re already here lots, for 
blood tests, for the clinic visit … their actual treatments… they really just don’t want to be back 
in hospital” and Doctor 2 said: “…they don’t want any more bother”.  Delays in recognising (See 
Category three: Making the connection) or accepting they needed help (See Category two: 
Getting away with it, wanting normality and control) meant patients also often felt too unwell 
to go to hospital when they developed neutropenic sepsis.  Alice said: “…when you collapse 
you are not really feeling like ringing anybody….” Sam was: “…mentally not in a state to get 
myself out of bed …” Hannah: “…just wanted to curl up in bed,” Sophia: “…wanted to stay in an 
armchair and I didn’t even want to put my head up… just leave me alone…” and Zeena 
appeared apathetic when she told her sons to leave her when she developed neutropenic 
sepsis because: “…one day I’m going to die…”. 
 
Doctor 3 spoke about patients: “…who say I’d rather not go there *A&E+… I’ll have to wait for 4 
hours” and Doctor 4 said usually:  “… they’re not neutropenic… and they have to sit around for 
four hours.  They know it’s a lot of hassle and think I’m probably going to be alright so they 
don’t bother”.  Carers particularly alluded to fatigue associated with hospital visits.  Zeena’s 
niece said: “…we didn’t want to just go to hospital for the sake of it and then it’s nothing and 
then we’re kept there for long” and Fayola’s husband said: “…because we’d been through quite 
a few sessions of chemo and a few things had happened along the line I thought maybe we 
could probably just leave it for a couple of days...”  Clinicians may have also contributed to 
some patients delaying getting to hospital with neutropenic sepsis because they did not 
explain what this was to patients who called the helpline and may have played down the 
importance (See Category one: Playing down the seriousness, piling on the fear).  Doctor 3 
said: “I don’t try and freak them out too much I just say we need to get a blood test done so can 
you get yourself to…hospital as soon as possible…I don’t make it seem like they’re going to die 
if they don’t unless they’re very ill”.  Consequently, Sam, Alice and Fayola did not get the 
message they needed to get to hospital quickly.  Sam waited for her husband to come home 
and: “…wasn’t massively worried.  I just knew I needed to get there at some point” Alice told 
the helpline: “I’ve got an appointment at 4.30pm, she said well you really should go soon.  I 
said well I’ll go at 5.30pm” and Fayola: “… didn’t tell her [helpline clinician] I was at work… she 
said make sure I go straight to A&E and I said OK.  I couldn’t leave my work”.   
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Delays in accessing the on-call service with neutropenic sepsis also appeared associated with 
having to attend A&E departments rather than the more familiar cancer centre.  Sam: “…felt 
slightly let down because … I was told there was no A&E at *name of hospital+…”.  Concerns 
about abandonment appeared particularly evident for patients who were bereaved or who 
had metastatic disease.  Alice said: “…although (name of hospital) is open until 6pm, they said 
go to your nearest Accident & Emergency” and Hannah and Sophia indicated they may put off 
calling because Hannah: “…dreaded having to go to the nearest hospital… are they going to 
really appreciate my situation”?  and Sophia found it: “…quite disturbing especially when you 
have been… nurtured by the breast cancer unit (laughs)…” Clinicians also spoke of concerns 
regarding management of neutropenic sepsis in A&E.  Doctor 4 said: “…it’s supposed to be 
door to antibiotics in an hour and that doesn’t happen and Doctor 2 said: “They need proper 
expert care, they spend much longer in hospital, they get the wrong antibiotics…” Doctor 1 
recognised: “…often that’s really traumatic for them *patients+ … they *A&E+ do things 
differently … it’s that sort of scariness of not being under your team”.  Doctor 5 who worked in 
A&E said patients felt: “…they shouldn’t have to come in through A&E…They should go to the 
oncology centre.  I’m not sure I disagree with that…” Doctor 5 also explained: “… the person 
that treats the patient with neutropenic sepsis is an F2 potentially… who doesn’t really 
understand it…” and CNS 8 who also worked in A&E said the oncology team had:  “…that more 
specialist training… we’re a jack of all trades…” .   
 
Patients did not have relationships with A&E clinicians and sometimes experiences in A&E 
contributed to a disinclination to return due to feeling a bother or because of poor 
communication between clinicians.  Fayola was reviewed in A&E several times and when she 
developed neutropenic sepsis decided she did not: “…want to keep ringing the hotline and 
becoming a nuisance...” Fayola said: “…they’re always nice but it’s something in you will feel 
like oh every little thing you are going to be calling, so I just thought I’d see how it goes…” 
Helen attended A&E with: “… terrible diarrhoea… terrible pains… everywhere… they [A&E 
clinicians] said I had a sore throat, gave me antibiotics and sent me home”.  Helen’s condition 
continued to deteriorate and she: “…was vomiting all day Saturday, all day Sunday, I couldn’t 
eat, I couldn’t drink and on the Monday… I actually thought I was dying”.  Helen did not call the 
helpline again because: “…*name of A&E] said…It’s just the side effects…..  I thought I can’t 
keep ringing them up every time I feel ill”. 
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Oncology clinicians promised they would communicate with A&E clinicians if patients were 
required to attend A&E due to chemotherapy side effects.  CNS 6 was observed to inform 
Melanie: “… they would talk to the team over here”.  CNS 1 said she advised:  “…we will liaise 
with the team that are admitting you to make sure you get the appropriate treatment” CNS 3 
said she too advised: “…once there is a bed they will transfer you, they will liaise with the 
hospital…” and Doctor 3 said: “…you are our patient and we will bring you here…”  Liaison 
between oncology and A&E clinicians did not always happen.  Doctor 4 said: “…we try to give 
them [A&E] a call then and let them know the patient is coming….which can often be very 
difficult because …no-one wants to take the responsibility for that patient coming in” and 
Doctor 1 said: “…some hospitals you know about it immediately …they’re on the phone, they’re 
asking for advice.  Other patients, you won’t know till they’re four, five days in to an 
admission”.  Clinicians who worked in A&E also spoke of poor communication.  Doctor 5 when 
asked if the oncology team called ahead said: “…sometimes…” and CNS 8 said: “…we struggle 
to get in touch with the… oncologists…”.   
 
Clinicians attempted to fill the communication gap by designating responsibility to patients to 
present their case to A&E.  CNS 1 said she advised: “… if you are admitted to your local 
hospital… make it clear with your chemo card that look I’m on chemotherapy…  So you’re 
triaged and seen quickly…” and CNS 2 advised patients to: “… bring … the blue book… and they 
have to say that the doctor told them to go to the local A&E and have a blood test and have 
necessary antibiotics”.  Fayola said: “…the first time I went to A&E they said they were going to 
ring them but when I got there nobody seems to know why I’m there so I have to be the one to 
tell them…” and Alice said: “…it was fine, I just showed them the card and said the chemo 
hotline told me to come”.  Clinicians who worked in A&E indicated patients who attended A&E 
with neutropenic sepsis expected clinicians to communicate about their care.  Doctor 5 said 
patients with neutropenic sepsis: “tend to arrive assuming we know all about them…we often 
know very little about them” and CNS 8 said: “…you often hear…you’ve got my records”. 
Patients further indicated they lacked confidence in care provided when communication was 
poor.  Lynda said her admission to hospital with neutropenic sepsis: “…was horrible… it was 
quite scary because I thought oh god… maybe they don’t see me as an emergency…I was 
transferred onto…an overspill kind of ward… *name of hospital+, had said they wanted me 
transferred but I mean that never happened”.  Oncology Clinicians spoke about worried 
patients informing them of their admissions to hospital with neutropenic sepsis.  Doctor 1 said: 
“…That’s when it’s awful when the patient pitches up saying… I was in Hospital X’ and you 
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know nothing about it...” and CNS 1 said: “…the sensible ones will just ring up the hotline and 
say oh I landed up in hospital… keep you informed”.   
 
When communication was poor, some patients appeared reluctant to return to the care of 
A&E.  Helen’s experience of being admitted to hospital with neutropenic sepsis resulted in her 
feeling: “… the care I got in the hospital was terrible and I said I’d never go back in again”.  
Further, patients who lacked confidence in care provided by other clinical teams appeared to 
pressurise for review at the cancer centre, which may have contributed to delayed 
presentation with neutropenic sepsis.  Alice was sent home from A&E when she developed 
neutropenic sepsis because:  “…you haven’t got a temperature you’ve obviously not got an 
infection...” Alice said the following day an oncology doctor: “…phoned me and said your blood 
count is incredibly low you shouldn’t have been allowed out of hospital last night…” Alice then: 
“…didn’t want to go back to Accident & Emergency… I rang *the chemotherapy day unit+… and I 
said to them can I go there…” Doctor 4 said patients asked to attend the chemotherapy day 
unit because: “…they know us here and we know them”.  CNS 3 said: “…they would rather to 
prefer come here…” and CNS 2 was told: “...I like to go there because I like the way you care for 
us”.  Clinicians also suggested patients felt safer at the cancer centre.  CNS 2 was told by 
patients that A&E staff: “… don’t know what they’re doing” and Doctor 3 said patients would: 
“…just rather… wait to be seen here as opposed to endure what they’ve had there”.  Doctor 4 
also said: “…things will happen more quickly here so even if it means they have to travel further 
they’ll get here….”  
 
Patients appeared more inclined to call the helpline following a good experience of accessing 
help for neutropenic sepsis and when they knew they were seriously ill (See Category three: 
Making the connection).  Patients also did not feel a bother for bypassing the system and 
checking out their symptoms with clinicians with whom they had an established relationship.  
Patients viewed the helpline as an emergency service despite being advised to call anytime to 
check out their symptoms and did not feel a bother for calling about symptoms which they 
considered serious (See Category three: Making the connection) and could not continue to 
ignore (See Category two: Getting away with it, wanting normality and control).  Fayola’s 
husband said they delayed calling when she developed neutropenic sepsis until: “...  it was 
starting to get gradually more serious...” and Jackie said: “…they told me to call if there’s any 
problem.  I just felt it was just for emergencies… because I could see they’re busy, they’ve got 
obviously people are more seriously ill so I didn’t want to ring for the sake of it”.  Jackie 
177 
subsequently delayed calling until: “… I didn’t feel well and I knew something was wrong….” 
Paula said:  “…I don’t like to cry wolf…” and called the hotline when she: “… just didn’t care I 
knew it wasn’t normal.” Sophia’s husband viewed the service as: “…a hotline in case of 
emergency…” and when Sophia developed a breast infection she: “… thought of ringing the 
helpline, but you don’t want to do it except as a last resort....  you’d want to be really sure you 
weren’t making a fuss about nothing”.  Sophia called when she knew: “…it was serious 
enough…there wasn’t even any question that I would be bothering them…”  Sam said she felt a 
bother for calling the helpline because advice about when to call:  “…wasn’t very concrete so 
the second time I, I had to be very sure that I was ill enough to ring up.  I think it’s quite a fine 
line.  You have to know yourself…” When Sam developed neutropenic sepsis she: “…phoned 
back when I’d got a temperature”.  Interestingly, before starting chemotherapy Melanie felt: 
“…confident to call [the helpline] totally… it’s there for reassurance as well as advice...  just to 
check something out.”  By her final interview Melanie felt: “…everybody being so franticly busy 
would actually put me off… you are not going to make a random phone call just to get 
reassured, you will make a phone call when you really think you’re either in a crisis or there’s a 
real problem”. 
 
Patients also appeared more inclined to access the on-call service after reported symptoms of 
neutropenic sepsis were taken seriously by clinicians and when they subsequently understood 
symptoms to look out for (See Category three: Making the connection).  When Sophia 
developed a chest infection she said:  “…they [helpline doctor] were very responsive… they 
were wonderful…” and Hannah was: “…very impressed the first time I rang the helpline… and 
even with a cold the fact that the doctor took the trouble to phone me”.  Doctors who had good 
relationships with Sam and Hannah reinforced risks they had taken by not reporting infections 
and conveyed the importance of reporting similar symptoms in the future (See Category three: 
Making the connection).  Hannah said she called the hotline with a second infection because: 
“…after that first very bad dose of chemo when it really hit me [name of doctor] said I should 
have phoned them much more and he said we’re going to nag you very kindly to phone us…He 
said it’s because if you get a genuine infection it can have serious consequences…” Sam was 
told: “… we’ve had two people who’ve been quite ill from Docetaxel and so, you must let us 
know… So that made me feel okay, it’s fine to, I will phone”.  When Sam called with a 
subsequent infection she indicated a positive response encouraged her to call again because: 
“…now I’ve done it and it’s actually just a doctor picking up a phone in an office… and…  he was 
dispensing sound advice”. 
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Patients also appeared to feel less of a bother and got to hospital quicker when they realised 
symptoms of neutropenic sepsis were taken seriously by clinicians who manned the helpline 
who also ensured they would be expected and treated as a priority when they got to hospital.  
Jackie said the: “…oncologist had phoned ahead and told the nurses to expect me and to do the 
blood tests straight away…”. Zeena’s niece said a doctor advised Zeena needed: “… to be put 
on a course of antibiotics and just to take her straight away to A&E and … we should call the 
ambulance…they’ll let the hospital know to expect us”.  Lynda also went to A&E straight away 
after calling: “the…helpline and erm they said to me to get to my nearest A&E as quickly as 
possible and that they would err fax them erm my last eh treatment letter, so that they would 
know to expect me”.  Zeena said: “…when I went [to A&E] told them that they rang from (name 
of hospital) and said yes and then just straightaway….they did everything…” Because Zeena 
was treated as a priority, got good care and understood more about infection risks (See 
Category three: Making the connection) she too appeared prepared to come forward earlier in 
the future.  Zeena said: “…If you leave it then it will take time to get well… but if you call they 
look after you … give you medicine…”. 
 
Patients also did not feel a bother for waiting to check out symptoms of neutropenic sepsis 
they suspected or hoped were not important (Category one: Playing down the seriousness and 
piling on the fear; Category two: Getting away with It, wanting normality and control and 
Category three: Making the connection) with clinicians with whom they had established 
relationships.  CNS 1 spoke about: “…a tendency to call the breast care nurses as opposed to 
call the hotline”.  She also said: “… it’s partly because they don’t want to bother people that 
they delay ringing and they like ringing you because they… know you”.  Adanna called a breast 
care nurse when she developed chemotherapy side effects because: “…they knew me 
already… That’s why I prefer to call them than the 24-hour hotline”.  Relationships with 
clinicians appeared particularly important to patients who had metastatic disease or were 
recently bereaved.  Wendy whose sister was dying of breast cancer called a breast care nurse 
when she developed neutropenic sepsis because: “…I didn’t think it was that important”.  
Jackie whose mother died just before she started chemotherapy said her breast care nurse 
had: “…been brilliant, she would always return my calls…” It was therefore unsurprising Jackie: 
“…would probably phone [name of breast care nurse+...” about chemotherapy side effects.” 
Sophia who had metastatic disease considered the breast nurse: “...was more concerned about 
me personally [than the chemotherapy nurses]...  I felt that I could ask her” and she was: 
“…reassured in good hands…” which may in part account for her waiting until a clinic 
appointment to report a breast infection.  The importance of therapeutic relationships in 
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accessing help was also evident in the account of Alice who had metastatic disease and did not 
consider calling a breast care nurse when she developed neutropenic sepsis.  Alice said she did 
not have:  “…much confidence and I don’t feel I’ve had a relationship with her *breast care 
nurse+ and I think it’s about a relationship…It didn’t occur to me to call her….” Alice also had: 
“…an uneasy relationship…” with an oncology doctor who Alice reported:  “...phoned me and 
said your blood count is incredibly low you shouldn’t have been allowed out of hospital last 
night, you’ve got to come back today and I refused, I said it’s my birthday, I’ve got things 
planned…”   
 
Paula who also had metastatic disease went to her GP when she developed infections on two 
occasions.  Paula perceived the breast team: “…gave up on me” and spoke of not seeing a 
breast care nurse since her diagnosis: “That was all the contact you had with her…” Paula also 
lacked confidence in the chemotherapy nurses who appeared not to know her case: “…it’s like 
you’re supposed to know that… It’s been like one thing after another”.  When asked if she 
thought of calling the helpline when she became unwell Paula said: “…It didn’t enter my head.  
Go down to the GPs and get some antibiotics”.  Helen and Melanie also went to their GP’s 
when they developed infections.  When asked about her relationship with the breast and 
chemotherapy nurses Melanie did not feel she had: “…a strong relationship with either…”  She 
said the breast nurses:  “passed me by… because a few times… I did ask them to do something 
the answer was kind of well we can’t… and I just never called again” and she thought the 
chemotherapy nurses saw her as: “…just another face…” Melanie’s confidence and relationship 
with the cancer nurses diminished when she developed a chest infection.  Melanie called: “… 
my so called breast nurse … because I was not sure I should have chemotherapy if I’m already 
this unwell but the answer from her on that day…as well as from the nurse [chemotherapy 
nurse]…was if your bloods are OK you have chemotherapy”.  Melanie was given the 
chemotherapy and did not call the hospital as she became progressively unwell because as her 
husband said:  “…it’s actually to feel that there’s actually some competence there … there 
wasn’t really…” Rather, Melanie saw her GP because: “…we’ve seen each other a lot more over 
many, many more years…, we do know each other.  I usually get sense out of her…”  Helen’s 
family also went to her GP after she had been made to feel a bother for calling the helpline.  
Helen who had metastatic disease said:  “…when I actually had to ring up and speak to a doctor 
[helpline].  I thought this is a waste of time”.  Helen’s GP had encouraged her to check out 
chemotherapy symptoms with him and advised her: “…be very careful…a slight sniffle anything 
I had to get erm in contact with him straight away” and when she was seriously ill with 
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neutropenic sepsis he: “...come out straight away...  he was quite concerned… he rang up erm 
[name of Hospital] and they said I was to come in straight away…”.   
 
Relationships with clinicians who patients trusted appeared core to their accessing help for 
neutropenic sepsis.  It further appeared that provision of ongoing chemotherapy side effect 
support within therapeutic relationships might promote earlier detection and treatment of this 
condition.  Patients indicated they found it difficult not being in touch with a member of the 
oncology team between treatments.  Jackie had thought a nurse would call her during 
treatment: “….because when they said you would be allocated a cancer nurse I thought that’s 
what would have happened but it didn’t…” and Sam found it: “…quite difficult because ...  
there’s no contact from the time that you have your chemotherapy to your next erm meeting 
with the doctors three weeks later...”  CNS 3 said if she could proactively call patients during 
chemotherapy: “…at least… any neutropenia then it can be treated straight away…”  Jackie  
said if a nurse called: “…it’s not left to you … it would be nice if the nurses would phone and just 
say…  how are you feeling because I wouldn’t just phone up and tell them how I’m feeling 
because they are busy”.  Helen said:  “Even though they knew I was going to the local hospital, 
nobody rung at all to see how I got on or what had happened, cos maybe if they had done and 
my husband would have been able to say how ill I was  I might have been, had my treatment  a 
lot quicker”.  Alice’s friend said: “…maybe they [patients] just need to know that they can just 
talk about it [side effects] they can just phone up and talk to someone and I don’t even know if 
that is possible…”  It appeared a relationship with clinicians to include proactive calling might 
encourage patients to call to check out their symptoms.  Fayola’s husband said:  “…it would 
have been fantastic if there could be someone from the chemotherapy team who would 
probably just call maybe during the first week of your chemo…to find out how you are doing 
and to impress on the person again that any problems at all call us...”  Melanie’s husband also 
believed her chest infection would have been treated sooner if someone were:  “…available 
and will actually get back and support her…had there been a relationship with the care nurse 
she would have actually called and said this is going on what do you think”.    
 
6.1.4.2 Property two: Carers an untapped resource 
Relationships with carers also appeared important to accessing help for neutropenic sepsis.  
Female carers (friends and family) who attended chemotherapy information sessions appeared 
able to persuade patients to call the helpline when they developed infections.  Male carers 
(partners and sons) who lived with patients (who had not attended chemotherapy 
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appointments) seemed unable to persuade.  Patients found it difficult to identify neutropenic 
sepsis symptoms (See Category three: Making the connection) and often felt disinclined to act 
because they ignored their symptoms (See Category two: Getting away with it, wanting 
normality and control) or did not want to be a bother (See Property one: Bothering the 
helpline).  Carers often noticed significant changes.  CNS 1 said: “…It’s the people around the 
patient who are really good at saying are you alright… maybe you should check your 
temperature…” and CNS 3 said carers noticed: “…that’s different from what her was before, 
another perspective”.  Doctor 1 thought carers were: “…more observant for the problems and 
side effects…” Clinicians though, also indicated carers sometimes had difficulties persuading 
patients with neutropenic sepsis to access help.  CNS 3 spoke about carers: “…trying to 
convince patients to come to the ward or to ring the ward…it’s kind of a bit difficult for 
them….” and Doctor 1 said: “Often the relatives take it on board that it’s serious… the patient 
doesn’t want to call but the carers are insisting…”.  
 
Clinicians advised patients to bring a carer to chemotherapy information sessions.  CNS 1 said: 
“…I always say if we’re going to talk to you about starting chemo bring someone with you…” 
and Doctor 4 said: “I’ll usually try and encourage them to bring someone...” Patients did not 
though, appear encouraged to bring the person most likely to be around if they became 
unwell, including male carers (usually partners) who lived with them.  Further, clinicians were 
not observed to engage with carers who attended chemotherapy information sessions to 
equip them to assist patients to access help should they became unwell during chemotherapy.  
Alice’s friend said:  “I don’t really know what is offered for friends and family… I don’t think 
they are equipped in any way…” Rather, clinicians who manned the helpline spoke of 
arrangements for getting to hospital being made during neutropenic sepsis episodes.  Doctor 3 
asked patients with suspected neutropenic sepsis: “… how are you going to get there…do you 
have a friend or family member to take you or would you be able to go yourself, if not you may 
need to call an ambulance” and CNS 2 said:  “…where are the other relatives? Maybe she can… 
leave her kids with the relatives or the husband….”  Delays in galvanising carers to assist in 
getting patients to hospital when they developed neutropenic sepsis were evident in the case 
of Sam who was: “…just waiting for my husband to come home so he could care for them [their  
children]”.   
 
Doctor 3 thought: “… you just have to target family members that take a more direct role with 
the patient…” Patients though, wanted to remain in control (See Category one: Playing down 
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the seriousness and piling on the fear) and they rather than their carers usually called the 
hotline when they developed neutropenic sepsis.  Doctor 3 said it was: “… primarily the 
patients…” CNS 1 said: “…it tends to be the patient…” and CNS 2 said: “…mostly the patients” 
who called.  When Sophia was asked if her husband should have been given more information 
about neutropenic sepsis, she said: “No, I like to have it I want all information”.  Before her 
treatment Jackie said her: “biggest worry…having to depend on other people…” Jackie retaining 
control appeared evident when her friend was asked during an informal interview if she felt 
included in consultations.  Jackie appeared to steer the interview away from her friend:  
 
Researcher:  And how have you found coming, do they involve you, do the doctors and 
nurses talk to you much? 
Friend:  No only today, cos Jackie’s been telling me what’s what…. 
Jackie:   (Jumps in) Yes, yes, but I have another friend as well who came…  
 
Patients wanted to retain control but some also wanted moral support so chose female carers 
(friends or daughters) to attend chemotherapy information sessions.  Female carers were 
often able to persuade patients to call the helpline about symptoms of neutropenic sepsis 
without undermining them, but they had to be persistent.  Alice’s friend accompanied her to 
chemotherapy information sessions:  “…to emotionally support me…” and Alice sought her 
friend’s advice when she developed neutropenic sepsis.  Alice’s friend said: “She was panicking 
a lot… I did have to keep saying it to her… Keep repeating it over and over.  Just call them, come 
on call them, they said you can call anytime…”  Wendy’s sister and Zeena’s niece accompanied 
them to chemotherapy information sessions. They recognised symptoms described by 
clinicians as important, which helped reinforce the message to call.  Wendy said: “…she [her 
sister] made me phone the hospital… I only did it to shut my sister up (laughs)… she just 
wouldn’t give me peace until I got it sorted out… if I had a temperature I had to go straight into 
hospital…” When asked how her sister knew that, Wendy said: “Because she came with me to 
appointments”.  When Zeena developed neutropenic sepsis she said her niece pointed out: 
“This is different, because everything the nurse explained to her … if you feel like this….” 
Zeena’s niece indicated why patients may seek support from female carers during 
chemotherapy.  She explained: “...boys, they deal with things differently than women … I just 
felt like I had to sort of be around…she finds it more  easier to speak to me….  She values my 
opinion a lot”.  Zeena’s niece also highlighted difficulties for carers in persuading patients to 
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call the hotline when normal family roles were challenged.  Zeena’s niece said: “…she’s like my 
Auntie and I can’t be so bossy to her and say come on we’re going…I was listening to her… we 
were discussing it…I wanted to call them...She felt so hot and then I said to her maybe we 
should call… up to her really…”  As Zeena’s condition deteriorated she spoke of her niece 
becoming more insistent: “… no Auntie, no I have to call her because you are just lying on the 
bed like that, so I said alright then”.  In a similar case, Helen’s daughter became increasingly 
concerned and finally took the decision to call.  Helen said: “I’d been so ill over the weekend 
she’d actually come here first thing in the morning when my husband went to work …she 
couldn’t get me to drink, she couldn’t get me to eat and I wouldn’t communicate with her.  
Erm, she said as the day went on I began to look worse and she knew then that it wasn’t right 
and that’s when she decided to ring my doctor.  If it had been down to me, no I would have just 
lay there”.  Only Melanie’s friend failed to recognise the significance of her symptoms because: 
“…we were all on the same page that it’s a viral infection and I don’t have a temperature, 
there’s nothing to be done…” (See Category three: Making the connection). 
 
Patients’ inclusion and exclusion of carers from the chemotherapy process appeared 
influenced by relationships between gender and carer which were also a reflection of their 
‘relationship to the patient’.  Female carers were all sisters, daughters, and friends whereas 
male carers were mostly husbands or spouses.  Female carers who attended chemotherapy 
information sessions appeared able to persuade patients to access help for neutropenic sepsis.  
However, patients who wished to remain in control appeared to exclude male carers perceived 
unable to provide moral support from chemotherapy information sessions.  Lynda said her 
husband: “...wasn’t at the meetings with the doctors” and her mother added he: “…went with 
her (laughs) to a few things but she said he was more stressed than she…” Sam excluded her 
husband because:  “…I don’t want him to…he’s not very good with needles” and Melanie chose 
a friend to accompany her who: “…wouldn’t be phased by the chemotherapy”.   
 
Zeena appeared to exclude her sons to protect them, as indicated by her avoiding clinicians 
speaking with them about her diagnosis: “…I said no don’t want to put my sons in problem...  
I’ll talk to them nicely then.”  Sam and Lynda who were younger than other patients did not 
recruit female carers for moral support during chemotherapy and managed neutropenic sepsis 
episodes alone.  Their husbands appeared to avoid chemotherapy information (See Category 
two: Getting away with it, wanting normality and control) and were not alert to signs or 
potential dangers when Sam and Lynda developed neutropenic sepsis (See Category three: 
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Making the connection).  Sam: “…asked him [her husband] to read the leaflets” and did not ask 
her husband to come home early from work when she developed neutropenic sepsis, rather 
she: “…told him I was going to [name of hospital] once he was home...  because he doesn’t 
know how I was feeling…” Lynda also said her husband: “…hadn’t read any of that 
information…” and when she became unwell he also failed to recognise she needed help.  
Lynda said her husband: “… just didn’t erm see it as that serious … they all went went to the 
pub… (laughs) and I stayed at home...” When Lynda eventually called the hotline she took 
herself to hospital: “…I got a taxi… my family and friends and they were all out…”.  
 
Some patients shared written chemotherapy information with male carers excluded from 
information sessions.  These carers noticed when patients became unwell with symptoms of 
neutropenic sepsis but still appeared unable to persuade them to call the hotline.  Sophia 
showed her husband: “…the card [chemotherapy alert card]…if we need to ring an emergency” 
and her husband said when Sophia developed mastitis she told him: “…no we’ve got an 
appointment tomorrow… it was going to be for her to judge how she felt”.  Melanie said she:  
“…would have talked him [her husband] through that [chemotherapy side effects]…” and when 
Melanie developed a chest infection her husband: “…kept saying why don’t you go to the 
doctors and she kept saying there’s no point...  She’s quite stubborn when she gets going 
really…although I didn’t really over insist”.  Zeena also gave her sons written chemotherapy 
information and said: “…they were looking at the computer on the internet...”  Zeena said her 
sons noticed when she became unwell with neutropenic sepsis because: “…if she doesn’t come 
out of the bed just know that she’s not well…” They told Zeena: “…is not good if you get 
infection…you should call the hospital…I said no…the temperature is not so high…” Zeena 
explained her sons turned to her niece to persuade her: “...  said *name of niece+ take mum...”. 
 
Lynda and Jackie also appeared to exclude female carers that they perceived unable to provide 
moral support.  Lynda’s mother wanted to do: “…everything to help…”  Lynda may have also 
sought to protect her because: “…my mother… is quite emotional about it all” and Lynda’s 
mother spoke about her daughter, sending her a photograph of her shaved head: “…so that 
when I saw her I wouldn’t be terribly shocked”.  Lynda’s mother realised her family knew 
nothing about neutropenic sepsis and were: “…dependent on her [Lynda] to be more aware of 
that ….  She also said: “…I should actually be much more aware of …because if she were with 
me… and she became ill...  we need to know that”.  Jackie’s sister also did not attend 
chemotherapy information sessions despite their living near to each other.  Jackie spoke about 
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her sister finding her cancer diagnosis difficult, and them both struggling to deal with a recent 
bereavement.  Doctor 1 at the chemotherapy consent appointment said: “she and her 
sister…was quite understandably sad.  I think a combination of the diagnosis and…just buried 
her mother”.  Jackie gave her sister: “…the information …all the stuff I was given…”  When 
Jackie became unwell her sister could not persuade her to call the helpline.  Jackie said her 
sister: “…saw me on Saturday that I looked really terrible and she said you know you need to go 




















Chapter summary:  
Four interrelated categories formed of eleven properties were developed.  The core 
category, to which all other categories related, was Playing down the seriousness and piling 
on the fear.  This suggests that clinicians may have underplayed the seriousness of 
neutropenic sepsis through a desire to balance frightening patients unnecessarily with 
encouraging them to call the helpline.  Consequently, out of frustration clinicians appeared 
to pile on the fear about neutropenic sepsis whilst minimising description of it to an 
infection.  This behaviour appeared further associated with a tendency to avoid in-depth 
discussions about possible benefits and consequences of chemotherapy, including the risk of 
neutropenic sepsis, through fears of treatment refusal.  Patients and carers often appeared 
to deal with their fears of neutropenic sepsis by avoiding knowing about it and 
concentrating on preventing infections and normal life.  They often did not pay attention to 
symptoms of neutropenic sepsis when these occurred.  Avoidance behaviours seemed 
complicated by patient and carers believing they should feel unwell with a fever of at least 
38OC to bother the helpline.  Furthermore, clinicians appeared more likely to underplay the 
seriousness of neutropenic sepsis with patients who seemed to perceive they had a poor 
prognosis.  It was these patients who appeared most pessimistic about their prognosis, most 
frightened by information about neutropenic sepsis and in whom avoidance behaviours 
seemed exacerbated.  Furthermore, patients from ethnic minority groups appeared more 
likely to take a fatalistic attitude to their risk of developing neutropenic sepsis.   
 
Relationships between patients, clinicians and carers appeared important to timely or 
delayed presentation.  Patient and carers suggested they may have presented to hospital 
earlier had they fully understood the seriousness of neutropenic sepsis and the symptoms to 
look out for.  Some patients also continued to believe risks of neutropenic sepsis were 
exaggerated when they understood this condition and the risks of dying.  Finally, some 
carers were able to influence patient behaviour to call the helpline and some were unable to 









Chapter Seven: Developing the 




The study outlined within this thesis was driven by anecdotal concerns in clinical practice and 
the literature that some patients die unnecessarily because they delay presenting to hospital 
when they develop neutropenic sepsis.  The study intent was to establish: 
 
Why do some patients delay reporting to hospital with signs and symptoms of neutropenic 
sepsis, and what assists patients to present earlier to reduce the effects of neutropenic sepsis? 
 
Ethnography was employed for data collection.  Grounded theory was applied to direct data 
collection and analysis and to develop a theory that was grounded in the data.   
 
7.2 Development of a model to illustrate the grounded theory 
Theoretical representation of the research findings were developed through application of a 
theoretical coding model (Morrow and Smith, 1995) described in chapter four.  By applying the 
model to developed categories and properties presented within the previous chapter, a theory 
began to emerge from the analysed data.  Application of the model provided insight into the 
processes involved (Glaser and Strauss, 1967) in delayed patient presentation with 
neutropenic sepsis.  The coding framework (Morrow and Smith, 1995) (figure 7.1) required 
identification of:  
 
(a) The causal conditions or the underlying components that lead to the responses to the 
threat of neutropenic sepsis by participants. 
(b) The central phenomena or core explanatory category, which provides an explanation 
for why participants have reacted in the manner described.  
(c) The contextual conditions that show how systems and processes might impinge upon 
the patient’s response to delay reporting neutropenic sepsis. 
(d) The intervening conditions that show factors that might influence how participants 
respond to the risks associated with neutropenic sepsis and their reaction to 
developing neutropenic sepsis. Intervening conditions have also been referred to as 
moderators within this thesis, in line with the applied Patient-Centred Communication 
in Cancer Model (Epstein and Street, 2007).  
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(e) Strategy development, which show the reactions and behaviours patients adopt to 
deal with the risk and / or development of neutropenic sepsis.  
(f) The consequence of strategies patients employ to cope with the threat of neutropenic 
sepsis which is their delaying presentation when it occurs. 
 
The process was assisted through moving between theory and category development.  
Application of analytical tools continued until the categories were filled out in terms of 
properties and dimensions.  Applied tools included theoretical sampling, constant comparison, 
and testing negative views or disconfirming cases, as described within chapter four.  Each 
component of the theoretical coding model is informed by, and draws together, the four 
developed categories described within the previous chapter. 
 
Figure 7.1. Model framework (Morrow and Smith, 1995) 
For permission see appendix 2 
 
      Context 
 
  
Causal conditions                 Central Phenomena                Strategies                Consequences     
                                                 (The Core Category) 
    
          Intervening Conditions 
                  (Moderators) 
 
 
7.2.1 Causal conditions or the principal factors that underlie the participants’ responses to 
neutropenic sepsis.  
(Informed by findings from the Core Category: “Playing down the seriousness and piling on 
the fear”) 
Two types of causal conditions that trigger the central phenomena (the core category) also 
emerged from data captured within the core category: “Playing down the seriousness and 
piling on the fear”.  Causal conditions relate to (a) clinicians fearing patients refusing 
chemotherapy or dying from neutropenic sepsis and (b) patients being hit by the reality of 
having a life-threatening illness.  More specifically, this suggests causal conditions for 
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clinicians’ behaviours include their fearing that being explicit about neutropenic sepsis may 
frighten patients - who are already reluctant to receive chemotherapy - into refusing it.  
Clinicians are also frustrated by and do not understand why patients delay presenting to 
hospital.  They worry that patients who develop neutropenic sepsis might die if they delay 
contacting the hospital.  Patient and carer associated causal conditions include those who fear 
they may die from cancer not wanting to know about neutropenic sepsis.  This is complicated 
because starting chemotherapy, and in particular hearing about neutropenic sepsis, brings 
home the reality of their having a life threatening illness.   
 
7.2.2 Central phenomena or the core explanatory category that explains why patients 
react to neutropenic sepsis in the manner described  
(Informed by findings from the Core Category: “Playing down the seriousness and piling on 
the fear”) 
The central phenomena is also the core category (“Playing down the seriousness and piling on 
the fear”) and results from the previously cited causal conditions.  “Playing down the 
seriousness and piling on the fear” is designated as the core category due to: (a) its centrality 
to the theory to explain delayed patient presentation with neutropenic sepsis; (b) its 
relatedness to all other categories; (c) multiple appearances within the data; and (d) implied 
relevance to a general theory.  Furthermore, the core category allows for optimal variation in 
dimensions, properties, conditions, consequences and strategies, whilst still representing each 
case studied (Strauss, 1987).   
 
The Core Category: “Playing down the seriousness and piling on the fear” suggests clinicians 
struggle in attempts to warn patients of the risks of neutropenic sepsis and to convince them 
to call for help if they become unwell.  They adopt tactics which pile on the fear by hinting at 
the seriousness whilst not explaining what neutropenic sepsis is.  This information is provided 
in a dispassionate way and as a standard repertoire.  Information provided about neutropenic 
sepsis by clinicians makes patients, who are already distressed about having a life threatening 
illness and starting chemotherapy, feel more fearful of dying and out of control.  Patients react 
by listening but not hearing important information about neutropenic sepsis.  Patients instead 
focus on information about reporting a fever and do not want to take responsibility for 
reporting neutropenic sepsis. 
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7.2.3 Contextual conditions or systems and processes that affect patients responses to 
neutropenic sepsis 
(Informed by findings from Category four: “Relationships core to accessing help”) 
Context refers to structural conditions that influence the nature of patients’ coping responses 
or strategies to deal with the central phenomena / core category (“Playing down the 
seriousness and piling on the fear”). Responses or strategies emerge through actions, 
interactions and emotions (Corbin and Strauss, 2008). The category looking at: “Relationships 
core to accessing help” provided some evidence of key contextual influences that affect coping 
strategies.  Contextual conditions were also identified by asking where, when, and how the 
central phenomena (core category) happened and with whom (Corbin and Strauss, 2008).  
Contextual conditions relate to: (a) the service infrastructure for delivering chemotherapy; (b) 
patients’ and carers’ fears of dying; and (c) poor evidence to explain neutropenic sepsis.    
 
The chemotherapy service infrastructure allows for information about neutropenic sepsis to be 
mainly delivered to patients before treatment starts.  This means patients struggle to hear 
information about it, because they are concerned about more imminent side effects of 
chemotherapy such as nausea and vomiting.  Furthermore, the service infrastructure and 
model of care is technically, or drug delivery focused.  This does not encourage therapeutic 
relationships to develop between clinicians’ and patients’.  In particular, chemotherapy nurses 
do not form bonds with patients that encourage early reporting of neutropenic sepsis.  
Patients’ and carers’ ability to hear about neutropenic sepsis (a life-threatening consequence 
of chemotherapy) is further confounded because they fear dying from cancer, (a life-
threatening illness) and fear chemotherapy.   
 
Patients’ and carers’ ability to engage with early reporting of neutropenic sepsis is further 
compromised by the poor evidence available to clinicians’ to support their explanations of it.  
Consequently, patients are reliant on being able to distinguish symptoms of neutropenic sepsis 
from expected chemotherapy side effects through experiential learning.  However neutropenic 
sepsis tends to occur during early chemotherapy treatments before patients have the 
experience to recognise “normal” chemotherapy symptom patterns. 
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7.2.4 Intervening conditions or influencing factors (situational, relational, emotional, 
cultural, beliefs and values) that moderate patients’ responses to neutropenic sepsis. 
(Informed by findings from category four: “Relationships core to accessing help” and 
Category two: “Getting away with it, wanting normality and control”)  
Intervening conditions moderate the nature of patients’ coping responses or strategies to deal 
with the central phenomena / core category (“Playing down the seriousness and piling on the 
fear”). Evidence for intervening conditions (moderators) were drawn from Category two: 
“Getting away with it, wanting normality and control” and Category four: “Relationships core 
to accessing help”.  Initially, constant comparison enabled development of the theoretical 
categories and properties within these by comparing “everything everywhere”.  As the 
research moved further towards theory development, the category dimensions were 
developed as suggested during the grounded theory summer school by Professor Janice 
Morse, through “thinking about these people act like this and these people act like that”.  This 
identified characteristics (intervening conditions) that appear to moderate patients’ 
engagement with reporting neutropenic sepsis.  These include having metastatic disease, 
being bereaved and being fatalistic, which may also be associated with having strong religious 
beliefs and being from an ethnic minority group.  In addition, having a poor relationship with 
their clinicians and poor or negative experiences of accessing chemotherapy helplines may 
prevent early patient presentation with neutropenic sepsis.  Relationships between patients 
and carers, and information avoidance behaviours may represent further moderating 
influences.    
 
7.2.5 Strategies or reactions and behaviours patients adopt to cope with the threat and / 
or the development of neutropenic sepsis.  
Previously cited contextual and intervening conditions influence overarching strategies that 
are adopted by patients’ and carers’ to cope with their fears of dying from cancer or 
neutropenic sepsis. These fears and an inclination to avoid knowing about neutropenic sepsis 
are also exacerbated by the central phenomena, which is the Core Category: “Playing down 
the seriousness and piling on the fear”.  Strategies for coping include: (a) ‘avoiding and 




7.2.5.1 Coping strategy: ‘Avoiding and normalising’ 
(Informed by findings from Category two:  “Getting away with it, wanting normality and 
control” and Category four: “Relationships core to accessing help”) 
The coping strategy ‘avoiding and normalising’ is informed by Category two: “Getting away 
with it, wanting normality and control” and Category four: “Relationships core to accessing 
help”.  Fears of neutropenic sepsis for patients and carers are intertwined with thoughts of 
dying from cancer.  Patients who receive information about neutropenic sepsis feel like they 
are going to die from the cancer.  Hearing about neutropenic sepsis heightens these fears 
further.  Consequently, encouraged by clinicians, they avoid thinking about this through 
adopting normalising and avoidance tactics.  Patients try to concentrate on normal life and 
block and resist knowing about neutropenic sepsis. They focus on infection prevention, put 
neutropenic sepsis to the back of their minds and think “if and when” they get an infection 
they might take it seriously.  Patients may take increasing risks by delaying reporting 
neutropenic sepsis if they have previously got away with similar behaviours.  Patients may also 
underplay the seriousness of neutropenic sepsis to male carers (usually partners), so 
sometimes do not invite them to attend chemotherapy information sessions to avoid worrying 
them.   
 
7.2.5.2  Coping strategy: ‘Acknowledging the seriousness’  
(Informed by findings from Category three: “Making the connection” and Category four: 
“Relationships core to accessing help”) 
The second coping strategy (‘acknowledging the seriousness’), adopted by patients and carers 
is informed by Category three: “Making the connection” and Category four: “Relationships core 
to accessing help”.  Clinicians may unintentionally discourage reporting of neutropenic sepsis 
symptoms because patients can see they are busy and rushed so do not want to bother them 
unnecessarily.  Patients are further discouraged from calling the helpline if they have 
previously felt abandoned by oncology clinicians to the care of those less skilled in the 
management of chemotherapy symptoms.  Clinicians encourage patient reporting of 
neutropenic sepsis by legitimising symptoms that are important to report and by taking 
responsibility for their care.  Female carers (friends and daughters) who attend chemotherapy 
information sessions, can also legitimise the seriousness of neutropenic sepsis symptoms 
through shared decision making, but need to be engaged by patients and clinicians to act.  
Patients underplay how unwell they feel when they develop neutropenic sepsis to avoid 
worrying carers or making a fuss.  Furthermore, they do not want to bother clinicians and 
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cannot face going to hospital.  Carers may not initially recognise symptoms of neutropenic 
sepsis as serious.  They may also fear patients dying when they become unwell with 
neutropenic sepsis, but they have to keep this to themselves and gently persuade them to call 
the hospital.  Carers only feel able to override patients when they become very ill with 
neutropenic sepsis.  When reality hits home and patients realise or acknowledge what 
neutropenic sepsis is, some take this seriously.  Others (especially those with metastatic 
disease or who are bereaved), cannot face knowing they might have neutropenic sepsis in 
addition to their cancer, its treatment, and the disruption it has on their lives.   
 
7.2.6 The consequences of strategies used by patients to cope with the threat of 
neutropenic sepsis 
Strategies employed by patients and carers to cope with fears of neutropenic sepsis have 
consequences for patients.  Focusing on normal life may assist them to feel more in control of 
their cancer and reduce fears of dying.  However, a consequence of avoidance behaviours is 
delayed presentation to hospital when neutropenic sepsis occurs.  Importantly, this may put 
patients at increased risk of morbidity or mortality from it. 
 
 
7.3 Diagrammatical representation of the theory 
A diagrammatic representation of the application of the coding framework (Morrow and 
Smith, 1995) to study findings is shown in Figure 7.2. This diagram shows the causal conditions, 
the phenomena, contextual and intervening conditions and strategies and consequences to 
explain why patients delay presenting to clinicians with neutropenic sepsis. Each of these 
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 Resisting knowing about 
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 Focusing on temperature & 
infection prevention 
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symptoms 
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For coping 
Acknowledging the seriousness  
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 Underplaying symptoms to self 
and others  
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alongside feeling  unwell 
 Taking it seriously after the event 
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 Having metastatic disease 
 Being bereaved 
 Being fatalistic 
 Ethnicity and having a 
strong religious faith 
 Having poor relationships 
with clinicians 
 Not involving  carers  
 Having poor experience of 
the helpline 
 Avoiding information  
Category   2:  Getting away with It  
 Ignoring the risk 
 Feeling protected from infection  
 Getting away with it  
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 Playing down the seriousness  
 Piling on the fear 
 Reality hitting  











(a) Clinicians fearing 
patients refusing 




(b) Patients being hit by 
the reality of having a 
life threatening illness  
Central Phenomena 
(Core Category) 
Arising from causal 
conditions 
Underplaying the 
seriousness and piling on 
the fear 
Clinicians 
 Minimising neutropenic 
sepsis to an infection 
 Piling on the fear and 
hinting at seriousness 
 Delivering Information as 
standard repertoire 
Patients and Carers 
 Information about 
neutropenic sepsis 
heightens fears of dying 
 Focusing on temperature 
 Listening but not hearing 





a) Service infrastructure 
 Timing of information 
 Informing multiple 
patients 
 Technically focused   
 On-call service lacks 
capacity and guidance  
b) Patients fear of dying 
c) Poor evidence to describe  
neutropenic sepsis  
 Difficulty distinguishing 
from other side effects 
 
 
Category 4:  Relationships core to accessing help 
 Bothering the helpline 
 Carers an untapped resource  
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7.4 The grounded theory   
In summary, what emerges from the data is that there are several interactive factors that 
affect why patients delay attending hospital with neutropenic sepsis.  At the outset clinicians 
underplay the seriousness or possibility of neutropenic sepsis to patients because they fear 
this may scare them into refusing chemotherapy.  Patients and carers therefore do not easily 
recognise the seriousness.  This is compounded because patients also underplay the 
seriousness of neutropenic sepsis to themselves because they cannot face knowing about this 
on top of other fears about a cancer diagnosis.  Furthermore, heightened fears of dying occur 
almost simultaneously with the information giving and consent for chemotherapy.   
 
Some patients underplay the seriousness to their carers by excluding them from the 
chemotherapy process.  This is because they do not want to frighten carers about the risks of 
neutropenic sepsis or bother them when this occurs.  Patients also underplay to clinicians the 
seriousness of neutropenic sepsis symptoms when these occur because they do not want to 
acknowledge this is happening to them.  Finally, carers underplay their fears about symptoms 
of neutropenic sepsis when these arise.  This is because they do not want to frighten or 
undermine patients who wish to remain in control of their treatment.  Moderators of patients’ 
seeking assistance for neutropenic sepsis include: undertaking information avoidance 
behaviours, having metastatic disease, being bereaved, being fatalistic which is sometimes 
associated with relying on god to protect, having poor relationships with clinicians, excluding 
carers from the chemotherapy process and having poor experiences of accessing help.    
 
Overall, the findings provide evidence for the development of a theory grounded in the data 
about why patients delay attending hospital with neutropenic sepsis.  The final grounded 
theory to emerge suggests that: 
 
Underplaying the seriousness of neutropenic sepsis is a subconscious collusion between 
clinicians, patients and carers.  
 
Importantly, the final grounded theory conceptualises the essence of why patients delay 
presenting to hospital when they develop symptoms of neutropenic sepsis.  Underplaying the 
seriousness of neutropenic sepsis is a behaviour that clinicians, patients and carers are not 
consciously aware of, but all engage in and is applicable to every participant in this study.    
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Chapter summary:   
The final grounded theory suggests patients delay presenting to hospital when they develop 
symptoms of neutropenic sepsis.  This is because of an unspoken interplay of behaviours 
where clinicians, patients and carers subconsciously conspire to underplay the seriousness 
and possibility of neutropenic sepsis occurring.  Each has their own reason and perspective for 
doing so.  This theory was refined through application of a model developed by Morrow and 
Smith (1995) to four identified categories and associated properties (theoretical coding).  
Causal conditions for the central phenomena include clinicians fearing patients might die from 
neutropenic sepsis.  They also fear treatment refusal if patients know the truth about 
neutropenic sepsis.  Causal conditions for patients relate to their experiencing heightened 
fears of dying from their cancer during chemotherapy information sessions.   
 
The central phenomena (Core Category), where clinicians underplay the seriousness of 
neutropenic sepsis whilst piling on the fear (in attempts to persuade patients to make early 
contact) heighten patients’ fears of dying.  Strategies adopted by patients to cope with the 
threat of neutropenic sepsis include avoiding and normalising behaviours.  These include 
patients’ focusing on their normal lives and avoiding infections, rather than thinking they 
might develop neutropenic sepsis.  Patients tend to acknowledge the possibility of 
neutropenic sepsis only when they develop a fever and feel unwell.  Many patients only take 
neutropenic sepsis seriously after having experienced it and thus when they understand more 
about it through experiential learning.  However, some patients, even after experiential 
learning, continue to feel the risk of neutropenic sepsis is exaggerated.  An important 
contextual factor is the infrastructure which does not nourish healing relationships to 
encourage ongoing support and self-management.  Variations in the process appear explained 
by intervening conditions that were identified through constant comparison and identification 
of participants who appear to behave in similar or different ways.  Intervening conditions that 
moderate reporting of neutropenic sepsis include having metastatic disease, being bereaved 
and being fatalistic, which in some cases include reliance on God to protect.  Intervening 
conditions also relate to relationships between patients and clinicians that cause patients to 
feel a bother for calling the helpline.  Finally, relationships between patients and carers, that 
















8.1 Introduction  
A grounded theory has been developed to explain why patients delay presenting to hospital 
with neutropenic sepsis.  This will now be discussed in relation to the relevant evidence and 
model of patient-centred communication (Epstein and Street 2007).  This is to identify what 
can be taken from the model to improve the care of patients who are at risk from neutropenic 
sepsis. 
 
8.2 Applying the model of patient-centred communication to study findings 
The PCC model as reported earlier (chapter three), is organised around four mediating 
pathways that describe the key elements of the process to effective patient-centred 
communication outcomes.  Pathway A is focused on patients’ and carers’ needs and the 
mediating relationship of six interrelated domains that represent interactive processes. These 
domains are: Fostering healing relationships; Exchanging information; Responding to 
emotions; Managing uncertainty; Making decisions; and; Enabling self-management. The 
model describes additional moderating factors between patient-centred communication and 
health outcomes.  Pathway B suggests effective patient-centred communication may lead to 
proximal communication outcomes such as trust and effective information exchange.  Next, 
through pathway C, intermediate outcomes may for example include patient engagement with 
self-management activities.  Finally, pathway D indicates the impact of the mediating process 
on overall patient health outcomes that include survival and health related quality of life.     
 
The pathways of the PCC model show a good fit with the findings from this grounded theory 
study and this will be discussed in detail.  In summary it has been demonstrated that 
communicating effectively with patients and their carers is fundamental to decreasing delayed 
patient presentation with neutropenic sepsis.  This is shown in figure 8.1 where the outcomes 
of communication about neutropenic sepsis are transposed onto the PCC model.  Findings will 
next be explored in relation to how the findings fit with each of the six PCC mediating domains.  
Where similar observations have been made in other studies these are summarised within 
table 8.1, along with the unique contributions of the observations from this grounded theory 
study. The table (8.1) also includes summaries of four theories that underpin the PCC model, 
and appear pertinent to delayed patient presentation with neutropenic sepsis.  These are self-
efficacy theory (Bandura, 1977), self-determination theory (Ryan and Decci, 2000), the 5A’s for 
200 
 
patient-centred counselling (Glascow et al., 2003) and Illness and uncertainty theory (Mischell, 
1988). 
Figure 8.1. Applying the grounded theory to the PCC Model (adapted from Epstein and 
Street, 2007; p43).  For permission see appendix 2 
 
Survival, health-related quality of life
Mediators of relationships between communication outcomes and health outcomes
Mediators of relationships between communication processes and intermediate 
health outcomes
DOMAINS: Fostering healing relationships, exchanging information, responding to 
emotions, managing uncertainty, making decisions, enabling patient self-management 





Patient and carer need to report neutropenic sepsis 
Communication between clinicians and patients/families
Underplaying the seriousness of neutropenic sepsis
(Proximal communication outcome)
Delayed presentation due to avoidance, normalisation
(Intermediate communication outcome)










Table 8.1. Comparison of findings with the patient-centred communication in cancer care model and other studies supporting these  
Domain one: Fostering healing relationships  
PCC model  Other studies supporting findings  Unique contribution of this study  
Clinicians: 
 Therapeutic relationships that include trust, 
honesty, openness and disclosure increase 
likelihood of patient adherence with self-care 
activities. 
 Male and female clinicians may communicate 
differently with patients.   
 Communication may depend on patient 
ethnicity, gender, age or educational status. 
 Should foster understanding of roles and 
responsibilities and negotiate goals. 
Clinicians:  
 Busy service, focused on technical care at the expense of 
developing relationships with patients. 
(1-7)
 







 Feel processed through chemotherapy systems. 
(1-2)
 
 Passive in chemotherapy side effect management. 
( 14)
 
 Do not want to bother busy clinicians and inclined to put up 




 May lose trust if oncology clinicians do not take responsibility 
for serious chemotherapy side effects. 
(15)
 
 May taking increasing risks if consequences are not apparent 
with non-adherence to oral chemotherapy 
(17) 
or with life-style 




 Lack of ongoing engagement with patients. 
 Gender of clinician or patient ethnicity, gender, 
age or educational status not observed to affect 
communication between clinicians and patients 
about neutropenic sepsis. 
Patients: 
 May delay reporting neutropenic sepsis, by  
bypassing the system and contacting a clinician 
they have a relationship with. 
References:  1.  Van Der Molen, (2000).  2.  Mcilfatrick et al., (2006).  3.  NCAG, (2009).  4.  Pilgrim et al., (2009).  5.  Francis, (2013).  6.  Maben et al., (2007). 7.  Maben, (2008).  8.  Morris and Thomas, 
(2001).  9.  Northouse et al., (2010).  10.  McCarthy, (2011) 11.  Hilton et al., (2000).  12.  Ream et al (2013b). 13.  Royal College of Physicians, (2012).  14.  Bakker et al.,(2001).  15.  Dubois and Loiselle 
(2009).  16.  Pedersen et al., (2012).  17.  Eliasson, (2011).  18.  Wiles and Kinmonth, (2001).
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(Table 8.1. continued)  
Domain two: Exchanging information   
PCC model  Other studies supporting findings  Unique contribution of this study  
Clinicians should: 
 Understand patients’ knowledge, beliefs and 
concerns. 
 Tailor information (does not always happen). 
 Convey key facts, rather than overwhelming.   
 Use plain English and summarise. 
 Check understanding through PCC behaviours, 
e.g. open ended questions, empathy and active 
listening.   
Patients: 
 Should understand information provided by 
clinicians including the rationale for healthy 
behaviour. 
 May seek or avoid information. 
 
Clinicians:  
 Deliver chemotherapy information as a tick box 
exercise 
(25)
 and in busy day units which 




 Struggle to absorb information about 
chemotherapy side effects because they fear 
having cancer and chemotherapy. 
(19-23)
 




 May choose to intentionally not adhere to 
medical recommendations based on own 
priorities and take increasing risks if 
consequences are not apparent. 
(17, 18, 21, 26-28) 
 Having metastatic disease is associated with 





 Deliver information as a standard dispassionate 
repertoire and assume compliance. 
 Timing of information about neutropenic sepsis may be 
important. 
 Lack evidence to describe neutropenic sepsis and 
symptoms of it to patients. 
Patients: 
 Find information about neutropenic sepsis can bring 
home the seriousness of a cancer diagnosis. 
 May avoid knowing about neutropenic sepsis because 
this exacerbates fears of dying. 
 May take increasing risks with infection prevention, 
monitoring and reporting as they “get away” without 
coming to harm.  This may be exacerbated in those with 
metastatic disease or who are bereaved, possibly 
because they are more fearful of dying. 
References:  19.  Treacy and Mayer, (2000).  20. Skalla et al., (2004).  21. McCaughan and McKenna, (2007).  22.  Rimer, (1984).  23.  McCorkle and Ehlke, (1992).  24. Dodd and Mood, (1981). 25.  
Ream et al., (2013a).  26.  Thorne, (1999).  27.  Rhodes and Cusick, (2000).  28.Rhodes and Cusick, (2002).  29.  Pollock et al., (2008) 30.  Cassileth et al., (1980), 31.  Butow et al., (1997) 32.  Mills and 
Sullivan, (1999) 33.  Fallowfield et al., (1995). 
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(Table 8.1. continued)  
Domain three: Responding to emotions    
PCC model  Other studies supporting findings  Unique contribution of  this study  
Clinicians:  
 Should elicit emotional concerns before 
delivering information (through sensitive 
questioning and responding with constructive 
help and empathy). 
 Often miss emotional cues and focus on physical 
aspects of health care. 
Patients:  
 Illness representations may differ to clinicians 
(These are shaped by past experiences, beliefs, 
emotions, goals, others’ experiences and 
information provided by clinicians). 
 May deal with fears of cancer and lack of control 
through avoidance. 
Clinicians:  
 May avoid emotional interactions with patients during 
chemotherapy and focus on physical care. 
(1, 38, 42)  





 Fear a cancer diagnosis and starting chemotherapy. 
(34-36)
 





















 Avoid informing patients about the risk of death from 
neutropenic sepsis. 
 Pile on the fear and underplay the seriousness to 
patients of neutropenic sepsis. 
 May encourage patients’ illness representation of 
neutropenic sepsis as unlikely, preventable and easy 
to treat (an infection not sepsis). 
Patients: 
 Hearing about neutropenic sepsis may heighten fears 
of dying for those who are already fearful of dying 
from cancer and chemotherapy (exacerbated with 
metastatic disease and bereavement). 
 May cope through adopting avoidance tactics 
(incorporated within PCC domain) and normalising 
tactics (not incorporated).   
 
References  34.  Mitchell, (2007).  35. Siminoff and Step, (2005). 36.  Ream et al., (2013a).  37.  Cowley et al., (2000).  38.  Farrell et al., (2005).  39.  Ream and Richardson, (1996).  40.  Pedersen et al., 
(2012).  41.  Dodd and Ahmed, (1987).  42.  Dennison, (1995).  43.  Schumacher et al., (2000).  44.  Ockerby et al., (2012). 
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(Table 8.1. continued)  
 
Domain four: Managing uncertainty   
PCC model  Other studies  supporting findings  Unique contribution of this study  
Illness and Uncertainty Theory (Mischell and Braden, 1988) that Informs 
the Domain:  Uncertainty during illness is the inability to make sense of 
illness related events, or to accurately predict future illness events and 
outcomes.  Uncertainty is affected by the stimuli frame (the ability to 
produce a mental schema of events) cognitive capacity (ability to process 
information) and structure providers (that through education, social 
support or credible authority enable patients to become familiar with likely 
illness related events). 
Clinicians: 
 Should target information to individual patient needs. 
 May exacerbate patient uncertainty through information overload. 
 Context and an agreed plan for dealing with uncertainty may moderate 
and assist patients to manage it. 
Patients: 
 Confidence may reduce where clinicians express uncertainty. 
 Relationships with carers, other patients and clinicians can modify 
uncertainty. 
Clinicians:  
 None.   
Patients:  
 May hold pre-conceived negative 
views of chemotherapy. 
(21)
 
 Information about chemotherapy side 




 May not know the chemotherapy side 




 Not knowing what to expect from 




 Dramatic, unexpected nature of 





 Do not modify information to patient’s 
educational ability. 
 Relationships with clinicians and carers are not 
optimised to assist patients with uncertainty 
about which symptoms to report and when.   
Patients: 
 Uncertainty about what to expect and 
preconceived fears may increase anxiety and 
reduce feelings of control and ability or 
willingness to hear about neutropenic sepsis 
or to engage in related self-management.   
 
References: 45.  Mishel and Braden, (1988).  46.  Mischel, (1990) 47.  Stiegelis et al., (2004).  48.  Henman et al., (2002).
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(Table 8.1. continued)  
Domain five: Making decisions   
PCC model  Other studies supporting findings  Unique contribution of this study  
 Most patients prefer to make decisions in 
partnership with clinicians. 
 Patients tend to weigh up the pros and cons of 
taking a particular course of action drawing upon 
beliefs and information available to them. 
 
Clinicians:  
 Do not discuss ‘pros and cons’ of having 
chemotherapy with patients. 
(1, 37,  48-50)
 
 May withhold information about 






 Feeling out of control with decisions to have 








 May not have enough information to manage 





 Fear patients will refuse treatment, so do not discuss with 
them the advantages and disadvantages of having 
chemotherapy, including open discussion about neutropenic 
sepsis and personal risk. 
 
Patients: 
 Lack of motivation to have chemotherapy may affect 
patients’ ability to hear about neutropenic sepsis and 
willingness to engage with associated self-management.   
 Struggle to make decisions to call clinicians about 
chemotherapy symptoms. 
 Indicate cognitive impairment (chemo brain) does not affect 
decision making to report neutropenic sepsis.   
 




(Table 8.1. continued)  
Domain six: Enabling self-management    
PCC model  Other studies supporting findings  Unique contribution of this study  
Theories that inform the domain: 
 
Self-efficacy theory (Bandura, 1997) 
Personal motivation to change a behavior, driven by a personal belief in 
ability to achieve the change or a specific goal.  Low self-efficacy and 
response efficacy may be associated with reduced intention to act. 
Self-Determination Theory (Ryan and Decci, 2000) 
Relates to motivating patients to draw on intrinsic resources to act in 
healthy ways.  Three basic innate psychological needs should be fulfilled 
to be self-determined.  Needs include relatedness (to experience 
reciprocal caring relationships, usually with clinicians), competence 
(mastery) and autonomy (to feel in control and responsible for ones’ 
own life). 
Five A’s for Patient-Centred Counselling 
(Glascow et al., 2003)  
Assess, Advise, Agree, Assist, Arrange model of behavioral change which 







 Deliver confusing, frightening information about 
neutropenic sepsis to patients.  They minimise it to 
an infection.   
 Do not encourage a self-management approach to 
enable patients to report neutropenic sepsis.   
 May encourage early presentation through 
legitimising symptoms and taking responsibility for 
their care.   
Patients: 
 Do not take neutropenic sepsis seriously. 
 Not engaged with advice/instructions of clinicians 
to urgently report symptoms of neutropenic sepsis 
to chemotherapy help-lines. 
 Struggle to recognise symptoms of neutropenic 
sepsis. 




8.2.1 Domain one: Fostering healing relationships  
Findings of this study and other research support the importance of the PCC ‘fostering healing 
relationships’ domain to the final grounded theory.  A Canadian interview study (n=40) 
identified that women with cancer who did not feel connected with clinicians adopted passive 
and submissive roles during chemotherapy consultations (Bakker et al., 2001).  Other studies 
conducted within the UK (Van Der Molen, 2000, Mcilfatrick et al., 2006) further indicate that 
the chemotherapy system can feel like a factory to patients.  A small qualitative study (n=6)  
found patients felt processed through a busy chemotherapy system (Van Der Molen, 2000).  A 
further phenomenological study conducted with 10 carers identified a “dehumanising 
element” to chemotherapy treatment delivery. Chemotherapy nurses were focused on 
efficient delivery of chemotherapy and not the needs of individual patients and carers 
(Mcilfatrick et al., 2006). 
 
Clinicians from this study who appeared too busy to develop therapeutic relationships with 
patients reflect a national picture.  Chemotherapy usage across the UK increased by 60% 
between 2002 and 2007 (NCAG, 2009).  This means chemotherapy nurses in particular are 
likely to find it increasingly difficult to get to know patients who pass through their service.  
Furthermore, a factory mentality observed within this current study was possibly influenced by 
the recession driven NHS cost reduction programme.  Quality measured through targets 
focused on chemotherapy waiting times, and financial reward is proportional to the number of 
patients treated rather than the quality of care provided.  Similar findings are identified in a 
literature review of mental health services (Pilgrim et al., 2009).  The review identified that a 
focus on health service targets detracted from the importance of relationships between 
patients and clinicians in improving mental health (Pilgrim et al., 2009).   
 
This finding is described at an extreme level within the Francis report of the Mid Staffordshire 
NHS Foundation Trust Public Enquiry into poor care at Stafford hospital (Francis, 2013).  The 
Francis report highlights exhausted staff working within an organisation focused on targets at 
the expense of patient-centred care.  Key in the Francis report was identification of a prevalent 
lack of organisational compassion towards employees and many recommendations concern 
increasing compassion within nursing.  Research into compassionate care within nursing and 
medicine also highlights that clinicians are usually intrinsically driven to care for others in an 
empathetic and compassionate manner.  When healthcare infrastructures and cultures do not 
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facilitate compassionate care, intrinsic motivation can be compromised or crushed leading to 
burnout, reduced job satisfaction, ability to empathise and poorer clinical care (Maben et al., 
2007, Maben, 2008, Epstein and Street, 2007).  Importantly, for the findings of the current 
study, Maben’s work with newly qualified nurses particularly indicates busy technically 
focused working environments are not conducive to promoting or sustaining compassionate 
care (Maben et al., 2007). 
 
Advocacy, in terms of clinicians acting in the best interests of patients, is a core component of 
the PCC enabling self-management domain.  Furthermore, trust is an intermediate outcome of 
patient-centred communication and may be important to adherence (Epstein and Street 
2007).  However, findings of the present study concur with conclusions from a National UK, 
consultation with clinicians.  This suggests that substandard care and loss of patient trust may 
result when oncology clinicians do not take responsibility for patients admitted to A&E 
departments with neutropenic sepsis (Royal College of Physicians, 2012).  The effect of lost 
trust and being made to feel a bother by clinicians on patients’ willingness and self-efficacy to 
present with symptoms of neutropenic sepsis on subsequent occasions supports other 
research (Dubois and Loiselle, 2009, Pedersen et al., 2012).  A small phenomenological study 
conducted in Denmark with nine patients also found some would rather not contact clinicians 
when they developed chemotherapy symptoms (Pedersen et al., 2012).  Furthermore, a mixed 
method Canadian study that included patient completed questionnaires (n=250) and follow-up 
interviews (n=20) identified patients who felt “fobbed off” and a “nuisance” when accessing 
help for chemotherapy side effects, which resulted in beliefs that they should put up with 
subsequent symptoms (Dubois and Loiselle, 2009).  Additional findings of the current study 
also suggest patients may wait to check out symptoms of neutropenic sepsis with clinicians 
they consider they have a relationship with, rather than reporting symptoms to emergency 
helplines.    
 
8.2.2 Domain two: Exchanging information  
Findings from this study supports other research, that identifies patients with cancer who 
could not recall information provided by clinicians about chemotherapy side effects (Rimer, 
1984, McCorkle and Ehlke, 1992, Treacy and Mayer, 2000, Skalla et al., 2004, McCaughan and 
McKenna, 2007). This is because patients become overwhelmed by having a cancer diagnosis, 
starting chemotherapy and information provided about chemotherapy side-effects (Rimer, 
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1984, Treacy and Mayer, 2000, Skalla et al., 2004, McCaughan and McKenna, 2007).  Within 
one study, two nurses who share their personal experience of having cancer report being 
unable to recall any information provided to them about chemotherapy, including expected 
side effects (McCorkle and Ehlke, 1992).  Furthermore, only 10 of 30 patients who completed a 
questionnaire following chemotherapy information sessions were able to name infection as a 
potentially fatal side effect (Dodd and Mood, 1981).  A UK action research study (Ream et al., 
2013b) included non-participant observations of interactions between clinicians, patients and 
carers. Findings replicate those of the current study because clinicians structured their 
chemotherapy information delivery around checklists, instead of checking patient 
understanding and tailoring information to the individual (Ream et al., 2013b).  A literature 
review to identify cancer patients’ information needs also concluded that delivering 
chemotherapy information to patients within busy clinical environments may compromise 
effective information exchange (Treacy and Mayer, 2000). 
 
New evidence from this study suggests that patients struggle to hear information about 
neutropenic sepsis because this heightens their fears of dying from cancer.  This situation 
appears to be exacerbated by clinicians who deliver information in an urgent and 
dispassionate manner and at the wrong time (before chemotherapy starts).  At this time 
patients are preoccupied with fears of dying from cancer (See Domain three: Responding to 
emotions), chemotherapy administration and more imminent chemotherapy side-effects than 
neutropenic sepsis.  Transfer of information about neutropenic sepsis is also complicated by 
poor evidence to enable clinicians to clearly explain this and early symptoms of it to patients.   
 
It has been suggested that people cope with threatening situations in one of two ways.  They 
either seek out information (monitoring behaviour) or avoid any information relating to the 
potential threat (blunting behaviour) (Miller, 1995).  This implies that information seeking 
behaviours are fixed or static.  As discussed within chapter three of this thesis, in reality this is 
often not so clear cut because information seeking or avoidance behaviours may change 
depending on circumstances (NICE, 2007).  Indeed, coping theory suggests people draw on 
different coping strategies depending on the severity of the stressor and how this is appraised 
(Lazarus and Folkman, 1984).  This may better explain seemingly extreme avoidance 
behaviours identified within the research presented here.  Identified moderators that may 
impede early patient presentation with neutropenic sepsis, include having metastatic disease, 
being recently bereaved and having fatalistic views about life (which included patients 
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deferring responsibility to God for protection rather than taking responsibility for protecting 
themselves). 
 
The PCC exchanging information domain may also be extended by findings of the current study 
and other research (Donovan and Blake, 1992, Thorne, 1999, Rhodes and Cusick, 2000, Wiles 
and Kinmonth, 2001, Rhodes and Cusick, 2002, Eliasson et al.,2011) by suggesting that some 
patients may intentionally choose not to adhere with medical advice.  Researchers challenge 
assumptions that non-adherence always results from a lack of clear thinking, beliefs, 
misunderstandings of information provided or through failed doctor patient communication 
(Thorne, 1999, Donovan and Blake, 1992).  Importantly, clinicians may assume that reporting 
neutropenic sepsis symptoms is a priority for patients and adherence studies position patients 
as passive and assume their only option is to comply with medical advice (Donovan and Blake, 
1992).  Similar findings within qualitative studies of HIV (Rhodes and Cusick, 2000, Rhodes and 
Cusick, 2002), rheumatology (Donovan and Blake, 1992), myocardial infarction (Wiles and 
Kinmonth, 2001) and oral chemotherapy (Eliasson, 2011) support the perspective that patients 
may actively choose not to comply with reporting of neutropenic sepsis.  Rheumatology 
patients were found to consciously weigh up the risks and benefits of actions, and at times 
chose to alter medication doses or ignore advice.  They took the course of action that made 
most sense to them and fitted in with the constraints of their everyday lives (Donovan and 
Blake, 1992).  Weighing up risks and benefits were also observed in a study where some HIV 
positive men and their HIV negative partners  made conscious decisions not to use condoms 
during intercourse, even though this represented significant risks to HIV negative partners 
(Rhodes and Cusick, 2000, Rhodes and Cusick, 2002).  Participants valued the loving 
relationship more than the risk of HIV infection and felt unprotected sex strengthened the 
relationship and condom use presented a relationship threat through emotional detachment.   
 
A further new finding relevant to exchanging information - and  not identified in the PCC 
model - was that patients apparently took increasing risks (especially those with metastatic 
disease or who were bereaved) with regard to infection precautions and delaying presenting 
with symptoms of neutropenic sepsis, as they believed they had “got away” without 
developing this condition.  Similar scenarios are reported within oral chemotherapy and 
myocardial infarction studies conducted within the UK.  An interview study with 21 patients 
diagnosed with chronic myeloid leukaemia, found intentional non-adherence with oral 
chemotherapy increased when patients were responding to treatment.  This was because 
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patients believed they could afford to miss a few doses (Eliasson, 2011).  Furthermore, an 
interview study conducted with 25 cardiac patients identified that receding feelings of shock 
following a myocardial infarction reduced motivation to continue with lifestyle changes in the 
longer term (Wiles and Kinmouth, 2001).   
 
8.2.3 Domain three: Responding to emotions  
Patients from this study appeared too anxious to take in information about neutropenic sepsis 
and avoided engaging with self-management of it.  However, clinicians often did not seem to 
identify or address patients’ emotional cues.  The responding to emotions domain suggests 
fears about cancer may negatively impact on successful information delivery.  Other studies 
have reported that patients (Mitchell, 2007, Siminoff and Step, 2005) and carers (Ream et al., 
2013a) experience heightened anxiety before chemotherapy.  A UK interview study found 
women with breast cancer (n=12), associated their requiring adjuvant chemotherapy with 
being seriously ill (Cowley et al., 2000).  Furthermore, a UK grounded theory study based on 
interviews with 27 patients identified a tendency to avoid chemotherapy information that was 
thought to be confusing or distressing (McCaughan and McKenna, 2007).  The current study 
extends understanding of this to suggest patients’ and carers’ ability to be attentive to 
information about neutropenic sepsis may be compromised because this heightens pre-
existing fears of dying associated with a life threatening illness and of starting chemotherapy.  
Moreover, such fears may be exacerbated through frustrated clinicians repeatedly stressing 
the urgency of calling the hospital with a fever. Clinicians did not explain why a fever was 
important or explore with patients why they may delay.  A similar phenomenon was seen in a 
non-cancer study where practice nurses persisted with repeated ineffectual didactic 
information when faced with patient resistance to self-management of chronic diseases 
(Macdonald et al., 2008). 
 
Patients interviewed in this study dealt with their fears of neutropenic sepsis through 
avoidance tactics (encompassed within the responding to emotions domain) and normalising 
tactics (that are not included).  Other literature has identified cancer and chemotherapy as 
threatening patients’ normal identity (Van Der Molen, 2000, Farrell et al., 2005, McCaughan 
and McKenna, 2007).  Furthermore, distraction through using avoiding and normalising 
strategies are common responses to chronic illness (Strauss et al., 1984).  This has previously 
been identified in patients undergoing chemotherapy who strove to maintain normal work, 
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home and social roles (Cowley et al., 2000, Mitchell, 2007).  The use of normalisation and 
avoidance strategies to distract from acknowledging and reporting neutropenic sepsis has not 
been previously described. 
 
The responding to emotions domain suggests clinicians’ illness representations of cancer and 
associated treatments can differ to those of patients.  Illness representations are used by 
patients to understand and make sense of the cancer experience and are informed by prior 
experiences, beliefs, others experience, knowledge, psychological status and goals (Epstein 
and Street, 2007, McCormack et al., 2011).  New evidence from the current research identifies 
that clinicians’ view neutropenic sepsis as a life-threatening complication of chemotherapy.  
However, verbal and written explanations of neutropenic sepsis delivered by clinicians to 
patients may encourage a view of this as not likely or serious (an infection rather than sepsis).  
A similar finding, where clinicians’ behaviour contributed to patients’ misconceptions is 
described within a grounded theory study to explore patient adherence with oral 
chemotherapy.  Intentional non-adherence appeared to be associated with encouragement by 
doctors that it was acceptable to miss the odd dose (Eliasson et al., 2011).  A further study 
identified that both verbal and written information provided by clinicians to patients following 
a myocardial infarction encouraged patients to view it as an acute recoverable event (rather 
than an indicator of a potentially life-threatening illness).  Clinicians apparently framed 
information about a myocardial infarction in this way because they recognised patients were 
fearful of dying.  However, this approach discouraged patients from making long term lifestyle 
changes to reduce the chances of further cardiac damage (Wiles and Kinmonth, 2001). 
 
Patients within the current study feared having cancer and starting chemotherapy.  Other 
research supports the emotional impact of cancer diagnoses, reporting that some patients may 
even be clinically depressed (Farrell et al., 2005, Cancer Research UK 2014, Walker et al., 
2014).  Estimates of the prevalence of depression in cancer patients across these studies are 
variable (9.3% - 58%).  A small study (Farrell et al., 2005) identified, through psychological 
screening, that 24% of 33 women undergoing chemotherapy were likely to be anxious or 
depressed.  Cancer Research UK (2014) estimate that up to 58% of patients with cancer in the 
UK develop depression (Cancer Research UK. 2014. Cancer incidence statistics : Cancer Research UK. 
[ONLINE] Available at: http://www.cancerresearchuk.org/cancer-info/cancerstats/incidence/. [Accessed 
28 January 2014). 
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Furthermore, a recent and important study conducted in the UK (Walker et al., 2014) identified 
the prevalence and treatment of major depression within 21,151 cancer patients.  This 
included 8461 women with breast cancer, 627 (9.3%) (CI 8.7-10.0) of whom were identified, 
through the study as having a major depression.  Importantly, over half of the women with 
breast cancer who were diagnosed with major depression (429 (68%) had not received 
treatment for it (Walker et al., 2014).   
 
Poor recognition and treatment of depression by clinicians may be reflective of evidence 
within the responding to emotions domain, and the findings of this study, that suggest 
clinicians may miss or ignore emotional cues from patients and focus more on physical aspects 
of care.  Two other studies observed conversations about chemotherapy between doctors and 
patients (Bakker et al., 2001) and between nurses and patients (Dennison, 1995).  These 
studies reported observation of conversations that appeared controlled by doctors or nurses 
and were focused on physical chemotherapy symptoms rather than patients’ emotional needs.  
The small UK study (Dennison, 1995) of conversations between eight female patients and eight 
nurses during administration of first chemotherapy treatments, observed little nurse 
interaction with patients. Non-technical conversations were superficial; only two nurses 
explored patients’ feelings and understanding about their chemotherapy treatment.   
 
A further cross-sectional study found chemotherapy nurses (n=7) were unable to identify 70% 
of concerns of 33 women they treated with chemotherapy for breast or gynaecological 
cancers.  Concerns unrecognised by nurses related to chemotherapy side-effects and 
emotional, relationship and financial worries (Farrell et al, 2005).  Similarly, a national UK 
chemotherapy patient survey of 16,000 patients indicated that few patients were offered 
opportunities to speak about emotional (62%), psychological (48%), spiritual (32%), or financial 
(44%) concerns before starting chemotherapy (NHS England, 2013). 
 
Findings presented here and in other studies suggest clinicians do not recognise or respond to 
emotional cues including signs of depression in women with breast cancer going through 
chemotherapy (Dennison, 1995, Bakker et al., 2001, Walker et al., 2014).  Importantly, a 
quantitative review and synthesis of 25 studies (Dimatteo et al., 2000) further suggests a 
significant relationship between depression and non-adherence with treatment (OR of 3.03, 
95% CI, 1.96-4.89) for a range of illnesses (including cancer, renal disease and angina).  
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Consequently, untreated depression may put patients at increased risk of poor adherence with 
reporting symptoms of neutropenic sepsis.   
 
8.2.4 Domain four: Managing uncertainty  
Uncertainty and illness theory (Mishel and Braden, 1988, Mischel, 1990) informs the managing 
uncertainty domain. Uncertainty is the inability to accurately predict future illness events and 
outcomes (Mishel and Braden, 1988).  The literature review chapter of this thesis (chapter 
two) identified difficulties in defining neutropenic sepsis.  The difference between being 
neutropenic and having neutropenic sepsis is complex to describe to patients.  In addition, 
there is an issue for clinicians about explaining neutropenic sepsis due to a lack of evidence 
regarding symptoms to watch out for and how these may vary in different people. This may 
explain findings presented here - supported by other chemotherapy studies – that patients 
find chemotherapy side-effect information confusing (Van Der Molen, 2000, Skalla et al., 
2004).  Regardless, clinicians do not appear to explain to patients what is clearer; the process 
of neutropenia, the likely timings of it occurring, and that once patients are neutropenic, they 
have a high risk of developing sepsis. 
 
Research has shown that patients tend to want to understand the treatment plan, likely side 
effects and how to manage these (Cassileth et al., 1980, Skalla et al., 2004, Kav et al., 2012,) in 
order to prepare and plan their life during chemotherapy (Ream and Richardson, 1996, Mills 
and Sullivan, 1999, Skalla et al., 2004, Pedersen et al., 2012).  Patients’ inability to predict or 
recognise normal chemotherapy symptoms (termed symptoms profile within illness and 
uncertainty theory) and to distinguish those that are abnormal (termed event congruence), 
can cause emotional distress (Mishel and Braden 1988, Pollock et al., 2008) (See Domain three: 
Responding to emotions).  This may further diminish a sense of control (Mishel and Braden, 
1988, Mishel, 1990, Stiegelis et al., 2004, Epstein and Street, 2007) and thus the ability to self-
care.   
 
Another grounded theory study, of newly diagnosed cancer patients information-seeking 
behaviours, also found patients often feared going through chemotherapy and held 
preconceived negative views about this (McCaughan and McKenna, 2007).  Uncertainty and 
illness theory (Mischel and Braden, 1988, Mischel, 1990) further accounts for new findings 
215 
 
from this study that suggest patients who are not informed about the reality of chemotherapy 
side effects may not be attentive to information about neutropenic sepsis, due to a 
preoccupation with lay perceptions of chemotherapy as toxic and poisonous.   
 
Not knowing the clinical reality is associated with uncertainty and unfounded fears.  For some 
cancer patients not knowing is worse than knowing (Cassileth et al., 1980).  Findings presented 
here suggest uncertainty may encourage avoidance behaviours (See Domain three: 
Responding to emotions).  Importantly, event congruence, defined within illness and 
uncertainty theory as the consistency between expected and actual chemotherapy symptoms 
(Mishel and Braden, 1988) were often diametrically opposed.  Consequently, patients and 
carers who developed grade four neutropenic sepsis often found the unexpected and dramatic 
symptoms of this frightening, a finding also reported by other researchers (Henman et al., 
2002, Skalla et al., 2004).   
 
8.2.5 Domain five: Making decisions  
Patients may make decisions to have chemotherapy that are not well informed about both 
benefits and risks. This may subsequently reduce patients’ motivation to engage in self-
management of chemotherapy, including reporting neutropenic sepsis.   
 
Other researchers have identified patients who were led to believe they could not decline 
chemotherapy, without compromising their prognosis (Cowley et al., 2000, McCaughan and 
Thompson, 2000, Henman et al., 2002).  The making decisions domain supports findings that 
patients’ willingness to engage with information about neutropenic sepsis may be reduced by 
the absence of open, honest discussions with clinicians (See Domain three: Fostering healing 
relationships) about possible benefits and risks of chemotherapy including individual risks of 
developing neutropenic sepsis.  Risk factors for neutropenic sepsis identified within the 
literature review chapter of this thesis (chapter two), that were present within the research 
participants, but not referred to by clinicians when communicating with them included: taking  
chemotherapy drugs with over 20% risk of causing neutropenic sepsis, being aged over 65 




The dealing with emotions domain (Epstein and Street, 2007) incorporates clinicians avoiding 
difficult conversations with patients, because they fear unleashing emotions they might 
struggle to deal with.  However, paternalism through underplaying the seriousness of 
chemotherapy side effects is apparent within other studies.  Twenty of 97 cancer patients, 
who participated in an American questionnaire study to explore their communication with 
clinicians, believed information about their diagnosis and treatment were withheld or 
incomplete (Lerman et al., 1990).  Paternalism was also observed through interviews with 12 
women with breast cancer whereby clinicians misled them about the seriousness of their 
condition.  Clinicians described adjuvant chemotherapy as an insurance policy rather than 
discussing patients’ prognosis and likely benefits and costs of treatment (Cowley et al., 2000).  
Furthermore, in a grounded theory study patients (diagnosed with breast (n=26), colon (n=10) 
and other (n=4) cancers) reported a mismatch between their needs for chemotherapy 
information and information that was provided to them by clinicians for chances of cure 
(94.6% versus 34.3%) and effectiveness of chemotherapy in other patients (90% versus 48.5%) 
(McCaughan and Thompson, 2000).  A more recent survey of patients conducted in Ireland 
(n=473) also suggests that patients do not know about neutropenic sepsis or their personal risk 
of developing it (Leonard, 2012).  Other researchers have identified patients who believe they 
suffered unnecessary physical harm because they did not have enough information to manage 
chemotherapy symptoms (Mazor et al., 2012).  This highlights not only significant issues for 
informed consent to chemotherapy but also a power imbalance in favour of clinicians as 
described by  Bakker et al., (2001).  They found some women undergoing chemotherapy 
believed clinicians withheld information so they held the power and control in their 
relationship.   
 
This literature and the making decisions domain may be informed by new findings that clarify 
that some clinicians may avoid discussions about neutropenic sepsis because they fear patients 
refusing chemotherapy if it is fully explained.  A possible association is also identified between 
patients feeling they cannot decline chemotherapy and their unwillingness to engage with self-
management of neutropenic sepsis.  Importantly, feeling out of control with decisions to treat 
cancer has also been associated with intentional non-adherence with oral chemotherapy self-
medication in women with breast cancer (Atkins and Fallowfield, 2006).  Related to this and 
the domain, is new evidence that poor knowledge of neutropenic sepsis and associated 
symptoms means patients are unable to make informed decisions about when and how to 
seek help when it occurs. 
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8.2.6 Domain six: Enabling self-management  
The focus of the PCC ‘enabling self-management’ domain is on clinicians enabling patients to 
become active and responsible participants in their health care (Epstein and Street, 2007).  
This was not achieved for patients within this study, because information provided by clinicians 
about neutropenic sepsis frightened patients and did not enable or encourage them to take 
responsibility for it.   
 
The ‘enabling self-management’ domain draws upon three theories of behaviour change that 
can be applied to understand why patients may delay presenting to hospital when they 
develop neutropenic sepsis: 1).  The “5A’s” (Assess, Advise, Agree, Assist, Arrange) model of 
behaviour change (Glasgow et al., 2006) will be discussed later in this chapter.  Essentially, this 
aims to help patients develop personal action plans through (a) assessing their beliefs and 
knowledge, (b) advising on the risks and benefits of actions, (c) agreeing goals, (d) assisting in 
identification of barriers to action and (c) agreeing and arranging follow up support.  2). Self-
efficacy theory: proposes that an individual’s personal motivation to change health behaviours 
is driven by a belief in their ability to achieve the change.  This thereby suggests that people 
who are led to believe their actions are (or will be) ineffective are likely to avoid the same 
activity in the future (Bandura, 1988).  3). Self-determination theory: is concerned with a 
natural inclination towards intrinsically (internally) rather than extrinsically (externally) 
motivated behaviours (Ryan and Deci, 2000).  Core to self-determination theory are three 
intrinsic patient needs of relatedness (to experience reciprocal caring relationships, usually 
with clinicians), competence (mastery) and autonomy (to feel in control and responsible for 
ones’ own life).  Self-determination theory suggests the presence of relatedness, competence 
and autonomy are likely to stimulate patients’ natural inclination to be self-organised; intrinsic 
motivation and internalisation of externally motivated behaviours.  If innate needs of 
competence, relatedness and autonomy are not met, the motivation, performance and health 
of the patient may decline (Ryan and Deci, 2000).   
 
Previous research has not been conducted to explore how effectively patients are equipped to 
manage reporting of chemotherapy symptoms.  Consultations observed during the current 
study, did not appear to encourage patients to engage in the process and report symptoms of 
neutropenic sepsis.  Witnessed consultations did not seem to meet patients’ needs of 
relatedness, competence or autonomy required to be self-determined (Ryan and Deci, 2000, 
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Deci and Ryan, 2000).  Further, clinicians were not observed to promote patient self-efficacy 
(Bandura, 1988) through instilling mastery and a belief in their ability to manage their 
chemotherapy side effects at home and to report these appropriately to clinicians.  Self-
efficacy appeared further compromised after patients felt a bother when they accessed help 
for chemotherapy symptoms.  Patient accounts do suggest that clinicians encourage early 
patient presentation, through legitimising symptoms of neutropenic sepsis and by taking 
responsibility for their care. 
 
New findings further suggest patients may struggle to emotionally and physically respond 
when they develop neutropenic sepsis due to its debilitating nature.  This finding is supported 
by weak evidence described within the literature review chapter of this thesis (chapter two) 
that suggests grade three and four neutropenia are associated with depression (See Domain 
three: Responding to emotions) and reduced physical and social functioning (Fortner et al., 
2006; Fortner and Houts, 2006).  Furthermore, self-efficacy theory suggests a negative stress 
reaction resulting from a physiological or emotional state is associated with reduced self-
efficacy and ability to perform (Bandura, 1988).  This has implications for the responsibility 
then placed upon the carers to make decisions about reacting to getting treatment for 
neutropenic sepsis.  Often carers have only the same - or less - knowledge than the patient 
about this iatrogenic condition. 
 
8.2.7 Moderators  
Mediating domains for patient-centred communication (Fostering healing relationships; 
Exchanging information; Responding to emotions; Managing uncertainty; Making decisions 
and Enabling patient self-management) that impact on patient reporting of neutropenic sepsis 
have been described.  The PCC model also includes factors that moderate relationships 
between patient-centred communication and the outcome (for the current study the desired 
outcome is early patient presentation with neutropenic sepsis).  The PCC framework includes a 
two dimensional model (figure 3.3., p70) that presents moderators along the horizontal axis 
that represent a continuum suggesting the extent to which a moderator is stable (difficult or 
impossible to change) or mutable (modifiable).  The vertical axis represents a continuum 
between moderators being extrinsic (external) or intrinsic (native/close) to relationships 
between clinicians, patients and carers.  Importantly, moderators on the left hand side of the 
grid may be less open to change and so may create greater barriers for adherence with 
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reporting of neutropenic sepsis.  Moderators on the right hand side may be more malleable 
through patient-centred communication behaviours.   
 
Findings from this study suggest that some of the mutable moderators included within the PCC 
model are important to the grounded theory.  These include access to care (extrinsic mutable 
moderator) and clinician attitude (intrinsic mutable moderator).  This is because patients who 
were made to feel they would be a bother for accessing the chemotherapy on-call service were 
more likely to delay presentation.  Further relevant intrinsic mutable moderators that are 
included within the PCC model are patient and carer perceived risk and illness representation 
(of neutropenic sepsis which is often minimised to an infection).   
 
Findings from the current study suggest new mutable moderators for adherence with 
reporting neutropenic sepsis that should be added to PCC model (figure 8.2).  These include 
being recently bereaved, having fatalistic attitudes towards having cancer and engaging with 
carers (intrinsic mutable moderators that may be malleable through patient-centred 
communication). Having metastatic disease was further identified as an extrinsic stable 
moderator. Importantly this suggests patients who have advanced cancer may need additional 















Figure 8.2. Updated PCC intrinsic and extrinsic moderating factors - suggested additions 
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8.2.7.1 Having metastatic disease and being bereaved  
Findings from this study supports other research that suggests patients with metastatic disease 
may avoid hearing bad news information about their diagnosis and may be passive during 
consultations with clinicians (Cassileth et al., 1980, Fallowfield et al., 1995, Butow et al., 1997, 
Mills and Sullivan, 1999, Pollock et al., 2008).  An Australian questionnaire study conducted 
with 80 cancer patients identified that patients with metastatic disease appeared most passive 
during consultations with doctors.  The researchers suggest this may be due to patients with 
metastatic disease preferring a paternalistic approach or seeking to avoid negative information 
(Butow et al, 1997).   
 
Avoidance behaviours during consultations, in people diagnosed with cancer who have also 
experienced a recent death or imminent death of a friend or family member (bereavement), is 
a new finding. Research has shown that where people were bereaved and the person that had 
died was perceived to die ‘young’ or before their time, or a person experienced multiple 
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bereavements of close family and friends in a short period of time, this could trigger 
complicated grief reactions (Kissane et al., 1998).  This may help to explain the differential 
findings of those bereaved. 
 
Previous research has shown an association between grief following a bereavement and 
delayed patient presentation to clinicians with cancer (Zakowski et al., 1997, Lund-Nielsen et 
al., 2011).  A longitudinal study conducted with women undergoing breast screening (Zakowski 
et al., 1997) reported that a family history of breast cancer was associated with having 
significantly increased intrusive thoughts.  These women appeared less inclined to observe for 
signs of breast cancer.  They also perceived themselves to be at greater risk of developing 
breast cancer than women with no family history.  Importantly, intrusive thoughts, avoidance 
and perceived risk were exacerbated in women  who had experienced death of a parent(s) 
from cancer (Zakowski et al., 1997).  The second interview study, identified reasons that 17 
women delayed presenting to clinicians when they developed malignant breast wounds.  
Delays were sometimes related to grief complicated by beliefs that doctors had been unable to 
help family members who had died from breast cancer (Lund-Nielsen et al., 2011).   
 
New findings of the current study suggest patients with metastatic disease or who are 
bereaved may be more fearful of neutropenic sepsis and more likely to adopt avoidance and 
normalising behaviours than other patients.  Importantly, this behaviour may also be linked to 
increased fears of dying and /or depression.  As discussed earlier in this chapter (See Domain 
three: Responding to emotions) depression in cancer patients often goes untreated (Walker et 
al., 2014). Depression may further be associated with non-adherence with treatment for 
cancer (Dimatteo et al., 2000). The possibility of a relationship between depression and/or 
patients’ pessimism about their chances of survival (due to having metastatic disease and 
being bereaved), and delayed presentation with neutropenic sepsis requires investigation in a 
future study.    
 
Heightened avoidance behaviours in those with metastatic disease is especially important 
because high level evidence identified within the literature review chapter (chapter two) 
suggests they are at increased risk of developing neutropenic sepsis (Smith et al., 2006, Aapro 
et al., 2011) and of having complications from it (Klastersky et al., 2000).  Weaker evidence, 
also suggests patients with metastatic disease are more likely to present late to hospital when 
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they develop neutropenic sepsis (Malik et al., 2001, Nirenberg et al., 2004).  Furthermore, the 
current study suggests therapeutic relationships with their clinician (See Domain one: 
Fostering healing relationships) are most valued by patients who have metastatic disease or 
who are bereaved.  These patients also appear more likely to call clinicians they feel connected 
to when they develop neutropenic sepsis.  Importantly, this may cause a delay in treating 
neutropenic sepsis if the chosen clinician is not immediately available.   
 
8.2.7.2 Engaging with carers 
The PCC model includes family functioning and social support networks as intrinsic mutable 
moderators of patient-centred communication.  Findings of this study more specifically 
suggests that a lack of engagement of carers in the chemotherapy process by patients and /or 
clinicians reduces the likelihood of patients and carers taking neutropenic sepsis seriously and 
of promptly reporting symptoms of it to clinicians.  A UK study also identified that 37% of 1,700 
cancer patients surveyed had not been asked by clinicians about their social support 
(Macmillan Cancer Support, 2013).  Furthermore, other studies have identified cancer (Morris 
and Thomas, 2001, Northouse et al., 2010, McCarthy, 2011) and chemotherapy (Hilton et al., 
2000, Ream et al., 2013b) information delivery to be patient-centred which leaves carers 
feeling excluded. 
 
Feeling unprepared to care for cancer patients reflects a general concern amongst carers 
(Morris and Thomas, 2001, Northouse et al., 2010, Macmillan Cancer Support, 2011, 
Northouse et al., 2012).  Furthermore, carers of chemotherapy patients report feeling unable 
to support patients to recognise and report symptoms of neutropenic sepsis (Royal College of 
Physicians, 2012, Ream et al., 2013b).  An interview study conducted within the UK with 47 
patients and 32 carers also identified carers who did not attend chemotherapy information 
appointments were often unaware of the risk of neutropenic sepsis, symptoms of it or who to 
call (Morris and Thomas, 2001).  Furthermore, a UK, mixed method study where carers 
completed questionnaires (n=49) and participated in interviews (n=13) identified a lack of 
knowledge about chemotherapy or who to call for symptom help.  This included a case where 
a patient haemorrhaged at home following chemotherapy (Ream et al 2013a).  Importantly, 
feeling responsible but unprepared to support patients through chemotherapy may heighten 
carers stress and reduce coping (Mcilfatrick et al., 2006, Northouse et al., 2012, Ream et al., 
2013a) and thus possibly their ability to support patients. 
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Research suggests patients and carers renegotiate their roles during chemotherapy (Mcilfatrick 
et al 2006; Ream 2013b) and more generally during having cancer (Morris and Thomas, 2001).  
The concept of family-based care suggests carer roles in chemotherapy side effect 
management cannot be understood in isolation from roles of patients’ (Schumacher et al., 
2000).  They describe three role scenarios to manage chemotherapy and normal life: patients 
take the lead; carers take the lead; or roles are divided or more commonly shared 
(Schumacher et al., 2000, Morris and Thomas, 2001).  In the study reported here, women with 
breast cancer appeared to take the lead in decisions to report neutropenic sepsis.  There is 
though bias inherent with the sample because all patients were female and most carers were 
their male spouses.  Therefore, this only allowed comparison of gender roles between carers 
who were male partners and female friends, sisters and children.   
 
Little is known about the experience of male partners who do not get involved in 
chemotherapy care, possibly because they are less accessible to researchers.  Nevertheless, 
gender associated relationships appear important.  New findings suggest women may exclude 
male partners/husbands from the chemotherapy process and request female friends and 
family members to support them instead.  Findings support other research as female friends 
and family members appear to more easily adopt a caring and emotionally supporting role 
during chemotherapy than male partners who are perceived as squeamish and unable to cope 
with seeing their partners receive chemotherapy (Schumacher et al., 2000; Ockerby et al., 
2012, Ream et al 2013b). 
 
Other research also identifies female carers who put more pressure on patients to call 
chemotherapy helplines as neutropenic sepsis symptoms worsen (Schumacher et al., 2000, 
Morris and Thomas, 2001, Ream et al., 2013b).  New findings from the current study, extend 
this literature to suggest female carers may initially not pressurise patients to call 
chemotherapy helplines, because they do not recognise neutropenic sepsis symptoms as 
serious or they seek to avoid frightening patients about the possibility of dying from 
neutropenic sepsis. 
 
There may also be reasons, other than women preferring the moral support of other women, 
that male partners do not attend chemotherapy appointments.  There is evidence that couples 
where one has cancer (Northouse et al., 2000, Hilton et al., 2000, Mitchell, 2007) seek to 
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protect each other through withholding emotions.  Patients going through chemotherapy have 
also been found to protect those close to them through hiding emotional distress (Cowley et 
al., 2000, Pedersen et al., 2012).  One mother from this study believed her daughter excluded 
her male partner because she wanted him to view her as normal, rather than a sick person.  
Interestingly, a systematic review of the experiences of men in relation to their partners’ 
mastectomy showed they often felt excluded.  This was because the women partners did not 
like them to see their scarred breast or mastectomy site (Rowland and Metcalfe, 2014).  A 
possible reason for sometimes excluding men from providing care was a fear by women, 
following a mastectomy; of their partner’s reactions to their changed or altered breast and 
that this may change their relationship (Rowland and Metcalfe, 2014).   
 
Male partners may also not attend pre-treatment chemotherapy consultations because of 
other priorities.  Carers from an intervention study reported that family and work 
commitments reduced their ability to get involved in the chemotherapy process (Ream et al., 
2013b).  It is possible, that some women prioritise their families support needs over their own 
during chemotherapy.  Childcare may be a priority and financial pressures caused by being 
unable to work may result in the protection of male partners’ jobs.  Consequently, childcare or 
work commitments may reduce male partners’ ability to attend chemotherapy consultations, 
which are usually held during working hours.  Whatever the reason for male partners being 
excluded, this leaves them unaware of the risk of neutropenic sepsis, symptoms or numbers to 
call and unable to persuade patients to contact the hospital.   
 
8.2.7.3 Being Fatalistic 
Development of the grounded theory identified fatalism as an intrinsic mutable moderator to 
be added to the PCC model.  Fatalism is evident in patients with other illnesses.  Fatalistic 
attitudes were noted in some patients following a myocardial infarction, which reduced their 
inclination to take up healthy lifestyle advice (Wiles and Kinmonth, 2001).  Cancer research has 
also identified an association between fatalistic attitudes and uptake of breast and cervical 
cancer screening, mainly in African American women.  Cancer fatalism is defined across these 
studies as a pessimistic belief that the presence of cancer means death is inevitable (Skinner et 
al., 2002, Behbakht et al., 2004, Powe et al, 2006, Cassibba et al., 2013).  Research consistently 
supports findings that ethnicity may be related to fatalism and an associated reduced 
inclination to undergo cancer screening (Skinner et al., 2002, Behbakht et al., 2004). 
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Findings of the current study suggest some patients may rely on God to protect them from 
harm during chemotherapy.  Similarly, a questionnaire study conducted with patients (n=105) 
with a chronic illness or cancer (Cassibba et al., 2013) identified secure attachment to God 
compared to insecure attachment is associated (p<.05) with higher levels of fatalism and lower 
levels of anxious preoccupation and hopelessness. Secure attachment to God may further lead 
to passive coping through devolvement of responsibility to God to protect (Cassibba et al., 
2013).  The role of religion in delayed patient presentation with neutropenic sepsis may be 
further explained by other literature.  This suggests beliefs held by some cancer patients that 
their destiny is “in the hands of God” may be stronger than their inclination to act.  A 
questionnaire study completed by 146 women with invasive cervical cancer identified that 
those who relied on their faith to direct health choices avoided knowing about a cancer 
diagnosis (Behbakht et al., 2004).  Furthermore, a questionnaire study with 80 patients 
identified a significant association between beliefs that God influenced cancer and preferences 
for less cancer information and detail (Butow et al, 1997).  Importantly, a systematic review 
found evidence that some black African American women believed the outcome of cancer was 
God’s will, so it was not for them to intervene (Jones et al., 2014).  Consequently, it is likely 
that the knowledge that clinicians would like patients with cancer to know regarding reporting 
neutropenic sepsis sometimes conflicts with patients’ strong religious beliefs, and it is these 
latter beliefs that ‘win’. 
 
 
8.3 Limitations of the study 
This study, as with any research, was constrained by a number of factors.  Limitations were 
evident within the following four areas of the research process: sample selection and 
recruitment, collecting interview data, collecting non-participant observation data and data 
analysis.   
 
8.3.1 Sample selection and recruitment 
The patient sample for this study was confined to women with breast cancer undergoing 
chemotherapy, so findings may not apply to patients with other cancer diagnoses.  
Furthermore, there was a confounding variable in that all partners were men, so the only 
comparison of gender that could be conducted was with friends, children and siblings of the 
women with cancer.  This was also a small study.  However, the purpose of grounded theory is 
226 
 
not population representativeness, it aims to develop a theory that emerges from the data 
Therefore, data collection ceased when nothing new emerged to contribute to the developing 
theory.   
 
Grounded theory directs researchers through constant comparison and theoretical sampling to 
identify participants likely to be of interest to the emerging theoretical inquiry.  Reliance on 
clinicians to identify and initially approach suitable patients was likely to introduce an element 
of selection bias.  Further, this was not their only priority so recruitment of specific patients of 
interest sometimes proved difficult and opportunities to include patients with particular 
characteristics were occasionally missed.  In particular, there were difficulties in recruiting 
patients with metastatic disease, who clinicians may not have wanted to approach to 
participate in this study.  Furthermore, this patient group often appeared to start 
chemotherapy quickly, which reduced the window of opportunity to obtain informed consent 
prior to non-participant observation.  It was also hoped that patients who had experienced 
multiple admissions to hospital with neutropenic sepsis may be recruited to establish if 
behaviour changed over time, as suggested in the data.  Unfortunately, such patients could not 
be identified.  It was envisaged male carers, who did not appear aware of neutropenic sepsis 
or how to act if this occurred, may have been of interest.  However, patients who appeared to 
exclude these male carers from the chemotherapy process also tended not to support their 
participation in the research. 
 
8.3.2 Collecting interview data 
The researcher had limited experience as an interviewer initially, which may have affected the 
quality of data generated for analysis in the earlier interviews.  However, interview and 
grounded theory training at the start of the research process, along with experience, assisted 
development of interviewing skills.  Interview bias was also likely due to the researcher’s 
experience as a chemotherapy nurse and in the beginning it was challenging relating to 
participants as a researcher rather than a nurse.  Conversely, bias may have been reduced 
through reflexivity (detailed later within this chapter) and because the researcher was not 
known at the research centre so lacked preconceptions about practice there.  Prior 
chemotherapy knowledge also sometimes helped identify phenomena that may be missed by 
other researchers.  An example is an awareness of the likely timing and symptoms of 
neutropenic sepsis.   
227 
 
Location of interviews differed because participants were offered a choice for these to be 
conducted either face to face (hospital or home) or via the telephone.  A limitation of 
telephone interviews may have included an inability to witness facial expressions and 
reactions, although some participants may have felt able to speak more freely over the 
telephone than through face to face interactions.  Most patients and carers chose to be 
interviewed over the telephone which proved problematic when mobile phone signals were 
lost or they became distracted so interviews had to be rescheduled.  Clinicians were 
interviewed either over the telephone or face to face and occasionally these interviews were 
cut short due to clinical commitments, which again may have affected the quality of data 
collected.   
 
8.3.3 Collecting non-participant observation data  
Initially, limited experience as a qualitative researcher may have also affected the quality of 
non-participant observation data.  Through discussion and reflection with supervisors, these 
skills developed over time and with more experience.  Most importantly a limitation of this 
study element was the potential influence of the presence of the researcher observing patient 
and clinician behaviours.  Clinicians knew the aim of observation was to identify how they 
communicated with patients and carers about neutropenic sepsis.  They may therefore, have 
stressed the risks of neutropenic sepsis more than usual.  This may have been overcome to 
some extent by not informing clinicians about the purpose of observation; however, a covert 
approach may have ethically compromised the research and clinician trust in the researcher.  
Filming consultations may have altered clinicians’ usual practice and behaviour in their 
explanations of neutropenic sepsis. Filming may also have more accurately captured 
consultation interactions.  Clinicians were though used to being observed (e.g. by students) 
and much less used to having a camera in the room.  Furthermore, it may be less intrusive to 
patients to have another person in the room – a nurse researcher – than to have a video 
camera.  In the event, clinicians, patients and carers appeared to relax into the observations as 
they became used to these and got to know the researcher. 
 
Witnessed behaviours of observed doctors’ consultations matched accounts given by patients 
and carers during interviews.  However, patients indicated chemotherapy nurses did not 
always present them with information about chemotherapy side effects.  Consequently, pre-
arranged observation of chemotherapy nurses providing information to specific patients may 
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have not reflected usual practice.  Participant observation through working as a chemotherapy 
nurse or general observation of patient care within the chemotherapy unit may have provided 
a more in-depth ethnographic account of the culture within which chemotherapy nurses 
interacted with patients about neutropenic sepsis.  However, attention to the grounded theory 
approach, through ongoing constant comparison between interviews and observation 
generated a rich descriptive picture of information and support provided to patients about 
neutropenic sepsis.     
 
8.3.4 Data analysis  
Grounded theory suggests only those deeply immersed in collecting data can truly analyse this 
because it may be misinterpreted by a third party.  An additional experienced grounded theory 
researcher(s), as a collaborative participant in data collection and analysis, may have enabled 
the grounded theory to develop more quickly and assisted validity.  This was not possible due 
to the research fellowship being undertaken by one researcher.  However, grounded theory 
training, reflecting on the data analysis and discussions with supervisors about possible 
interpretations (in addition to mentorship by Juliette Corbin, who is an International expert in 
the grounded theory method) ensured a thorough exploration of the data that was true to the 
grounded theory method.  Analysis was carried out alongside data collection and breaks from 
this were taken at regular intervals to enable ongoing in-depth analysis.  In addition, following 
the completion of data collection, nine months full-time commitment was dedicated to 
produce the final analytical description, ensuring this was of high quality.  Further, rigour of 
analysis is demonstrated because the final theory can be applied to each case studied which 












8.4 Reflexivity within the research process 
Constructivist grounded theory requires clarity about the place of the researcher within the 
research as a reflexive co-constructer of knowledge who puts participants’ stories at the heart 
of the final theoretical interpretation (Charmaz 2006).  Reflexive thought included 
consideration of how my experience as a chemotherapy nurse and other literature impacted 
on each stage of the research. The intention was to use pre-existing knowledge to inform areas 
of enquiry and to compare and contrast emerging findings rather than to drive data collection 
and analysis. However, consideration must be given to how my personal biases and experience 
may have influenced generation and interpretation of data (Charmaz, 2006). I am a white 
middle class, British female in my late forties who works as a senior chemotherapy nurse and 
holds postgraduate qualifications.  Balancing my emic or insider perspective as a 
chemotherapy nurse against an etic perspective as an outside researcher was challenging.  I 
naturally acted and was perceived as a chemotherapy nurse within the research field.  Some 
patients sought my advice about chemotherapy side effects and during one observation I 
instinctively attended to a patient whom I believed was about to accidently pull out his drip.  
Clinicians related to me as a chemotherapy nurse which appeared to allow them to speak 
openly about their experiences.  My insider perspective also sometimes got in the way of my 
seeing the research field with fresh eyes.  I, for example, believed I provided good explanations 
of neutropenic sepsis to patients.  I could not understand why they did not act upon my advice 
to report symptoms of it urgently.  I also, as discussed earlier in this chapter, made 
assumptions that nurses carried out chemotherapy pre-treatment consultations which may 
have resulted in the process being altered as indicated by Sophia:  
 
“I wonder sometimes whether the effect of you coming in as a researcher when that nurse gave 
quite a long spiel about it I wondered actually whether it was slightly for your benefit… “     
           
                   (Sophia) 
 
My background may also have affected my ability to engage with patients and carers from 
different backgrounds and with different life experiences, about sensitive issues relating to 
having a life threatening illness.  Two examples are provided.  Wendy who was older than 
myself, educated only to secondary school level and had never worked was particularly 
challenging to interview.  Wendy dismissed neutropenic sepsis as unimportant and tended to 
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give short answers to my questions.  Wendy had a strong regional accent, and on subsequently 
listening to her interview recording, I realised she had failed to present to hospital on a 
previous occasion with apparent symptoms of neutropenic sepsis.  On reflection, Wendy may 
have believed I could not identify with her.  Wendy had been reprimanded by other clinicians 
for not complying with instructions to report neutropenic sepsis symptoms.  She may have 
believed I would also judge her.  A similar scenario was observed on reflecting on the interview 
carried out with Zeena, a Somalian women in her 60’s whose husband had been killed in 
Somalia.  Zeena was also educated to secondary school level and English was her second 
language.  The following is an extract from my reflective diary that documented my thoughts 
following my interview with Zeena: 
 
Reflective diary extract:  
I felt like a dog with a bone.  Kept asking her the same questions.  It was only 
when I put my questions to one side that I felt we were getting somewhere.  She 
finally came out with the fact her family were trying to persuade her to come to 
hospital, she didn’t want to talk about it.     
 
 
Zeena came from a different cultural and religious background than myself.  Her culture and 
religious beliefs appeared important to her coping with cancer.  She may therefore have not 
believed I would understand her perspective and might judge her for initially refusing to come 
to hospital.  Had Zeena felt more of an affiliation with myself, she may have been more open 
to discussing her reactions to having cancer and going through chemotherapy from the start of 
the interview.  Interestingly, I had a more productive interview with Zeena’s niece with whom I 
felt more comfortable talking to.  Zeena’ niece was younger than myself, born in the UK, 
educated to postgraduate level and was interested in undertaking nurse training.   
 
I do not have personal experience of a life threatening illness or death.  It challenged me to 
think clinicians might be as equally culpable for patients delayed presentation with 
neutropenic sepsis as patients were to not reacting to their symptoms.  My supervisors and 
mentor assisted me in understanding that initially I was thinking like a clinician rather than a 
researcher.  I needed ‘to get inside the heads of participants’ to understand the process from 
their perspective.  As a result, this new insight, understanding and training associated with this 
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doctoral thesis has strengthened my observation and interviewing skills and ability to see the 
perspective of others.   
 
I also felt more comfortable interacting with other female nurses than doctors which reflects 
my clinical practice.  This is also reflective of the hierarchy inherent in medicine between 
doctors and nurses due to gender.  I consequently found it difficult to challenge doctors’ 
practice and views.  Further, a male researcher may have connected with male carers in a 
different way to myself as a female researcher. A male perspective may have assisted, better 
understanding of any impact of relationships between couples on reporting of neutropenic 
sepsis.   
 
The most important element of bias related to me being part of a culture where clinicians did 
not talk to patients about the risk of death from neutropenic sepsis.  Observed explanations of 
neutropenic sepsis replicated my clinical practice and I was not initially open to the concept 
that patients were not told about it.  I noted in my reflective diary: 
 
Reflective diary extract:  
It was beyond me that people did not know about it.  I kept making a note of 
it……when a patient said they weren’t told about it I was a bit resistant  
 
I became uncomfortable when I observed Doctor 2 to be more explicit about the risk of death 
from neutropenic sepsis with Adanna, because I thought he was being too harsh.  I became 
further aware of my discomfort during my MPhil upgrade examination when I expressed a 
strong resistance to speaking to patients and carers about the risk of death from neutropenic 
sepsis.  I later noted in my reflective diary: 
 
Reflective diary extract: 
I didn’t want to tell them what it was… I didn’t want to talk about the risk of 
death with patients and carers… I would have got more out of earlier participants 
if I had felt more comfortable  
 
I feared causing distress and being reprimanded for informing patients they could have died 
from neutropenic sepsis and on reflection these feelings were related to this being a taboo 
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subject.  When I gained the courage to talk about this with patients and carers I preferred to 
do so via telephone rather than face to face to save embarrassment and remained worried I 
may have caused upset.  I have learnt that patient and carers do not mind having these types 
of conversations as documented in my reflective diary, following an interview with Zeena:  
 
Reflective diary extract:  
I was worried about upsetting her by talking about the fact she could have died, I 
think this is difficult for me in practice too.  I don’t know, maybe it wasn’t as bad 
as I thought.  I think she liked talking about it   
 
I further understand that beliefs and frustrations I held prior to this research (shared with 
other clinicians) that I was not getting the message through to patients about the risks of 
neutropenic sepsis, and an assumption that patients could be persuaded to comply with 
clinicians’ instructions to present early with neutropenic sepsis may have biased the research 
question: 
 
Why do some patients delay reporting to hospital with signs and symptoms of neutropenic 
sepsis, and what assists patients to present earlier to reduce the effects of neutropenic sepsis 
 
I have learnt that relationships with clinicians are likely to be core to patients’ adherence to 
advice / instructions from clinicians.  Furthermore, people with a life-threatening cancer 
diagnosis may make informed choices not to adhere with clinical advice to present early with 
neutropenic sepsis.   
 
Reflexivity ensured transparency of my influence on the research process and identification of 
researcher bias that importantly included my being part of a culture where the risk of dying 
from neutropenic sepsis is not spoken about with patients.  Further, close supervision and 
regular breaks from data collection to concentrate on theory development ensured this was 






8.5 Implications of findings for clinical practice and research 
8.5.1 Introduction  
A key challenge for clinical practice and future research is to change the interactions where 
clinicians, patients and carers meet around the issue of neutropenic sepsis.  Interactions 
should move from a subconscious focus on underplaying the seriousness to one that promotes 
openness and early patient presentation.  Implications of findings for clinical practice and 
research will next be discussed and will draw on four theories incorporated within the PCC 
model (Epstein and Street, 2007).  These are self-efficacy theory (Bandura, 1997), self-
determination theory (Ryan and Decci, 2000), the 5A’s for patient-centred counselling 
(Glascow et al., 2003) and Illness and uncertainty theory (Mischell, 1988).  These theories 
(previously described in chapters three and five and summarised in table 8.1) are potentially 
important to encouraging patients to voluntarily present earlier with neutropenic sepsis or to 
provide a safety net to capture high risk non-conformists. 
 
8.5.2 Implications for clinical practice  
Delayed patient presentation with neutropenic sepsis is a multi-factorial issue that has many 
implications for practice at organisational and individual, clinician levels.  At an organisational 
level it, is recommended that service models move from target focused, factory systems that 
process patents through chemotherapy.  New, person-centred models should be developed to 
encourage ongoing, trusting and supportive relationships to develop between clinicians, 
patients and carers to promote adherence.   
 
Such ambitious system changes may be incorporated within existing chemotherapy services.  
Remodelling could ensure both treatments are delivered safely and patient supportive care 
needs are met within existing budgets.  Capacity may be released by combining the 
chemotherapy consent appointment (currently doctor led) with the nurse led pre-treatment 
consultation. Time spent by nurses to deliver pre-treatment chemotherapy information 
sessions may also be reduced.  A group interactive education session followed by separate 
personalised consultations may be more effective.  A similar approach has been implemented 
at a UK cancer centre and evaluated through patient surveys (n=56).  Findings suggest patients 
find the group approach supportive and feel less worried about impending chemotherapy 
(Sullivan et al., 2013).  Capacity from chemotherapy nursing roles may further be released 
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through creating less expensive technician roles to support chemotherapy delivery.  Time 
saved through such initiatives may be more effectively used by chemotherapy nurses to 
interact with patients about their chemotherapy symptoms throughout treatment.  
Furthermore, junior nurses or even volunteers could be recruited to assist more experienced 
chemotherapy nurses with proactive monitoring of patients undergoing chemotherapy.  Any 
service change should be piloted and include economic analysis within evaluations.   
 
Investment should also be made in communication skills training for clinicians who interact 
with patients about chemotherapy.  This should replicate qualities of the UK Connected 
National communication skills training programme (National Cancer Action Team, 2008).  This 
programme is informed by evidence that facilitated experiential learning can enhance and 
sustain effective clinician communication skills (Maguire et al., 1996, Fallowfield et al., 2003, 
Wilkinson et al., 2008). This may result in a clinician communication manner that does not 
encourage patients to feel a bother for reporting chemotherapy side effects.  It may also equip 
clinicians to speak with patients about difficult issues (including the risks of neutropenic sepsis, 
reasons patients may delay presenting with it and their fears of dying), that if not addressed, 
may get in the way of early patient presentation with neutropenic sepsis.   
 
Importantly, clinicians need to be shown compassion in order to be compassionate with 
patients (Youngson, 2011).  Research on compassion in nursing (Maben et al., 2007, Maben, 
2008, Maben et al., 2010, Maben et al., 2012) offers insight into how this may be achieved 
through extrinsic motivation including: ensuring clinicians feel valued and listened to, have 
access to clinical supervision, work within a culture that does not overstretch them, and that 
values and provides time for compassion.  This type of culture may be promoted though 
application of initiatives encompassing NICE guidance on ‘Promoting Mental Well Being at 
Work’ (NICE, 2009).  This suggests that monitoring and promoting clinicians mental well being 
enables them to achieve greater job satisfaction (NICE, 2009).  Clinicians who feel cared for are 
more likely to work to their potential, develop positive relationships with others and 
contribute more to the service (NICE, 2009).  Engagement of clinicians in the development of a 
new person centred chemotherapy service will be core to successful service change and may 




… a culture of participation, equality and fairness that is based on open 
communication and inclusion  
                                        (NICE, 2009, p. 8) 
 
Schwartz rounds (Lown and Manning, 2010) may further encourage and sustain 
compassionate care.  Developed in America, Schwartz rounds provide multi-professional 
forums that facilitate safe discussions about social and emotional issues that arise from 
clinicians caring for patients.  The model was evaluated through surveys of American clinicians 
who regularly attended these rounds (n=478).  The evaluation suggests Schwartz rounds 
improve team work, reduce clinician perceived distress and increase and sustain their ability to 
address and deal with patients’ psycho-social concerns (Lown and Manning 2010).  Schwartz 
rounds were brought to the UK in 2009, by the King’s Fund’s Point of Care programme.  This 
included a pilot at two UK hospital trusts that demonstrated a similar positive impact to the US 
experience (Goodrich, 2012).  Schwartz rounds have had rapid uptake within the UK over the 
last few years and an NIHR funded national evaluation is currently underway (NIHR Evaluation, 
Trials and Studies | 13/07/49. [ONLINE] Available at: 
http://www.nets.nihr.ac.uk/projects/hsdr/130749. [Accessed 01 November 2014]. 
 
Implications for practice at the individual clinician level may be understood within the context 
of: relationships between clinicians and patients; information exchange; and patients who are 
at increased risk of delayed presentation.  Framing information and promoting self-
management are also important to clinical practice and will be discussed later (in this chapter) 
within recommendations for research.  The PCC model and other literature suggests trusting 
relationships between patients and clinicians that promote continuity of care (i.e. seeing the 
same clinician more than once), may reduce patient uncertainty and emotional distress, 
increase coping and control (Sitzia and Wood, 1998, Mills and Sullivan, 1999, Bakker et al., 
2001, Epstein and Street, 2007). Continuity of care can also facilitate self-efficacy to perform 
self-care (Cassileth et al., 1980, Given and Given, 1984).  The PCC model suggests a partnership 
approach between clinicians and patients is likely to encourage patient adherence with 
reporting of neutropenic sepsis and identify those more likely to delay reporting it (e.g. due to 
being fatalistic, having metastatic disease or being bereaved).  Relationships should encourage 
exploration of patients’ concerns and interactive, tailored information exchange to promote 
problem focused self-management based on patients agendas, rather than adherence with 
instructions (Doak et al., 1996, Bakker et al., 2001, McCaughan and McKenna, 2007, Epstein 
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and Street, 2007, Pollock et al., 2008, Kennedy and Lloyd-Williams, 2009, Ormandy, 2011, 
Kazimierczak et al., 2012).  Informed patient decisions to have chemotherapy should be 
supported by honest discussion about the likely benefits of chemotherapy and risks including 
neutropenic sepsis.  Shared decision making has been shown to increase self-efficacy and 
subsequent adherence with cancer screening (Manne et al., 2003, Friedman et al., 2004).  
Furthermore, this may also help clinicians, as they may be less worried about patients refusing 
treatment if the decision is collaborative. 
 
Patients and carers need guidelines as to the timelines of when patients are most likely to 
become neutropenic and thereby at risk from sepsis.  Research also suggests cancer is an 
evolving journey and patients become interested in cancer related information when they feel 
in control (McCaughan and McKenna, 2007), accepting of their diagnosis (Van Der Molen, 
2000) and when information about chemotherapy side effects appears personally relevant 
(Skalla et al., 2004, Pollock et al., 2008).  Patients may consequently benefit from hearing 
about neutropenic sepsis following administration of the first chemotherapy, when initial 
perceived threats may have subsided and also nearer the time point, when they are at risk of 
developing neutropenic sepsis.  Furthermore, information about chemotherapy should be 
delivered within a quiet environment rather than busy chemotherapy day units (Treacy and 
Mayer, 2000).  This should enable information exchange between patients and clinicians that is 
free from distractions.   
 
Clinicians should be aware of patients who may require additional support and monitoring 
during chemotherapy.  Patients who are bereaved or have metastatic disease may be more 
frightened and resistant to knowing about neutropenic sepsis.  Furthermore, some patients 
maybe more inclined to be fatalistic towards the risks of neutropenic sepsis, which may 
include reliance on God to protect.  
 
Clinicians should not struggle with providing patients and carers with complex explanations of 
neutropenic sepsis. Rather, they should focus on encouraging patients and carers to report a 
fever or chemotherapy symptoms that are different (to their normal symptoms) or that worry 
them.  Importantly, patients should not be advised to wait to feel unwell with a fever of 380C 
or for a rapid deterioration to call chemotherapy help-lines.  It may also be important to be 
honest with patients that the healthcare system is not perfect and so relies on patients to keep 
oncology clinicians informed if they attend A&E departments.   
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Illness and uncertainty theory (Mishel and Braden, 1988, Mishel, 1990) stresses the 
importance of social support to reduce patient uncertainty.  Findings of the current study 
support the concept of family based care (Schumacher et al., 2000, Morris and Thomas, 2001).  
This suggests clinicians should explore potential family roles for chemotherapy support and 
capitalise on these through legitimisation, fostering collaborative patterns where carers and 
patients work together, and through developing targeted interventions for carers.  Only one 
intervention study involved carers who supported patients during chemotherapy (Ream et al., 
2013a).  Findings of this study identified that a facilitated group education session, DVD and 
written information reduced unmet need for information and support and increased feelings 
of legitimisation as carers (Ream et al., 2013a), which can improve the wellbeing of patients 
and carers (Morris and Thomas, 2001, Northouse et al., 2012).   
 
New findings of this study further suggest women may exclude male partners from their care 
during chemotherapy.  Clinicians should encourage patients to invite partners who live with 
them or a friend or family member, who they see regularly, to get involved in their care during 
chemotherapy.  This should at least include attendance at chemotherapy pre-treatment 
consultations, which should be offered at different times (e.g. evenings and weekends) to 
accommodate carers who work.  Clinicians should also assist patients and carers to plan for 
getting to hospital should the patient become unwell during chemotherapy.  The latter may 
include identifying people who could be on standby to support patients through driving them 
to hospital or by caring for children if required.  Patients could also be advised to have an 
overnight bag packed.  Patients and carers should be forewarned that the patient may feel 
quite low in mood during an episode of neutropenic sepsis.  This may be due to their having 
cancer and going through chemotherapy or being unwell from symptoms of neutropenic 
sepsis.  It is therefore, imperative that clinicians facilitate carers’ authority to intervene and call 
the helpline on patients’ behalf, should patients be unable to judge the seriousness of a 
neutropenic sepsis episode.  It is estimated 23% of cancer patients in the UK do not have 
support from family and friends (Macmillan Cancer Support, 2011).  Consequently, some 
patients who lack social support or exclude male carers (partners) may require additional 







8.5.3 Recommendations for research  
The grounded theory developed through the study outlined within this thesis suggests: 
 
Underplaying the seriousness of neutropenic sepsis is a subconscious collusion between 
clinicians, patients and carers  
 
Recommendations for future research relate to (1) the design of studies to test and develop 
the theory further and (2) the development of interventions (to promote early patient 
presentation with neutropenic sepsis) informed by the grounded theory developed through 
the current study.   
 
The grounded theory may be applicable to study other high risk conditions where there is a 
reliance on patients to report symptoms (e.g. acute oncology emergencies such as spinal cord 
compression) to generate the theory further.  Initially, it is recommended the grounded theory 
is applied to future studies to explore delayed patient presentation with neutropenic sepsis to 
test its validity.  There are also a number of aspects of the theory that may be tested and 
developed, in relation to observation and through applying the theory to different samples.  As 
identified in the limitations section of this thesis, the design of a future grounded theory study 
may be improved through filming consultations.  Pre-arranged observations of patients’ pre-
treatment consultations, with chemotherapy nurses also may not have reflected normal 
practice.  A more accurate account may be gained through a general observation of activities 
within a chemotherapy day unit.  This may be achieved through non-participant observation or 
participant observation through working as a chemotherapy nurse.  It is further suggested the 
grounded theory is tested and developed with patients who have different cancer diagnoses, 
those receiving different chemotherapy drugs, male patients, children and teenagers, to 
identify any differences between groups.  Patients with more than one admission to hospital 
with neutropenic sepsis should also be recruited.  This may assist in developing a greater 
insight into changing behaviours or attitudes towards reporting neutropenic sepsis over time.   
 
Patients with fatalistic attitudes towards chemotherapy side effects or who had metastatic 
disease and / or those who were recently bereaved appeared more likely to take risks in not 
reporting neutropenic sepsis within this small study.  The grounded theory may be further 
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developed through screening patients for depression and by conducting a more in-depth 
exploration of patients’ perceptions and beliefs about their prognosis to validate any 
relationship between these and reporting of neutropenic sepsis.  Furthermore, relationships 
between patients and their carers during chemotherapy are likely to be complex and may 
differ dependent on many variables such as age, gender or stability of relationships.  
Consequently, these variables and reasons patients may exclude carers, or carers cannot get 
involved in the chemotherapy process should be further explored.  Any relationship of gender 
/ relationships that may impact on symptom reporting also warrant further exploration. 
 
Most importantly findings from the current study should inform the design of intervention 
studies that incorporate a patient self-management approach. Interventions developed 
through a whole system approach described briefly within the PCC model and applied to 
chronic disease management (Rogers et al., 2005, Protheroe et al., 2008) may be beneficial.  
This approach connects patients, clinicians and the healthcare system.  It reflects the chronic 
care model which aims to position self-care within the larger context of professional behaviour 
change and community engagement.  This model refers to whole systems, informing, self-
management and engagement and aims for:  
 
“informed patients who receive support and guidance from trained practitioners 
working within a healthcare system geared up to patients’ needs”   
       (Kennedy et al., 2007, p. 968) 
 
This type of approach would require engagement and participation of chemotherapy nurses.  
Research suggests a starting point should be exploring further the impact of the chemotherapy 
environment on nourishing or eroding compassion in chemotherapy nurses towards patients 
(Maben et al., 2007). Exploration should further identify chemotherapy nurses feelings about 
engaging with patients’ emotional issues, reasons for choosing to work in this field of nursing 
and the type of service they would like to provide to patients.  This may identify potential 
willingness of nurses to participate in interventions, likely to require closer engagement 
between themselves and patients to promote earlier reporting of neutropenic sepsis.  In 
addition, any impact of communication skills training, including talking about the risk of death, 
on clinician engagement with patients about neutropenic sepsis should be evaluated.  
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New findings of the study presented here suggest patients may avoid hearing about 
neutropenic sepsis due to fears of having a life threatening illness, starting chemotherapy and 
the way neutropenic sepsis is presented to them.  Importantly, explaining neutropenic sepsis 
to patients and carers is a problem for clinicians due to a lack of evidence to describe it (see 
chapter two).  A mixed method study (incorporating quantitative and qualitative methods) is 
recommended, as part of an intervention focused programme of work to generate more 
accurate and acceptable descriptions of neutropenic sepsis for patients.  Symptoms or 
symptom clusters for neutropenic sepsis may be identified through a quantitative approach.  
This knowledge should be combined with qualitative data from patients to (1) describe their 
feelings/experience of having neutropenic sepsis and (2) to identify descriptions of 
neutropenic sepsis that most effectively communicates the risk, using words that patients and 
carer understand and find acceptable.   
 
Research suggests that descriptions of symptoms of neutropenic sepsis that are generated by 
other patients with experience of neutropeinc sepsis may be beneficial.  These can promote 
understanding of an unfamiliar territory through the eyes of someone with shared 
experiences, perspectives and associated meanings (Mishel and Braden, 1988, McCaughan and 
McKenna, 2007, Pollock et al., 2008).  Patient stories are often the most valued aspect of 
interventions proven to reduce uncertainty related to chronic disease self-management within 
primary care (Rogers et al., 2005).  In addition, advice from other patients has been described 
as the most useful source of cancer treatment side effect information (Skalla et al., 2004, 
Pedersen et al., 2012) and may increase positivity (Cassileth et al., 1980, McCaughan and 
Thompson, 2000).  This approach is termed descriptive norms by NICE (2007); vicarious 
experiences or modelling within self-efficacy theory (Bandura, 1988) and falls under one of 
three structure providers described by illness and uncertainty theory (Mishel and Braden 
1988).   
 
Interventions generated to include descriptions of neutropenic sepsis that are acceptable to 
patients, should also seek to address different information seeking behaviours.  Application of 
Miller’s Monitoring and Blunting theory (Miller, 1995) to the study presented here suggests 
patients apparently coping through monitoring may prefer to be told about the risk of death 
from neutropenic sepsis and the threat lowered by focusing more on the benefits of acting 
promptly than the risk of dying.  Miller’s theory also indicates those who adopt a blunting 
coping style should be told in a straightforward, succinct and non-threatening manner what 
neutropenic sepsis is and the actions they should take (Miller, 1995; Miller, 1998).  As 
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highlighted earlier in this chapter, monitoring and blunting theory (Miller, 1995) may be overly 
simplistic to explain avoidance in patients with cancer and information seeking behaviours may 
change depending on the perceived threat of a situation (Lazarus and Folkman, 1984).  
Interventions designed to equip patients to manage reporting of neutropenic sepsis should 
consequently, be carefully developed and not aimed at all patients independent of their coping 
style or clinical situation.   
 
Findings of this study suggest self-management interventions may promote patient autonomy 
to report neutropenic sepsis.  Application of the five A’s (Assess, Advise, Agree, Assist and 
Arrange) of Glasgow et al’s (2006) “5A’s” self-management model suggests clinicians should 
‘Assess’ patients’ concerns (e.g. cancer, chemotherapy, social or work related) and their beliefs 
and knowledge of neutropenic sepsis.  Clinicians should ‘Advise’ on the risks of non-adherence 
and benefits of adherence in reporting neutropenic sepsis.  Clinicians should also ‘Agree’ on 
goals for early presentation and this may be promoted by asking patients to articulate when 
and how they would access advice for chemotherapy symptoms.   
 
The fourth A ‘Assist’ of Glasgow et al’s (2006) “5A’s”model, is encompassed within NICE 
guidance for behaviour change (2012) and the Royal College of Physicians report on acute 
cancer care (2012).  This suggests clinicians should ‘Assist’ patients to identify potential 
barriers to early reporting of neutropenic sepsis (e.g. child care or work commitments or 
difficulty getting to hospital) and develop strategies to overcome them (e.g. galvanising family 
and friends, or pre-warning work colleagues they may need urgent treatment should they 
become ill during chemotherapy).  Self-management interventions should also ‘Assist’ patients 
to recognise and report neutropenic sepsis.  These could be based upon problem solving which 
can increase patients’ self-efficacy with chemotherapy symptom management (Braden et al., 
1998, Dodd and Miaskowski, 2000, Given et al., 2004).  Symptom triggers focused on the 
severity of symptoms to report urgently may help patients and carers to identify and report 
neutropenic sepsis.  This would seem like a worthwhile approach.  However, this type of 
intervention must be developed alongside previously mentioned research that is required to 
identify the relevance of symptoms to neutropenic sepsis.  A traffic light system to assist with 
patient recognition and reporting of urgent (severe) and non urgent chemotherapy symptoms 
was the most highly patient evaluated aspect of an oral chemotherapy diary developed within 
the UK (Oakley et al., 2010).  Furthermore, patient advice developed by the UK Sepsis Trust 
highlight the following signs of early sepsis, all of which could be classified as severe 
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symptoms.  These symptoms were noticed by patients and carers in this study (although some 
may be difficult to distinguish from normal chemotherapy side effects) and are highlighted 
within the literature review chapter of this thesis (chapter two):  
 
 Felt very cold and shivery  
 Felt very hot and looked flushed 
 Had a high temperature 
 Had aching muscles 
 Felt very tired 
 Have had sickness and/or diarrhoea (upset stomach) 
 Not felt like eating 
 Seemed confused or drunk, or had slurred speech 
                           (The UK Sepsis Trust 2012, p. 5) 
Further, event congruence (consistency between expected and actual events) (Mishel and 
Braden, 1988) may also be promoted through a UK public health campaign.  This has been 
recommended within a report about unnecessary patient deaths from severe sepsis, including 
cases of chemotherapy induced neutropenic sepsis (Parliamentary and Health Service 
Ombudsman, 2013).  Such a campaign should be developed and tested in partnership with 
patients and carers to ensure the message is appropriate and effective.  This report highlights 
the following later symptoms of severe sepsis, which findings from the current study indicate, 
may heighten fears and avoidance behaviours or encourage patients to ignore earlier 
symptoms:  
 Slurred speech 
 Extreme muscle pain 
 Passing no urine 
 Severe breathlessness 
 I feel I might die 
 Skin mottled or discoloured   
                         (Ombudsman 2013, p. 5) 
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The fifth A (Arrange) of Glasgow et al’s., (2006) “5 A’s” model is associated with the need for 
relatedness (to experience a reciprocal caring relationship) to be self-determined (to be 
motivated to draw on intrinsic resources to act in healthy ways).  Advocacy incorporates 
clinicians being available when needed.  Findings of this study suggest interventions that 
incorporate ongoing supportive relationships between clinicians, patients, carers and A&E 
clinicians should be developed.   
 
Interventions should also evaluate any impact of proactive support in reducing patient delays, 
associated with uncertainty regarding which chemotherapy symptoms to report.  Effectiveness 
of pro-active care on capturing cases of intentional non-adherence should also be assessed.  
Intentional, non adherence may be more prevalent in patients who are bereaved or who have 
metastatic disease (possibly due to pessimism about prognosis); or who are fatalistic about the 
risks of chemotherapy or lack social support.  Two examples of proactive approaches to 
managing chemotherapy symptoms  may be important to future interventions (Molassiotis et 
al., 2009, Cowie et al., 2013).  The first study, evaluated a home chemotherapy nursing 
intervention to support patient self-management of oral chemotherapy (Molassiotis et al., 
2009).  Patients in the intervention group (n=83) had fewer chemotherapy symptoms 
(measured by the National Cancer Institute Common Toxicity Criteria, 1998) than a control 
group (n=81) and significantly reduced inpatient days (57 versus 167 days).  These findings 
suggest this type of intervention may promote earlier identification and treatment of 
neutropenic sepsis, and would be cost effective if costs of the intervention are offset by 
savings made on inpatient bed day usage.   
 
Proactive, interventions are likely to be of most support during the first two chemotherapy 
treatments as patients become more expert in managing their symptoms after this time 
(Molassiotis et al., 2009).  Consequently, even a home visit or telephone call from a 
chemotherapy nurse (or a trained and supervised more junior nurse), following the first 
chemotherapy treatment, may make a difference to early reporting.  The intervention could be 
delivered at day seven, following chemotherapy.  At this time patients have experience of 
other chemotherapy side effects and may be more receptive to hearing about neutropenic 
sepsis. Day seven following chemotherapy is also close to the risky time for developing 




The second proactive intervention is delivered as part of a programme of research centred 
upon the Advanced Symptom Management System (ASyMS).  This enables patients to input 
chemotherapy symptoms, including their temperature reading, into a mobile phone (Maguire 
et al., 2005, Kearney et al., 2006, Maguire et al., 2008, McCall et al., 2008, Gibson et al., 2009, 
Kearney et al., 2009, McCann et al., 2009, Cowie et al., 2013).  Patients next receive electronic 
symptom management advice or if triggered are connected to a nurse.  The nurse follows a 
symptom management protocol and triages a hospital review if required.  Patients reported 
ASyMs was easy to use (Maguire et al., 2005, McCann et al., 2009) and their confidence in 
symptom pattern recognition and management improved (Maguire et al., 2005, Kearney et al., 
2006).  Patients also felt ASyMS improved communication with clinicians (Maguire et al., 2005, 
Kearney et al., 2006, McCann et al., 2009).  Nurses reported that patients beliefs about 
bothering the helpline were reduced, that serious side effects (including neutropenic sepsis) 
were identified earlier and hospital admissions were avoided (Kearney et al., 2006, Maguire et 
al., 2008).  An economic evaluation of ASyMS is currently underway, as is the impact on patient 
reported outcomes including symptom burden and self-efficacy (Cowie et al., 2013).  
Furthermore, morbidity and mortality data in relation to neutropenic sepsis is being collected 
through a new European randomised controlled trial through Electronic Symptom 
Management System Remote Technology (eSMART) (European Commission) [ONLINE] 
Available at: http://ec.europa.eu/research/health/medical-research/cancer/fp7-
projects/esmart_en.html). Accessed 4th October 2014. 
 
As mentioned earlier in this chapter a generic intervention has been developed and tested 
with carers of patients going through chemotherapy (Ream et al., 2013a).  Development of a 
more tailored intervention for male carers is further recommended.  An expressed mantra 
from male partners from the study reported here was: ‘just tell me what to do and I will do it’.  
Other research also suggests men need to feel legitimised as carers during chemotherapy and 
prefer practical roles (Hilton et al., 2000, Ream et al., 2013a).  Primary care research has 
further identified men as preferring a practical approach to their own health (Talley, 2011, 
Robinson and Robertson, 2013) as demonstrated by a popular practical men’s health guide 
based on the Haynes car manual (Banks, 2002, Banks, 2007, Talley, 2011).  Men may, therefore 
be receptive to interventions based upon clear instructions to equip them to recognise and 
report neutropenic sepsis.  This also fits with task specialisation often adopted during 




Finally, enhancing perceptions of control is important to successful behaviour change (NICE, 
2007).  Results of the study presented here and other research suggests framing messages 
about neutropenic sepsis to promote self-efficacy (motivation, driven by a belief in ability to 
act) and response efficacy (belief in effectiveness of taking particular actions) may influence 
motivation to act (Miller, 1995, NICE, 2007).  Findings from this study suggest chemotherapy 
nurses may not have the skills to empower patients to manage chemotherapy side-effects.  
Interventions that include motivational interview training for nurses are therefore 
recommended.  Motivational interviewing has been suggested as useful to support self-
determination theory interventions to move patients from being passive to being active 
participants in their healthcare (Vansteenkiste et al., 2012).  This is a counselling client-centred 
approach to motivating behaviour change that does not seek to directly persuade or influence.  
Rather, this is based on encouraging clients to explore ambivalent feelings and choice about 
whether to change a behaviour.  It has been suggested that self-determination theory provides 
a theoretical explanation for why motivational interviewing is effective (Vansteenkiste, 2012).  
Motivational interviewing provides an autonomy stimulating environment so people can draw 
upon their own motivation and achieve positive outcomes (Markland et al., 2005).  
Importantly, relatedness may encourage internalisation of externally motivated behaviours 
when people are not eager to spontaneously engage (Vansteenkiste, 2012), which appeared to 
be the case for some patients who participated within the study reported here. 
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Chapter summary:   
The study findings and the grounded theory were examined in relation to the PCC model.  
This identified the PCC model is not only useful in looking at how patients cope with a cancer 
diagnosis but also how they respond to the risks associated with neutropenic sepsis.  
Relationships with clinicians (Domain one: Fostering healing relationships) that are built upon 
trust are important to patients’ engagement with reporting of neutropenic sepsis.  However, 
clinicians may avoid emotional interactions with patients (Domain three: Responding to 
Emotions) and do not fully explain neutropenic sepsis not only due to a lack of evidence 
(about early symptoms of neutropenic sepsis and how to explain associated risks) but also 
out of fear patients may refuse treatment (Domain five: Making decisions).  Preoccupation 
with uncertainties (Domain four: Managing uncertainty) about having chemotherapy and 
overwhelming, confusing and dispassionate information provided by clinicians about 
neutropenic sepsis (Domain two: Exchanging Information) exacerbates patients’ fears of 
dying and encourages avoidance behaviours.  Patients are not equipped to be responsible for 
reporting symptoms of neutropenic sepsis (Domain six: Enabling Self-management).  
Uncertainty (Domain four: Managing uncertainty) about symptoms of neutropenic sepsis 
affects patients willingness and ability to engage with reporting of it.  Furthermore, patients 
may be put off from calling chemotherapy helplines by busy technically focused clinicians and 
may delay contact in order to speak to clinicians who they feel connected to (Domain one: 
Fostering healing relationships).   
 
Patients may be motivated to report neutropenic sepsis through relationships with clinicians 
that encourage emotional engagement, openness, ongoing information exchange and 
support, shared goal setting and shared decision making.  Accurate messages about the risks 
of neutropenic sepsis framed to increase self-efficacy and response efficacy through 
understanding the benefits of early reporting may reduce delays.  Variations within the 
process relate to newly identified mutable moderators that are: being fatalistic towards 
having cancer, being bereaved and not engaging with carers and a stable moderator that is 
having metastatic disease.  The extended PCC model now requires testing through further 
research to explore delayed reporting of neutropenic sepsis and patient responses to other 
oncology emergencies to validate and further refine it.  It is also recommended the findings 
of this grounded theory study inform the development of interventions to assist patients, 




Limitations of the study include findings that may not be applicable beyond patients who 
have a breast cancer diagnosis and may under represent those with advanced cancer.  
Furthermore, the impact of gender and relationships between patients and carers on 
reporting of neutropenic sepsis require further exploration.  Researcher’ presence may have 
affected participants’ behaviour, areas of inquiry pursued and interpretation of findings and 
analysis to develop the grounded theory.  However, reflexivity, supervision and close 
attention to the grounded theory method enabled researcher influence to be managed and 
accounted for throughout the research process. 
 
 
8.6 In conclusion   
Diligent attention to the constructivist grounded theory approach and application of the 
Patient-centred Cancer Communication Model (Epstein and Street, 2007) and other literature 
to inform, rather than drive, data analysis and interpretation enabled development of a unique 
theory grounded in the data.  This suggests patients may delay presenting to hospital when 
they develop neutropenic sepsis due to a subconscious collusion between clinicians, patients 
and carers that underplays the seriousness of it.  Importantly, the research process enabled a 
deep understanding of the dread and fear experienced by patients starting chemotherapy.  
Fears include having a life threatening illness and potential death from neutropenic sepsis.  
This often left patients and carers not wanting or being able to hear about neutropenic sepsis.  
Processing patients through a system that relies on them to recognise and report neutropenic 
sepsis symptoms, that clinicians cannot describe, may discourage early presentation to 
hospital.  Indications that patients feel a bother for reporting neutropenic sepsis symptoms, 
further suggests patients may suffer unnecessarily with other chemotherapy side effects that 
go unreported.   
 
Findings from this study suggest a need to step back and review chemotherapy services with 
fresh eyes and remodel these to incorporate ongoing, supportive relationships that enable 
open discussions between clinicians and patients about the potential benefits and risks of 
chemotherapy, including neutropenic sepsis.  New models of care should equip and support 
patients and carers to manage chemotherapy side effects at home.  Importantly, these should 
be informed by research to identify descriptions of neutropenic sepsis that patients 
understand and enable early recognition of it.  A review of the literature suggests results from 
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this study have International implications for chemotherapy services.  It is consequently hoped 
these will inform further research and changes in practice to enable better chemotherapy 
symptom management and earlier treatment of life threatening chemotherapy side effects 
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Appendix 1: Scoping review: Characteristics of included papers  
Reference   Country Study population 
and sampling 
Methodology Important findings  (Superscript numbers refer to foot 
note, indicating  relevance to scoping review themes) 
Evidence rating for quality 
of findings   
Neutropenic sepsis clinical guidelines 
US Department of Health and 





Literature review  CTCAE: Widely used grading system for neutropenia (see table 2.4). (1)  
Suspect sepsis if temperature 38.30C, or 380C for > 1 hour. (1). 
High: Validated measure  
Dellinger et al., (2012) Ten countries / 
four continents  
General population with 
sepsis. 
Literature review  IV broad spectrum antimicrobials should be administered within one 
hour of sepsis recognition. (1) 
High: GRADE (validated tool) 
applied to assess quality of studies.  




IVABS within 1 hour (1) (low quality evidence). Suspect NS if temperature 
>38oC, or clinical signs of sepsis (1) (high evidence). Poor prognosis: 
Mucositis, temp >39oC, infection, chills, confusion (1) (low evidence). 
Early symptoms (2) and patient education (4) (low evidence). 
High: Comprehensive  systematic 
review  
The UK Sepsis Trust, (2012) UK  General sepsis population.  Literature review.  Symptoms of severe sepsis (1) (see table 2.7).  High   
The UK Sepsis Trust, (2013) UK  General sepsis population. Literature review. Administer intravenous antibiotics and fluids within one hour. (1). High  
Aapro et al., (2006; 2011) 
(EORTC) 
European / 





High risk indices for NS: Chemotherapy > 20% risk of causing 
neutropenia, age >65 years, advanced disease, no antibiotic cover. (1)  
High: Weighted evidence with a 
grading system developed by ASCO. 
Klastersky et al., (2000) 
(MASCC) 
Six countries / 
four continents  
Consecutive patient 
episodes of NS (n=757)  
Quantitative. 
Validation of MASCC  
High risk indices for complications from NS: Age >60 years, 
haematological malignancy and co-morbidities. (1) 
High: Validated. Detects patients 
with low risk NS.  
Smith et al., (2006) 
(ASCO) 
USA   Cancer patients 
undergoing chemotherapy 
Literature review.  High risk indices for NS: Regimens with high (>20%) risk of causing 
neutropenia; age>65 years, advanced disease, co-morbidities. (1) 
High: Comprehensive literature 
review. 
Scoping review themes: (1) Defining neutropenic sepsis and the risks of this to patients undergoing chemotherapy for cancer. (2) Symptoms of neutropenic sepsis that patients should report to clinicians. (3) Knowledge 
about delayed patient presentation to hospital with neutropenic sepsis. (4) Education of patients about neutropenic sepsis. Abbreviations: ASCO (American Society of Clinical Oncology); CTCAE (Common Terminology Criteria 
for Adverse Events); EORTC (European Organisation for Research and Treatment of Cancer); GRADE (Grading of Recommendations, Assessment Development and Evaluation); IVABs (Intravenous Antibiotics); MASCC 





(Appendix 1:   continued)  
 
Reference  Country Country Study population and 
sampling   
Methodology Important findings  (Superscript numbers refer to foot 
note, indicating relevance to scoping review themes) 
Evidence rating for quality of  
findings   
Cancer guidelines 
NCEPOD, (2008) UK 546 cancer deaths  





Identified poor clinical practice in relation to neutropenia. (1) 
Patients delayed presentation with NS symptoms by > 24- hours which 
may contribute to increased mortality risk. (1) 
Moderate:  Expert review.  
Low: Relied on clinician reports to identify 






Cancer patients  undergoing  
chemotherapy 
Expert panel. Recommend patient education is improved. (4) 
Recommend 24-hour on-call services are provided for cancer patients 
during chemotherapy. (4) 
Low: (opinion). 
Low: (opinion). 
Royal College of 
Physicians, (2012) 
UK Acute oncology admissions 
(n=262) Sampling method 
unclear.  
Patient experience  
Survey  
68% of admissions associated with feeling unwell or fever. (1) 
Some patients delayed presenting with NS for > 2 days. (3)  










UK Acute oncology measures  Expert opinion. Require emergency cancer services to be in place. (4) Low: (opinion). 
Scoping review themes: (1) Defining neutropenic sepsis and the risks of this to patients undergoing chemotherapy for cancer. (2) Symptoms of neutropenic sepsis that patients should report to clinicians. (3) Knowledge about 
delayed patient presentation to hospital with neutropenic sepsis. (4) Education of patients about neutropenic sepsis. Abbreviations:  NCAG (National Chemotherapy Advisory Group ); NCEPOD (National Confidential Enquiry into 
Patient Outcomes and Death). 
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Reference   Country Study Population  and 
Sampling 
Aims of the Study Methodology Outcome Measure(s) Important findings 
(Superscript numbers 
refer to foot note,  
indicating  relevance to 
scoping review themes) 
Evidence Rating for 
quality of findings  
Primary Research: Effects of neutropenia on symptoms and functioning 
Fortner et al., 
(2005a) 
USA 71 patients with 
Lung, breast or ovarian 
cancer or Lymphoma. 
Convenience sampling   
To determine differences 
in symptoms and 
functioning between 




site. ANC data. 
Symptoms and functioning.  
Validated Measures:  CTCAE, SF-
36; HADs. Study Specific 
Measure : CCM. 
Reduced physical and social 
functioning in grade 4 compared 
to grades 0-3 neutropenia. (2) 
Low: Convenience 
sampling and small 
sample. 
Fortner et al., 
(2006) 
USA 84 patients mainly with 
breast or lung cancer. 
Convenience sampling.   
To determine differences 
in symptom and 
functioning between 




ANC data.  
Symptoms and functioning. 
Validated Measures: RSC, HAD, 
SF-36.  Study Specific Measure:  
CCM-MIS. 
Reduced physical and social 
functioning in grades 3-4 
compared to grades 0-2 
neutropenia. (2) 
Low: Convenience 
sampling and small 
sample. 
Fortner et al., 
(2005b) 
USA 34 patients (100 interviews) 
Convenience sampling. 
Mainly breast or lung cancer. 
To determine symptom 
and functioning changes 
with grade 4 neutropenia 
Qualitative. 
Longitudinal. 
Interview. ANC data. 
Symptoms and functioning 
Qualitative analysis. Method not 
stated.   
Neutropenia associated with 
reduced physical and social 
functioning. (2)   
Low: Convenience 
sampling. No comparison 
between grades.  
Fortner and 
Houts, (2006) 
USA 51 patients, Convenience 
sample. Mostly, lung, breast 
or haematological cancers.    
Validation of the PCM-N 




Study Specific Measures  
CCM , CCM-MIS and CCM 
Neutropenia index. 
Reduced physical and social 
function in grades 3-4 compared 
to grades 0-2 neutropenia. (2)  
Low: Only 51 (741) 
patients were eligible. 
Scoping review themes: (1) Defining neutropenic sepsis and the risks of this to patients undergoing chemotherapy for cancer. (2) Symptoms of neutropenic sepsis that patients should report to clinicians. (3) Knowledge about 
delayed patient presentation to hospital with neutropenic sepsis. (4) Education of patients about neutropenic sepsis. Abbreviations: ANC (Absolute Neutrophil Count); CCM (Cancer Care Monitor); CCM-MIS (Cancer Care 
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Reference   Country Study Population 
 and Sampling 
Aims of the Study Methodology Outcome Measure(s) Important findings  Superscript 
numbers refer to foot note,  
indicating relevance to scoping 
review themes) 
Evidence Rating for 
quality of findings  
Primary Research: Effects of neutropenia on symptoms and functioning continued  
Nirenberg et al., 
(2004) 
USA 19 patients (23 visits) with 
solid organ cancer, myeloma 
and NHL. Convenience 
sample. 
To determine time to 
treatment for NS in 




Risk factors. Presenting 
symptoms. Mean time to 
treatment. No tools described 
to assess research outcomes. 
Mucositis: 7 (37%) of cases. (2) Mean 
delay in presenting: 21 hours (range 1-
72). (3) Patients with co-morbidities or 
advanced cancer presented later. (3)  
Low: Small convenience 
sample, failed to capture 
all NS episodes. Relied on 
patient reports.  
Wagner et al., 
(2008) 
 
USA Patients on chemotherapy 
for lymphoma, lung, breast, 
or ovarian cancer. (n=852). 
Convenience sample  
To establish the 
psychometric properties of 
the FACT-N  
Quantitative. 
Prospective. 
Validation of FACT-N 
subscale. 
Symptoms and functioning.  
Validated Measure: HADS. 
Study Specific Measure: 
FACT-N. 
Detected negative effects of 
neutropenia on symptoms and 
functioning. (2)  
Low: Convenience sample. 
The FACT-N could not 
distinguish between 
grades of neutropenia. 
Olsen et al., 
(2011) 
 
USA 424 (4 groups). Included 
samples from Fortner and 
Houts (2006) and Fortner et 
al (2005b).  
Evaluation of Psychometric 




PCM-N score. ANC. 
Febrile status. 
Symptoms and functioning. 
No tools described to assess 
research outcomes. 
Strong internal consistency (0.81-0.91). 
Scores of 20 out of 130 are sensitive to 
81% of patients with grades 3-4 
neutropenia and 78% without 
neutropenia. (2) 
Moderate: Strong internal 
consistency suggests the 
PCM-N  is an internally 
valid model.  
Scoping review themes: (1) Defining neutropenic sepsis and the risks of this to patients undergoing chemotherapy for cancer. (2) Symptoms of neutropenic sepsis that patients should report to clinicians. (3) Knowledge about 
delayed patient presentation to hospital with neutropenic sepsis. (4) Education of patients about neutropenic sepsis. Abbreviations: FACT-N  (The Functional Assessment of Cancer Therapy-Neutropenia Instrument); NHL (Non 
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Referenc
e   
Country Study Population 
 and Sampling 
Aims of the Study Methodology Outcome Measure(s) 
 
 
Important findings  
(Superscript numbers refer to 
foot note,  indicating  
relevance to scoping review 
themes) 
Evidence rating for 
quality of findings 
Primary Research: Effects of neutropenia on symptoms and functioning continued  







363 cancer admissions 
Fever and or FN 85 (23.4%). 
Mostly breast, lung or 
colorectal cancer diagnosis. 
Convenience sampling.   
To understand reasons 







Reasons for unplanned 
admissions. 
Time since chemotherapy. 
 
Symptoms (not just FN) frequently 
present for 2-7 days prior to hospital 
presentation. (3) 
No data provided to suggest the 
number of patients with FN. 
Low: Convenience 
sampling, no tools 
described to assess 
research outcomes. 




UK 53 patient survey responses. 
88 patient case note reviews. 
Convenience sampling.   
 
To audit a NS clinical 
pathway. 
Retrospective audit of 
NS admissions. 
Presenting symptoms.  
Morbidity. 
Mortality. 
Time to antibiotics. 
 
Presenting symptoms:  
Fever < 36oC (n=2), 37.5oC-400C (n=68), 
> 36OC - <37.2oC (n=88). (2) 
Thirty (34%) patients waited > 24 hours 
before presenting. (3) Data missing for 
10 patients.     
Low: Relied on self-report 
and did not capture all 
episodes. Study design did 
not incorporate finding 
out what information and 
support assist patients to 
access help for NS.  
Scoping review themes: (1) Defining neutropenic sepsis and the risks of this to patients undergoing chemotherapy for cancer. (2) Symptoms of neutropenic sepsis that patients should report to clinicians. (3) Knowledge about 
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Reference   Country Study Population 
 and Sampling 
Aims of the Study Methodology Outcome Measure(s) 
 
 
Important findings  (Superscript 
numbers refer to foot note, 
indicating relevance to scoping 
review themes) 
Evidence Rating 
for quality of 
findings  
Primary research: Mortality and morbidity associated with neutropenic sepsis 
Okera et al., 
(2011) 
UK 64 cancer patients 
(71 admissions with NS). 
Mainly with breast cancer or 
a haemto oncology diagnosis. 
Sampling: attempted to 
capture all episodes.  
Compare findings from 
NCAG and NCEPOD with  
organisational, clinical and 




Symptoms. Management of 
febrile neutropenia. 
Study Specific Measure  
Non validated 58-item proforma 
Demographics: Advanced disease 39 
(54%). Age >65years 25(35%). Previous NS 
18(25%). No G-CSF or antibiotic 43(60%). 
Chemotherapy > 20% risk 23(32%). (1) 
Mortality 3(4.2%). (1) Infections: 
respiratory 35(49%), GI 33 (46%), 
mucositis 13 (18%). (2) 
Low: Small sample. 
Could not identify all 
episodes of NS. 




41,779 cancer hospital 
admissions for neutropenic 
sepsis. Convenience sampling  
To identify NS morbidity, 




Mortality. Length of stay 
Cost per admission. 
No tools described to assess 
research outcomes. 
Mortality rate 9.5% (range 0-50%). (1) 
Risk factors for mortality included co-
morbidities. (1) 
Cost estimate $1.06 billion. 
Low: Data may be 
incomplete due to 
coding issues. 




793 patients undergoing 
adjuvant chemotherapy for 
breast cancer. Convenience 
sampling.   
To evaluate dose 
response effect of 
adjuvant chemotherapy.  
Quantitative   Disease free survival.  
Overall survival.  
 
Disease free survival is positively affected 
by reduced treatment delays and 
maintaining dose intensity. (1) 
High: Large study 
(n=793). Valid and 
reliable outcome 
measures. Clinically 
important findings.  
Scoping review themes: (1) Defining neutropenic sepsis and the risks of this to patients undergoing chemotherapy for cancer. (2) Symptoms of neutropenic sepsis that patients should report to clinicians. (3) Knowledge about 





    (Appendix 1:    continued)  
 
Reference  Country Study Population  Aims of the Study Methodology Outcome Measure(s) 
Tools applied to  assess 
research  outcome(s) 
Important findings  (Superscript 
numbers refer to foot note,  
indicating  relevance to scoping 
review themes) 
Evidence Rating for 
quality of findings  
Primary research: Mortality and morbidity associated with neutropenic sepsis continued  
Vincent et al., 
(2006) 
European 3,147 patients with sepsis 
from 198 intensive care units 
in 24 countries. 
To define the incidence of 
sepsis and characteristics 





centre.   
Site of infection.  
Prognostic indicators. 
Infective organism.  
No tools described to assess 
research outcomes 
Important prognostic variables: Older age 
(OR,1.0 per year;95% CI, 1.0-1.0, p< .001); 
Co morbidities (OR, 2.8; 95% CI 1.06-5.0 
P<.001). (1) 
High: Large sample 




Malik et al., 
(2001).  
Pakistan 576 NS episodes. 
22 (3.8%) patients presented 
with septic shock. 
To identify the incidence 
of septic shock,  
characteristics of 
presenting patients and 
association with morbidity 
and mortality.  
Quantitative.  
Prospective.  
Morbidity and mortality. 
No tools described to assess 
research outcomes, 
 
Most patients in shock presented to A&E. 
They were older and had advanced 
disease. (1) Symptoms of septic shock 
included diarrhoea, altered mental state, 
bleeding and dyspnoea. (1)  
Patients delayed presenting. (3)  
Low: underpowered to 
detect differences - 22 
(3.8%) of 576 episodes 
were related to septic 
shock. Delayed time to 
presentation is unclear.   
Scoping review themes: (1) Defining neutropenic sepsis and the risks of this to patients undergoing chemotherapy for cancer. (2) Symptoms of neutropenic sepsis that patients should report to clinicians. (3) Knowledge about 






        Appendix 1:    continued  
 
Reference   Country Study Population  Methodology Important findings  (Superscript numbers 
refer to foot note, indicating relevance to 
scoping review themes) 
Rating or strength  of the 
evidence  
Information and support 
Nirenberg et al., (2006b) 
 
USA n/a  Review of clinical guidelines. 
Literature review.  
Inconsistent guidelines, including symptoms of NS. (2)  
Poor evidence to guide NS education for patients. (4)  
Low: Method for review is not 
presented.   
Nirenberg et al., (2010)  
 
USA 4000 cancer nurses 
(309 participated) 





Knowledge and confidence in identification of 
patients at risk of NS increased with greater 
experience and education. (1)  84% of nurses claimed 
they risk assessed and educated patients about NS. 
61% of nurses were unaware that NS is most likely 
after the first chemotherapy. (4) 
Low: Low response rate (50%). 309 
suitable responses from 4000 nurses 
approached. Locally developed survey 





UK 57 patients 
 
Patient survey to evaluate 
their experience of having a 
chemotherapy alert card  
89% of patients had an alert card. 82% kept it with 
them. Patients felt reassured there was a 24-hour on-
call service. (4)  
Low: Convenience sampling, the survey 
did not appear piloted or validated. 
Study design did not incorporate 
establishing if the alert card promoted 
early presentation with NS.  
Scoping review themes: (1) Defining neutropenic sepsis and the risks of this to patients undergoing chemotherapy for cancer. (2) Symptoms of neutropenic sepsis that patients should report to clinicians. (3) Knowledge about 
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 To advise on research, which is being carried out by Catherine Oakley, who is a nurse and 
PhD student at Kings College London, University.   
 The research is looking at why chemotherapy patients sometimes delay presenting to 
hospital with a low white count (neutropenic sepsis).  The study title is: How are risks of 
neutropenic sepsis conveyed to, and interpreted by, patients undergoing chemotherapy 
and their carers? 
 
MEMBERS  
 There are 12 members who include patients and carers, a doctor, researchers, senior 
chemotherapy/cancer nurses and a cancer information specialist.   
 
COMMITMENT 
 To attend three meetings between July 2012 and April 2015.   
 The meetings will last between 60-90 minutes. 
 To discuss the research findings, as these develop, to get different views on these.    
 To refine the research question. 
 To provide guidance on new questions to ask patients, carers and clinicians to make sure 
the researcher does not miss anything important and obtains as complete a picture as 
possible. 
 Minutes of the meeting will be kept and information gathered will be referred to in the final 
report findings.  Information that could identify any member of the steering group will not 
be included in the final report. 




Neutropenic Sepsis Study Steering Group  




REFRESHMENTS AND REIMBURSEMENT 
 Refreshments will be provided during the meeting. 
 Travel expenses will be funded. 
If you have any questions or concerns about the steering group, please contact the 
researcher, Catherine Oakley on 07989659857 














CO NIHR Research Fellow 
Dr  JM Consultant Medical Oncologist  
KS Patient Representative  
AM Carer  Representative  
PB Patient Representative  
AW Cancer Information Specialist, Dimbleby Cancer Care 
AH Acute Oncology Nurse. 
DH Patient Representative 
Apologies 
LL Patient Representative 
EG  Carer  Representative 
MF Chemotherapy Nurse Consultant 
 
 
1. Welcome and Introductions 
CO introduced the meeting and explained the purpose as detailed in the terms of reference.  
Essentially, her PhD research is looking at why patients sometimes delay presenting to hospital 
with symptoms of neutropenic sepsis.  This is a complication of chemotherapy which is life 
threatening and requires urgent hospital treatment with intravenous antibiotics. 
 
The group agreed they were able to provide advice on areas of research enquiry and 
questioning.  Three meetings will be held.  The second meeting will focus on the emerging 
results.  The final results will be presented at the last meeting when ideas will be generated for 
an intervention to be tested in a subsequent study. 
 
The group introduced themselves and shared their experience of chemotherapy and any 
experience of neutropenic sepsis.  AH spoke about her experience of developing a patient 
chemotherapy alert card which has been used nationally.  She also told us about a recent 
neutropenic sepsis admission audit, which found 50% of patients delayed presenting to 
hospital by at least 24 hours. 
 
Neutropenic Sepsis Study Steering 
Group. 
 Minutes of Meeting One Held on 
23rd July 2012  
 
 
Minutes of Meeting One Held on 
23rd July 2012 
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AW said that patients have told her they do not like to bother the helpline, that information is 
sometimes confusing and they sometimes get mixed messages.  Patients often say they are 
not sure of the process for calling.   
 
PB told us his wife was diagnosed with Bowel cancer in 2009 and is currently in remission 
having undertaking 6 months (12 cycles) of Chemotherapy.  PB is currently working as a 
manager of an Advocacy service supporting a variety of clients in the mental health, mental 
capacity and learning disabilities arena.  He deals with diverse issues, including 
accommodation, safeguarding, care reviews and serious medical treatment issues.   
 
JM thought it would be helpful for the group to understand that neutrophils are a type of 
white blood cell, needed to fight infection.  It is a reduction in neutrophils that can lead to 
neutropenic sepsis.  JM has also recently been a member of the acutely ill cancer patient 
working group at the Royal College of Physicians.  The group has carried out a national patient 
survey and will be launching guidance for patients and healthcare professionals to improve 
emergency cancer care.  The group have developed a patient wallet to help patients navigate 
the healthcare system.   
 
KS, DH and AM are all members of a CPWG (Chemotherapy Patient Working Group).  We heard 
that patients are often frightened before they start chemotherapy, when they are trying to 
take information in.  Early signs of neutropenic sepsis may be subtle and more obvious to 
others (friends, family, and colleagues) than the patient.  Patients may not feel that unwell to 
start with and the deterioration can be surprisingly fast.  As AW mentioned, patients 
sometimes don’t want to bother the staff.  When patients come into hospital issues include 
accessing veins.  This is a particular problem for breast patients who often have limited venous 
access due to a risk of lymphoedema.   
 
2. Outline of research and discussion 
CO  presented her research methodology which involves observing breast cancer patients 
being given information about chemotherapy side effects by doctors in outpatient clinics and 
by chemotherapy nurses in a chemotherapy day unit.  She is also interviewing patients who 
have been admitted to hospital with neutropenic sepsis as well as doctors, patients and carers.  
Our discussion continued and the group came up with additional aspects for CO to look out for 
during interviews and observation 
 
 
Things to look out for: 
 Be aware that the Patient-centred Communication model is American and they have a 
different model of health care.  They may prepare patients for chemotherapy differently to 
the UK. 
 How do people feel about presenting themselves with the alert card to A&E? 
 Does age/culture impact on behaviour in terms of reporting symptoms of neutropenic 
sepsis? 
 How do patients perceive information from other patients compared to healthcare 
professionals? 
 What happens if patients do not have a carer? 
 How clear are messages about picking up symptoms and calling?  
 What impact might they way information is given have on reporting (Is it a tick in the box?). 
 Find more out about the hotline calls.  How difficult is it to get through.  What are these 
calls about, how appropriate are these?  Interview on-call doctors.   
 Talk to people who had a bad experience of calling. 
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 Ask patients and carers how many people they have spoken to about chemotherapy and 
the advice given.  See if there is anything different in terms of information and support 
between those who do and don’t present early. 
 Ask how people deal with other risky situations, what would their normal response be and 
does this differ to neutropenic sepsis? 
 Flip it over – ask patients – if somebody you cared about had these symptoms what would 
you do? 
 The group felt that patients generally do as they’re told in relation to chemotherapy side 
effects.  Why is it different with neutropenic sepsis? Is it because it’s not so obvious? 
 Do patients know what it feels like to have a temperature? Do they own a thermometer?  
Do they know how to take the temperature? 
 Look at the literature around screening – do certain types of people present more readily? 
 We discussed patients wanting to have a normal life e.g.  going to work, going on holiday 
and the impact of chemotherapy treatment and infection prevention on that.  We spoke 
about the extent we work with patients on an individual basis to identify priorities and try 
to accommodate these.   
 Why do people think they are being a nuisance – explore further  
 
 
3. AOB – None 







CO NIHR Research Fellow 
JM Consultant Medical Oncologist  
KS Patient Representative  
AM Carer  Representative  
PB Patient Representative  
AW Cancer Information Specialist 
MF Chemotherapy Nurse Consultant 
Apologies 
AH Acute Oncology Nurse 
 EG  Carer  Representative 
DH Patient Representative 
 
The aim was of the meeting was to discuss emerging study findings to share experiences and 
see if the findings resonate with others.  Attendees agreed not to change practice based on 
emerging findings.  The following areas were broadly discussed  
 
1. Telling patients about it – need to look at other areas of research about conveying scary 
information  
2. Difficult Recognising it – Temperature or not 
3. Feeling protected – think can avoid- what advice to give people – Patients talk to AW 
about mixed messages 
4. Avoid or seek out information  
Information overload.  Too much going on in pre treatment consultation 
Think patients tune into a scenario/patient stories 
5. Accessing Help – reluctant to go back if had bad experience.  Relationships important.  
What is a bad experience? Who do chemotherapy patients have a relationship with?  
Not sure people know what to say to A&E.  Government are saying don’t go to A&E.  AW – 
patients tell her no one is expecting them in A&E.  When do patients get told to go to the 
GP? Mixed messages.  ?NHS Helpline confusing for chemotherapy patients.   
6. Carers not engaging- Want to help and need a job e.g.  looking out for neutropenic sepsis.  
Discussed giving carers permission to call during the pre-treatment consultation. 
7. Ignore symptoms – even with acute oncology service patients call and play down the 
temperature.  Good message would be that going early to A&E is better for the patient.   
Agreed to meet following completion of the research, to discuss the final findings and a new 
intervention study. 
Neutropenic Sepsis Study Steering 
Group. 
Minutes of Meeting Two Held on 29th 




Appendix 4: Ethical and research and development permission   
 
Ethical and local research and development approval were obtained as detailed below: 
 
1. Ethical approval for the study was submitted on the 1st April 2011.  Following review by the 
ethics committee clarification was required about action the researcher would take if she 
witnessed an issue of clinical concern, how contact would be made with patients and the level 
of participant observation.  Minor changes were further required to written participant 
information.  The proposal was amended and resubmitted and ethical approval was finally 
granted on the 25th July 2011. 
 
2. Approval from the local cancer research governance committee was granted on the 4th July 
2012.   
 
3. Local research and development approval was gained on the 2nd September 2011. 
 
4. Amendments were submitted to the ethics and the research and development offices on 
the 13th February 2012 and approved on the 16th March 2012.  These included audio 
recording of consultations and informal interviews, not informing observation patients the 
study interest was neutropenic sepsis and inclusion of patients who received chemotherapy at 















































Florence Nightingale School of Nursing & Midwifery, King's College 
London.  James Clerk Maxwell Building.1st Floor, Room 1.32.  57 








Re: PhD Study: How is information about chemotherapy side effects received by patients 
undergoing chemotherapy and their carers? 
I am a researcher from Kings College London University and am writing to ask if you may be 
willing to participate in my research study which aims to understand more about patients, 
carers and healthcare professionals’ experiences of chemotherapy side effects.  You are being 
invited to get involved in this research because you will be starting chemotherapy treatment in 
the near future.   
I have provided a study information sheet with this letter which provides further details about 
my research and what this would mean for you, should you decide to take part.  Essentially, 
this research would involve my attending two appointments with you and your carer (if 
applicable) where a doctor or nurse will provide you with information about your proposed 
chemotherapy treatment.  I would then discuss the information provided with you and your 
carer.  I would also like to carry out one audio recorded interview after your last treatment to 
discuss your experience of the chemotherapy. 
If after reading this letter and the information sheet you decide you would like to find out 
more about the study I will be introduced to you by the doctor or nurse caring for you.  If you 
decide you would rather not take part in the research your care will not be affected in any 
way.   
Thank you very much for taking the time to read this letter and the information sheet.   
 
Yours sincerely  





Project Title:  How is information about chemotherapy side effects received by, 
patients undergoing chemotherapy and their carers? 
 
You are being invited to take part in a research project.  The following information will 
help you to decide if you would like to take part.  Your participation in this project is 
voluntary.  The researcher will be happy to answer any questions you have about the 
research so please do not hesitate to ask.  Please take time to read this information 
and discuss it with your family if you wish, before deciding whether or not you wish to 
take part in the project.  Thank you for reading this information. 
 
Introduction 
There is little research looking at how patients are prepared for chemotherapy 
treatment and its side effects.  Researchers at Kings College London University are very 
interested in patients’ experiences of chemotherapy information and are currently 
undertaking research in this area.  The project involves patients starting chemotherapy 
treatment for breast cancer.  If you are in agreement they would also like to involve 
the person who accompanies you to your hospital appointments in the research (your 
carer).   
 
What the project is about 
The purpose of this project is to understand the experience of cancer patients being 
treated with chemotherapy, their carers and healthcare professionals.  In order to 
understand as much as possible about your experience a researcher will observe you 
and your carer (if applicable) contacts with healthcare professionals when you attend 
your first appointments.  Then the researcher will ask you and your carer (if applicable) 
views on these meetings.  Later, when you have finished your chemotherapy 
treatment, the researcher will interview you once to see how you got on with this.   
 
 
Why have I been chosen to take part? 
You have been chosen because the plan is for you to receive chemotherapy treatment 
for cancer at xx Hospital.  A small number of people, around 20, like you will be invited 
to take part.   
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Do I have to take part? 
You are under no obligation to take part in the research.  If after reading this 
information sheet and discussing it with the researcher you decide not to take part, 
this is not a problem.  If at any time during the project you decide that you no longer 
wish to take part please inform the researcher.  This will not affect your care in any 
way. 
 
What will happen during the study? 
The researcher is based at Kings College London University London.  Her name is 
Catherine Oakley.  If you are interested in taking part in the study she will talk to you 
and your carer (if present) about it following your outpatient appointment today.  The 
researcher will also provide an information sheet for you to pass onto the person you 
consider to be your carer.  She will then telephone you in the next two to three days to 
discuss the project in more detail.  The researcher will also ask you if your carer would 
like to participate in the study and will contact them separately to answer any 
questions they may have.  If at that point you decide that you would like to participate 
in the study the researcher will arrange to meet you at your next outpatient 
appointment.  There will be a further opportunity for you to ask questions at that time 
and if you still wish to participate the researcher will ask you to sign a consent form.    
 
If you do take part in the study the researcher will be present during two of your 
chemotherapy consultations and will observe discussions you have with health 
professionals regarding your treatment.  She will talk to you (and your carer if 
appropriate) about your time at the hospital and will make notes of her observations 
and conversations with you.  With your permission the researcher will also digitally 
record the observed consultations and informal conversations.  She will then interview 
you once to at the end of treatment.  The interview will be carried out at a time and 
place convenient to you (home, hospital or over the telephone) and will last around 45 
minutes.  With your permission the interview will be audio recorded to allow the 
researcher to accurately remember what was discussed.  If at any time you feel 
uncomfortable about being observed or interviewed you may ask for these to be 
stopped.  If you are in agreement the researcher will ask you some additional 
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questions about your ethnicity and social situation and will request permission to look 
in your medical notes.   
 
What are the possible disadvantages of taking part? 
You may feel uncomfortable about the researcher attending outpatient appointments 
with you.  You may also find it difficult or upsetting to talk about issues related to your 
diagnosis of cancer and its treatment.  You may also at times not feel well enough to 
be interviewed or that the time taken up is inconvenient.  If this is the case the 
interview can be rescheduled or you may decide you no longer wish to take part in the 
study. 
 
What are the benefits of taking part? 
There are no direct benefits to taking part in the study although some patients find it 
comforting to have someone attend their appointments with them and to talk about 
their illness and treatment.  It is also anticipated that this research will benefit patients 
in the future as the research results may lead to a change in practice. 
 
What if there are any problems? 
The researcher will raise any concerns regarding observed clinical care with the head 
of nursing.  If you feel uncomfortable at any time during the research please ask the 
researcher to stop.  If you would rather raise your concerns with someone else please 
do contact xxx, Head of Nursing for Cancer, at  xxx Hospital on xxx. 
 
Will my taking part in the project be kept confidential? 
All information you provide during the research will be confidential.  Quotes from 
conversations or interviews may be used in the final report and published papers to 
highlight the findings of the project.  Your name will not be recorded on the notes used 
to write down the observations nor will it appear in any written report or talks given 
about the project.  If you would like to receive a copy of the study when it is finished 
the researchers would be delighted to send this to you.  Data will be stored for seven 
years on a secure data base by the university.  Only the researcher and her supervisors 
will have access to the data.  Recordings of interviews will be destroyed once data 
analysis is complete. 
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What will happen to results from the study? 
Information you provide the researcher during informal or formal interviews will be 
used in the results section of the researchers PhD thesis.  The research will also be 
published in cancer journals and presented at conferences, nationally and 
internationally 
 
Who is organising and funding the project? 
The project forms part of a PhD programme funded by the National Institute for Health 
Research.  The research is being organised and carried out by a researcher, Catherine 
Oakley who is based at King’s College London University.   
 
Who has reviewed the research? 
The research has been reviewed and commented on by the National Institute for 
Health Research (who are funding the research) and Professor XX and Dr XX who are 





Contact point for further information 
If you have any queries regarding the project do not hesitate to either contact: 
Catherine Oakley, NIHR, Research Fellow 07989659857 or xxxl, Head of Nursing for 
Cancer, at xxx Hospital on xxx. 
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Consent form (Patient, partial-participant observation and interview) 
 
Project Title: How is information about chemotherapy side effects received by patients 
undergoing chemotherapy and their carers? 
I confirm that I have read and understood the information sheet for the above 
research project.    □ 
I understand that I am entering the project on my own free will and am free to 
withdraw at any time without my care being affected □ 
I am happy for the researcher to attend my chemotherapy consultations  with 
me, to speak to me about my experience of these and to audio record the 
consultations and informal conversations 
□ 
I am happy for the researcher to interview me on one occasion   
and to audio record the interview 
□ 
I am happy for the researcher to ask me about my ethnicity and social status 
□ 
I confirm the researcher may access my hospital records 
□ 
 
------------------------------------ -------------------- ------------------------------- 
Name of Patient   Date   Signature 
 
-------------------------------------- -------------------- ------------------------------- 





Appendix 6: Example interview guides (January 2012) 
Early Interview Guides  
Semi-structured interview guide: Patient admission with neutropenic sepsis 
 
Admission to hospital 
 Can you tell me what happened from when you first became unwell and during your 
admission to hospital? 
 What symptoms did you have and for how long? 
 How long did you wait before calling the hospital?  
 
Understanding of risk of neutropenic sepsis 
 Could you tell me what you understand by a low white count? 
 How much were you looking out for signs and symptoms of it? 
 What do you think can happen to people with a low white count? 
 How useful was the information you were given at the start of treatment in helping you to 
recognise the fact you had a low white count? 
 What advice would you give a patient starting chemotherapy about looking out for a low 
white count and reporting this side effect to the hospital? 
 
 
Semi-structured interview guide – Clinicians (February 2012) 
 
Risk and conveyance of risk 
 How much of a risk is neutropenic sepsis? 
 How do you convey this risk to patients and carers? Do you treat any patient groups 
differently in terms of neutropenic sepsis risk information? 
 How do you think patients and carers interpret the risk of neutropenic sepsis? 
 How difficult or easy are these kinds of conversations to have with patients and carers? 
 When should this kind of information be conveyed to patients and carers? 
 Who should the information be conveyed to? 
 How should the information be conveyed to patients and carers? 
 
Experience of patient presentation 
 What is your experience of patients presenting with neutropenic sepsis? 
 Do patients with signs of neutropenic sepsis present in a timely fashion? 
 Why do you think patients delay presentation?  
 How does that make you feel? 
 Whose responsibility is it to identify signs and symptoms of possible neutropenic sepsis? 
 What do you think helps patients and carers recognise the symptoms of neutropenic sepsis 
and present early? 













Examples of a later interview guide: 
 
Doctor 2 (December 2012) 
 
Introduction 
 Introduce self and KCL. 
 Introduce the study, who is it for, what is it about. 
 Purpose of the interview.    
 Length of interview. 
 Voluntary nature of participation and right to withdraw. 
 Reasons for recording the interview. 
 Confidentiality and how findings will be reported. 
 Any questions? 
 
Icebreaker 
 Explore experience of neutropenic sepsis and delays. 
 Why do you think they delay? 
 How do you feel when they delay? 
 Any worse offenders? 





 How do you explain neutropenic sepsis to patients?  
 Do they ask any questions about it? 
 Any patients you give different information too? 
 Explore difficulty with giving same information? Standard repertoire. 
 How well do they take information in? What stops them? What helps? 
 What do they seem most concerned about?   
 Do you think they read the information? 
 Could you tell me a little bit about your workload and how you manage this or not ... 
 
Presentation 
 How do people typically present? What symptoms? TEMP 
 Where do they present? Helpline, clinic, A&E 
 What do they seem to know about it? How seriously do they seem to take it? 
 How honest do you think they are about their symptoms and length of these? 
 How easy or difficult do you think it is for patients and carers to recognise neutropenic 
sepsis symptoms?  
 Do patients/carers ever argue about coming up? Or disagree with each other? 
 Do you say anything different about neutropenic sepsis then? 
 Explore experience of fast deterioration. 




 Do you get involved with arranging for review or admission elsewhere? 
 How does that work? Any issues with that?  
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 Do you have a feel for the benefits of going to A&E or Oncology? 
 Liaison with A&E and GP’S – How clued up do they appear about neutropenic sepsis? 
Support  
 Where do they get there support from? Who should support them through chemo? 
 What role do you think carers play? 
 How do patients and carers view the helpline? 
 Do you know much about the pressures and priorities on the chemotherapy nurses? 
 Would this impact on ability to support chemotherapy patients? 
 Are the chemo nurses able to support the patients - symptom management? 




 Do you think that your perceptions of neutropenic sepsis differ to patients? How would you 
explain it to a colleague?  
 I notice there is very little conversation about the risk of death with neutropenic sepsis?  
 Is that your experience? Do you know why that might be?  
 Do you mind me asking how you personally feel about having that type of conversation? 
 Could anything be done to improve the service and early presentation? 




Interview schedule for Alice following admission to hospital with neutropenic sepsis 
(November 2012) 
 Introduce self and KCL. 
 Introduce the study, who is it for, what is it about. 
 Purpose of the interview.    
 Length of interview. 
 Voluntary nature of participation and right to withdraw. 
 Reasons for recording the interview. 
 Confidentiality and how findings will be reported. 
 Any questions? 
 Complete demographics. 
 
Icebreaker Ask to tell story leading up to admission to hospital. 
 What were you doing when it happened? Who were you with?  
 
Explore Symptoms 
 What sort of symptoms? 
 How long? 
 Getting better or worse? 
 How much did they bother you? 
 Fever - How did you know? Taking temperature? Wait until 38? Was it like any other illness 
e.g.  flu? 
 How quickly did you become unwell? Surprise? What imagined? 
 
Calling for Help 
 Trigger? Had you called before? 
 Did you discuss with anyone whether to call? 
 Did you look on the internet or in the chemo information? BEFORE OR AFTER 
 Feelings about calling the hotline urgently? What’s it for? Routine or emergency? 
 What’s it like calling that hotline?  
o How easy was it to get through? 
o Who did you speak to and what was said?  
o Did they know about you?  
o How quickly were you advised to get to the hospital with the infection? 
o Feelings about calling out of hours? Who prefer to call? 
o How would you feel about calling again? 
 
Admission  
 Feelings about going to hospital e.g.  worried about waiting, infection, prefer to stay at 
home? Any concerns about possible chemo delay 
 Any issues about getting there e.g.  transport 
 If been to A&E in the past, did you think it was necessary compared to other occasions? 
 How ill did you think you were?  
 Were they expecting you? 
 What discussion did you have – e.g.  Did you have to present your own case; did you show 
chemo card.  Did you tell them everything – like being in bed unwell? 
 How seriously did A&E take it?  
 What was the care like? Was it what you expected? Liaison? 
 
Chemotherapy Information at the Start 
 Explore information sessions – tell me about  
o What sort of information were you given? 
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o How was it given? 
o How easy was it to take in?  
o What effect did the information have on you? 
o What were you most worried about? 
o  What advice did they give you about other side effects? 
o Was there anything you didn’t like or didn’t want to hear about? 
o How felt about needing chemotherapy? Did you think you had a choice? 
o Did the conversations about chemo make you think about the cancer more? 
o How did feelings about starting chemotherapy compare to your diagnosis? 
 
Focusing on the low white count  
o Do you remember them talking to you about neutropenic sepsis or infection? (WHAT 
DO THESE WORDS MEAN) What is understanding? 
o What key messages?  
o Did you ask any questions? 
o How much did you take in the information? 
o How serious/important did the low white count seem to be?  
o How ill did you think patients with neutropenic sepsis would be? 
o How easy to treat did you think it was? 
o Any idea about when you were most at risk? 
o Did you think it would happen? Were you worried about it? 
o Were you looking out for it? What symptoms? 
o Did you plan ahead - think about what you would do if you got the symptoms? 
o How were you told about looking out for neutropenic sepsis and calling? How did it 
make you feel?  Do you think it encourages people to call (or resist)? 
 
Preventing Infection  
 How concerned were you about getting infection? 
 Were you concerned about picking up infection in hospital? 
 Did you think that getting an infection would be different for you? 
 Patient/ family doing anything to protect against infection? Can you boost your immunity? 
 Has normal/social life been affected by the infection risk?  
 What effect did you think these sorts of things might have? 
 
What support is there for you? 
 Which doctor/nurse would you be inclined to contact? (Who is your key relationship with?). 
 How would you describe your relationship with the hospital? 
 Has the support from the breast team changed since starting chemotherapy? 
 
Normal Life 
 Explore how normal/work life was affected by the chemotherapy - other commitments? 
 Did anyone go with you to information sessions? What was their role 
 Involvement of friends and family.  Change in relationships 
 How feel about being reliant on others? 
 Do you get advice from friends or family? How is this different to information from doctors 
or nurses? 
 What do friends and family know about neutropenic sepsis? 
 
Making Decisions 
 Are you the sort of person who goes to the doctor? 
 Any delay in cancer diagnosis? 
 Who normally makes decisions in your relationship? 
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 Are you the sort of person who generally thinks I want to know every detail or do you 
tend to say I will wait and see what happens?  
 It’s quite unusual but do you think you realised that people can die from this low white 
count? 
 When people have this low white count, so reduced immunity, the earlier we treat it the 
better, the faster they recover from it and the longer it’s left the more unwell people get? 
Risk of treatment delays.  Do you think you and your family realised that?  
 Do you remember the words used to describe the seriousness, e.g?  Life threatening? What 
does that mean to you? 
 I am interested in why people delay. 
 What might delay patients? 
 Do you understand something now that would help you to call earlier? 
 Opinion on timing of information? 
 Would talking to someone who had it help? 
 



























































Appendix 9: Example of memo exerts to building up the core category:  Playing down the seriousness and piling on the fear  
Holding in the frustration  
Date  Memo Title Memo Exert  




Her information delivery style appeared quite forceful, possible due to her experience of patients not doing as they were told in reporting 
neutropenic sepsis.  She appeared to find patients who delayed frustrating and talked about them suffering the consequences of not calling 
early enough.  She feels she provides individual support.  For high risk patients she hammers home the message.  Clinicians seem to provide 
more information about neutropenic sepsis to non-compliant patients.  She did not talk about any kind of discussion with patients about 
neutropenic sepsis.  She recognised that patients don’t want to bother us, but finds this odd.  Neutropenic sepsis is a high profile symptom and 
is drummed into clinicians as something that is important, serious and should be looked out for.  Need to talk to clinicians about how they view 








Clinicians consider that patient delay is a significant problem.  They can’t understand why patients delay presenting.  They use the word 
DESPITE a lot; in terms of despite our instructing them to call they still delay.  They really do feel they are doing their best for patients to get the 
message across.  Use words like frustrating, disappointed, pissed off, annoyed, cross.  I get a sense that clinicians think patients are instructed 
and therefore responsible.  Patients are foolish (D1).  Is there an element of blame? Explore.  Good example with D1 where a GP spent a day 
trying to contact her.  She felt the patient should have known better.  Even where they think patients do understand they are not convinced 
they are going to call.  Clinicians also use the word WORRIED a lot.  They tell patients they worry about neutropenic sepsis – need to explore 
what they are worried about in more depth.  Are they worried that they will be responsible if patients delay? They don’t tell patients 
specifically why they worry.  They say patients make excuses not to come up (e.g. childcare, no transport, nobody to bring them), don’t want to 
bother the staff.  This all points to patients not seeing neutropenic sepsis as important or a priority (ask patients what they would do if they had 
to go to A&E urgently about something else…Clinicians appear exasperated by this situation and don’t know what else to do.  What is the 





Clinicians worry about patient delays in reporting neutropenic sepsis.  They don’t understand it and are frustrated by the de lays.  They are very 
concerned because patients can die from neutropenic sepsis and feel they do their very best to prepare patients to present early.  This links to 
piling on the fear as it appears to cause clinicians to behave in a paternalistic way.  They transfer a list of must do’s to patients about 






(Appendix 9 continued) 
Playing Down the Seriousness  




No mention of risk of death.  I wonder if this has been discussed before or if the patient knows it.  Patient asks no questions about neutropenic 





Participants’ accounts suggest the seriousness of neutropenic sepsis is underplayed.  Possible link to taking infectious precautions.  LINK to 
realise after the event and what would have helped recognise.  Some patients feel clinicians do not stress the seriousness.  Although CNS 1 talks 
of scaring patients.  How do clinicians feel about talking about the risk of death? What are the difficulties? Do patients recognise the 
seriousness and how do they feel about it? Source of information – How and when is the internet used in relation to neutropenic sepsis.  What 
written information is made available and how is it used.  Some patients check the internet when they develop symptoms of neutropenic 
sepsis.  Is this the same for other patients? Patients refer to the chemotherapy record book but I am not sure how well it is used.  Some 
patients didn’t keep this with them.  One patient said that neutropenic sepsis was not mentioned in the literature.  Do other patients and carers 
think the same? How clear is it in the literature? Maybe caught up with not linking low WBC, neutropenic sepsis and infection risk.  Do patients 
read the information? Ask them what they understand by written information about neutropenic sepsis.  Read it to them. 
 
30.8.12 Talking about 
death 
Clinicians do not like talking about life threatening risks of neutropenic sepsis with patients.  This is something I recognise from my own 
practice.  Generally, they are concerned not to scare patients about something they may never get.  Doctor 1 considers breast cancer patients 
are at very low risk of getting neutropenic sepsis and told me she doesn’t labour risks of chemotherapy induced organ damage either, which 
are also rare in this patient group.  Consequently, clinicians tend to skirt round the issue and do not fully disclose life threatening risks (D1, 
CNS2, and CNS3).  Observed clinicians generally used words like its serious, we worry, you need to call us quickly when talking about 
neutropenic sepsis, rather than people can die from it. 
13.11.12 Talking about 
death 
I need to probe much deeper why there are no conversations/questions when life-threatening is mentioned? Are we afraid that patients will 
refuse the treatment? 
27.11.12 Telling and not 
telling 
Oncologists may not want to explain the risk of death for different reasons to nurses.  Nurses may be concerned not to frighten, whereas 
Oncologists may in addition be worried about patients refusing chemotherapy.  Doctor 1 mentioned a patient refusing to continue treatment 





(Appendix 9: continued) 
Playing Down the Seriousness continued 
Date  Memo Title Memo Exert  
09.02.13 Playing down 







Clinicians don’t want to tell and patients and carers don’t want to hear about it.  Seriousness is skirted around.  Patients are told to report a 
high temperature urgently but there is no discussion and the reasons for this are not explored.  Clinicians counteract scaring by underplaying, 
inferring it is unlikely to happen and easy to treat.  Some patients are scared by the chemotherapy information and don’t want to hear about 
neutropenic sepsis.  They don’t take it seriously or treat it as important – think clinicians are doing their job, but it won’t happen.  Clinicians 
treat those thought to be at high risk of not complying differently and attempt to scare them.  Information is given in a negative way and 
benefits to the patients of attending early are not conveyed.  The seriousness is recognised by some patients and carers once they have had 
neutropenic sepsis (making the connection).    
Piling on the fear   
Date  Memo Title Memo Exert  
6.6.12 Playing down 
the seriousness 
Interacting/asking questions.  Extent to which questions are asked or encouraged to enable self management.  There appears to be little 
interaction or opportunity to ask questions.  Some patients don’t want to ask questions – maybe they can’t cope with any more information, 
maybe they feel they won’t understand.  Some clinicians invite patients to generally ask questions, but the offer is rarely taken up, so may not 
be encouraging a response or maybe patients are too overwhelmed to respond.  What questions are asked by clinicians and patients/carers? 
What would they like to ask?  How interactive are the conversations? Do patients and carers feel able to ask questions and to whom? Standard 
Repertoire (the chemo chat) – Information sessions appear scripted.  Seems common and I recognise this from my own practice.  Need to 
explore to what extent this is personalised and what is the effect of standard repertoire on patients? How do clinician participants find 
providing the same information to multiple patients? Drumming it into me – it’s their job – Stressing and repeating information.  Duty to 
transfer the information.  CNS1 thinks scaring the patient and repeatedly stressing the information will get them to conform.  Some patients 
say they were not told about neutropenic sepsis.  To what extent is information reinforced? How does this make patients and carers feel and 
what effect does it have?  In my previous research, clinicians felt they needed to transfer responsibility to the patient and this may be the case 
here? Is there something different about patients who felt they weren’t told?   
 
29.7.13 Piling on the 
fear 
Clinician‘s frustrations about patient delays and reluctance to discuss neutropenic sepsis (Playing down the seriousness) emerged through their 
piling on the fear about infections rather than explaining neutropenic sepsis.  This alongside the reality of starting chemotherapy may have 
affected patients’ ability to take on board information about neutropenic sepsis, as fears about cancer and chemotherapy were heightened, 




(Appendix 9: continued) 
Reality hitting  
Date  Memo Title Memo Exert  
6.6.12 Drip feeding- 
timing of 
information 
Information about neutropenic sepsis is provided when patients are trying to take in a cancer diagnosis.  CNS 1 said information should be drip 
fed but patients said neutropenic sepsis was never mentioned after the initial chemo consultation...To what extent is information drip fed? 
When do patients want the information? When would they most benefit from the information?  Amount of information given and effects of 
this.  Some patients felt overwhelmed and frightened by the information.  Many patients referred to not hearing the information.  How much 
information are patients given? How do they attempt to process this or not? What is the effect? How much do they forget? 
 
11.10.12 Being hit by the 
gravity  
When patients attended chemotherapy information sessions, they hadn’t got to grips with the cancer diagnosis.  They were on a  roller coaster 
(P10)...still shocked from the diagnosis (CNS3; D1) and threat to mortality and what that meant, what treatment was needed and the likely 
benefit.  Information about neutropenic sepsis was given whilst these fears were present.  Death was the fear for most (CNS3; P3).  People 
perceive chemo as nasty stuff – so they come along with this baggage (D1).  I think the seriousness or gravity of their situation seemed to hit 
people as they were repeatedly given information about serious chemotherapy side effects...basically neutropenic sepsis (P1).  P1 felt 
frightened and out of control.  P1 said...the information made her feel doom and gloom.  During observations patients gradually appeared 
more anxious as information about nasty side effects was delivered.  Observations were good here as patients couldn’t always remember this 
afterwards...Patients indicated they did not like hearing scary information about neutropenic sepsis and knowing they had to call the helpline 
urgently with a temperature or you could be dead makes the seriousness of the cancer more real (P1; P7; P10).  P3 taking the temp is a 
reminder of the illness.  Does this affect people taking a temperature seriously or do they avoid thinking about it? Annotation P7 - This lady 
didn’t like hearing about the temperature, the fact you need to call straight away and can die quickly.  So she got the message but didn’t want 
to hear it.  ...  How do people view the actual chemo treatment? Need to look at views about being given information in the day unit.  How did 
they feel when they went in? P10 – during first chemo another patient collapsed… I wonder if there are differences with people who are in a 







(Appendix 9: continued) 
Reality hitting  
Date  Memo Title Memo Exert  
(cont’d)  Conversations about chemotherapy side effects are given at the same time as discussions about prognosis and future treatments.  With 
metastatic patients these other conversations may be more protracted and the focus is much more on will I live or die, so the need for chemo is 
more important /urgent and may detract from hearing information about chemotherapy side effects.  P6 though was not palliative and was 
more worried about the cancer than the chemo.  Ask patients how they felt about chemo and the cancer.  Highly stressful situation and all 
these worries – means people can’t take the information in (C2)Avoidance HCP – CNS1 try to scare some patients into taking on board the 
seriousness of neutropenic sepsis, but they are already scared (How does scaring make patients and carers feel in context of the bigger 
picture) Do some people avoid scary information more than others... (Getting Away with it).  Indication by C2 that she is terrified of what 
someone is going to tell her– cancer is death sentence so anything that makes that more certain like neutropenic sepsis is avoided.  How do 
people feel about hearing about life threatening risks of chemotherapy?  CNS2 says patients don’t want to hear it and look blank and maybe in 
denial and are afraid of hospital.  But are people afraid of the chemo? P1 blocked out negative thoughts, the more she heard about side effects 
the more she didn’t look for them.  Struggles to realise its serious.  Told me the reality was hard to take on board, tries to squash feelings she 
may feel like she is dying on chemo...Need to see if different people avoid or confront serious information.  Look to see how others view heart 
damage – P12 I know did ask about it and P10 was also interested...P1 thinks chemo poisonous so between that and risk of infection makes it 
not great.  Lots of negative information (P1).  Other Life events impacting.  I need to remember that patients and carers have other life events 
that might occupy them and impact on reporting.  Patient 1 and carer 1 speak of a relative dying whilst the patient was going through 
chemotherapy...they both took risks in reporting infections...  It must be difficult to make rationale and safe decisions when undergoing the 
stress of someone dying in another country.  P10 too had recently lost her mother and I wonder what impact that might have on her ability to 
report... 
 
